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ABSTRACT
Description of the cellular and systemic consequences of cancer and its 
treatment shows that biochemical and nutritional changes may affect both 
nutritional status (NS) and quality of life (QL); techniques of measuring 
both parameters are considered.
A new technique of QL measurement is described and found valid, reliable 
and feasible for clinical use; it is shown to be sensitive to changes in 
the patient's condition, to have discriminative ability and to yield 
meaningful results. Tiredness, identified as the symptom causing most 
distress, appears to result primarily from discomfort arising from 
physical symptoms; changes in mobility, appearance and mood also caused 
distress. The activities of daily living most affected were recreation, 
sleeping patterns and eating behaviour.
Investigation of the relationships between food intake, NS and QL 
showed that food consumption in cancer patients is generally inadequate 
and closely linked to QL, although no clear cause and effect relationship 
was demonstrated. Similarly, although NS clearly depends on food intake, 
no relationship was found between NS and QL, perhaps because no current 
method of nutritional assessment is satisfactory in this population. 
However, marked differences in the pattern of weight change were observed 
between male and female patients.
Attempts to improve food intake using nutritional supplements found 
that the products tested were organoleptically unacceptable to both normal 
and cancer-bearing subjects. Recipes, incorporating the products, were 
developed in attempts to improve acceptability but it was not possible to 
try these in a patient population.
Overall the studies revealed that many of the changes accompanying 
cancer may significantly affect QL causing tiredness, changes in mood, 
appearance and the ability to eat and affecting normal patterns of 
activity. Although there are indications that QL and NS are inter-related 
this was not confirmed.
Suggestions are made for future research.
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CHAPTER 1.
WHAT IS CANCER?
'Cancer' is a collective term describing a large group of diseases 
characterised by the uncontrolled growth and spread of abnormal tissues. 
Cancers may arise from different tissues and organs and differ markedly 
from one another in appearance and in their pattern of growth and spread; 
they may follow a different course of development, cause individual 
difficulties for affected patients and respond in different ways to the 
many treatments applied to them. They may have different extrinsic causes, 
reflected by differences in age, sex, occupational and racial incidence, 
and may result from fundamentally different mechanisms of neoplastic 
change (Louis, 1978). Although cancer itself is difficult to define, the 
diseases of which it is comprised have in common their ability to destroy 
the host if attempts at eradication are unsuccessful. Such attempts are 
hampered by a lack of understanding of the malignant cell which cannot, 
yet, be successfully defined. Becker (1975) states 'A vast amount of 
information exists that describes what this cell does and how it does what 
it does but the why evades us'. He suggests that, although malignancy 
can be described in comparison to normal cells, only a general description 
can be applied to the malignant cell viz: 'A cell that has lost its sense 
of belonging to a larger community'.
1 .1 CHARACTERISTICS OF THE NORMAL CELL.
Knowledge of the cell cycle has greatly increased understanding of 
cellular reproduction in both normal and malignant cells. The cycle is a 
continuous process in which cells in cycle are in dynamic equilibrium with 
those in prolonged rest and is described as 'the interval between the 
mid-point of mitosis in a cell and the mid-point of subsequent mitosis in 
one or both daughter cells' (Baserga, 1971).
The cycle is described in terms of 4 stages. Following mitosis, cells in
active division (the growth fraction) pass from an initial resting phase 
(G,) into the synthetic (S) phase during which the deoxyribonucleic acid 
(DNA) content is doubled. After a further resting phase, (Gjj.) cells 
undergo mitosis producing 2 identical daughter cells which then enter 
either the active cycle or a prolonged rest phase (Gc). It seems likely 
that most human cells cycle over a period of 14-40 hours (Hancock & 
Bradshaw, 1981). The length of 6, is the most variable although, in 
mammalian cells, this is believed to last between 6-8 hours (Louis, 1978). 
This variability accounts for the difference between fast and slow 
dividing cell populations.
Cell division is normally controlled so that the function of the tissue 
or organ is maintained. Thus, in the adult, cells that die are replaced 
but no additional cells are produced and tissue size remains constant. 
Secondly normal cells are able to differentiate in order to take on the 
specialist function of the particular tissue/organ to which they belong. 
The more highly differentiated, the less likely is the cell to divide.
1 .2 CHARACTERISTICS OF NEOPLASTIC CELLS.
Neoplastic cells differ from normal cells in terms of appearance, 
patterns of growth and function. The extent to which their appearance is 
abnormal depends upon whether the tumour is benign or malignant. A benign 
tumour is one which grows slowly by expansion, remains well localised and 
does not recur after surgical removal; its cells closely resemble those of 
its tissue of origin. A malignant tumour is usually characterised by cells 
bearing little resemblance to those of its tissue of origin and grows by 
invasion of adjacent tissues, becomes fixed to surrounding tissues, 
spreads (metastasises) and often recurs locally after surgical removal. 
There may, however, be wide variation in the degree of differentiation; 
tumours are usually less differentiated and organised than normal tissues 
although de-differentiation is not an inevitable characteristic of
malignancy. In the extreme state there is a complete lack of 
differentiation (anaplasia) and the tumour shows little or no resemblance 
to its parental tissue. In general, the more malignant the tumour, the 
less its degree of differentiation and the worse the prognosis.
In terms of growth, Busch (1974) noted that 'the biological
characteristics of cancer cells would seem to indicate that they are 
specialised for growth and survival under adverse conditions1. It is clear 
that tumour cell replication differs from that of normal cells since the 
rules governing healthy cellular reproduction seem unable to halt or 
restrict their proliferation (Table 1.1). Thus, Robbins and Angell (1976) 
raise the hypothesis that 'the fundamental nature of cancer might be the 
loss of cell control, as a consequence of membrane changes'. Certainly, 
contact inhibition is lost and there is considerable evidence to suggest 
that this is due to membrane changes (Taussig, 1979) since the control of 
normal cell growth depends on cellular interactions which, in turn,
involve the surface membranes of interacting cells. As a result cell 
growth is uncontrolled/unrestrained and the number of tumour cells 
increases. It is the number of cells that appears to account for the high 
mitotic rate observed in tumours rather than an increased rate of
division. However, Prescott and Flexer (1982) have suggested that G f 
arrest is defective so that cell cycle time (Tc) is erratic thus cells may 
increase in number by shortening the length of the cell cycle.
TABLE 1.1, COMPARISON OF THE IMPORTANT FEATURES OF THE CELL CYCLE IN
NORMAL AND MALIGNANT CELLS.
Feature Normal Cells Malignant Cells
Regulation of reproduction Controlled Defective
Transition from G, to S Regulated Poorly/not regulated
Differentiation Normal Abnormal
Life span Die on schedule Do not die on schedule
Based on Prescott & Flexer (1982).
Alternatively, the growth fraction may be increased by a reduction in the 
number of resting cells or a decrease in cell loss so that there is an 
imbalance between tumour cell formation and loss and tumour mass 
increases. However, it is suggested that, as tumour size increases the 
slower its growth (Hancock & Bradshaw, 1981) as the number of resting 
cells increases, although this varies between the different types of 
tumour.
1.3 TUMOUR GROWTH.
Tumour growth is commonly described in terms of its 'doubling time1 
(Td) (ie. the time taken for a tumour to double in size) which is, as 
previously discussed, subject to considerable variation. The Tc of a 
tumour is clearly of marked clinical significance since the slower the 
cycle the longer the period required before the tumour can be identified.
As tumour size increases the doubling time increases [Gompertzian 
growth (Carter et al, 1977)]. Since the human tumour Tc ranges from 40-80 
hours [which is believed to be longer than that of normal tissues 
(Priestman, 1977)] this suggests that the Td should also be in this range. 
However, the Td of human tumours has been found to range between 4 and 500 
days (Priestman, 1977) showing that, since there is a marked discrepancy 
between Tc and Td, other factors must also affect tumour growth. These 
include the decreased vascularity of large tumours; local anoxia may
account for focal necrosis in some solid tumours. Exfoliation may result
in the loss of cells from the tumour surface (eg. gastrointestinal 
tumours) and cells may migrate from the periphery of the tumour into the 
bloodstream or lymphatic system from where they may 'seed' elsewhere
causing metastasis. Alternatively, since tumour growth is abnormal, many
of the cells formed are not viable or are unable to divide. Finally tumour 
cells may be overcome by the host's immune system.
Cancer cells form a heterogeneous population varying not only
morphologically and biochemically but also in terms of its growth pattern. 
Thus tumour growth depends on three main factors - the growth fraction, 
the clonogenic fraction (stem cells) and end (non-clonogenic) cells.
The growth fraction represents those cells which are actively dividing 
and may be very large (>70%) or very small (<10%) (Caiman et al, 1980) 
although this is difficult to estimate with any accuracy. The clonogenic 
fraction represents those cells which although quiescent are capable of 
dividing if given an appropriate stimulus. Thus, if the growth fraction is
reduced by effective . therapy, cells in the clonogenic fraction are
\-
'recruited1 to maintain tumour growth. The remaining fraction, the end 
cells, may be viable although unable to divide; many are already dead. 
Clearly one of the aims of anti-tumour therapy is to increase the number 
of cells in this fraction thus reducing the potential for growth.
Priestman (1977) suggests that this 'cell loss factor' may account for 
50-90% of all cells produced by a tumour. Although this figure appears
high it must be remembered that the cell loss of normal tissues is 100% so
that zero growth occurs. Thus, although studies suggest that tumours
divide at an apparently normal rate, cell loss is reduced and they will 
gradually increase in size. Clearly a tumour with a large growth fraction, 
and with a large reserve of clonogenic cells, is likely to increase in
size more rapidly than one with a low growth fraction and smaller
reserves.
The changes observed in malignant cells are accompanied by changes in 
their biochemical function. Significant abnormalities may occur which 
affect cellular respiration, the levels of enzymes characteristic of 
particular tissues and the type and quantity of cell products. Such 
changes may have marked effects on the host.
Tumours of endocrine origin may secrete hormones resulting in the
clinical syndromes associated with excess hormonal secretion. Others may
secrete hormones (ectopic hormones) which induce similar clinical effects. 
Such hormone secretion can be a useful diagnostic tool, and in assessing 
the response to therapy, they can be used as 'biological markers' of 
tumour activity.
1.4 EFFECTS OF CANCER.
The symptoms of cancer are not necessarily produced by the tumour 
itself but rather by complications such as pressure on, or obstruction of, 
vital organs such that they fail to function. Benign tumours usually 
produce serious effects only when they obstruct an important site or when 
they secrete hormones. Malignant tumours carry additional risks due to 
their ability to expand and infiltrate at their site of origin, their 
ability to metastasise and to the occurrence of remote (para-neoplastic) 
effects.
The local effects of a tumour are primarily determined by its size and 
location and may give rise to anatomical disfigurement, obstruction or an 
increase in pressure causing compression. Taussig (1979) suggests that 
cancers spread along the 'line of least resistance' so that, if a tissue 
is soft, the cells can move more easily (Louis, 1978). Certain tissues, or 
their components, (eg. organ capsules, the periosteum and arterial walls) 
are particularly resistant to invasion. Cartilage and other dense, fibrous 
tissues may also act as barriers to invasion. It is suggested (Caiman, 
1980) that the following mechanisms may account for local invasion:
1. Pressure which 'forces' cells into adjacent tissues
2. Loss of contact inhibition, together with increased amoeboid 
activity, decreased adhesiveness and increased negative surface 
charge (Louis, 1978) may permit malignant cells to propel themselves 
through surrounding tissues.
3. Release of lytic enzymes, such as collagenase, hyaluronidase and 
lysosomal enzymes, when cells divide or die (Taussig, 1979) with the
result that local protective barriers break down and malignant cells 
move rapidly into tissue spaces.
4. Tumour angiogenesis factor may be released by malignant cells thus 
increasing the vasularity of the tumour and contributing not only to 
localised spread but also to metastasis.
Metastasis is often present at the time of diagnosis (Willis, 1972; 
Sugarbaker et al, 1977, Weiss, 1977). Identification and quantification of 
such spread (staging) is a vital part of the diagnostic process. However, 
even before overt metastases have developed, micro-metastases may be 
present and may, in fact, develop even before the primary disease is 
recognised. Metastasis is a poorly understood phenomenon and little is 
known about the factors involved in either the establishment or growth of 
secondary malignant deposits. Nonetheless they are the major feature 
distinguishing between benign and malignant tumours. Whatever the 
mechanism it is clear that malignant cells can invade and spread 
throughout the body via one of several routes:
1. Local spread by direct invasion
2. Spread via the lymphatic system when the regional nodes are involved 
first before spread to other areas
3. Direct spread via the bloodstream when tumour cells may seed at any 
site throughout the body giving rise to secondary tumours
4. Direct spread across a body cavity.
The effects of metastases depend largely on the site at which they are 
deposited. However, malignancy is also associated with a wide range of 
general effects including anaemia, secondary infection, pyrexia and 
cachexia all of which may have marked effects on the host.
Anaemia is common; its development may result from a variety of factors 
including:
1. Bleeding from ulcerated lesions or erosion of blood vessels
2. Infection
3. Metastases affecting bone marrow which may inhibit erythropoiesis
4. Bone marrow depression due to radiotherapy or chemotherapy
Infection may affect the tumour surface, such as in an ulcerated tumour
of the breast, or be associated with specific tumours such as bronchogenic 
carcinoma, which causes bronchial obstruction, or tumours of the bladder, 
which cause urinary obstruction. Tumours of the lympho-reticular system 
are particularly associated with infection due to disturbances of the 
immune system and bone marrow depression, resulting from chemotherapy and 
radiotherapy, means that many cancer patients are particularly vulnerable 
to infection. Infection is the commonest cause of pyrexia although it is 
also an infrequent accompaniment to certain tumours such as Hodgkin's 
disease.
Malignant disease is also associated with many marked biochemical and 
nutritional effects which are, in turn, major contributors to the cachexic 
syndrome. Those relevant to this thesis are discussed in Section 1.6.
1.5 THE TREATMENT OF CANCER.
Some treatments can be prolonged and difficult to tolerate and hold no 
guarantee of success. Other approaches, however, regularly result in cure, 
or prolonged survival, together with a good quality of life. A particular 
cancer can be said to be cured when the survival of a group of patients 
parallels that of a similar 'normal' population not suffering from that 
cancer (Chamberlain, 1985). Achievement of cure is, usually, the aim of 
treatment although affected patients must also be helped to cope with both 
the psychological and symptomatic (physical) problems they face. 
Palliative treatment is provided for those in whom the hope of cure is no 
longer realistic.
Cancer therapy may be local or systemic and falls into 3 main 
categories - surgery, radiotherapy and chemotherapy.
Surgery.
Surgery is the oldest form of treatment and, until recently, was the 
only chance of cure for certain cancers. It is intended primarily for 
localised cure of a primary tumour, or for the removal of solitary 
metastases, but it may also be used to define the extent of spread of the 
disease. Although surgery can be used to provide short-term relief from 
symptoms extensive surgery is generally only carried out when the intent 
is curative. Surgical procedures may precede or follow other methods of 
treatment, such an approach being adopted to improve the chance of cure.
The side-effects may range from minimal scarring to significant changes 
in body image (eg. after a mastectomy) or loss of function (such as that 
following amputation of a limb) and, on occasion, surgical procedures may, 
themselves, pose a threat to life.
Radiotherapy.
Radiotherapy relies on the use of ionising radiation to damage and 
destroy malignant cells. It may be the primary form of treatment or be 
used in conjunction with surgery or chemotherapy or both, with either 
curative or palliative intent. Its use in alleviating painful or 
disruptive manifestations of cancer may significantly improve the quality 
of life.
Two main types of ionising radiation are used to treat cancer: 
electromagnetic radiation (x-rays and gamma rays) and particulate 
radiation (protons, electrons, neutrons, alpha particles, beta particles 
and pions). As a tissue is exposed to radiation a proportion of its energy 
is deposited in the cells causing ionisation. This, in turn, causes the 
production of free radicals within the cell (Pizzarello & Witcofski, 
1975). These highly reactive, although short-lived, substances induce 
physical and chemical changes within the cells altering their structure 
and function through interactions with DNA thus causing faulty
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transcription of genetic information, defective repair, metabolic 
disturbances, accelerated ageing and mutations, all of which may affect 
the ability to divide. The lethal effects of radiation may not be 
apparent until the cell divides, though sometimes five or six divisions 
are required before cell death occurs. Radiation-induced injury is most 
likely to occur during the Gz phase of the cell cycle or during mitosis 
when the amount of DNA present is doubled. This means that all cells have 
an inbuilt radiosensitivity although normal cells can repair partial 
damage whereas cancer cells cannot. Neither normal or malignant cells can 
repair damage affecting both strands of the DNA helix and cell death 
occurs in similar ways in both (Table 1.2).
TABLE 1 .2. MECHANISMS OF CELL DAMAGE/DEATH.
Immediate cell death - due to irreversible damage to DNA; cells die
within 2 hours of exposure. This causes the 
immediate side-effects of radiotherapy.
Delayed cell death - occurs after mutation of DNA. Limited
functions continue until the M phase when 
the cell cannot divide. May occur within 
24 hours or be delayed, depending on 
generation time of affected cells. Causes 
long-term effects of radiation.
'Natural' death - Exposure to radiation can result in formation
of giant (sterile) cells which continue to 
function but cannot divide. These degenerate 
slowly dying a 'natural' death
Generation times vary between different cell types; those which divide 
rapidly are more radiosensitive than those dividing slowly. Thus, the 
greater the number of cells in active replication, the greater the 
cytotoxic effect. This, together with the fact that poorly differentiated 
and immature cells are particularly radiosensitive, is used to good effect 
when the tumour lethal dose is calculated. Sensitivity also depends on the
11
presence of oxygen; killing hypoxic cells requires a dose of radiation two 
to three times higher than that needed to achieve the same effect in well 
oxygenated cells. Thus, it is common to deliver the total dose in daily 
fractions so that, as each fraction is delivered, tumour shrinkage occurs 
and previously hypoxic cells are brought closer to the blood supply 
enhancing the effects of successive treatments. Fractionation also reduces 
acute radiation exposure which is likely if the total dose is delivered in 
a single treatment. As normal cells have a greater capacity for repair, 
and can achieve this more rapidly and effectively, fractionation also 
helps reduce damage to normal tissues which is also reduced by careful 
control of the size of the treatment field to include only the tumour and 
the smallest possible amount of normal tissue.
The severity and duration of tissue responses can be described in terms 
of three categories although the effects are, to some extent, dependent on 
the tissue involved.
Acute side-effects occur during, or shortly after, treatment due to 
immediate responses to radiation. Primarily related to the total dose and 
degree of fractionation, they are often increased in areas of rapid 
cellular turnover such as the skin, GI tract and bone marrow. Such effects 
generally subside once treatment ceases.
Subacute side-effects occur weeks or months after treatment making it 
difficult for the patient to accept their relationship to previous 
therapy. They may be difficult to differentiate from disease progression 
and relate to the total therapeutic dose, particularly in tissues with a 
slow rate of cell turnover (eg. epithelial tissues) when damage may not 
occur for months (Pizzarello & Witcofski, 1975).
Late/chronic responses. Related to the total therapeutic dose received 
by particularly radiosensitive tissues, these may arise between 1 and 5 
years (or longer) after exposure. Cellular changes may not be seen for
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considerable periods due to slow cellular proliferation but include tissue 
necrosis, fistula formation and dense fibrosis which may be related to 
previous acute or subacute effects (Bloomer & Heilman, 1975).
Carcinogenesis is another potential complication which is not seen for 
many years after exposure.
The risk of damage to normal tissues means that treatment is carefully 
planned so that the treatment field includes only the tumour and an
adequate safety margin to achieve the desired effect; treatment is 
optimally effective when there is maximum exposure of the tumour and 
minimal exposure of adjacent and underlying tissues (Kramer, 1976). Yet, 
despite the many precautions, some degree of damage to normal tissues is 
inevitable although this occurs only when that tissue is included in the 
treatment field. Thus some side-effects are to be anticipated in all 
patients undergoing radiotherapy.
Chemotherapy.
The use of drugs to treat cancer is the most recent form of treatment 
being developed after the second world war when nitrogen mustard was shown 
to be effective in the treatment of lymphomas. Since surgery and radio­
therapy have reached a plateau in their ability to cure most kinds of
cancer and are, in any case, only of value in the treatment of localised
disease, there has been a continuing search for other drugs which will be 
equally effective in causing tumour regression (McElwain, 1985). The 
advantage of chemotherapy is its ability to destroy malignant cells 
throughout the body so that it can be used as an adjunct to both surgery 
and radiotherapy as well as the primary form of treatment. However, such 
drugs are not only toxic to malignant cells but also to normal body 
tissues; this lack of selectivity is the cause of many of the side-effects 
resulting from this form of treatment.
Drugs used in chemotherapy (Table 1.3) generally interfere with
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TABLE 1.3. CLASSIFICATION OF CHEMOTHERAPEUTIC DRUGS.
ALKYLATING Highly reactive compounds which cause cross-linking
AGENTS and abnormal base pairing of DNA so that transcription
and replication cannot occur. Synthesis of DNA, and 
other cellular components, continues leading to 
cellular imbalance and, eventually, cell death. 
Generally cell cycle phase non specific. Example: 
Cyclophosphamide.
ANTIMETABOLITES Structural analogues of metabolites normally used by 
cells during replication. Act by competing with, or 
substituting for, metabolites or by binding to them in 
such a way that dysfunction results. Generally cell 
cycle phase specific, the exception being 5-Fluoro- 
uracil. Examples: cytosine arabinoside, methotrexate.
Derived from various strains of soil fungi these drugs 
are used to inhibit synthesis of both DNA and RNA 
although they do have some anti-infective properties. 
Generally cell cycle phase non-specific.
Examples: Adriamycin, Bleomycin.
Derived from the periwinkle (vinca rosea) these are 
believed to act by binding the microtubular proteins 
necessary to cell division. Effect is cumulative so 
that, once high concentrations are reached, protein 
synthesis is inhibited. Examples: Vincristine and
Vinblastine.
Used to decrease tumour growth by decreasing the 
growth fraction. Several theories have been put 
forward to explain their action in cancer treatment 
Some tumours appear dependent on certain hormones; 
antagonistic steroids can alter the environment and 
inhibit growth. Hormone receptors can be 'blocked' to 
deprive cells of a growth stimulant. Oestrogens, anti- 
oestrogens, androgens and progestogens have all been 
used.
A wide variety of drugs may be employed all of which 
exhibit cytotoxic effects. Examples: Cisplatin,
Procarbazine.
cellular function or replication causing cell death (cytotoxicity). Many 
cytotoxic agents act at specific phases of the cell cycle (such as DNA 
synthesis or mitosis) and, therefore, have activity only against cells 
which are actively dividing. These are regarded as cell cycle specific and 
do not adversely affect other phases of the cycle. Other drugs, cell cycle
ANTITUMOUR
ANTIBIOTICS
PLANT
ALKALOIDS
HORMONES
MISCELLANEOUS
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non-specific agents, destroy the cell by interupting or destroying 
functions not limited to a specific phase of the cycle. Cells in the 
resting phase may be particularly resistant to chemotherapy due to their 
lack of activity and their ability to repair damage while resting. Resting 
cells may later begin cycling, replacing killed cells.
Those cancers which are most vulnerable to anti-neoplastic agents are 
those with a high growth fraction. However, although it is believed that 
cancer cells possess certain characteristics which render them vulnerable 
to such agents (van Eys et al, 1977), these drugs do not discriminate 
between normal and cancer cells so that normal cells which proliferate 
rapidly are often subject to damage. It is this toxicity which may limit 
their use. The most dramatic effects are seen on the bone marrow, GI tract 
and hair follicles although toxicity may also affect the kidneys, liver 
and cardiovascular system. Neurotoxicity can also be a serious sequel of 
chemotherapy, particularly with the vinca alkaloids (Calabresi & Parks, 
1980). Pulmonary and dermatological reactions may also be seen.
1.6 BIOCHEMICAL/NUTRITIONAL EFFECTS OF MALIGNANCY.
Protein energy malnutrition (PEM) affects some 40% of all patients 
hospitalised for the treatment of cancer (Landel et al, 1985) and is 
associated with a poor prognosis, a reduced response to anti-neoplastic 
therapy and prolonged/enhanced morbidity of therapeutic side-effects, 
and a reduced quality of life (Harvey et al, 1979; DeWys, 1980). Its time 
of onset varies and PEM may occur at different stages of the disease. It 
is not correlated with food intake, the stage, histological type or site 
of the tumour, the duration of disease or the presence/absence of 
metastases nor is it always associated with a large tumour burden; in fact 
PEM may occur with a small primary tumour even preceding diagnosis (DeWys, 
1980). Shils (1977) reported that 45% of newly hospitalised adult cancer 
patients had lost at least 10% of their body weight and 25% had lost 20%
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or more. Such weight loss is accompanied by a marked reduction in both 
body fat and muscle mass.
This condition is well recognised and, in its most severe form, is 
known as 'cancer cachexia1, a syndrome characterised by emaciation, 
debilitation and inanition associated with anorexia, early satiety, 
anaemia and marked asthenia together with profound disturbances of host 
metabolism including disturbances of carbohydrate (Lundholm et al, 1978; 
Lundholm et al, 1982), protein (Stein et al, 1978; Norton et al, 1981) and 
fat (Mider, 1951; Begg & Lotz, 1956; Begg & Lotz, 1957) metabolism. Such 
effects are believed responsible for many of the observed nutritional 
problems of the cancer-bearing host particularly when weight loss occurs 
even when food intake is apparently adequate. It has been argued 
(Theologides, 1974) that weight loss can largely be attributed to anorexia 
and the consequent reduction in food intake such that cancer patients fail 
to compensate for any increase in energy requirements by increasing their 
food intake. Yet, some patients fail either to gain weight, or maintain 
their current weight, despite an energy intake in excess of 3-4,000 
kcal/day (Heber et al, 1985). Thus, in the absence of any coexistent 
endocrine disorder or sepsis, it appears that cancer per se induces 
profound nutritional problems placing great emphasis on the metabolic 
changes induced by malignancy.
It has also been suggested (Theologides, 1979) that at least some 
tumours produce active metabolites and/or peptides which interact with 
both host and tumour tissues inducing metabolic derangements and releasing 
peptides and/or amino acids for use by tumour tissues (Holroyde et al,
1975). Recent evidence, however, suggests such changes may be mediated by 
the immune system (Beutler & Cerami, 1986) and, in particular, by 
cachectin, a polypeptide released by macrophages, since this has been 
implicated in the causation of both shock (Beutler et al, 1985) and the
cachexia of chronic disease (Kawakami & Cerami, 1981). Cachectin, when 
administered to animals, induces a state of weight loss, anorexia and an 
unkempt, apathetic appearance (Beutler & Cerami, 1986) features which are 
characteristic of human cachexia. It, therefore, seems that cachectin­
induced catabolic effects may account for at least some of the physical 
wasting accompanying malignant disease (Torti et al, 1985; Pekala et al, 
1983). It may be that cachectin 'orchestrates' the complex metabolic 
changes contributing to cachexia (Beutler & Cerami, 1986). In general, 
however, cachexia appears to be of a multifactorial aetiology in which the 
factors act synergistically to produce the complex clinical picture 
(Caiman, 1982); the relative importance of each factor is subject to 
considerable individual variation (Beutler & Cerami, 1986).
Inadequate Food Intake.
Food intake may be affected by many factors including any, or all, of 
the following: anorexia, early satiety, taste aberration, food aversion, 
methods of treatment and psychological/emotional responses. The anatomic 
location of a tumour may affect the ability to ingest, digest or absorb 
nutrients via the GI tract and it has been suggested that malignancy 
anywhere in the body may be associated with secondary changes in the small 
intestine leading to malabsorption (Creamer, 1964; Wangel & Deller, 1966) 
Certainly, protein-losing enteropathy has been shown to follow secondary 
disorders of the GI lymphatic channels or ulceration of a region of the 
mucosa (Erlich et al, 1968; Waldman et al, 1974) although it is far from 
clear whether such changes are the cause or the effect of cachexia (Barry, 
1974). GI efficiency is severely reduced by malnutrition (Viteri & 
Schneider, 1974) when mucosal changes are associated with a reduction in 
the brush border and a decline in intestinal enzyme activity (Becciolini 
et al, 1973). A decrease in GI motility and an overgrowth of facultative 
and anaerobic bacteria within the gut (Viteri & Schneider, 1974) may also
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contribute to malabsorption.
The severity of anorexia is variable and its onset may go unnoticed by 
the patient (Wesdorp et al, 1983). Its aetiology has yet to be elucidated 
although it too is believed to be of multifactorial origin. Suggested 
contributory factors include:
1. Production of toxic factor(s) or hormone(s) which interact with one,
or more, of the mechanisms involved in the control of feeding
behaviour (Theologides, 1976)
2. Abnormalities of hypothalamic control of feeding behaviour (eg. 
Morrison, 1973)
3. Psychological and emotional responses to disease/treatment (eg.
Holland et al, 1977)
4. Metabolic abnormalities of uncertain origin
5. Effects related to methods of treatment (eg. Donaldson & Lenon,
1979).
Theologides (1976) suggested that 1toxohormones1, released from/by 
tumours, exert peripheral or direct effects on neuroreceptor or 
neuroendocrine cells, or on the hypothalamus and other sensors within the 
central nervous system thus disrupting feeding behaviour. This hypothesis 
has received some support (McAllister et al, 1976; Caiman et al, 1977) 
yet, despite the isolation of cachectin, others (Heber et al, 1985) 
suggest that no such anorexigenic peptides have yet been identified. 
Another approach suggests that tumour metabolites may disrupt the 
regulation of those compounds believed responsible for the regulation of 
nutritional homeostasis (eg. the catecholamines and serotonin) 
(Wurtmann, 1979).
The control of 'normal' feeding behaviour is complex and subject to a 
variety of internal and external influences despite which body weight 
remains remarkably constant. This suggests some form of physiological
control and raises the question of whether this mechanism fails in the 
presence of malignancy. One such mechanism is generally regarded as the 
central site of both organisation and integration of feeding behaviour. 
It has been suggested that the hypothalamus and other related centres play 
a central role in the genesis of both hunger and satiety operating a 
reciprocal excitation or inhibition system (Theologides, 1978). The 
proposition that spurious signals, generated by the tumour, are 
interpreted centrally as indicators of satiety before true satiety signals 
have been generated (Leibelt et al, 1971; Theologides, 1974) has, 
therefore, received some support. Yet, neither damage to the ventromedial 
nuclei, which characteristically causes hyperphagia (Leibelt et al, 1971; 
Baillie et al, 1965) nor damage to the lateral nuclei, which causes 
anorexia (Lyttle, 1977), with subsequent recovery, can prevent anorexia or 
cachexia. This suggests that depression of food intake is mediated 
extra-hypothalamically (Morrison, 1976) and is consistent with previous 
findings (Lehr & Goldman, 1973; Kruk, 1976) suggesting that increased 
serotonin is associated with a decreased food intake whilst a decreased
turnover results in hyperphagia (Briesch et al, 1976; Sailer & Strieker,
1976)
Studies of plasma and cerebral amino acid patterns, together with 
central serotonin (5-HT) metabolism (Krause et al, 1979a; Krause et al, 
1979b) have shown that, in malignancy, brain tryptophan levels fall 
as 5-HT rises correlating closely with the onset of anorexia. It appears 
that tumour-induced changes result in a fall in plasma albumin in 
conjunction with an elevation of plasma free fatty acids (FFA). As
tryptophan is the only amino acid which is bound by serum albumin, and as
FFA compete for the same binding site, plasma free tryptophan rises. This, 
in turn, leads to an increased cerebral tryptophan concentration causing 
an increased synthesis of 5-HT. When this is considered together with
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serotonergic mechanisms of satiety (eg. Lehr & Goldman, 1973; Kruk, 1976) 
it can be suggested that anorexia is mediated by serotonin although 
subsequent studies (Von Meyendfeldt et al, 1980) have shown that
inhibition of serotonin synthesis can postpone but NOT eliminate anorexia; 
others have failed to reproduce previous findings (Chance et al, 1983; 
Leathwood et al, 1986). Thus, although serotonergic mechanisms may play a 
contributory role, other mechanisms must also be involved in the
pathogenesis of anorexia.
Although it seems that metabolic factors are important the contribution 
of behavioural and symptomatic factors must not be overlooked. Clearly, 
emotional responses to the diagnosis can adversely affect appetite and 
there are periods during the course of the disease when the patient is 
particularly vulnerable to emotional distress. Before the diagnosis is 
confirmed, patients are subject to considerable stress; confirmation 
promotes further emotional trauma and a weight loss of 5-10 lbs during 
this period is not unusual being related primarily to psychological or 
emotional factors rather than to the disease process itself (Holland et 
al, 1977). Previous beliefs and attitudes towards cancer and its 
treatment (Schmale, 1979), combined with continued fear of recurrence, 
appearance of a new symptom (whether or not this is disease related) and 
anxiety regarding methods of treatment are all important contributors to 
anorexia. Thus, as an emotional response, anorexia may be experienced 
throughout the course of the disease.
Depression may accompany continued disease progression and could be 
regarded as a psychological basis for anorexia. Anti-depressive therapy 
would, therefore, be expected to reduce its incidence. However, it has 
been noted that anorexia is unresponsive to tricyclic drug therapy 
(Wesdorp et al, 1983) and Plumb et al (1976) have shown that, although 
physical symptoms are common complaints, the incidence of the non-physical
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symptoms of depression (eg. feelings of worthlessness, low self esteem, 
pessimism, guilt and suicidal tendencies) is not significant. This 
suggests that depression is not a significant factor in the pathogenesis 
of anorexia and that symptoms suggestive of depression reflect the 
physical rather than the psychological condition (Holland et al, 1977). 
Physical symptoms, such as pain, nausea and vomiting, may also influence 
food intake; control of such symptoms is essential if nutritional status 
is to be maintained.
Taste Aberration.
Both appetite changes and anorexia may be attributable to taste 
aberration which, together with anosmia, may blunt the normal excitatory 
stimuli associated with food intake (DeWys, 1979). Such aberrations 
largely concern alterations in bitter and sweet thresholds (Caiman, 1982; 
DeWys & Walters, 1975) although there is no consistent pattern. The cause 
of taste changes is not clear though evidence suggests they improve in 
patients showing an objective response to treatment (DeWys, 1978). 
Evidence also suggests a correlation with trace mineral deficiencies
(Hambidge et al, 1972) although this remains to be confirmed in cancer
patients.
Damage to the intestinal mucosa may, as previously discussed, cause 
significant losses of zinc (Wolman et al, 1979); rapid tissue breakdown, 
such as that induced by chemotherapy or radiotherapy, will increase
excretion. Zinc deficiency has been associated with hypoguesia and 
dysguesia. This mechanism may, therefore, be responsible, at least in 
part, for the taste aberrations associated with cancer (Schwartz, 1975).
Taste changes, together with an association between symptoms and 
disease or treatment, may contribute to food aversion (Leathwood et al, 
1986; Bernstein & Bernstein, 1981) which is not uncommon in the cancer 
patient. Learned aversion is regarded as a variant of classical
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conditioning when a conditioned stimulus (eg. taste) becomes associated 
with an unconditioned response (eg. discomfort) (Bolles, 1975). Animal 
studies (Garcia et al,1974; Leathwood et al, 1986) have shown that just 
one pairing of a food with GI discomfort due to radiotherapy is sufficient 
to promote continued avoidance of that food. Repeated pairings of food 
with discomfort may cause aversion to even the most familiar foods. This 
may persist long after symptoms have subsided (Theologides, 1978; 
Bernstein & Bernstein, 1981) and may be significant in the genesis of 
anorexia in patients treated for cancer (Bernstein & Bernstein, 1981).
1.7 METABOLIC ABNORMALITIES.
Changes in Energy Expenditure.
Many of the metabolic changes resulting from malignancy are manifest 
by alterations of energy expenditure. Although there is considerable 
variation, many workers have demonstrated increased energy expenditure in 
the tumour-bearing host (eg. Warnold et al, 1978). Following tumour 
transplantation in rats spontaneous motor activity declines (Morrison, 
1973) yet oxygen consumption is increased (Bramante et al, 1963) 
suggesting the initiation of an unexplained process which increases energy 
requirements (Mider et al, 1951). Two hypotheses have been considered 
(Fenninger & Mider, 1952). Firstly, the metabolic activity of malignant 
tissue is continuous, in contrast to the diurnal periodicity of normal 
tissues, thus imposing a greater energy demand. However, the metabolic 
activity of tumour cells is low when compared to that of the host (Kleiber 
& Chernikoff, 1956). Secondly, alterations in pathways of intermediary 
metabolism could result in a selective removal of nutrients by the tumour 
thus forcing the host to use more energy-expensive pathways. For example, 
animal studies (Fenninger & Mider, 1952), have suggested that a tumour may 
act as a 'nitrogen trap', sequestering host proteins in a competition for 
nutrients. However, hyperalimentation does not decrease energy expenditure
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although both the nutrient supply and the metabolic pool are augmented.
This could be explained by the demonstrated increase in whole body 
glucose production (Heber et al, 1985; Holroyde et al, 1975) which has 
been accounted for by an increase in Cori cycle activity, particularly in 
metastatic disease (Holroyde et al, 1975). This energy-wasting process 
circumvents aerobic glycolysis consuming energy resulting in a net energy 
loss. It has, however, been estimated that this increased activity is 
unlikely to have significant effects on daily energy expenditure (Young, 
1977).
Disturbances of glucose metabolism are common and have been reported 
variously as impaired glucose tolerance (Marks & Bishop, 1957; Carter et 
al, 1975), decreased insulin sensitivity (Bishop & Marks, 1959; Lundholm 
et al, 1978), decreased insulin release in response to a glucose load 
(Marks & Bishop, 1957; Lundholm et al, 1977) and decreased activity of 
energy-producing enzymes in skeletal muscle (Lundholm et al, 1977). Since 
fasting plasma alanine levels are significantly decreased, it is suggested 
that an increased alanine flux for gluconeogenesis reflects a basic 
metabolic abnormality which could be explained on the basis of insulin 
resistance (Heber et al, 1985).
Alternatively, Lundholm et al (1982) suggest differences in the 
intermediary metabolism of glucose in non-tumour involved host tissues, 
(such as skeletal muscle) such that glucose turnover is increased. It is 
suggested that this primarily comprises increased Cori Cycle activity 
(80%) but also increased glucose oxidation (15%) which has been calculated 
to explain 30-40% of the increased oxygen consumption in the cachectic 
patient (Warnold et al, 1978; Lundholm et al, 1982).
Clearly these effects, whatever their cause, lead to inappropriately 
high oxygen consumption and negative energy balance and may explain, at 
least in part, the progressive weight loss accompanying some forms of
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malignancy. However, research to date is equivocal; not all tumours are 
associated with an elevated metabolic rate so that this is not the only 
factor contributing to nutritional depletion. However, the patient with 
an elevated metabolic rate, who is also anorectic, is at considerable risk 
of malnutrition (Shils, 1986). Such individuals cannot be easily 
identified and, until the mechanism(s) underlying these effects is 
elucidated, it will prove difficult to promote anabolism in affected
individuals.
Protein Metabolism.
Although tumour cells have been shown to have a high capacity for 
concentrating amino acids, the difficulties associated with the precise 
control of nutrient intake in man, and the use of radio-isotopes in
patients with malignant disease, have meant that many aspects of protein 
metabolism have been studied in animals making direct extrapolation of 
information gained difficult. However, although the studies of Fenninger 
and Mider (1952) were carried out in a limited number of neoplasms, they 
have led to the concept of 'nitrogen trapping1. Subsequent evidence 
suggests this concept may indeed apply to some forms of cancer in
experimental animals but it is questionable whether it applies in human
cancers as the ratio of tumour size to body size in man is much lower than 
in experimental animals (Heber et al, 1985). It has been suggested that 
progressive weight loss, abnormal gluconeogenesis and lactate recycling 
may result from an imbalance of essential amino acids due to selective 
uptake of amino acids by tumour cells (Stein, 1978).
Administration of radio-labelled amino acids initially results in 
marked labelling of normal tissues but, as normal protein turnover 
occurs, tumour tissue displays significantly higher specific activity. It 
has been shown (Busch et al, 1961) that tumour tissues take up 
radio-labelled proteins to a greater extent than non-neoplastic tissues,
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suggesting that they have a selective advantage in extracting whole 
proteins, such as albumin, from the circulation. It is, therefore, 
suggested that such changes in amino acid metabolism prevent an effective 
decrease in gluconeogenesis. It is also possible that malignancy alters 
the regulatory mechanisms of normal tissue. For example, Sidransky and 
Verney (1979) have shown that the livers of hepatoma-bearing rats fail to 
respond to nutritional stressors, such as a protein-free diet, in the same 
way as those of non tumour-bearing animals.
Malnourished cancer patients have been reported to differ from 
malnourished, but non cancer-bearing, individuals by increasing both
protein synthesis and protein turnover (Jeevanandam et al, 1975) thus 
demonstrating that, even in the presence of cachexia, there is a failure 
of adaptation since the tumour fails to recognise normal control 
mechanisms maintaining its activity despite host starvation (Brennan,
1977). The reasons for this failure have not yet been elucidated.
Albumin Metabolism.
Both the synthesis and catabolism of albumin are affected by many 
factors including nutritional status, physiological stress, osmotic
pressure, hormones and disease status (Rothschild et al, 1977). The 
exogenous supply of amino acids is particularly important since even 
short-term deprivation will markedly decrease albumin synthesis.
Hypoalbuminaemia is common in malignancy and, when this is associated 
with cachexia, both synthesis and catabolism of albumin are reduced (Picou 
& Waterlow, 1962). The causes of such hypoalbuminaemia have not been 
established and the results of studies to date are equivocal. It has been 
suggested that it results from reduced synthesis, possibly associated with 
a low catabolic rate (Steinfield, 1960; Waldmann et al, 1964; Costa & 
Bernbeck, 1966; Mariani et al, 1976) whilst others (eg. Rossing, 1968) 
have reported increased catabolism. Albumin metabolism has been studied in
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patients with lesions of the GI tract, with an associated reduction in 
food intake, and compared with that of malnourished patients with anorexia 
secondary to widely disseminated malignancy (Raines et al, 1982). The 
results obtained from those with GI lesions correlated closely with those 
of patients suffering PEM displaying a low to normal fractional catabolic 
rate (FCR) and a normal to high fractional synthetic rate (FSR). The 
malnourished patients, however, displayed normal to high FSR and a
markedly increased FCR. It is, therefore, suggested that an elevated FCR 
may correlate with a poor prognosis unless the tumour is responsive to 
anti-neoplastic therapy. However, it is to be expected that the response 
to such therapy will be reduced by hypoalbuminaemia as albumin functions 
in the binding of many substances within the circulation including many of 
the cancer chemotherapeutic agents. Furthermore, the apparent 
inevitability of hypoalbuminaemia clearly means that this cannot be used 
as an index of nutritional status in these patients (Moore et al, 1982). 
Changes in Fat Metabolism.
It is generally agreed that the loss of fat accounts for most of the 
weight loss seen in cancer patients (Warnold et al, 1978; Watson & 
Sammon, 1980) and studies have shown that, as a tumour grows, carcass fat 
(exclusive of that present in the tumour) declines to less than 10% of its 
normal value in a number of tumour systems (McEwan, 1955; LePage & 
Henderson, 1960; Begg, 1978). Yet, even in the presence of anorexia, 
this fat loss cannot be exclusively attributed to inadequate food intake 
since pair-fed controls carry considerably more fat and force feeding does 
not prevent the loss (Stewart & Begg, 1953a; Stewart & Begg, 1953b).
Hyperlipidaemia has been noted in tumour-bearing animals (Mider et al, 
1951) and is not accompanied by either ketosis or ketonuria. This 
suggests that fat lost to the body during tumour growth is completely 
oxidised and, as energy expenditure is greater in tumour-bearing animals,
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it is possible that fat is mobilised to meet the increased demand for 
energy particularly as the energy value of the 'lost' lipid could, 
quantitatively, meet this need (Mider et al, 1951; Begg & Lotz, 1956; Begg 
& Lotz, 1957). However, it is worth noting that, although some tumours 
studied in vitro have demonstrated a preference for fatty acids as an 
energy substrate (Weinhouse, 1961), in vivo studies show a slower 
tumour growth when the majority of calories in a total parenteral feeding 
regime are given as fat (Buzby et al, 1980). Thus it seems unlikely that 
a tumour will elaborate lipid mobilising substances (Liebelt et al, 1971) 
since this may restrict its growth. However, fat-mobilising peptides have 
been isolated from the urine of both fasted animals and humans (Weil & 
Stetten, 1947; Chalmers et al, 1981) and in those with widespread 
malignant disease even when food intake is 'normal1. Peptides with lipid 
mobilising activity have been isolated in pituitary (Rudman et al, 1970; 
Lee & Lichton, 1973) and hypothalamic (Redding & Schally, 1970) extracts, 
and lipolytic activity has been reported in extracts from other parts of 
the brain. Such peptides could account for the hyperlipidaemia of 
malignant disease although studies suggesting a relationship between the 
rise in plasma FFA and tumour activity (Mueller & Watkin, 1961) have not 
been confirmed (Holroyde et al 1975; Schein et al, 1975). Although, in 
controls, FFA oxidation can be reduced by administration of glucose this 
is reduced to a lesser extent in malignancy indicating failure of normal 
homeostatic mechanisms which could be the result of insulin resistance 
(Stein et al, 1976).
These effects again confirm that malignancy results in alterations of 
normal control mechanisms. Evidence for the role of lipid-mobilising 
substances in the genesis of hyperlipidaemia is equivocal since this may 
restrict growth in some tumours. It may be that the degree and extent of 
hyperlipidaemia is dependent on the type of tumour. Nonetheless, the loss
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of body fat, combined with the inappropriate oxygen consumption and loss 
of lean body mass can only contribute to a state of negative energy 
balance and continuing weight loss.
Micro (Trace) Nutrients and Malignancy.
Table 1.4 shows that patients with cancer are likely to suffer some 
degree of vitamin deficiency which may significantly affect their 
continuing resistance to disease and determine the response to treatment.
TABLE 1.4. VITAMIN ABNORMALITIES IN CANCER PATIENTS.
% affected
Abnormal Leucocyte Ascorbic Acid 71
Anaemia 49
Thiamine 37
Abnormal Folic Acid 23
Vitamin A 15
Carotene 15
Abnormal Vitamin Bl2 0
Based on Caiman (1978)
Although much of the depletion can be attributed to inadequate intake it 
may, in some cases, be exacerbated by abnormal losses through the 
alimentary and renal tracts (Shils, 1977). The mechanisms through which 
such deficiencies arise remains unresolved (Soukop & Caiman, 1979) 
although they may result from administration of anti-neoplastic drugs 
(Dickerson, 1985).
The growing awareness of the importance of trace elements has also led 
to increased interest in their role in disease, particularly in 
malignancy. It is clear that trace metals are fundamental to many 
biological processes which may be disrupted by impaired intake, increased 
utilisation and/or increased excretion. The cancer patient may be subject 
to any, or all, of these effects so that trace element deficiency may 
contribute to many of the metabolic alterations noted in the presence of
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malignancy through effects as yet unidentified; this area may be worthy of 
investigation particularly since, to date, the role of trace metals in 
carcinogenesis has received more attention than their metabolism in the 
cancer-bearing host.
Fluid and Electrolyte Disturbances.
Cancer patients often present with systemic symptoms the severity of 
which may bear no relationship to the site or extent of the tumour. Fluid 
and electrolyte disturbances are common and, in patients with advanced 
disease, both intra- and extra-cellular water are increased (Craig & 
Waterhouse, 1957). Such fluid retention can mask a loss of body tissue so 
that, as disease progresses, measurement of body weight declines in value 
as a means of assessing nutritional status.
Hyponatraemia is the most frequent electrolyte abnormality and is 
usually of multifactorial origin although both fluid retention and 
increased urinary sodium losses have been attributed to an inappropriate 
secretion of vasopressin seen particularly in conjunction with oat cell 
carcinoma of the bronchus (Kleeman, 1970).
Hypercalcaemia is also common and, in hospitalised patients, is most 
commonly due to malignant disease (Coombes et al, 1976). Its cause is 
uncertain although it has been suggested that, in those with bone 
metastases, hypercalcaemia is due to the release of calcium following 
bone destruction (Coombes et al, 1976). However, hypercalcaemia can occur 
even when there is no direct bone involvement, when removal of the tumour 
may result in the return of serum calcium to within the normal range. 
Such effects are most common in squamous cell carcinomas of the head, neck 
or bronchus or in renal cancers (Coombes, 1982), thus suggesting a role 
for a circulating mediator, such as parathyroid hormone (PTH), although 
circulating PTH is elevated in only about 10% of hypercalcaemic cancer 
patients (Coombes, 1982). Nonetheless, the hypercalcaemia resembles that
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associated with primary hyperparathyroidism since there is enhanced bone 
resorption, often accompanied by a reduced renal phosphate threshold and 
increased renal tubular calcium reabsorption (Anon, 1987).
Other electrolyte abnormalities, together with disturbances of
acid-base balance, may result both from complications of the disease or 
its treatment (Blackburn et al, 1979; O'Regan et al, 1979). Weight loss 
and accelerated catabolism may result in urinary losses of sodium and 
potassium although serum levels remain within the normal range.
The preceding discussion shows that most tumours result in significant 
nutritional and biochemical disturbances. These may appear early in the 
course of the disease or later as the tumour grows and metastasises 
resulting in changes which act synergistically to create 'chaos' in host 
metabolism (Theologides, 1972). Although the mechanisms through which 
such changes arise are not yet understood, it is clear that cancer 
cachexia may have a significant impact on the patient's ability to 
withstand the effects that both the disease and its treatment may have on 
his nutritional status and quality of life.
However, our incomplete understanding means that it is not yet possible 
to prevent the development of cachexia except by control of the primary 
disease by effective anti-neoplastic therapy. There are, however, 
secondary factors which may exacerbate the decline in nutritional status; 
these include side-effects and complications of treatment.
1.8 NUTRITION AND CANCER THERAPY.
Cancer treatment can impose significant nutritional disabilities due to 
factors which limit food intake, cause malabsorption or result in 
metabolic changes which, in turn, increase nutritional requirements. Such 
effects may be transient or permanent; they assume particular importance 
when viewed in the context of the many other factors which may interact to 
put the patient at nutritional risk.
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Surgery.
Although surgery is followed by many physiological and biochemical 
disturbances they are generally short-lived and result in no long-term 
nutritional disability unless surgery is extensive, complicated or super­
imposed on the nutritional consequences of cancer per se. However, as 
surgery is the treatment of choice for most tumours lying within the GI 
tract, it is not surprising that many such tumours, and their treatment, 
have a major impact on nutritional status. The extent of the nutritional 
disability depends upon the site of the tumour and the extent of 
resection (Table 1.5).
TABLE 1.5. POSSIBLE NUTRITIONAL EFFECTS OF GASTROINTESTINAL SURGERY.
Oropharyngeal Resection
Oesophagectomy 
Oesophageal reconstruction
Gastric resection 
(Partial/total)
Small intestine: Duodenum 
Jejunum 
Ileum
Massive resection
Colon
Pancreatectomy
Chewing/swallowing difficulties 
Prolonged dependence on tube feeding
Gastric stasis 0 Secondary to
HypochlorhydriaJ vagotomy
Fat malabsorption - steatorrhoea 
Diarrhoea
Dumping syndrome 
Ma1absorpt ion
Achlorhydria - Pernicious anaemia 
(lack of intrinsic factor)
Iron deficiency
Pancreatobiliary deficiency
Decreased efficiency of absorption
Bile salt malabsorption
Pernicious anaemia (B,z malabsorption)
Hyperoxaluria
Severe malabsorption
Malnutrition
Metabolic acidosis
Fluid and electrolyte imbalance
Pancreatic exocrine insufficiency 
Diabetes mellitus
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Chemotherapy.
Drugs used to treat cancer exert profound cytotoxic effects and, since 
they cannot discriminate between normal and cancer cells, may have marked 
effects on previously healthy 'normal1 tissues. It is this lack of 
selectivity which causes many of the toxic effects associated with such 
treatment and which contributes to host malnutrition through a variety of 
direct and indirect mechanisms. They may also cause symptoms such 
as nausea and vomiting, mucositis/stomatitis, organ injury and learned 
food aversions. In addition, many drugs affect intestinal function, the 
degree being dependent on the dose and duration of treatment, the rate of 
drug metabolism and individual susceptibility. The current tendency to 
administer cyclic chemotherapy in multiple combinations, whilst offering 
an increased opportunity for cure, can increase both the range and 
severity of side-effects. As most chemotherapeutic agents adversely 
affect the dietary intake (Donaldson, 1977), there may be prolonged or 
recurrent periods during which food intake is impaired leading to weight 
loss and progressive debility.
Many drugs cause nausea and vomiting which can have a significant 
impact on affected individuals causing anorexia and a decline in 
voluntary oral intake as well as fluid and electrolyte imbalance, general 
weakness, fatigue and weight loss.
The general mucosal toxicity may lead to diarrhoea associated with 
severe abdominal pain and, in severe cases, mucosal ulceration, proctitis, 
haemorrhage and/or intestinal perforation. However, since the renewal 
rate of the GI epithelium is rapid, these effects are generally 
short-lived. However, if high dose therapy is employed, prolonged 
dehydration, electrolyte imbalance, inanition and accelerated malnutrition 
may result due not only to diarrhoea per se but also to malabsorption.
Alternatively, constipation may accompany therapy when this includes
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the vinca alkaloids, causing pain and adynamic ileus through effects on 
the autonomic nervous system (Holland et al, 1973; Weiss et al, 1974; 
Rosenthal & Kaufman, 1975).
The indirect effects of chemotherapy may also be important in the 
decline of nutritional status. For example, moniliasis or candidiasis are 
common, particularly in patients with leukaemia and lymphoma, causing a 
sore, painful mouth, dysphagia and a dramatic decline in oral intake. 
Learned food aversions may result when there is an apparant association 
between specific foods and GI discomfort; it has been estimated that 43% 
of patients receiving GI toxic chemotherapy develop such aversions 
(Bernstein & Bernstein, 1981). These are most likely to develop against 
novel foods (Revusky & Bedarf, 1967) although repeated associations 
between GI discomfort and specific foods can cause aversion to even 
familiar foods. Such effects may be prolonged and continue long after 
symptoms have subsided and may have significant implications for the 
nutritional support of affected patients indicating the need for flexible 
feeding regimes and the availability of a variety of flavours and 
textures.
Radiation Therapy.
Although radiotherapy per se may result in a generalised syndrome of 
fatigue, malaise and anorexia (radiation syndrome) it is its effects on 
the intestinal tract (Table 1.6) which are of the greatest significance in 
terms of its nutritional consequences.
Since the intestinal mucosa is second only to the bone marrow in its 
sensitivity to radiation, curative doses of irradiation, particularly when 
directed at any part of the GI tract, can result in severe nutritional 
deficiencies in a small, but significant, number of patients when 
intestinal toxicity may prove a limiting factor to intensive 
treatment. Like chemotherapy, radiation is unable to discriminate between
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TABLE 1.6. SEQUELAE OF RADIATION THERAPY: NUTRITIONAL IMPLICATIONS.
TREATMENT AREA DURING TREATMENT POST TREATMENT
Oropharyngeal Region Loss of taste Altered taste
Xerostomia Xerostomia
Damage to teeth Poor dentition
Stomatitis/mucositis Mandibular necrosis
Lower Neck/Mediastinum Oesophagitis
Dysphagia
Ulceration
Fibrosis
Oesophageal stricture
Stenosis/stricture
Abdomen/Pelvis Acute bowel damage 
(enteritis)
Chronic bowel damage
Diarrhoea Diarrhoea
Malabsorption Malabsorption
(Based on Yasko, 1982)
normal and cancer cells and it is the effects on normal cells (ie. the 
side-effects) of treatment which are responsible for the resultant 
symptomatology. Their severity is dependent on the dose, time and
fractionation of the total dose as well as the area of the treatment
field.
Acute or chronic effects may arise during, immediately following or 
many years after radiotherapy and include changes in the vasculoconnective 
tissue which result in changes in the small blood vessels, destruction of 
the endothelium and degeneration of the muscle. Affected tissues are 
fibrotic and poorly vascularised so that they are less resistant to 
mechanical injury and infection and, after irradiation, even minor 
trauma, or infection, may induce serious complications in an already 
compromised tissue.
Flattening and/or ulceration of the mucosal epithelium, telangiectasis, 
arteritis, fibrosis, stenosis or fistulae may arise and patients
undergoing abdo-pelvic irradiation may experience nausea, vomiting, severe
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diarrhoea and abdominal cramps (Douglass & Leonard, 1972). Alternatively, 
they may develop partial or complete intestinal obstruction. On occasions, 
these symptoms fail to respond to conventional treatment although they may 
clear spontaneously after 4-5 days (Mennie et al, 1975).
Although such symptoms must be accepted, at least to some extent, if 
adequate treatment is to be administered to a tumour lying in or near 
the GI tract, they are both distressing and debilitating and can result 
in malabsorption and malnutrition as the patient ingests less food and is 
less able to digest and absorb those nutrients available. This makes 
nutritional support an obligatory adjunct to radiotherapy both to prevent 
deterioration of nutritional status and to allow compensatory hyperplasia 
of the undamaged bowel for which an adequate nutrient intake is essential 
(Stein, 1978).
It is clear that, as malignancy progresses, an affected individual is 
subject to many anatomical, physiological, biochemical and pharmacological 
effects which may result from the disease or its treatment. These may 
interact to affect both his nutritional status and his quality of life.
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CHAPTER 2.
QUALITY OF LIFE IN CANCER: INTERACTIONS WITH NUTRITIONAL STATUS.
Although individuals respond to the diagnosis of cancer in different 
ways there is little doubt that suffering from a disease such as cancer 
introduces a number of difficulties for affected individuals (Young & 
Longman, 1983) who face many adjustments not only to the diagnosis but 
also to the physical symptoms associated with both the disease and its 
treatment (McCorkle, 1983). At the same time systematic observation has 
shown that cancer patients may experience a wide range of emotional and 
psychological reactions (Goldberg & Cullen, 1985) such as anxiety, 
depression, sexual difficulties and changes in body image (Maguire, 1985) 
all of which may be associated with anger, guilt, helplessness and lowered 
self-esteem. Yet the patients' notes rarely reveal the difficulties of 
living with either the diagnosis or its treatment (Schneider, 1978) 
although both are subject to considerable individual variation and may 
interact significantly to affect the quality of the patient's life. For 
too long we have emphasised the survival rates associated with particular 
types of the disease and/or its treatment, only rarely do we comment on 
the quality of that survival. For example, a survey by Bardelli and 
Saracci (1978) showed QL was a measured end-point in fewer than 4% of the 
clinical trials undertaken during 1956-76. However, Jones et al (1987) 
found more than 200 papers referring to studies carried out between 
1978-80.
Yet concern over the quality of life (QL) is, clearly, an appropriate 
outcome for evaluating the impact of cancer nursing care since this can 
be seen to reflect the caring aspects of nursing (Arcand, 1985; Padilla & 
Grant, 1985). Nursing care involves consideration of the whole patient 
and, in oncology, necessitates not only helping the patient to adjust to 
changes in body image, function and appearance but also helping him to
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cope with the many physical effects associated with his disease and the
possible side-effects of his treatment, whilst coming to terms with his
diagnosis. Such effects, combined with the psychosocial consequences of 
cancer, may necessitate many alterations in life-style so that focussing 
on the patient's adaptation to such changes can help him to live life as 
normally as possible (ie. to maintain his quality of life). It has been
suggested that the quality of the patient's life depends not only on his 
personal strength but also on the ability of the nurse to help him to 
adjust to the necessary changes (Padilla & Grant, 1985). This emphasises 
the crucial role of the nurse involved in the care of the cancer patient 
although it must be recognised that it is not always possible to separate 
the impact of nursing interventions from those made by other health care 
professionals. However, the nurses' continued and prolonged contact with 
the patients, and her role as patient advocate, put her in the ideal 
position to liase between members of the health care team to design 
appropriate care and interventions designed to maintain QL. This does, 
however, pose difficulties since, before we can help the patient to
achieve the highest possible quality of life,it is necessary to define 
those qualities which make both life and survival valuable (Bayles, 1980) 
even in the face of a chronic, debilitating or potentially fatal disease, 
such as cancer. Furthermore, if the effects of nursing interventions are 
to be evaluated, it is essential that a means of measuring the quality of 
life is identified. This, in turn, depends upon a satisfactory definition 
of the quality of life.
2.1 DEFINING THE QUALITY OF LIFE.
According to Campbell (1977) the term 'Quality of Life' first entered 
the vocabulary after the second world war when it was used to emphasise 
the fact that the 'good life' depended on more than material affluence 
although, even today, identification of other contributory factors is
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difficult and complicated by the fact that individuals value different 
things. Nonetheless the term 'Quality of life', and various synonyms, is 
widely used throughout the psychological, sociological and medical 
sciences although definition remains elusive. However, most people have an 
intuitive understanding of quality of life and, as a result, it means 
different things to different people so that any definition is highly 
subjective and is likely to change as life circumstances change. Thus, 
although maintaining QL is a desirable objective in health care, this can 
be difficult to achieve and may be complicated by the carer's own bias and 
emotions which may affect their interpretation of the patient's problems. 
This means that any attempt at definition must be based on objective 
criteria although these can be difficult to identify.
Despite these difficulties attempts at definition have been made and 
the literature now reports many methods of assessment although the concept 
is seldom specified and definitions have tended to lack precise meaning. 
Since QL is 'a term everyone understands but few can define' and is 'a 
vague and ethereal entity, something that many people talk about but which 
nobody very clearly knows what to do about' (Campbell, 1977) it is not 
surprising that the concept is particularly difficult to frame and to 
analyse or that this is reflected in the literature.
For example, Shin and Johnson (1978) suggested that QL consists of the 
'the possession of resources necessary to the satisfaction of individual 
needs, wants and desires, participation in activities enabling personal 
development and self-actualisation and satisfactory comparison between 
oneself and others'. La Mendola and Pelligrini (1979), however, suggested 
that QL depends upon 'individual achievement of a satisfactory social 
situation within the limits of perceived physical capacity' although this 
makes no allowance for comparison with past or future satisfaction and, 
like other workers (Karnofsky et al, 1948; Zubrod et al, 1960), links QL
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to physical performance; surely life's quality is not determined only by 
physical ability?
Others have approached this differently describing QL as 'the degree to 
which an individual succeeds in accomplishing his desires' (Gerson, 1976), 
'the extent to which a person's hopes and ambitions are matched/fulfilled 
by experience' (Downie & Caiman, 1987) or 'the degree of need 
satisfaction' (Hornquist, 1982). Such descriptions represent a narrowing 
of the gap between hope and reality implying that QL involves many 
dimensions thus lending credence to the more global approaches to 
definition.
For example, Patterson (1975) identified those areas which he believed 
to be the major contributors to QL and which he deemed essential to any 
evaluation of QL. These included general health, performance status, 
physical comfort, emotional status and economic status. This was further 
developed by Hornquist (1982) who suggested that structural and material 
factors should also be considered (eg. political participation, justice 
and contact with authority together with support, housing and other 
material goods).
Campbell (1977), on the other hand, proposed that QL be identified with 
measures of happiness, a term he used as a synonym for satisfaction or 
freedom from stress. However, it is clear that, like QL, happiness is 
difficult to define so that no-one knows exactly what it is or how it can 
be achieved (Shin & Johnson, 1978). It can be viewed 'simply' as a 
hedonistic concept (Bradburn, 1969), as a measure of satisfaction (von 
Wright, 1963) or as an appraisal of the overall quality of experience 
(Beneditt, 1974) the latter being consistent with the suggestion that the 
quality of life depends on the experience of life itself (Campbell, 1977). 
This takes into account all aspects of the general condition and allows 
for individual circumstances. Austen (1968) claimed that happiness
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represents the highest assessment of the total condition and Brenner 
(1975) that it be viewed as a global assessment of QL rather than equated 
solely with affective feelings. It therefore appears that the terms 
'happiness' and 'quality of life' may be used inter-changeably to describe 
the overall quality of individual experience.
Even then we have not reached a definition. It has, however, become 
clear that QL is a highly subjective and individual concept which 
represents individual responses to the physical, mental, social and 
psychological factors contributing to 'normal' daily living. These, in 
turn, influence the degree to which satisfaction with life circumstances 
can be achieved and the extent to which favourable comparison with others, 
according to the selected criteria, is possible. In other words, it
represents a highly individual evaluation of the present situation. This 
highlights the fact that QL cannot be regarded as a fixed set of 
circumstances but rather as a variable (dynamic) phenomenon consisting of 
changing values which vary in importance according to individual 
circumstances (Slevin, 1984). So that, although the quality of life of
patients with cancer depends on the same factors that influence it in
healthy individuals they must, at the same time, cope with the
psychosocial stress and physical symptoms caused by the disease and its 
treatment. Thus any attempts at assessment must identify those factors 
or traits which are most affected by the presence of malignant disease so 
that their effects on the individual can be identified. Without such an
approach it will prove impossible to help the patient to come to terms
with the imposed changes (Luce & Dawson, 1975) and the difficulties he 
must face, or to help him to maintain a satisfactory quality of life.
The conceptual framework used in this study, and, therefore, the
definition reached is as follows: Quality of life is recognised as a
dynamic concept; it is an abstract and complex term representing
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individual responses to the physical, mental and social factors which 
contribute to 'normal' daily living.
2.2 EFFECTS OF THE DISEASE AND TREATMENT ON THE QUALITY OF LIFE.
The diagnosis of cancer holds considerable fear such that the newly 
diagnosed are faced with many threatening possibilities including 
disabling illness, mutilative surgery, loss of a body part, deteriorating
physical function and death (Mastrovito, 1972) so that it is not
surprising that Cohen (1982) views malignancy as a 'massive assault on the 
physical and psychological integrity' of the affected individual. Cancer 
continues to denote many terrifying connotations of being untreatable,
incurable and fatal yet, today, cancer can often be regarded as a chronic
disease since sufferers can live for many years after diagnosis (Kaplan, 
1983). Thus affected individuals must often meet a new set of demands 
which have previously been outside their sphere of knowledge, skills and 
experience (McCorkle, 1983) not only in terms of its physical effects but 
also with regard to its psychosocial impact which may affect not only the 
patient but also his family and 'significant others'. Cancer is rarely 
experienced in isolation since the patient is, usually, part of a family 
unit which acts as his 'first line of defence' and represents the context 
in which the illness occurs (Welch, 1981). Thus its impact on the family 
unit may be significant altering roles and changing the usual patterns of 
activity to cope with the patient's illness or to enable him to meet the 
demands of treatment regimes. Since the patient may be reliant on members 
of his family for much of his care and support the stress of cancer may 
have significant effects on family relationships and, in turn, on QL.
Patients with progressive disease may suffer physical effects which may 
affect QL directly or indirectly through their interactions with other 
factors such as social dependence, ability to work or self-esteem. 
However, the effects on QL will be subject to considerable individual
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variation not least because, as has been shown, QL is unique to the 
individual.
Initial responses to the diagnosis, together with those associated 
with disease progression, may be compounded by reactions to the treatment 
employed whether this be surgery, chemotherapy, radiotherapy or a 
combination of them all. The effect any treatment has on QL is determined 
largely by the balance of its beneficial effects against its toxicity. 
Slevin (1984) suggests that the significance of side-effects may be 
greater in those patients who were previously asymptomatic and Harvey et 
al (1977) found definite improvement in the QL of patients with severe 
symptoms, even if treatment had severe side- effects, since those symptoms 
associated with the disease were reduced by treatment.
Nonetheless, responses to treatment are highly variable and may have 
significant effects on QL. For example, patients who have undergone 
surgery for ano-rectal tumours, with formation of a colostomy, often 
display marked psychiatric morbidity which profoundly influences sexual 
and social behaviour (Devlin et al, 1971). Similarly, amputation of a limb 
(Parkes & Napier, 1970), surgery to the head and neck (Rosillo et al, 
1973) and gynaecological surgery (Lamont et al, 1978) have been shown to 
have deleterious psychological and social effects which, since they are 
important components of life, may, in turn, significantly affect its 
quality.
Cytotoxic therapy has also been associated with adverse effects in part 
due to its toxicity and, in part, due to the cognitive impairments which 
have been associated with a wide variety of chemotherapeutic agents 
(Silberfarb et al, 1980). High levels of depression and anxiety have been 
found in patients undergoing radiotherapy (Peck, 1972; Mitchell & 
Glicksman, 1977; Peck & Boland, 1977; Forester et al, 1978) such that Lyon 
(1977) has reported that 51% of all patients suffer depression and 13%
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display suicidal tendencies. Such effects are common because such 
therapy acts as a forceful reminder of the disease (Feder, 1966).
Combination therapy has been found to be a particularly potent cause of 
both psychiatric and social disturbances (Maguire, 1976) which may be 
exacerbated by the presence of persistent physical symptoms whether or not 
they are treatment-related (Worden & Weisman, 1977; Woods & Earp, 1978). 
There is little doubt that these effects may significantly affect the 
quality of the patient's life so that affected patients require not only 
physical care but also considerable psychological and emotional support.
It is now clear that the effects of cancer and its treatment can 
significantly influence QL. It is for this reason that measurement is 
increasingly attempted.
2.3 INTERACTIONS BETWEEN NUTRITION AND THE QUALITY OF LIFE.
Patients with cancer may share many similar nutritional problems 
regardless of the site of their primary disease and protein energy 
malnutrition (PEM) is, as previously shown, a common secondary diagnosis. 
The presence and/or severity of such problems cannot be attributed to any 
single cause; the disease, treatment and complications of that treatment 
may all contribute to its development.
Whilst malignant disease per se may affect the patient's well-being 
the continuing weight loss and physical wasting associated with 
malnutrition, combined with its clinical effects (Table 2.1), may also 
have profound emotional and psychological effects thus significantly 
TABLE 2.1 THE CLINICAL EFFECTS OF MALNUTRITION.
Weight loss - depletion of body fat and protein
Skin breakdown
Impaired wound healing
Decreased immunocompetence
Increased toxicity of drugs
General debility, weakness, malaise
Apathy, depression, lethargy
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decreasing the quality of life. However, malnutrition itself, whatever 
its cause, is also associated with a poor prognosis, a reduced response to 
therapy and prolonged or enhanced morbidity of therapeutic side-effects 
all of which may, themselves, decrease the quality of life (DeWys, 1980; 
Harvey et al, 1979).
It has been suggested that much of this decrease results from a 
clinical depression and, whilst psychiatric effects have been demonstrated 
(Maguire, 1985), anti-depressant therapy is not always effective in 
relieving such depression. Plumb et al (1975), using the Beck Depression 
Inventory, found that although physical symptoms of depression (eg. 
anorexia, weight loss, insomnia and fatigue) were common complaints the 
incidence of the non-physical symptoms of depression (eg. feelings of 
worthlessness, loss of self-esteem, pessimism and suicidal tendencies) was 
not significant. This could suggest that, as anorexia is associated with 
the physical rather than the non-physical symptoms of depression, and, as 
it is a major contributor to malnutrition, this contributes to feelings of 
depression as well as apathy and malaise. Thus malnutrition may compound 
the already present psychological damage as well as increasing the 
liklihood of undesirable physical effects such as decreased 
immunocompetence, tissue breakdown and increased drug toxicity.
A decrease in immunocompetence is an important functional consequence 
of PEM and may exacerbate that due to the treatment employed. PEM is the 
most common cause of acquired immuno-deficiency (Bistrian et al, 1975) and 
the risk of infection is great in the malnourished individual (Chandra, 
1983). Indeed, depression of cell mediated immunity is associated with an 
increase in both morbidity and mortality (Scrimshaw et al, 1968) due to 
secondary, opportunistic infection. When these effects are added to those 
of cancer itself, and those of its treatment, it is possible to suggest 
that they are closely related to the decline in the quality of life.
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2.4 APPROACHES TO MEASUREMENT OF THE QUALITY OF LIFE.
Since quality of life is difficult to define how is it possible to 
measure it either objectively or quantitatively? Which dimensions should 
be included in attempts to assess the impact of disease or therapy on the 
patient's life?
There is a growing body of literature concerning QL measurement
although there is considerable variation in the approaches selected,
perhaps reflecting the difficulties of definition. In general, two 
extremes have been adopted and reflect the problems to be overcome. For 
example, should an assessment tool (instrument) be focussed on a single 
area or all-embracing (global) giving an overall sense of individual
well-being? The latter tend to be comprehensive but may fail to identify 
areas of particular concern and require considerable concentration so that 
interviewees find difficulties in its completion. Alternatively, a 
focussed approach may limit its value by failing to assess a dominant 
symptom/concern which may exert a significant impact on QL thus failing to 
assess effectively the impact of disease or treatment on the patient's 
whole life (Selby, 1985).
In general the methods of assessment used have been developed for the 
evaluation of specific problems in other patient groups; a smaller number 
have been developed specifically for use with cancer patients. The former 
have included the Sickness Impact Profile (Bergner et al, 1981), the 
Activities of Daily Living Scale (Katz & Akpom, 1976), the Present State 
Examination (Wing et al, 1978) and the Psychosocial Adjustment to Illness 
Scale (Morrow et al, 1978).
Examples of Approaches to Measurement in Cancer Patients.
If QL has been measured in clinical trials the Karnofsky (Karnofsky et 
al, 1948) and Zubrod (Zubrod et al, 1960) scales are the most commonly 
used, both of which are completed by the physician. The Karnofsky
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TABLE 2.2. THE KARNOFSKY PERFORMANCE INDEX.
Definition %
Able to carry on normal 100
activity and to work. No 
special care is needed. 90
80
Unable to work. Able to 70
live at home, care for 
most personal needs. A 
varying amount of 60 
assistance is needed.
50
Unable to care for self. 40
Requires the equivalent 
of institutional or 30 
hospital care. Disease 
may be progressing 
rapidly. 20
10
Criteria
Normal; no complaints; no evidence 
of disease
Able to carry on normal activity; 
minor signs or symptoms of disease 
Normal activity with effort; 
some signs of symptoms of disease 
Cares for self. Unable to carry on 
normal activity or to do normal 
work
Requires occasional assistance but 
is able to care for most of his 
needs
Requires considerable assistance 
and frequent medical care. 
Disabled; requires special care 
and assistance.
Severely disabled; hospitalisation 
is indicated although death not 
imminent
Very sick; hospitalisation is 
necessary; active supportive 
treatment necessary 
Moribund; fatal processes 
progressing rapidly
Performance Scale (KPS) evaluates physical performance on a scale of 
0-100 (Table 2.2). The Zubrod index represents a variation of the KPS and, 
more recently, Priestman (1984) has modified it further relying on a scale 
of 1-10. Neither appears to be any more effective in assessing QL in part 
because the KPS, although a useful measure of health performance status, 
is not a satisfactory estimation of QL (Clark & Fallowfield, 1986) and, in 
part, because it is unreliable (Hutchinson et al, 1979; Yates et al,
1980).
Spitzer's (1981) assessment tool was designed specifically for use in 
cancer research and has content validity since it was evaluated by 
patients, their relatives and members of the health care team; reliability 
was high. However, like the KPS, it relies on ratings made by an observer, 
again the physician. It includes 5 items - activity, living, health,
support and outlook on life - which are rated on a 3-point scale (0-2) 
giving a maximum score of 10 but, like most scales, it has some 
limitations. Chief amongst these is the criticism that it gives equal 
weighting to all the items; this is probably unrealistic. However, 
although this is a valid criticism, it may represent an insoluble 
methodological problem (Clark & Fallowfield, 1986) since a weighting 
system would require the ability to judge the relative importance of 
factors included and would be difficult to achieve, particularly when 
ratings are made by an observer (Priestman & Baum, 1976; Abdellah & 
Levine, 1986) since the relative importance of items will vary with the 
individual concerned.
More recently tools have been developed which rely on linear analogue 
scales, designed for self-assessment, and have been used to evaluate QL in 
a variety of cancer patient populations including those with breast cancer 
(Priestman & Baum, 1976; Selby et al, 1984) and other, ill-defined 
'convenience' samples (Padilla et al, 1981). Again each has failed to 
define the construct under consideration and included different domains. 
Moreover, each index was of a different length making comparison between 
results impossible. Yet, in each case, the method is reported to be 
simple, sensitive and reproducible. The technique employed (ie. a linear 
(visual) analogue scale) relies on lines the length of which is taken to 
denote the continuum of the subjective experience. The line is usually 
10cm long and the ends are labelled with words/phrases descriptive of the 
experience being measured.
This brief discussion has highlighted the difficulties associated with 
assessment of QL many of which are due to the lack of a universally 
accepted definition which, in turn, has led to problems with regard to the 
selection of the content of measurement instruments. At the same time 
there is considerable confusion regarding the objectivity/subjectivity of
such measures. For example, some workers regard objective measures to be 
those rated by anyone other than the patient whereas Campbell (1981) 
suggest that objective indicators simply describe those factors which 
influence the experience of life (such as income, level of education, 
return to work or length of survival); subjective indicators are, they 
suggest, those which measure that experience directly and which can only 
be obtained from the individual concerned.
Another area must also be considered when discussing the merits of any 
measurement instrument, that of the reliability and validity of the 
measures employed, since for an instrument to be useful it must be both 
reliable and valid. It is, however, clear that not all authors have 
considered this aspect thus casting doubt on their findings (eg. Burge et 
al, 1975; Vera, 1981; Meyerowitz et al, 1983). Others have introduced a 
greater degree of psychometric evaluation (eg. Priestman & Baum, 1976; 
Padilla et al, 1981; Selby et al, 1984) including, with respect to 
reliability, assessment of internal consistency and test-retest 
reliability. However, since it has already been shown that QL is dynamic, 
the test-retest method appears to be an inappropriate index with which to 
assess reliability.
Validity of an instrument is dependent in the extent to which it 
measures what it is intended to measure (Table 2.3) although, when 
referring to QL, this cannot be easily established since it is difficult 
to validate the depth of subjective feelings. Furthermore, there are no 
accepted criteria against which to validate empirical data as there is no 
universally accepted method of measurement. Content validity is 
established by showing that the items included are representative of the 
universe in which the investigator is interested (Cronbach & Meehl, 1955) 
although, in many cases, content is assessed from the literature, which 
constitutes 'expert' opinion; only rarely are the views of the subjects
TABLE 2.3. CATEGORIES OF VALIDITY.
Type of Validity Definition
Face Validity Extent to which an instrument appears to be a
logical and reasonable measure of what it is 
supposed to measure.
Also known as pragmatic validity.
Content Validity Extent to which an instrument adequately
encompasses the pertinent range of subject 
matter, ie. assesses the comprehensiveness 
and content of the measure.
Construct Validity Extent to which the measure is consistent
with or reflects, the underlying theory, 
ie. reflects whether the measure is 
consistent with the purpose to which it 
is addressed and the theoretical framework on 
which it is based.
(ie. the patients) considered. Construct validity implies the embedding of 
the construct in a theory (De Haes & van Knippenberg, 1984) ; this is 
difficult in the case of quality of life studies when the concept under 
investigation cannot, yet, be adequately defined.
Such methodological problems have further complicated an already 
complex area. Apart from the difficulties in selecting the content of a 
measurement instrument most of the scales discussed have been tested in 
very small samples and selection criteria have often been omitted. The 
emphasis on attempts to ensure objectivity has meant that, in many cases, 
the patient's feelings have been either ignored or considered to be too 
subjective for reliable assessment (Priestman & Baum, 1976). This largely 
ignores the subjective nature of the quality of life and, in the case of 
the cancer patient, ignores those factors which are most affected by the 
presence of malignant disease so that their effects on the individual 
cannot be identified (Luce & Dawson, 1975).
It is clear that the 'perfect' test with which to evaluate quality of 
life has yet to be developed.
2.5 ASSESSMENT OF NUTRITIONAL STATUS.
Since it is the intention of this study to investigate the relationship
between QL and nutritional status it is necessary to review methods of
nutritional assessment.
Nutritional status represents the degree to which an individual's need 
for nutrients is being met by his nutrient intake, ie. the state of 
balance between the intake, expenditure and need. Assessment of 
nutritional status is the first stage in the treatment of malnutrition 
(Blackburn et al, 1977). It is, however, a developing art and, to date, 
methods of assessment are imperfect, particularly in the clinical setting 
where complex assessment may be both impractical and expensive whilst 
practical and relatively inexpensive tests may be non-specific or 
inaccurate. Nonetheless, since nutritional assessment can identify those 
patients 'at risk', and provide guidelines for nutritional support 
(Blackburn et al, 1977; Baker et al, 1982), and, since many cancer
patients are malnourished, some means of assessment must be found.
However, although many assessment techniques are available the 
facilities and background knowledge of nurses is such that their use, by 
nurses, is limited. Thus, for the purpose of this study, only those
techniques which can be both adopted and interpreted by nurses in the 
clinical setting are discussed in detail. This approach also has 
advantages for the patient since the techniques employed are non-invasive.
2.5.1 Methods of Assessment.
A thorough evaluation of nutritional status relies on many different 
areas of study as no single clinical or laboratory parameter will 
determine nutritional abnormalities (Blackburn et al, 1977).
A. Assessment of Food Intake.
An estimate of food intake, designed to provide information on the 
intake of nutrients, is often believed to play a role in assessing
nutritional status although, it has been suggested (Durnin & Fidanza, 
1985), this is of only limited value as it indicates only current eating 
habits and may have little relevance to previous patterns of food 
consumption. Similarly, the importance of short term data, combined with 
inter- and intra-individual variations make it difficult to conclude that 
a low intake represents a change from normal in any given individual. 
However, in the cancer patient, in whom there is, clearly, a significant 
risk of malnutrition, a low food intake may be of clinical importance.
Accurate recording and evaluation of individual food consumption is 
both difficult and frustrating as it is difficult to record dietary intake 
without influencing it. Several methods may be employed in attempts to 
achieve this.
i) 24 Hour Recall is the most popular, and the simplest, method of 
gaining an overview of the food intake. The subject may be asked to 
complete a questionnaire, or be interviewed, and asked to recall all food 
and drink consumed during the preceding 24hrs. It has been used to good 
effect in population studies but is of less value in individual assessment 
when it is known to be associated with several significant sources of 
error. For example, the subject may fail to recall accurately the amount 
of food eaten, the previous day's intake may be atypical or the patient 
may not be telling the truth. There is also a tendency to underestimate 
portion size as this increases and to overestimate as portion size 
decreases (Young, 1953; Stunkard & Waxman, 1981).
ii) Food Frequency Questionnaires may be used to overcome some of 
these difficulties and provide data which indicates how many times per 
day, week or month the subject eats particular foods and so may be 
specific, providing information about nutrients suspected of being 
deficient/excessive in the diet, or general concerning all foods likely to 
be eaten. Such information can validate that provided by 24hr recall and
clarify food consumption.
iii) A Food Diary (Record) is more complete than either of the above 
but relies on considerable motivation, understanding and interest from the 
subject since its success depends on his willingness to record everything 
he eats/drinks over a given time period. Three days, including one weekend 
day, is sufficient for most studies but the period required depends on the 
individual concerned and whether or not he has a regular eating pattern. A 
regular pattern necessitates a shorter recording period than one which is 
random or haphazard. This techniques permits estimation of the average 
daily consumption of particular foods and, if the quantity of that food is 
also recorded, permits nutrient consumption to be established.
iv) Dietary History. This is more complete than any of the methods 
previously described. It can provide information about patterns of food 
intake prior to illness and identify changes in either type or quantity of 
food consumed since its onset. Of particular importance is the presence of 
symptoms which may affect consumption or absorption of nutrients (eg. 
anorexia, nausea, diarrhoea). Chronic disease, or the use of long-term 
drug therapy, may both significantly affect nutritional status.
v) Observation of Food Intake is the most accurate means of assessing 
food consumption but is also the most difficult and time-consuming. A 
weighed dietary record can reduce errors due to memory lapses and 
inadequate estimation of portion size but the respondent burden is high 
and problems with compliance may arise. If measured by members of the 
caring team it is a time-intensive and intrusive procedure, particularly 
when accurately weighed intakes are required since the amount and kind of 
food presented, and a record of the plate waste, is required. Ideally 
observation is unobtrusive and involves no delay in service as this 
affects aesthetic appeal and may adversely affect consumption. However, 
such observation provides only an approximation of intake which, although
suitable for some studies, gives rise to 'guesstimates’ of the actual 
nutrient intake. Nonetheless weighed intake studies introduce the 
possibility of behavioural bias. The reason for the study must be 
carefully considered before either of these methods is selected.
B. Evaluation of Dietary Data.
Whichever method is selected the nutrient intake can be calculated 
using standard tables of food composition (eg. Paul & Southgate, 1978) and 
compared with the UK recommended daily intakes (DHSS, 1979) which permit 
identification of gross deficiencies. However, care must be taken in 
making comparisons with such standards since they are derived from 
population studies and an individual whose intake falls above or below the 
recommendation is not, of necessity, nutritionally 'at risk'. Furthermore, 
such recommendations refer to the 'normal' healthy population making no 
allowance for the demands of illness. It is, in any case, not possible to 
judge nutritional status from dietary data alone. Moreover, since, for 
most nutrients, the intra-subject variation in intake usually exceeds the 
inter-subject variation (Beaton et al, 1983; Gibson et al, 1985) the 
average intake of a group can be assessed with greater precision than that 
of an individual. Thus dietary data can be valuable in estimating the 
nutrient intake of a group or population although its precision as an 
assessment tool is a function of the variability of nutrient intakes once 
any measurement error has been taken into account. Such error is largely 
determined by the extent of both inter- and intra-subject variation and, 
since duplicate observations are not possible, can be difficult to 
estimate. In general, variation is greater for those nutrients which,' 
although found in high concentrations, are present in only a few foods 
(eg. vitamins A & D) and lower for nutrients, such as protein and 
carbohydrate, which are widely distributed (Liu et al, 1978; Beaton et al, 
1979; Gibson et al, 1985).
2.5.2 Clinical Examination.
This includes a complete physical examination, a medical history and 
careful observation. Since advanced cases of malnutrition are obvious on 
physical examination this should permit detection of overt under- or 
over-nutrition as varying degrees of nutritional deficiency can be 
identified by general appearance. This may indicate the need for further 
evaluation. However, many of the signs of deficiency are non-specific and 
may, in any case, be indistinguishable from the signs of systemic disease 
(Woods et al, 1981) or the side-effects of cancer therapy so that clinical 
signs suggestive of nutritional deficiency must be confirmed by dietary or 
biochemical data.
2.5.3 Anthropometry.
The main components of body mass are fat and the fat free mass [lean 
body mass (LBM)] which consists of skeletal muscle (40-50%), non-skeletal 
muscle, soft, lean tissues (40-50%), and the skeleton. Anthropometric 
techniques provide the means with which these components can be assessed 
since variations in their amount and proportion can be used as indices of 
nutritional status. They are non-invasive, readily and quickly applied 
and, compared to laboratory techniques, require the minimum of equipment. 
They can, therefore, be easily used in the clinical setting to identify 
those patients who may be over- or under-nourished, to identify those who 
are vulnerable to nutritional depletion and/or to evaluate the
effectiveness of nutritional intervention.
a) Body Weight provides a rough estimate of body energy stores 
since, under normal circumstances, daily weight varies less than + 0.5kg 
(Garrow, 1974). Positive energy balance results in weight gain, negative 
balance promotes weight loss (Sukhatme & Margen, 1982). However, although 
body weight is the single most important component of anthropometric
evaluation it is open to distortion for a variety of reasons. For example,
since weight is the sum of fat, protein, water and bone mineral mass, 
changes in any one component may invalidate body weight as an index of 
nutritional status. Thus pathological factors, such as obesity, oedema, 
ascites, organomegaly and tumour growth, can distort weight for height 
estimations.
The weightiheight ratio is often used as an index of nutritional 
status, it can, however, give misleading information if used to determine 
whether or not an individual is at some 'desirable' or 'ideal' body weight 
(Durnin & Fidanza, 1985) since the concept of 'ideal body weight' is 
seldom scientifically determined and is derived from life assurance 
tables, such as those of the Metropolitan Life Assurance Company (1979). 
Although such tables have the benefit of relating height and weight to 
mortality they also have several drawbacks (Knight, 1984) since the 
information they contain is derived from a restricted sample of applicants 
for life insurance policies. They are also related to frame size in an 
attempt to allow for the bone component although the categories (small, 
medium and large) are not specified or clearly defined in terms of 
anthropometric measurements and it is difficult to ensure any consistency 
between measurers in judgement of frame size.
Quetelet's index (W/H2, ) (Body Mass Index) has been used as an 
alternative means of classifying body weight. Whilst such indices are, 
perhaps adequate for use in population surveys, their validity in 
classifying the individual is questionable (Durnin & Fidanza, 1985).
b) Assessment of Body Fat. Fat is the most variable of the body 
constituents even among individuals of the same sex, height and weight 
(McKay et al, 1981). In general, the fat content of the female exceeds 
that of the male representing 26.9% of the total body weight compared to 
only 14.7% in males (Gibson, 1988). It is deposited in two major storage 
sites. Essential lipids, found in the bone marrow, central nervous system,
breasts and other organs, are required for normal physiological function. 
Storage fat, the amount of which is relatively constant, averages 12% of 
the total body weight in males and 15% in females and consists of inter- 
and intra-muscular fat, fat surrounding the organs and GI tract and the 
subcutaneous fat (Lohman, 1981). Approximately one third of the total body 
fat is located subcutaneously (Allen et al, 1956).
Total body fat (TBF) can be assessed by measurement of one or more 
skinfold thicknesses (Table 2.4) either alone or in conjunction with limb 
circumference measurements. This can provide an estimate of the 
subcutaneous fat depots which, since empirical equations exist relating 
skinfold thickness to TBF, can, in turn, provide an estimate of TBF 
(Durnin & Rahaman, 1967; Durnin & Womersley, 1974). Measurement is made 
using precision skinfold calipers designed to exert a constant, defined 
pressure of 10g/mm throughout the range of measured skinfolds; the contact 
surface area is 20-4Omm .
TABLE 2.4. SKINFOLD SITES IN COMMON USE.
Triceps Measured at the mid-point of the posterior
aspect of the upper arm
Biceps Measured at the mid-point of the anterior
aspect of the upper arm
Subscapular Measured just below, and laterally to, the 
angle of the shoulder blade with the shoulder 
and arm relaxed
Suprailiac Measured approximately 1cm above, and 2cm medial 
to the anterior superior iliac spine (iliac 
crest in the mid-axillary line
Compressibility of skinfolds varies with age (Brozek & Kinzey, 1960), 
sex (Lee & Ng, 1965) and anatomic site (Himes et al, 1979) as well as 
under normal physiological conditions such as changes in hydration status
(Hass & Flegal, 1981) and compositional changes due to under- or 
over-nutrition. In general, the relative amounts of water and protein 
increase as fat decreases in those individuals with very little fat 
(Grande & Keys, 1980). Thus a 90% decrease in skinfold thickness does not, 
of necessity, indicate a 90% fat loss; it may, in fact, indicate a greater 
loss (Wright & Heymsfield, 1984). However, since skin is included in the 
fold, and is usually 1-2 mm thick, a 100% fat loss can never be associated 
with a 100% decrease in skinfold (ie. a skinfold thickness of zero).
Imprecision may result from both intra- and inter-observer error. 
Intra-observer errors arise when an observer fails to achieve the same 
results on repeated measurement of the same subject and may be a function 
of the skinfold site, the experience of the observer and the fatness of 
the subject (Hass & Flegal, 1981; Lohman, 1981). Inter-observer errors 
arise when two or more observers fail to achieve the same measurement on 
the same subject; such errors usually exceed intra-observer errors 
although care and training can reduce their magnitude (Burkinshaw et al, 
1975).
Skinfold measures are used to assess either the total body fat or the 
percentage of body fat and may be used singly or in combination. If a 
single measurement is used it is vital that the most representative site 
is selected since subcutaneous fat is not uniformly distributed. There is, 
however, no general agreement as to the best single site as an index of 
TBF. For example, Sloan et al (1962) concluded that the suprailiac 
skinfold was the best index of total skinfold thickness in young women 
whereas Siervogel et al (1982) recommend the triceps (TSF). TSF is also 
recommended in boys under 16 years of age whereas, for adult males, both 
the subscapular and mid-axillary sites are believed to be equally 
representative (Siervogel at al, 1982).
These differences are not surprising since subcutaneous fat
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distribution varies not only between the sexes (Young et al, 1963) but 
also between individuals of the same sex (Garn, 1955), between races 
(Robson et al, 1971) and with age (Skerlj et al 1953). This emphasises the 
problems associated with the use of single skinfolds to assess either 
total or percentage body fat although, when measured sequentially, they 
can provide an estimate of changes occurring in individual patients.
Multiple skinfold measurements have also been used although the optimum 
combination of sites for assessment of TBF has not yet been identified. 
Although no body region appears to 'have skinfold sites which are 
consistently representative of the total subcutaneous fat layer (Siervogel 
et al, 1982) a combination of skinfold measurements may provide 
information the distribution of subcutaneous fat. In particular, one limb 
skinfold (left TSF) and one body skinfold (left scapula) has been used to 
account for the differing distribution of subcutaneous fat and appears 
useful for assessing changes during a weight reduction programmes (Bray et 
al, 1978).
Limb Fat Indices, relying on calculation of the cross-sectional area 
of limb fat, can be derived from skinfold thickness and limb circumference 
measurements. Since this is more highly correlated with total body fatness 
it is believed to provide a better estimate of TBF than a single skinfold 
thickness at the same site (Himes et al, 1980). However, as an estimate of 
percentage body fat, limb fat area is no better than the corresponding 
estimate from skinfold measurements (Himes et al, 1980)
As reference data are available for mid-upper arm fat area (Frisancho, 
1981; Bowen and Custer, 1982) this is most commonly used in nutritional 
assessment. The equation for calculation of arm fat area is given below:
i
A = TSF x C - 3.142 x (TSF)
2 4
in which: A = arm fat area (mm ), C = arm circumference (mm),
TSF = triceps skinfold thickness (mm).
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This is, however, based on several assumptions which may result in 
inaccuracies. For example, the equation assumes that the limb is
cylindrical and that fat is evenly distributed about the circumference. 
Equally it makes no allowance for variations in skinfold compressibility, 
as previously described. Such assumptions limit the value of this 
calculation in clinical practice. Its validity is also restricted by 
obesity (since it will underestimate the fat area), by oedema and by 
ascites (Himes et al, 1979). Furthermore, this technique should not be
used in patients with oedema, ascites or other distortions of body
composition (Wright & Heymsfield, 1984).
c) Assessment of Fat Free Mass (FFM).
FFM comprises water, protein and minerals; chemically it is 19.5% 
protein, 72.5% water and 8% bone mineral (Garrow, 1974). Since muscle 
serves as the major protein 'store' assessment of muscle protein can 
provide an index of body protein reserves and, since upper arm muscle 
circumference and arm muscle area are both correlated with measures of
total muscle mass, can be used to evaluate protein nutriture.
Mid-arm muscle circumference (MAMC) is defined as the circumference
of the inner circle of muscle surrounding the small, central core of bone 
(Gurney & Jelliffe, 1973) and is derived from measurement of the mid-arm 
circumference (MAC) and TSF and calculated from the following equation:
MAMC = MAC - 3.142 x TSF
(It should be noted that this equation is valid only when all measurements 
are in the same units).
MAMC can be used to assess the total body muscle mass but it is an 
insensitive index since it is a one dimensional measurement, unlike that 
of arm muscle area which is 2 dimensional, so that, if the volume of arm 
muscle declines, MAMC will decrease proportionately less than arm muscle 
area. Thus arm muscle area AMA is the preferred index since it more
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adequately reflects the magnitude of tissue changes (Frisancho, 1981). 
Studies (Trowbridge et al, 1982) have consistently shown higher
correlations between AMA and the creatinine-height ratio (often used as an 
index of body mass) than between MAMC and AMA which is calculated by means 
of the following equation:
AMA = (MAC - 3.142 x TSF)1'
4 x 3.142
(Consistent units should be used throughout)
Both the equations given above include bone area and assume a circular 
limb and muscle area and a symmetrically distributed fat rim. Furthermore, 
they also include non-muscle tissues, such as the neurovascular bundle. 
Thus, calculation of AMA overestimates actual muscle area by between 20% 
and 25% (Heymsfield et al, 1979) and may underestimate the severity of any 
atrophy. Heymsfield et al (1982) suggest that, by expressing the values as 
a percentage of standard, this error is corrected since the same
overestimate is included in the standard. Alternatively, the equations 
below take account of errors resulting from the non-circular nature of the 
muscle compartment and the inclusion of both neurovascular tissue and 
bone and give an approximation (+8%) of the actual muscle area 
(Heymsfield et al, 1982).
AMA (cm ) Males =(MAC - 3.142 x TSF)2 - 10
4 x 3.142
Females = (MAC - 3.142 x TSF)*- - 6.5
4 x 3.142
[It should be noted that, in this case, the equation assumes that the
measurement has been made in centimetres for uniformity with the original
reference (Heymsfield et al, 1982)]
There are, however, other difficulties associated with estimation of 
FFM since this comprises skeletal and non-skeletal muscle, soft tissue and 
skeletal mass (Cohn et al, 1980). Water retention creates a major
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problem since a relative increase in total body water follows weight loss 
(Keys et al, 1950). Thus, if bone mass remains relatively constant, 
protein will constitute a smaller percentage of FFM. Skeletal muscle 
composition also changes during semi-starvation; functional protein mass 
decreases whilst total collagen, proteins, lipids and water increase. 
Changes in muscle glycogen (plus bound water) can result in a 5-10% change 
in muscle size (Heymsfield et al, 1982). Small changes in body composition 
may not, therefore, be an accurate guide to changes in body protein. 
Nonetheless, one skinfold thickness, limb fat and muscle area are commonly 
used in assessing nutritional status thus raising the question of the 
relationship between a single limb muscle group and total body muscle mass 
(TBMM). It has been suggested (Wright & Heymsfield, 1984) that arm muscle 
area decreases more rapidly than that of either the thigh or calf in the 
presence of PEM although the differences are not marked and it is not 
clear which limb muscle area most accurately reflects muscle mass or how 
this correlates with TBMM.
d) Hand-Grip Dynanometry (Maximal Momentary Grip Strength).
It has been suggested that measurement of hand-grip strength (HGS) is a 
logical extension of measuring muscle mass and, therefore, reflects muscle 
function. As other anthropometric techniques may be unreliable in the 
presence of oedema or dehydration, HGS may prove valuable in assessing 
nutritional status although it is, clearly, unsuitable for use when grip 
strength is impaired by other factors.
Klidjian et al (1982) have found HGS a highly sensitive predictor of 
post-operative complications in patients undergoing major abdominal 
surgery in whom 'appreciable' protein depletion was defined as an HGS 
below 85% of control values (males 48.8 + 7.0 kg, Females 34.4 + 4.7 kg). 
However, Elia et al (1984) have shown that short-term starvation (4 days) 
results in no significant changes in grip strength in either the dominant
or non-dominant hand thus suggesting HGS is an insensitive indicator of 
acute dietary deprivation. However, although manual muscle testing is a 
reliable procedure (Lilienfield et al, 1954), and can be used to predict 
specific (Kauffman, 1982) or general (Logigian et al, 1983) function, it 
is neither precise nor sensitive (Bohannon, 1987). It is, in addition, 
significantly affected by the patient's understanding of the technique and 
his motivation. As a result it may be that this is an inappropriate index 
of nutritional status. Nonetheless, it is generally agreed that 
substantial weight loss, due to prolonged semi-starvation uncomplicated 
by disease, is associated with a reduction in HGS which is proportional to 
the changes in MAC (Keys et al, 1950). This has not, yet, been validated 
for use in cancer patients.
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CHAPTER 3.
DEVELOPMENT OF A MEASUREMENT INSTRUMENT.
The previous chapter has shown that quality of life, even in health, is 
particularly difficult to frame and to analyse and so is peculiarly 
difficult to measure; these problems are exacerbated when attempting 
such measurement in the cancer patient. Thus, before measurement can be 
achieved it is necessary first to identify those factors which are most 
affected by malignant disease so that their effects on the normal
lifestyle can be assessed (Luce & Dawson, 1975).
This chapter discusses first an attempt to identify the areas of 
concern and anxiety to a cancer population and then covers the design of a 
measurement instrument. The results of the pilot study are reported.
3.1 IDENTIFICATION OF AREAS OF CONCERN AND ANXIETY TO CANCER PATIENTS.
Previous studies, primarily in the USA, have identified common causes 
of concern and anxiety in affected patients (eg. Schneider, 1978) and 
McCorkle and Young (1978) have studied symptom distress in patients with 
advanced medical conditions, the majority (87%) of whom had cancer. Others 
have studied family needs throughout the cancer experience (Wright & Dyck, 
1984). In general, their findings fall into 5 broad categories: 1.
Problems caused by symptoms of disease and its treatment, 2. Fear about
the future, of 'unfinished business' and of dying, 3.. The 'worrying and 
waiting' syndrome (Welch, 1981), 4. Difficulty in obtaining information 
and 5. The reactions of family and friends to the disease.
Such studies also suggest that the concerns and anxiety, as well as the 
degree of symptom distress, change as the disease progresses. For example, 
the newly diagnosed are often concerned with the difficulties associated 
with coming to terms with the disease and anxiety over the future. The 
long term patient, however, is primarily concerned with physical 
discomforts which interfere with the ability to pursue a 'normal' life
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(Schneider, 1978).
Thus, from a nursing perspective, it seemed necessary to identify the 
common concerns and anxieties of British cancer patients and to identify 
those symptoms causing most distress. Such an approach is essential if 
assessment of the quality of life is to be attempted (Luce & Dawson, 
1975).
The study described below follows the American studies looking at a 
British patient population and represents the first stage in the 
development of a technique through which quality of life may be evaluated. 
It is a descriptive, cross-sectional investigation attempting to define 
the concerns and anxieties of a mixed group of cancer patients and to 
identify those symptoms causing greatest distress.
3.1.1 Method.
A convenience sample was drawn at random from those admitted to the 
oncology unit of St Luke's Hospital, Guildford.This approach meant that 
patients suffering different primary disease, and at varying stages of the 
disease, were included as were those undergoing different therapies. This 
provided a heterogeneous cross-section of the patients admitted to the 
unit at any given time and enabled identification of various sub-groups 
within the sample of 86 patients (Table 3.1).
An informal, guided interview permitted each patient to present his/her 
concerns and anxieties from an individual perspective. Although the 
interview was unstructured it was guided towards the difficulties to be 
faced on a general basis, the intention being to identify those factors 
having the greatest impact on the normal lifestyle. This techniques is 
useful as it ensures that all the information required is obtained whilst 
allowing the subject freedom of responses and discussion to illustrate 
concepts. At the same time it provides comprehensive and comparable data 
and, because all subjects have been asked the same questions, allows the
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results to be tabulated and descriptive terms used in exploration of the 
data.
After an introduction the interview was initiated by means of a 
general, non-threatening question 'How are you getting on?1 the aim being 
to start a conversation through which the following general areas could
be explored: 1. General health - including the impact of particular
symptoms, 2. Mobility and functional status, 3. Mood, 4. Areas of major 
concern and anxiety 5. Family relationships and 6. Effects on lifestyle. 
This flexible approach, similar to that used by Hinton (1963), although 
time consuming, was felt to be the most appropriate in obtaining the 
general information required.
The Sample. Of the 90 patients approached 86 immediately agreed to 
participate. 4 patients (3 male, 1 female) refused, 2 on the basis that 
they 'felt too ill' and 2 (1 male, 1 female) that they had no concerns, 
were happy with their care and treatment and had nothing to say.
The majority (83%) had been diagnosed within 3 years of the interview 
although 15 (17%) were suffering disease of longer duration (5-10 years). 
65% were receiving active treatment involving radiotherapy and/or 
chemotherapy and, of these, 25% had previously received surgical
intervention; 30% were undergoing their first course of specific
anti-neoplastic therapy. A further 9% (8 patients) were undergoing
diagnostic or staging procedures; 25% were receiving palliative or 
terminal care (Table 3.1).
The Interviews took place at the bedside or in the patients' day room 
this being determined by the patient since it was important that they were 
comfortable and relaxed throughout. Both situations were far from ideal 
due to the need for both privacy and uninterrupted discussion. Although 
confidentiality was promised with regard to the handling of data, the 
privacy of interviews carried out in the ward setting cannot be assured;
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TABLE 3.1. CHARACTERISTICS OF THE PATIENT SAMPLE (N = 86).
A. Site of Disease No of Patients F M Age Range F M
(%) (N = 46) (N = 40)
Breast 23 (27) 23 0 42-72 42-72 —
Gastrointestinal 19 (22) 7 12 37-65 38-60 37-65
Gynaecological 13(15) 13 0 36-57 36-57 -
Lymphoma 13(15) 2 11 43-59 46-48 43-59
Genitourinary 7 (8) 0 7 47-52 - 47-52
Lung 6(7) 0 6 46-59 ■- 46-59
Head and Neck 5 (6) 1 4 57-73 59 57-73
B . Social Circumstances
Male (N = 40) Female (N = 46)
30 Married, living with spouse 32
2 Single 5
6 Widow/widower 6
2 Divorced 3
C. Active Treatment First Course of Treatment Prior Surgery
Treatment 56 RT 27 RT 7 RT 5
CT 29 CT 10 CT 9
Diagnosis & 8 3
Staging
Palliative 22 RT 10
Treatment PC 12
RT = Radiotherapy. CT = Chemotherapy. PC = Pain Control.
those carried out in the day room were usually more satisfactory. However, 
it was not uncommon for the interview to be interrupted by the attending 
physician, nurses or domestic staff.
The average interview time was 50 minutes (range 37 - 75 minutes) yet
no patient chose to withdraw from the study once the interview commenced. 
In general the patients chose to share a considerable amount of 
information with the interviewer, giving more details of their experiences 
and feelings than was required. Many patients commented that it had been 
a valuable experience giving them the opportunity to talk; several also
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found it personally beneficial providing them with the chance to 'get
their thoughts in order1. Many expressed the wish that this opportunity
was available to them on a regular basis. This willingness to impart 
information and share experiences added a great deal to the value of the 
material obtained. At the same time it extended the length of the 
interview and increased the time required for completion of the study.
3.1.2 Results.
Most patients (73%) were aware that they had cancer although several 
were unsure but thought it was 'likely1. One patient stated '.. the other 
patients on this ward have cancer but I'm different, I've got Hodgkin's 
disease' and another, unaware of his diagnosis, asked '... the other
patients all seem to have cancer have I?' Several suggested that '... 
no-one knows what is wrong', 'nobody will tell me what is wrong' and 2 
asked directly 'Have I got cancer?'
Many of those whose diagnosis was confirmed were surprised at how well 
they felt and the majority expressed a desire to 'fight' stating that they 
'were not ready to die'. All patients anticipated severe pain at some 
stage in their disease, usually 'towards the end' and believed little
could be done to provide relief.
When asked 'what has caused you the most concern or difficulty since 
you have been ill' most patients identified a wide range of pyschosocial 
difficulties related to acceptance of the diagnosis, and the fear and 
uncertainty this engenders, as well as a range of physical inconveniences 
related to the symptoms of disease and/or the side-effects of treatment. 
These findings are summarised in Tables 3.2 and 3.3.
Many patients complained that their level of mobility was markedly 
reduced and that they were no longer able to perform many of their usual 
activities and recreational pursuits. This was, usually, due to a
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TABLE 3.2. IDENTIFIED CONCERNS AND DIFFICULTIES IN THE PATIENT SAMPLE.
Patient Group CT RT Palliative/Terminal Staging
(N = 29) (N = 27) (N = 22) (N = 8)
A. Concern/Difficulty
Psychological Impact 25 22
Acceptance,
uncertainty, fear of
disease or treatment,
fear of death.
RT PC
(N = 10) (N = 12)
Physical Difficulties 28 19 10 10 4
Symptoms of disease or 
treatment, fatigue, 
appetite loss etc.
Social Difficulties 22 21 7 9 7
Inability to
communicate, isolation
& loneliness, financial
concerns
Patient Group 0-3 years First Treatment Advanced Disease
(N = 55) (N = 9) (N = 22)
B. Concern/Difficulty
Psychological Impact 55 8 8
Acceptance, uncertainty, 
fear of disease or 
treatment, fear of death.
Physical Difficulties 55 6 10
Symptoms of disease or 
treatment, fatigue, 
appetite loss etc.
Social Difficulties 54 6 6
Inability to communicate, 
isolation & loneliness, 
financial concerns.
RT = Radiotherapy. PC = Pain Control. CT = Chemotherapy. 
Staging = patients undergoing staging/diagnostic procedures.
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TABLE 3.3. SYMPTOMS IDENTIFIED AS AREAS OF CONCERN TO PATIENTS.
Number of patients affected
Symptom Total CT RT P/T S
(N = 86)(N = 29) (N = 27) (N = 22) (N = 8)
RT PC
(N = 10)(N = 12)
Tiredness 73 22 24 8 12 6
Mood Changes 72 26 21 8 12 5
Appetite changes 70 29 22 6 6 7
Taste 40 24 15 0 0 1
Texture 20 14 6 0 0 0
Get full quickly 50 15 14 3 12 6
Ability to concentrate 61 27 12 7 11 4
Pain 59 28 17 9 2 3
Altered bowel pattern 56 20 19 2 12 3
Constipation 18 5 0 0 12 1
Diarrhoea 38 15 19 2 0 2
Changes in appearance 51 19 15 8 9 0
Weight loss 48 18 12 6 10 2
Hair loss 21 19 2 0 0 0
Mutilative surgery 21 20 0 0 1 0
Other 14 10 3 1 0 0
Breathing difficulties 48 10 9 12 6 3
Level of mobility 46 15 9 9 10 3
Insomnia 45 15 14 9 1 6
Nausea 38 23 10 2 3 0
Sore mouth 6 5 1 0 0 0
Tingling of extremities 4 3 0 0 1 0
Earache 1 0 1 0 1 0
CT = Chemotherapy RT = Radiotherapy P/T = 
S = Staging or diagnostic procedure. PC
Palliative/Terminal 
= Pain control.
care
generalised weakness and excessive tiredness although some found that 
movement was restricted by pain which may be generalised or provoked by 
movement whether or not analgesia was prescribed or administered. This 
created particular anxiety in those patients living alone, those involved 
in caring for a home and family and in those with young children. Those 
who were continuing to work between their periods of treatment found the 
weakness and tiredness disabling and disruptive to their daily routine. It 
was clear that these effects had a significant impact on the usual 
lifestyle and markedly affected the patient's mood. Although most
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expressed great confidence in the medical team and were 'sure the doctor 
will cure me1 many expressed fear related primarily to the way in which 
the disease would progress and to the pain they believed to be inevitable. 
Others claimed to be 'depressed' and 'fed up' suggesting this 'is not 
surprising when I've got cancer' and 'anyone would be depressed' results 
which are consistent with the findings of Maguire (1985). None of the 
patients had a clinical diagnosis of depression.
Others complained of periods of depression interspersed with periods of 
heightened activity, finding these marked mood swings difficult to cope 
with and finding them a considerable source of stress and anxiety. Such 
feelings were exacerbated by feelings of uncertainty both with regard to 
the disease itself and to individual concerns regarding proposed treatment 
or side-effects. Many felt such feelings could be relieved by greater 
communication between themselves and members of the caring team although 
they were quick to defend the staff. The majority felt that 'the doctors 
and nurses are very kind but they don't tell me what's going on or what to
expect'. The staff were often seen to be 'too busy' so that the patients
'don't like to ask' for information. As a result it appeared that many 
patients were receiving therapy whilst failing to understand its purpose 
or the liklihood of side-effects so that these were often perceived as 
progression of disease thus inducing further concern/anxiety.
At the same time, of those awaiting the results of diagnostic tests, 
many were understandably anxious about the results. Others were often
surprised when blood samples were taken with no explanation, it was not
uncommon for more than one sample to be taken on the same day, perhaps by 
different people. They were also concerned that they were rarely apprised 
of the results except when a delay in chemotherapy was necessary.
It seems clear that the stress and anxiety generated by the diagnosis 
and accompanying uncertainty contribute to the mood swings noted. At the
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same time over half the patients complained of an inability to sleep 
normally without the aid of sleeping pills and the majority of persistent 
tiredness. However, in some patients, the incidence of diarrhoea was such 
that it prevented sleep and created significant discomfort, both emotional 
and physical.
Both diarrhoea and constipation appeared to contribute to appetite 
changes although these were also due to taste alterations as well as
reported changes in the texture of food since a small but significant 
number complained that all food felt 'rough' and was difficult to swallow. 
However, the majority of those complaining of appetite changes felt this 
was because 'I get full quickly, even when I'm hungry'. No patient had an 
increase in appetite although this is a common side-effect of hormonal or 
steroid therapy; several said they 'forced' themselves to eat. Appetite 
loss per se was the predominant change.
Nausea also affected food consumption in a significant number of
patients (38/86), predominantly in those undergoing chemotherapy. A sore 
mouth also contributed to eating difficulties in a small number (6) of
patients the majority of whom (5/6) were subsequently found to be
suffering Candida albicans infection.
Breathing difficulties also contributed to an inability to eat since 
this was often inhibited by shortness of breath. Such difficulties also 
presented problems with regard to general mobility and participation in 
normal activities. These effects primarily arose in those with disease 
affecting the head, neck and lungs whether this was due to primary disease 
or to metastatic deposits.
Pain was another common symptom affecting 68% of the patients although 
this was clearly well controlled in those admitted for pain control. 
However, on occasions, patients admitted that they had not reported the 
problem to either the medical or nursing staff and several were reluctant
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to ask for analgesia since they were afraid they would 'get hooked on 
drugs1. The abdomen was a common site of pain; this appeared to coincide 
with the incidence of constipation. Diarrhoea too was a source of
considerable abdominal discomfort.
3.2 COMMENT.
This study has shown that, although the spectrum of disease and 
discomfort which may result from the presence of malignancy is wide 
patients share many common concerns and anxieties. It must also be
recognised that the therapies employed may have additive or synergistic 
effects and cause problems which are almost unrelated to the disease 
itself. Nonetheless the above discussion has identified the predominant 
symptoms and concerns in the patient population. Patients themselves were 
uncertain whether their problems stemmed from the disease or its 
treatment. Indeed, since the effects were the same, the majority regarded 
the cause as unimportant. However, it seems safe to assume that symptoms, 
such as those discussed, may have a significant effect on the quality of 
life. On this basis it was considered appropriate for such symptoms to be 
included in any subsequent attempt to assess quality of life.
3.3 DEVELOPMENT OF THE MEASUREMENT INSTRUMENT.
3.3.1 Selection of Framework.
The process of developing a reliable measure of quality of life 
depends on valid selection of an appropriate conceptual framework which, 
in turn, delimits the scope of the study. As previously stated quality of 
life is recognised as a dynamic concept; it is an abstract and complex 
term representing individual responses to the physical, mental and social 
factors which contribute to 'normal' daily living.
Nursing theories and models have provided a basis for assessing the 
patient's ability to cope with the demands of daily living and for 
defining this objectively. For example, Henderson (1969) has identified 14
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basic needs of all individuals, and Roper et al (1981) 12 activities of 
daily living (ADL), which can be used as criteria against which the 
efficacy of nursing interventions can be judged. Such interventions are 
primarily directed towards maintaining/improving the patient's quality of 
life. As a result it was decided that assessment of the ability to meet 
basic needs, combined with the effects of identified symptoms on the ADL, 
provided an appropriate basis for assessing QL.
It was, therefore, considered appropriate for the symptoms identified 
in the previous study to be included in any subsequent attempt to assess 
QL. As these were consistent with those selected by McCorkle and Young 
(1978), for inclusion in their Symptom Distress Scale, this scale was 
adapted to form the first part of the measurement instrument. Such an 
approach helped to limit the scope of the instrument by selecting only 
those items identified as common areas of concern. This was particularly 
important since it was recognised that attempts to measure the severity of 
all possible symptoms, although comprehensive, may fail to assess their 
overall impact on QL (Selby et al, 1984). It was also recognised that a 
'global' instrument may fail to identify areas of particular concern and 
be too lengthy so that interviewees find difficulty in its completion. A 
lengthy instrument, although relevant, may have excellent psychometric 
properties but fail because the patients are too fatigued to complete it. 
Anticipated fatigue and difficulty with prolonged periods of 
concentration (see Table 3.3) precludes the use of a lengthy instrument. 
From this discussion it can be seen that the instrument designed was to be 
based on a self-assessment technique since, as discussed in Chapter 2, 
individuals themselves are the only proper judge of their well-being 
(Neugarten et al, 1961; Campbell, 1981; Dam et al, 1981).
Thus the instrument finally developed (Appendix 1) consisted of 26 
items and included aspects related to both the symptoms of disease and the
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side-effects of treatment (Section 1) and their effects on the activities 
of daily living as outlined by Henderson (1969) (Section 2). It included 
also several items related to psychosocial problems, such as social 
isolation, as affected individuals commonly report that they feel 
'separated' from their 'significant others' as a result of having the 
disease (Welch, 1981) (Table 3.4). It had been hoped to include also 
items related to the 'normality' of the sex life and the ability to work. 
Ethical committee restrictions meant that these items had to be deleted. 
Approval was sought, and granted, for the instrument finally adopted.
TABLE 3.4. ITEMS SELECTED FOR INCLUSION IN THE MEASUREMENT INSTRUMENT.
SECTION 1 (SYMPTOMS) SECTION 2 (ADL)
1 Pain 12 Ability to eat
2 Nausea 13 Flavour of food
3 Appetite 14 Texture of food
4 Sleep 15 Sleep
5 Mobility 16 Respiration
6 Bowel habits - diarrhoea 17 Urination
7 Bowel habits - constipation 18 Change in bowel pattern
8 Tiredness 19 Recreational activity
9 Concentration 20 Life changes
10 Mood 21 Worry about future
11 Appearance 22 Concern over earning ability
23 Isolation
24 Communication with family
25 Communication with doctors
26 Communication with nurses
3.3.2 SELECTION OF THE SCORING SYSTEM.
The next difficulty to be faced in developing any measurement 
instrument is selecting the way in which the items should be measured. A 
variety of methods has previously been adopted in attempts to assess QL in 
both patient and non-patient samples including questionnaires (Lefebrve, 
1979), interviews (Hutchinson et al, 1979; Lefebrve, 1979) and observer 
ratings (Burge et al, 1975) each of which have been based on different 
methods of scoring. These have included Likert type scales (Burge et al, 
1975) based on 5 or 6 points, structured interviews with open or closed
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choices (Lefebrve, 1979) and linear (visual) .analogue scales (LASA) 
(Priestman & Baum, 1976).
LASA scales have several advantages as they are easy for the subject to 
grasp and, as they are not restricted to quantitative terms, allow the 
subject to make as fine a discrimination as he wishes (Freyd, 1923). 
However, some workers (McCorkle & Young, 1978) believe that this lack of 
quantification makes it difficult to estimate the degree of change. It 
appears that these authors have failed to recognise that quantitative data 
can be obtained from such scales by simple measurement, although this 
merely provides a rank order of the responses from each individual 
(Abdellah & Levine, 1986). Nonetheless, in an attempt, to overcome such 
difficulties, a five- or six-point Likert type scale has been used (eg. 
McCorkle & Young, 1978; Young & Longman, 1983). Yet a five-point scale has 
a mid-point which may provide an 'easy way out' for individuals not 
wishing to make a clear decision and, in any case, a numerical scale may 
force the responses into artificial categories. As a result it was decided 
to compare the relative merits of these three scoring systems. A 
questionnaire (Appendix 1) was designed which could be based on a linear 
analogue, a five-point and a six-point scale at each end of which were 
written statements representing the possible extremes of the subjective 
response to particular questions (Figure 3.1 overleaf).
3.4 THE PILOT STUDY.
An unselected convenience sample of 72 patients was drawn at random 
from those admitted to the oncology unit over a three month period thus 
giving a heterogeneous cross-section of the patients in the unit at any 
given time. Participants were asked to complete the questionnaire on two 
occasions separated by an interval of 1-1.5 hours during which time they 
were closely observed to ensure that no intervening factors affected their 
responses. The three types of questionnaire were allocated on a random
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FIGURE 3.1. EXAMPLES OF POSSIBLE SCORING SYSTEMS.
1. LINEAR ANALOGUE
Worst pain I No pain.
have ever had.
2. 5-POINT SCALE
I cannot face 1 
food at all.
2 3 4 5 My appetite is 
normal for me.
3. 6-POINT SCALE
I cannot sleep 1 
at all.
2 3 4 5 6 I sleep as well 
as ever.
basis the aim being to obtain 20 completed pairs in each group.
3.4.1 Analysis of Results. (Table 3.5)
The acceptability of the scale was assessed by determining the 
frequency with which patients agreed to participate and by the number who 
withdrew during the study. The feasibility of the instrument as a clinical 
assessment tool was evaluated by noting the time required for completion 
by the patients and that necessary for scoring the completed 
questionnaires.
Reliability was assessed using the test-retest method and by 
computation of Cronbach's coefficient alpha (Cronbach, 1951).
As discussed in Chapter 2 validity of a measurement instrument depends 
on the extent to which it measures that which it is intended to measure. 
However, when attempting to evaluate subjective feelings, it is difficult 
to validate their depth and there are few accepted criteria against which 
to judge empirical data. In addition, as has been shown, there is no 
universally accepted method of assessing the quality of life thus validity 
was evaluated indirectly.
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TABLE 3.5. SUMMARY OF STATISTICAL METHODS EMPLOYED (Appendix 2).
Method Statistical Technique Property Evaluated
Completion time _ Feasibility
Test-retest Correlation 
Inter-item & 
Total scores
Reliability 
(Reproducibi1i ty)
Split-half reliability 
(Internal consistency)
Cronbach's oc Reliability 
(Reproducibi1i ty)
Patient Interviews 
(pre-test studies)
- Validity 
(Content)
Relationship between Inter-Item Validity
scores for different 
items
correlation (Content)
Patient Interviews 
(post test)
- Validity 
(Content)
Comparison to Karnofsky Selective item-total Validity
Performance Index (KPS) correlation (Concurrent)
Comparison of 
Questionnaires
Analysis of variance Differences 
between the types 
of questionnaire
The Karnofsky Performance Status Index (KPS) (Karnofsky et al, 1948), 
which has previously been used as a measure of the quality of life, was 
used as a criterion against which to attempt to establish concurrent 
validity.
Construct validity can only be derived from an evaluation of 'gestalt' 
of evidence (ie. a body of research) (Barker Baussell, 1986) involving 
different researchers over a number of different studies.
3.4.2 Results.
Most patients (93%) agreed to participate in the study and there were 
few problems associated with completion of the instrument which took an 
average of 10-12 minutes in all cases. A total of 7 completed 
questionnaires were found to be invalid for further study since they had
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not been completed correctly.
In completing the 5-point scale many of the subjects responded to the 
absence of a symptom or change by circling the question rather than the 
last point on the scale (5). Further questioning established that this 
meant 'normal1; this problem did not arise in completion of either the 
six-point or the LASA scale but was noted for future reference.
Test-retest reliability was established for all forms of the instrument 
on both individual items and total scores. The highest reliability 
coefficient was obtained using the LASA scale (r = 0.97, P<0.001); the 
six-point scale produced the lowest coefficient (r = 0.72, 0.01P<0.001). 
Analysis of variance showed that there was no significant difference 
between the responses using any of the scales so that there was no 
statistical basis for selecting one scale in preference to another. Use of 
the LASA scale was associated with fewer problems of completion; once 
explained to the patients this was found to be simple and straightforward 
to use and allowed greater flexibility and discrimination between the 
responses to individual items. It was possible to distinguish between 
areas of greater and lesser concern. The problem of response sets was 
minimised by use of this scale and the occurrence or apparent practice 
effects reduced. On this basis it was decided that the responses given by 
the LASA instrument were more likely to accurately reflect the patient's 
true feelings. Correlation with the KPS was high (r = 0.77 P<0.001).
Computation of Cronbach's coefficient alpha yielded an oc of 0.89 (total 
instrument), 0.9 (Section 1, Symptom distress) and 0.7 (ADL).
The correlation matrix (Figure 3.2) yielded several interrelated areas 
of concern chief amongst them being those between pain, nausea, tiredness 
and an inability to eat, and those between appearance, nausea, tiredness, 
concentration and mood. It should be noted that most of the patients 
studied linked their feelings of isolation with an inability to talk to
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FIGURE 3.2. CORRELATION MATRIX: QUALITY OF LIFE PILOT STUDY.
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25 .32 .11 . 
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64 .50 .52 . 
60 .44 .48  . 
73 .57 .09 . 
70 .81 .47 . 
52 .43 .38 . 
22 .2 2 - .0 3  .
14 .27 .53 - .  
32 .33 .47 . 
0 6 - .1 7 - .3 1  . 
30 .1 1 - .0 7  . 
13 .2 0 - .2 4  . 
04 .0 6 - .0 7  . 
16 .0 8 - .2 2  . 
25 .1 3 - .0 7  . 
13 .0  .16 .
15 .3 0 - .2 7  . 
04 .38  .13 . 
32 .0 7 - .1 3  .
15
10 .34 
41 .28 .
31 .06 . 
30 .02 .
22 .32 . 
41 .38 .
32 .18 . 
47 .09-. 
04-.09 . 
28 .21 . 
10 .14-. 
07 .06 . 
22 .26 . 
27 .22-.
23 .27 . 
18-.07 . 
03 .09-. 
09-.12 . 
17 .28-. 
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1. Pain
2. Nausea
3. Appetite
4. Sleep
5. Physical Activity
6. Diarrhoea
7. Constipation
8. Tiredness
22. Earning ability
23. Isolation
24. Communication - family
25. Communication - doctors
26. Communication - nurses
27. Total score
9. Concentration
10. Mood
11. Appearance
12. Ability to eat
13. Flavour
14. Texture
15. Sleeping pattern 
74  16. Breathing
49 .68 17. Urination
16 .52 .85 18. Bowel pattern
44 .71 .66 .70 19 Recreation
62 .79 .63 .49 .71 20. Life changes
48 .61 .46 .26 .41 .61 21. Future concern
14 .09 .10 .19 .36 .22-.19
09 .27 .31 .29-.09 .08 .01 .15
03 .19 .01 .12 .13 .13-.18 .54 .61
13-.07 .07 .02 .37-.16-.24 .20-.23 .0
44 .42 .25 .25 .37 .28 .46 .14-.45 .36 .28
25 .20 .04-.17 .27 .12-.21 .26 .52 .53 .28-.18
01 .05 .11-.14 .16-.10-.37 .30 .27 .46 .25-.04 .80
23 .07-.01 .07 .10 .01-.35 .22 .48 .40 .0 -.24 .64 .50
01 .04-.19 .22-.01 .21-.15 .26 .04-.04-.18 .02 .17 .03 .36
41 .25-.07 .21-.08-.25-.23 .28 .60 .34 .15-.47 .06 .08 .47 .04
0 .08-.01 .05 .02 .08-.41 .62 .02 .08-.09-.27 .14 .01 .14 .34 .03
36 .06-.17 .09 .15-.06-.29 .68 .38 .73 .05-.43 .38 .45 .26 .10 .46 .24
42 .34-.02 .02-.19-.28-.04 .09 .65 .09-.19-.61 .17 .06 .40 .15 .73-.04 .33
1 8 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Correlation coefficients >0.25 significant at P<0.05 or above.
the nursing staff but not with the medical staff. Table 3.6 shows 
the number of patients distressed by particular symptoms in the total 
sample. As these were consistent with those previously identified this 
appears to support the validity of the measurement instrument.
The division of items into 2 sections was intended to allow calculation 
of the contribution of symptom distress to the overall score. Those 
achieving a low symptom distress score also achieved low scores in the 
second section (ADL) (r = 0.88, P<0.001) thus appearing to confirm that 
the severity of symptoms has a significant impact on the activities of 
daily living.
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TABLE 3.6. SYMPTOMS CAUSING MOST DISTRESS IN CANCER PATIENTS.
Symptom Total Number of Affected Patients (%)
Changes in appearance 27 (45.0)
Tiredness 21 (35.0)
Inability to concentrate 21 (35.0)
Depression of mood 21 (35.0)
Loss of mobility 21 (35.0)
Inability to sleep 17 (28.3)
Loss of appetite 14 (23.3)
Constipation 12 (20.0)
Pain 7 (11.7)
Nausea 4 ( 6.7)
Diarrhoea 4 ( 6.7)
*Receiving ratings <50 on linear analogue scale
3 or less on six-point scale 
2 or 1 on 5-point scale
3.4.3 Discussion.
The purpose of this study was to design and evaluate a means of 
assessing quality of life in patients suffering from cancer. It recognised 
that quality of life is dynamic and, therefore, subject to continual 
change but which represents individual responses to the physical, mental 
and social effects of illness which influence the extent to which personal 
satisfaction with life circumstances can be achieved, and which allows 
favourable comparison with others according to the selected criteria. In 
other words it represents a highly individual evaluation of the present 
situation and an investigator must be careful that he/she does not impose 
his/her values on any such evaluation. The use of self-assessment 
techniques should help to overcome this difficulty. It was also recognised 
that, although QL may be significantly affected by illness, it may also be 
influenced by other, pre-existing factors. However, since this instrument 
was designed to estimate the changes resulting from the presence of 
disease, or from its treatment, it was felt that these could be 
disregarded since the use of self-assessment techniques should compensate 
for such pre-existent factors.
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The items selected for inclusion were intended to cover those areas 
important to general health as well as those identified as being of 
particular concern to the cancer patient. No distinction was made between 
those symptoms arising from the disease or those from its treatment as 
patients felt this was not important when assessing their impact on life 
as a whole.
Subsequent evaluation of the chosen design was encouraging since 
patients found all three scoring systems acceptable and the instrument was 
quick and easy to complete. It was, therefore, found to be both 
acceptable and feasible for use in the clinical setting. The relevance of 
the items was established by direct questioning of all patients (after 
participation) which indicated that the items included were both relevant 
and important to the sample and that the instrument represented a valid 
assessment of the important areas of their lives which had been affected 
since the onset of their disease. Several patients wondered why no 
questions relating to sexual function had been included as this was an 
area which had undergone significant change; others questioned the 
omission of 'work' particularly when a question relating to concerns over 
earning ability had been included. It is hoped that it will be possible to 
rectify these omissions in future studies.
The reliability of both individual items and the total instrument was 
established using both the test-retest method and computation of 
Cronbach's coefficient alpha. The limitation of the test-retest method is 
recognised particularly since the time interval between the two 
completions was short. This meant that it was not possible to ensure that 
the respondents had not remembered the level of their previous responses, 
although this is unlikely in an instrument consisting of 26 items. The 
second requisite for establishing test-retest reliability is to ensure 
that nothing has intervened in the interval that is capable of affecting
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the responses to the instrument since, if this is the case, spurious 
results will be obtained. Clearly, in an in-patient population, changes in 
condition are likely and it is not possible to withold treatment for the 
periods necessary to ensure that sufficient time has elapsed. It is, in 
any case, suggested (Barker Bausell, 1986) that, when the subject of 
interest is the consistency with which a measuring instrument assigns 
scores, then Cronbach's coefficient alpha is the procedure of choice.
The reliability of the instrument was, therefore, evaluated by this 
means which is, in effect, equivalent to splitting the test into its 
smallest possible components and taking the average of them all thus 
representing an average of all possible split-half reliabilities which can 
be computed for any given measure and overcoming the difficulties inherent 
in the split-half procedure. An alpha coefficient of 0.89 supports the 
reliability of the instrument (Carmines & Zeller, 1979) and, since this 
provides a conservative estimate of reliability (Novick and Lewis, 1967), 
suggests that the internal consistency of the instrument is high. 
Coefficient alpha has other advantages since it is calculated on a single 
test administration and was, therefore, calculated on the first test 
results thus overcoming any effects due to memory or practice effects.
Establishing validity was, as previously shown, a more difficult 
procedure since it is not possible to establish the extent to which the 
instrument measures quality of life due to the absence of an accepted 
alternative measure which can be used as a criterion against which it can 
be judged.
Clearly, face validity was ensured by means of the earlier studies so 
that the instrument appeared to measure what was intended. However, since 
all tests would pass this criterion face validity could, more correctly, 
be described as validity by assumption (Mosier, 1947) and, as such, is of 
little value. Content validity was ensured by inclusion of items
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identified by previous studies and, by subsequent questioning, supported 
by the patients included in the study.
Whilst recognising the limitations of the Karnofsky Performance Index 
(KPS) this has commonly been used as an indicator of the quality of life 
and was, therefore, used as a criterion against which to judge the 
concurrent validity of the present instrument. However, since the KPS is 
restricted only to performance status it was possible only to attempt 
selective item-to-total correlation as well as correlation of the total 
scores. The results obtained appeared to establish concurrent validity 
although this assumes that both indices are measuring the same construct 
(abstract variable). As previously stated, construct validity can only be 
established by a pattern of consistent findings involving different 
researchers over a number of different studies.
The extent to which scores on individual items were correlated with the 
scores on those items believed, on clinical grounds, to be related, serves 
to support the validity of the instrument (Table 3.7). For example, the 
positive correlation between pain and constipation can be explained as a 
consequence of the regular administration of narcotic analgesics (eg. 
diamorphine). The incidence of tiredness may also result from the use of
TABLE 3.7. CORRELATIONS BETWEEN SOME ITEMS RELATED ON CLINICAL GROUNDS.
Factor A Factor B r
Pain Nausea 0.7
Tiredness 0.7
Ability to eat 0.6
Constipation 0.7
Nausea Tiredness 0.8
Concentration 0.6
Ability to eat 0.7
Tiredness Constipation 0.7
Ability to eat 0.8
Appetite Tiredness 0.7
Ability to eat 0.8
Mood Tiredness 0.7
Appearance 0.7
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such agents or from the regular use of anti-emetics thus explaining the 
relationship between pain, nausea, tiredness and constipation; inability 
to eat is an understandable consequence of such symptoms. The problem 
causing most concern in this patient sample related to changes in 
appearance which correlated strongly with nausea, tiredness, concentration 
and mood, thus emphasising the close relationships between symptoms in 
these patients.
It is recognised that a number of statistical techniques (such as 
multiple regression analysis and factor analysis) can be employed in 
estimating validity. However, since the samples were small, their value 
was limited in this study. In any case, since the coefficient 
alpha was sufficiently high (0.89), it has been argued (Barker Baussell, 
1986) that the instrument is capable of being useful and, by implication, 
valid. These points will be addressed in later studies. Future studies 
will also investigate its ability to discriminate between groups of 
patients and to detect change with time in individual patients since this 
is essential if the instrument is to be of any practical use.
Overall, it appears that the measurement instrument developed provides 
a reliable, reproducible and valid means of assessing patient well-being 
and quality of life. It is simple to use, easy to complete and quick to 
score. Evaluation suggests that this may be a valuable tool for use by 
all those involved in caring for cancer patients.
CHAPTER 4.
FURTHER EVALUATION OF THE QUALITY OF LIFE INDEX.
As the pilot study suggested that the Quality of Life Index (QLI) is a 
reliable and valid means of assessing patient well-being further studies 
were undertaken to evaluate its use not only in terms of reliability and 
validity but also in terms of its ability to discriminate between groups 
of patients and to detect changes with time in individual patients.
Repeated reliability estimates are required since there is no single 
reliability coefficient for any given instrument. This is not a stable 
property of the method but rather is related to the use of that method in 
any given population or sample (Cronbach, 1970; Nunnally, 1978). Thus 
reliability is affected not only by the range of the variables being 
measured but also by the conditions under which the measurements are 
obtained; variation in the reliability estimates obtained in different 
populations is, therefore, to be expected. However, repeatedly high
reliability estimates serve to support the use of the instrument for a 
variety of population studies.
4.1 THE SYMPTOM DISTRESS SCALE (Section 1).
Although the McCorkle and Young (1978) Symptom Distress Scale, which
was adapted to form the first part of the measurement instrument, appears 
to provide a standardised method of assessing a patient's symptoms and 
degree of distress this has not, in itself, been evaluated for use in a 
large sample as McCorkle and Young studied only 53 patients, of whom 45 
had cancer. This study included 120 cancer patients so that a more
complete evaluation was possible.
4.1.1. Method.
A heterogeneous, cross-sectional sample of 120 patients (60 male, 60 
female) was drawn from those admitted to the Oncology Unit. Participants 
were asked to complete the Symptom Distress Scale (SDS) which represented
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a modification of that of McCorkle and Young (1978) since their study 
relied on the use of a 5-point scale and on the use of 'flash cards' so 
that each question was asked independently rather than by means of a 
questionnaire. This approach simplifies administration of the test but may 
increase the risk of response sets; completed questionnaires were closely 
studied to ensure that this did not distort the findings. At the same time 
it allows the patient to take as long as he wishes to complete the 
questionnaire and to re-read the questions as often as he wishes.
Reliability was estimated by calculation of Cronbach's coefficient
alpha which is attractive due to its mathematical simplicity and because 
it offers an estimation of the lower bound of all other reliability 
estimates (Novick & Lewis, 1967). Coefficient alpha, based on internal 
consistency, estimates the proportion of variance due to all the common 
factors among items and 'provides a good estimate of reliability in most 
situations since the major source of measurement error is because of the 
sampling of content' (Nunnally, 1978).
As it was expected that many of the symptoms would be inter-correlated, 
due to their clinical interactions, forward stepwise multiple regression 
analysis was undertaken to study the relationships between the independent 
variables and to establish their relationship with the total SDS score 
(the dependent variable). As it is common to find 3 or 4 variables 
explaining almost as much of the variation in the dependent variable as 
can be explained by a much larger number of variables (Barker Baussell, 
1986) this may enable simplification of the scale permitting selection 
of a subset of items having a predictive power as great as that obtained
by the entire set of variables.
4.1.2. Discussion of Findings.
Of the 120 patients included 88 (73%) indicated a high level of
distress from at least one symptom and 66 (55%) from 2 or more; a further
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TABLE 4.1, SYMPTOMS CAUSING DISTRESS TO PATIENTS IN THIS STUDY.
(Score < 50 on a given item)
Item No of Patients Affected (%)
Tiredness 52 (43.4)
Mobility 42 (35.0)
Mood 40 (33.3)
Appearance 37 (30.8)
Concentration 32 (26.7)
Sleep 28 (23.3)
Appetite 26 (21.7)
Pain 24 (20.0)
Constipation 20 (16.5)
Nausea 16 (13.3)
Diarrhoea 12 (10.0)
34 (28%) patients indicated a high level of distress for at least 5 
items. Table 4.1 shows the number of patients suffering significant 
distress from particular symptoms.
Further investigation showed that, of those indicating distress from 2 
or more symptoms, only 25% were known to be suffering metastatic disease 
and, of those reporting significant pain, only 12 were receiving regular 
pain medication. However, pain was not generally rated as a significant 
cause of distress a finding which is consistent with the work of Twycross 
(1972) who suggests that most patients with cancer do not experience 
severe pain and that, of those who do, only in limited numbers is this 
severe.
Space was also given for the patients to include any extra variable(s) 
which they felt had not been covered so that they were able to identify 
those symptoms causing particular concern at the time of the study, 
although not all patients completed this part of the questionnaire. Some 
found it difficult to identify only one area of concern and, therefore, 
listed more than one whereas others found it impossible and made no 
attempt at this question. As a result the findings cannot be directly 
compared with those of the pilot study although similarities can be seen.
For example, in both studies patients specifically identified loss of 
appetite, weight loss and mood changes as significant causes of concern in 
this section. Similarly they record alterations in bowel pattern (both 
diarrhoea and constipation), pain, tiredness and a lack of energy and 
motivation as marked areas of concern. Other symptoms, related 
specifically to the primary disease or its treatment, were also 
identified. Thus, 6 patients with bladder tumours identified urinary 
frequency as their major problem, a sore mouth affected a patient with 
severe stomatitis and hair loss caused distress to 4 patients undergoing 
therapy with Adriamycin. It is clear that symptom distress may have a 
significant impact on affected patients causing considerable concern 
and anxiety exacerbating that caused by the disease itself. It is also 
clear that it is necessary to identify symptoms of particular concern to 
individual patients if appropriate care is to be given.
The coefficient alpha of 0.97 indicated that reliability was high in 
this population. The correlation matrix, from which coefficient alpha was 
calculated, is shown in Figure 4.1. Study of the matrix reveals that most 
of the items, with the exception of diarrhoea, were significantly 
correlated suggesting that most symptoms are closely inter-related and 
contribute significantly to the overall symptom distress score (SDS). 
Such findings are not unexpected since the symptoms selected for inclusion 
in the scale were those previously identified as common causes of concern 
and/or anxiety to affected patients (Chapter 3); this further supports the 
validity of the tool.
The failure to demonstrate a relationship between diarrhoea and 
concentration, mood, physical activity and appearance is not surprising 
since there is no real clinical basis for believing such symptoms are 
inter-related. It is, however, possible to suggest that diarrhoea may be 
associated with both mood changes and tiredness although this was not
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FIGURE 4,1. CORRELATION MATRIX DERIVED FROM THE RESULTS OF THE SYMPTOM
DISTRESS STUDY.
1 1 .00 = Not significant at 5% level.
2 0.49 1.00 (P<0.05)
3 0.28 0.46 1.00 Remainder significant (P<0.001).
4 0.36 0.35 0.42 1.00
5 0.46 0.46 0.43 0.29 1.00
6 0.25 0.20 0.31 0.13 0.15 1.00
7 0.30 0.26 0.44 0.22 0.35 0.13 1.00
8 0.44 0.40 0.56 0.47 0.52 0.09 0.53 1.00
9 0.31 0.45 0.45 0.55 0.42 0.09 0.39 0.64 1.00
10 0.29 0.54 0.52 0.50 0.43 0.13 0.42 0.48 0.69 1.00
11 0.32 0.45 0.60 0.32 0.54 0.19 0.44 0.62 0.57 0.51 1.00
12 0.60 0.67 0.75 0.62 0.69 0.33 0.62 0.80 0.76 0.74 0.77 1.00
1 2 3 4 5 6 7 8 9 10 11 12
1 = Pain. 2 = Nausea. 3 = Appetite. 4 = Sleep. 5 = Physical Activity.
6 = Diarrhoea. 7 = Constipation. 8 = Tiredness. 9 = Concentration.
10 = Mood. 11 = Appearance. 12 = Total Score.
found to be the case in this study. Since few of the patients were
reported to be suffering diarrhoea (12), a fact borne out by careful study 
of the responses to this item, it is probable that the apparent lack of 
sensitivity of this item can be explained on this basis.
Figure 4.1 shows that all correlations are positive indicating that, as
a change occurs in one variable, for example pain, an associated change 
occurs in a second, such as nausea, suggesting a linear relationship 
between many of the variables studied. It is, however, not always clear 
which of the variables is the cause and which the effect since the 
relationship need not be unidirectional and could, instead, be
bidirectional thus confirming the close clinical relationship between
items. Since, in clinical studies, it is often impossible, and frequently 
unethical, to control one or two factors it is not always possible to
identify those factors responsible for producing spurious associations and 
to establish the probability of a relationship as a real occurrence
capable of a causal explanation. Thus, inferring a causal relationship
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between variables can lead to spurious conclusions. However, it is not 
always necessary to identify a causal relationship but simply to know that 
variables may be related. Nonetheless, regression analyses can be used to 
provide a means of testing whether a relationship remains after possible 
confounding variables have been taken into account.
Stepwise multiple regression procedures allow systematic investigation 
of the relationship between the dependent and independent variables and 
permit determination of the predictive ability of the independent 
variables by estimating whether or not the regression coefficient improves 
with the addition of a second, or subsequent, variable(s). In this study 
the dependent variable was the degree of symptom distress [the total score 
(SDS)]; the independent variables were those listed in Table 4.2.
TABLE 4.2. INDEPENDENT VARIABLES IN THE SYMPTOM DISTRESS SCALE.
1. Pain 7. Constipation
2. Nausea 8. Tiredness
3. Appetite 9. Concentration
4. Sleep 10. Mood
5. Mobility 11. Appearance
6. Diarrhoea
The best predictor of the level of symptom distress was tiredness which 
explains 63.5% of the variance amongst this sample of hospitalised cancer 
patients. This figure is highly statistically significant (P<0.001) 
(Table 4.3).
Mood, described on a continuum between 'could not feel more miserable1 
and 'could not feel happier', explained a further 16.8% of the variance 
followed by appetite and pain which contribute similar amounts to the 
total variance. These factors, taken together, accounted for 91.3% of the 
variance. The remaining items made only minor contributions to the total.
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TABLE 4.3. RESULTS OF MULTIPLE REGRESSION ANALYSIS - SYMPTOM DISTRESS.
Symptom Variance (%) Cumulative 
Variance (%)|
■f P
Tiredness 63.5 63.5 14.49 <0.001
Mood 16.8 80.3 10.11 <0.001
Appetite 5.6 85.9 6.94 <0.001
Pain 5.4 91.3 8.52 <0.001
Appearance 2.6 93.9 7.14 <0.001
Concentration 1.2 95.1 5.41 <0.001
Mobility 1.1 96.2 5.82 <0.001
Constipation 1.0 97.2 6.58 <0.001
Sleep 1.1 98.3 8.16 <0.001
Diarrhoea 1.0 99.3 12.46 <0.001
Nausea 0.7 100.0
These findings are interesting since the majority of the simple 
correlation coefficients between the independent variables were 
statistically significant. This is not, however, unusual since one of the 
functions of multiple regression procedures is to identify only the most 
important variables when the inter-correlations between them have been 
taken into consideration.
4.1.3 Conclusions.
Since from the correlation matrix (Figure 4.1), it can be seen that the 
correlation between tiredness and the total SDS is 0.8 (P<0.001), and 
since, with the exception of its relationship to diarrhoea, its 
correlation with all other variables is highly statistically significant 
this supports the use of tiredness as a predictive variable and suggests 
that the level of tiredness experienced by the patient is indicative of 
his general distress. However, tiredness alone will not account for all 
the distress as mood, appetite changes and pain also make statistically 
significant contributions to the total score. As can be seen from Table
4.4 these variables are significantly inter-related (P<0.001) and the 
relationship between them is supportive of their use as predictor 
variables although the contribution made by both appetite changes and pain
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TABLE 4.4. CORRELATION BETWEEN TIREDNESS, HOOD, APPETITE, PAIN AND THE
SYMPTOM DISTRESS SCORE.
Tiredness 1.00
Mood 0.42 1.00
Appetite 0.56 0.52 1.00
Pain 0.44 0.30 0.29 1.00
SDS Score 0.80 0.74 0.76 0.60 1.00
Tiredness Mood Appetite Pain SDS Score
is small and does not significantly improve prediction as they are closely 
correlated with the first two variables. These findings are consistent 
with those of the interview studies and, therefore, appear to support 
validity of the Symptom Distress Scale. However, it must be recognised 
that all items, with the exception of diarrhoea, make statistically 
significant contributions to the degree of symptom distress suggesting 
that, as expected, they are of equal importance in determining the extent 
of that distress and should be considered when planning the care for such 
patients.
It can be seen that the modified symptom distress scale provides a 
valid and reliable means of assessing the impact of individual symptoms in 
affected patients as well as providing an assessment tool for 
population studies. Subsequent measurement was also quick and provided a 
simple means of differentiating between areas of greater or lesser concern 
to individual patients.
Multiple regression analysis permits the conclusion that significant 
prediction of the degree of symptom distress can be obtained by 
consideration of just four variables (ie. tiredness, mood, appetite and 
pain). However, although these could be used to indicate the presence of 
distress, and to identify affected patients, simplification of the scale 
to include only these factors would limit its value in the assessment of
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the individual since it would fail to identify symptoms of particular 
concern with a consequent effect on patient care.
It seems likely that the presence of symptoms, such as those included 
in this scale, will affect the quality of the patient's life. The study 
discussed above confirms the validity of this scale and justifies its use 
as a part of the Quality of Life Index.
4.2. FURTHER INVESTIGATION OF THE QUALITY OF LIFE INDEX.
Since the pilot study indicated that the Quality of Life Index (QLI), 
based on a linear analogue scale (LASA), could be a useful tool for the 
assessment of the quality of life of cancer patients, and since 
evaluation of the Symptom Distress Scale showed it to be an effective 
means of assessing the degrees of distress, the QLI was used to evaluate 
the quality of life of a further heterogeneous, cross-sectional sample of 
121 patients (60 male; 61 female). The study was carried out over a 3 
month period using the methods previously described. The questionnaire was 
modified by the addition of a 'Uniscale1 (overall score) as described by 
Selby et al (1984). This is shown in Figure 4.2.
FIGURE 4.2. THE UNISCALE (Overall Score).
OVERALL SCORE,
Please score how YOU feel that your life has been affected by the 
state of your health as of today (the last 24 hours).
My life has become My life is normal
extremely unpleasant ______ ______________________ for me with no
due to the state of changes due to the
my health state of my health
4.2.1. Findings and Discussion.
All patients approached agreed to participate in the study and few 
problems were identified with the use of the LASA scale. Completion time 
was 10-15 minutes. The completed questionnaires were quick to measure and
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to score; there was no evidence of response sets.
Internal consistency (reliability) was established by computation of 
Cronbach's coefficient alpha yielding a coefficient of 0.99 and 
indicating that the instrument was extremely reliable in this patient 
population.
Validity was re-examined by interviewing patients after participation 
and inviting their comments on the use of this instrument as an assessment 
tool. Clearly individual patients found particular items of greater or 
lesser concern but, overall, the comments indicated that they felt the QLI 
represented a valid assessment of the effects of the disease, and its 
treatment, on their lives as a whole. Although the value of such 
interviews is limited this helps to support the content validity; no 
significant omissions were identified by this population.
The correlation matrix, on which further analysis was based, is shown in 
Figure 4.3 (overleaf). From this it can be seen that all correlations 
between variables were positive although not all were statistically 
significant. Of the 325 correlations shown in the matrix, 239 were 
significant at the 95% level (P<0.05) or greater suggesting that most of 
the items are closely inter-related. All items contribute significantly 
(P<0.001) to the total score the lowest being the correlations those 
between the total and diarrhoea, earning ability and communication with 
both family and the nursing staff although these too were statistically 
significant.
The questionnaire (Appendix 1) also permitted the patients to 
identify areas of particular concern although, as before, not all patients 
answered this part of the questionnaire. Factors causing greatest concern 
are summarised in Table 4.5. It is interesting to note that not all 
changes were negative and that 7 patients (5.8%) found their outlook had 
become more positive since the onset of their illness.
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FIGURE 4.3. CORRELATION MATRIX: QUALITY OF LIFE STUDY.
1 I 1.
2 j .48 2.
3 I.28 .46 3.
4  | .36 .35 .42 4.
5 I.46 .46 .43 .15 5.
6 I .25 .20 .31 .13 .15 6.
7 j .30 .26 .44 .22 .35 .13 7.
8 I .44 .40 .56 .47 .52 .09 .53 8.
9 I .31 .45 .45 .55 .42 .09 .39 .64
10 l .29 .53 .52 .50 .43 .13 .42 .48 .69
1 1 1.32 .45 .60 .32 .54 .19 .44 .62 .57
1 2 1.34 .49 .76 .42 .41 .27 .35 .41 .43
13 j .43 .42 .48 .38 .39 .08 .32 .48 .49
14 j
CM .38 .46 .37 .32 .08 .34 .37 .43
15 j .36 .36 .49 .78 CO to .19 .35 .55 .60
16 l .22 .29 .37 .26 .37 .02 .27 .36 .32
17 j .22 .36 .31 .43 .14 .03 .42 .32 .30
18 j .26 .36 .56 .33 .33 .29 .68 .46 .36
19 j .45 .32 .44 .45 .59 .23 .34 .56 .49
20 j .34 .29 .47 .47 .49 .30 .26 .40 .44
2 1 1.19 .19 .23 .30 .32 .26 .26 .25 .30
22 j .12 .30 .14 .18 .19 .06 .06 .10 .12
23 j .20 .18 .39 .42 .09 .21 .22 .33 .56
2 4 1.04 .42 .04 .20 .01 .06 .17 .14 .16
25 j .17 .35 .34 .16 .14 .31 .13 .19 .35
2 6 1.01 .67 .19 .18 .14 .02 .06 .04 .22
2 7 1.54 .64 .74 .65 .63 .32 .57 .72 .73
1 2 3 4 5 6 7 8 9
Pain
Sleep
9. Concentration
10. Mood
11. Appearance
12. Ability to eat
 Physical Activity 13. Flavour
Diarrhoea 14. Texture
15. Sleeping pattern
16. Breathing
17. Urination
18. Bowel pattern 
19 Recreation
20. Life changes
21. Future concern
22. Earning ability
23. Isolation
24. Communication - family
25. Communication - doctors
26. Communication - nurses
27. Total score
.75
.37
.04 .38
.34 .36 .15
.19 .16 .15 .40
.27 .08 .05 .49 .25
.07 .11 .13 .41 .29 .45
.67 .49 .26 .60 .34 .45 .33
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Correlation coefficients >0.25 significant at P<0.05 or above.
Forward stepwise regression analysis reveals 3 major predictors of 
the responses to the QLI. These were changes in the ability to sleep 
(62.1%) and appetite (16.2%); nausea was common (6.3%). Table 4.6 shows 
that other factors act as minor predictors of variance although their 
contribution, together with that of the remaining variables, is 
negligible. These figures are highly statistically significant and are 
consistent with those identified in the Symptom Distress studies when 
tiredness was found to predict 63.5% of the variance and appetite 5.6%; 
they are also consistent with the findings of the interview studies. 
Interestingly, although nausea accounts for variability in responses to
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TABLE 4.5. FACTORS OF PARTICULAR CONCERN TO THE PATIENTS INCLUDED IN THE
QUALITY OF LIFE STUDY.
Number affected (%)
Generalised weakness/loss of energy 38 (31.7)
Loss of weight 37 (30.8)
'How will family cope?1 26 (21.7)
'I am not prepared properly to die1 21 (17.59
Urinary frequency 10 ( 8.3)
Lack of motivation 10 ( 8.3)
Hair loss 9 ( 7.4)
Backache 6 ( 5.0)
'Makes you feel older' 6 ( 5.0)
Loss of job 6 ( 5.0)
'My family don't appear concerned' 3 ( 2.5)
Positive Outcome
Re-examined lifestyle - life now 3
more enjoyable & worthwhile
Mind has become concentrated 2
Outlook more positive » 2
the QLI this is less significant in accounting for the degree of symptom 
distress. Similarly, mood changes account for 16.8% of the variance in the 
SDS but contribute an insignificant percentage in determining the total 
QLI score.
Multiple regression was terminated after identification of these ten 
items since no others could be found which would improve the total 
prediction when these variables were held constant.
TABLE 4.6. MULTIPLE REGRESSION ANALYSIS (QUALITY OF LIFE STUDY).
Symptom Variance (%) Cumulative 
Variance (%)
't* P
Sleep 62.1 62.1 14.07 <0.001
Appetite 16.2 78.3 9.46 <0.001
Nausea 6.3 84.6 7.01 <0.001
Recreation 3.6 88.2 6.02 <0.001
Texture 2.8 91 .0 6.28 <0.001
Constipation 1.2 93.2 6.18 <0.001
Isolation 1.6 94.8 5.91 <0.001
Appearance 1.1 95.9 5.60 <0.001
Earning ability 0.7 96.6 5.10 <0.001
Mobility 0.4 97.0 3.88 <0.001
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TABLE 4.7. COMPONENT CORRELATIONS (LOADINGS) OF THE FIRST FIVE
PRINCIPAL COMPONENTS (Quality of Life Index).
(Details of the first five components; an abbreviated version of the 
statement at the favourable end of each scale is also shown).
1 2 3 4 5
1. No pain 0.2
2. Not feeling sick 0.2
3. Appetite normal 0.2
4. Sleep well 0.2 0.3
5. Physical activity normal 0.2
6. No diarrhoea 0.6
7. Not constipated 0.2
8. Not tired 0.2
9. Concentration normal 0.2
10. Feel happy 0.2
11. Appearance unchanged 0.2
12. Eat normally 0.2
13. Food tastes normal 0.2
14. Texture of food feels normal 0.2
15. Sleeping normally 0.3
16. Breathing normal 0.2 0.3
17. Urination normal 0.3
18. Bowel function unchanged 0.2
19. Recreational activity normal 0.2 0.3
20. Can do everything I used to do 0.2
21 . Not worried about the future 0.4
22. Not worried about earning ability 0.5
23. Do not feel isolated 0.2 0.3 -0.3
24. Can discuss feelings with family 0.3 0.3
25. Can discuss feelings with doctors 0.2 0.4 0.3
26. Can discuss feelings with nurses 0.5
VARIANCE ACCOUNTED FOR 36.8% 7.7% 6.2% 5.4% 5.0% TOTAL
61 .1%
NB Only the main contributors of each component are shown.
Principal components analysis (PCA) (Table 4.7) shows that the first 
component accounts for 36.8% of the variation in the total score and the 
first five, together, account for 61.1% of the variance. The contribution 
of the remaining components accounts for a total of 38.9% although the 
individual contribution of each is small (ie. <5.0%).
The first component may be interpreted as representative of 'physical 
comfort' or 'symptom distress' and the relationship between such symptoms 
and 'isolation' can be explained on clinical grounds. For example, pain
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can serve as an isolating factor, sufferers feeling 'separated1 by their 
feelings and discomfort. A failure in communication between doctors and 
patients could contribute to an increase in symptom distress since
patients may feel unable to discuss their occurrence with the attending 
physician. The second component can be seen to largely represent
'communication' or the 'psychosocial' domain. Feelings of isolation may 
also be increased by enforced changes in patterns of recreational activity 
which may also affect communication with family and friends. The third 
component comprises concern over the future and includes concern over 
earning ability; this could be abbreviated to 'future concerns' although 
further elucidation would then be required.
An inverse relationship is revealed between feelings of isolation and 
an ability to discuss feelings with the family, sleep, breathing and 
urinary function; these factors, together, comprise the fourth component. 
Although, when taken together, they contribute only 5.4% of the variance 
they are obviously significant in determining the quality of life of 
affected patients. Clearly the link between isolation and an inability to 
communicate with the family is a matter of concern and will markedly
affect QL. Changes in sleeping pattern may result from breathing
difficulties or alterations in urinary function so that this may explain 
the relationships between these factors whilst an inability to sleep, or 
disturbed sleep, may exacerbate tiredness which has, previously, been 
identified as a major factor in predicting the QL of cancer patients.
Diarrhoea stands alone as the fifth component although, interestingly, 
it does not appear to be a major factor in the 'physical comfort' 
component. This may be because diarrhoea was identified as an area of 
concern by only 27 (22.5%) patients in this study. Changes in bowel 
pattern do contribute to the first component although, in this case, the 
changes relate to constipation rather than to diarrhoea. This could be
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seen to suggest that the scale could be simplified to include a single 
question on changes in bowel habits although this would not identify the 
form such changes take.
Since these components accounted for 61.1% of the total variation, and 
since no clear interpretation was possible for the remaining 
components, further analysis was not attempted. However, it should be 
noted that the component correlations were low so that no single, highly 
loaded component could truly be identified. In view of the relative 
importance of the 'physical factors' in determining the total quality of 
life score a second PCA was carried out looking only at the first part of 
the instrument (the Symptom Distress Scale), with total QLI score as the 
dependent variable, in an attempt to identify the primary contributors. 
The results are given in Table 4.8.
As the five components shown in Table 4.8 accounted for most of the
observed variance further analysis was not attempted on this section.
Instead, the second section [Activities of Daily Living (ADL)] was
examined in an attempt to identify the major causes of variance in this
part of the instrument. The total QLI score was the dependent variable.
TABLE 4.8. COMPONENT CORRELATIONS (LOADINGS) OF THE FIRST FIVE 
PRINCIPAL COMPONENTS (SECTION 1 OF THE QL INDEX).
1 2 3 4 5
1. Pain 0.3 0.5 -0.4
2. Nausea 0.3 0.5
3. Appetite 0.3 -0.5
4. Sleep 0.3 -0.4
5. Mobility 0.3 0.4
6 Diarrhoea 0.8 0.5
7. Constipation 0.3 0.6 0.4
8. Tiredness 0.3
9. Concentration 0.3
10. Mood 0.3
11. Appearance 0.3
VARIANCE ACCOUNTED FOR 46.4% 9.9% 8.3% 7.9% 6.4%
NB. Only the main contributors of each component are shown.
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TABLE 4.9. COMPONENT CORRELATIONS (LOADINGS) OF THE FIRST FIVE 
PRINCIPAL COMPONENTS (SECTION 2 OF THE QL INDEX).
1 2 3 4 5
Ability to eat 0.3
Flavour of food 0.3
Texture of food 0.3
Ability to sleep 0.3
Breathing
Urination 0.5
Bowel pattern
Recreational activity
Life changes
Concern about the future 0.5
Earning ability 0.6 0.5
Isolation
Communication - family 0.5
Communication - doctors
Communication - nurses 0.5
VARIANCE ACCOUNTED FOR 46.4% 9.9% 8.3% 7.9% 6.4%
NB. Only the main contributors to each component are shown.
Table 4.9 shows that, again, five principal components can be 
identified which, together, comprise 78.9% of the variance. Although it is 
possible to single out further components their individual contribution is 
minor and adds little information to that provided since the factors 
concerned are, in any case, contributors to the major components already 
identified.
The first component suggests a relationship between the ability to eat, 
together with changes in the flavour and texture of food, and the ability 
to sleep. These appear to be important predictors of QL; these results are 
consistent with those obtained from multiple regression analysis (Table 
4.6) and from the correlation matrix.
The second component, accounting for 9.9% of the variance in responses, 
relates to communication between the nursing staff and the patient 
suggesting that this is an important predictive variable in determining 
the well-being of the hospitalised patient. This finding is consistent 
with that of the pilot study (Chapter 3).
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Concern over both the future per se and future earning ability are 
revealed as the third principal component. This is consistent with the 
earlier findings when 'future concerns' also comprised the third 
component. Concern over earning ability also stands alone as the fifth 
component. These factors are clearly of considerable importance in
determining well-being.
Two apparently unrelated factors, urination and communication with the 
family, together comprise 7.9% of the variance and represent the fourth 
component. As passing urine is usually an easy and pain free task it is 
likely that changes in urinary function will cause considerable disruption 
and, as a result, affect QL. The fact that this appears to be related to 
communication with the family seems to represent a spurious relationship 
and would, rather, suggest that they both contribute equally to the
variance.
4.3. Discussion.
The LASA scale was found to be easy to use and quick to score and 
displayed good discriminative ability thus confirming the findings of the 
pilot study. Its reliability was excellent in this population and, since 
Cronbach's coefficient alpha provides a conservative estimate of
reliability (Carmines & Zeller, 1979), the alpha of 0.99 is again 
supportive of its use as an assessment tool in this patient population and 
also supports the validity of the instrument (see below). The repeatedly 
high reliability estimates serve to support the use of this instrument for 
a variety of studies. Response sets were not apparent in the studies 
discussed in this chapter. The addition of the Uniscale, as proposed by 
Selby et al (1984), further supports the validity of the tool (r = 0.9 
P<0.001).
Barker Baussell (1986) suggests that, in developing an instrument, the 
first step - selection of items for inclusion - represents an attempt to
ensure content validity and is, in reality, an a priori consideration of
construct validity. Since the concept of content validity is directly 
proportional to the amount that is known about the entity to be measured 
assurance of such validity becomes increasingly difficult as this becomes 
more abstract. However, no instrument can be valid if it is not reliable 
and if its content validity does not match or reflect its purpose.
The internal consistency of this instrument supports its reliability 
and, therefore, its validity; patient interviews (following participation) 
indicated that the QLI represented a valid assessment of the impact of
changes in their life (ie. their quality of life). It is not clear
whether it is appropriate to give equal weighting to all items included in
the scale and it is possible that the tool may lack sensitivity for this
reason. Nonetheless, it does appear to discriminate between areas of
greater and lesser concern to individual patients, which supports its 
content validity, and weighting of individual items would, in any case, 
prove difficult since the items of particular concern are subject to 
marked individual variation so that it would be difficult to identify an 
appropriate weighting scheme.
The internal structure of the instrument was further evaluated by 
statistical means. Principal components analysis (a variant of factor 
analysis) revealed four major dimensions and suggested that symptom
distress (physical comfort) is a major contributor to changes in the
quality of life of patients hospitalised for the treatment of cancer thus 
lending further support to the hypothesis that the severity of symptoms 
has a significant impact on the quality of life of such patients.
In view of the significance of the first section of the instrument and 
the influence of physical symptoms on quality of life attempts were made 
to identify the primary contributors to the distress they cause. However, 
statistical analysis shows that all symptoms, with the exception of
diarrhoea, contribute equally to the variance in responses and suggests 
that they are all important determinants of the degree of distress 
suffered by the patients. Thus, although principal components analysis 
appears to suggest that simplification of the item relating to changes in 
bowel habits would be appropriate, the net effect only served to further 
support the original hypothesis.
Further study of the ADL also revealed 'physical factors' (appetite and 
sleep) as the primary components of the variance although, pyschosocial 
factors, such as concern about the future and communication with nursing 
staff and family, were also significant.
Feelings of isolation also appeared to be exacerbated by an inability 
to discuss feelings with the family; this was supported by a 
statistically significant zero order correlation (r = 0.41 P<0.001). Quite 
how this problem can be overcome is unclear but it is possible that both 
medical and nursing staff could help to improve this by talking to the 
patient and his family together and by providing increased psychosocial 
support for both groups.
Principal components analysis resulted in a reduction of the 
dimensionality of the data from 26 to 5 items (ie. physical comfort, 
psychosocial (communication) factors, future concerns, isolation and 
changes in bowel habits); these are consistent with those areas outlined 
by Patterson (1975) (see Chapter 2). Thus it appears that the statistical 
methods employed were effective in simplifying the data and could permit 
development of a simplified, and more concise, index. However, as 
previously shown, the items included were chosen to represent a particular 
selection of characteristics, all of which were deemed significant to the 
cancer patient, and, prior to data collection, groupings of the questions 
were perceived which, with the exception of the changes in bowel habits, 
were similar to the components extracted. However, although simplification
of the index may make population studies easier a great deal of 
information would be lost in attempts to assess the individual and limit 
its use in clinical practice since simplification would mask individual 
tendencies and could result in a loss of discriminative ability.
4.4 SENSITIVITY, VALUE AND DISCRIMINATIVE ABILITY.
For an instrument to be useful in clinical practice it must be not only 
reliable and valid but also sensitive and 'meaningful1. This means that it 
must be sensitive to change and display an ability to discriminate between 
individual patients or groups of patients (Selby, 1985). At the same time 
the results obtained must be useful and provide a means of assessment 
which reflects the patient's true condition. The previous discussion has 
explored the reliability and validity of the QL Index concluding that it 
is a valid and reliable means of assessment and showing that it is both 
feasible for use in clinical practice and acceptable to patients. The 
evaluation process has been continued by consideration of its sensitivity 
and value (meaningfulness) through study of its ability to discriminate 
between both individuals and groups of patients.
Sensitivity describes the ability of a tool to detect fine 
differences among subjects. Since ordinal and nominal scales cannot 
distinguish significant differences in the dependent variable (Abdellah & 
Levine, 1986) it was felt that a linear analogue scale would increase 
sensitivity since the subject is not restricted to direct quantitative 
terms and so can make as fine a discrimination as he wishes (Freyd, 1923). 
Although the scores obtained using this technique have no true 
quantitative terms they do represent positional values indicative of the 
patient's response. Thus, although we can say that a patient scoring 70 
has less distress from a particular symptom than one with a score of 40, 
we cannot actually say how much lower is his degree of distress. 
Nonetheless it is possible to estimate the number of patients suffering
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significant distress by arbitrary subdivision of the scale.
1 Meaningfulness1 has been used to describe the value of an 
instrument (ie. does it have practical meaning and value?) (Abdellah & 
Levine, 1986). It, therefore, represents a pragmatic test of the 
instrument as a whole. The value of an instrument is related to the three 
tests previously described (ie. validity, reliability and sensitivity) so 
that, if it is not valid, it cannot be meaningful; if it is not reliable 
it cannot yield meaningful results and, if it is insensitive, it loses 
its meaningfulness.
4.4.1 Methods.
Three studies were undertaken in an attempt to evaluate the 
sensitivity, discriminative ability and 'meaningfulness' of the QLI.
1. A heterogeneous sample of 40 patients (20 male, 20 female) was
randomly selected from those admitted to the oncology wards. Patients were 
assessed on two occasions at 2 week intervals at which time they were
asked to complete the QLI and their physical condition was assessed both
by clinical assessment and by discussion with the medical and nursing 
staff. This enabled patients to be classified into one of three categories 
- improving, unchanged or deteriorating on clinical grounds. 2 patients 
died during the course of study; the data discussed relate to the 38 
remaining patients.
The sensitivity of the instrument was evaluated by comparison of the 
results obtained using Student's 't' test for paired data. The mean and 
standard deviation of the change in the totals of both sections and 
overall score were calculated.
2. Discriminative ability was studied by comparison of the results
obtained from a further random sample of 30 patients (17 male, 13 female) 
with widespread metastatic disease with those of a similar sample (15 
male, 15 female) of newly diagnosed patients with no known metastases.
3. The results obtained from another cross-sectional sample of 60 
patients (31 male, 29 female) undergoing radiotherapy on an in-patient 
basis were compared with those of a similar sample of patients undergoing 
out-patient therapy.
Data from studies 2 and 3 were analysed by means of Student's 't' test 
for unpaired data and by calculation of the mean and standard deviation of 
the scores obtained on each section of the instrument as well as that of 
the total score.
4.4.2 Findings.
The findings indicate that the instrument is sensitive to changes in 
individual patients, particularly with regard to the incidence of symptom 
distress. However, when looking at the population as a whole, or at 
individual patients, changes in symptom distress score (SDS) were not 
always associated with the expected change in the activities of daily 
living (ADL). For example, those patients whose condition was found to be 
improving on clinical grounds (Table 4.10) obtained, as predicted, an 
increased SDS although, overall, ADL remained unchanged. This effect was, 
however, subject to considerable individual variation but, of those 
reporting improvement in ADL, much of this could be attributed to an 
improvement in communication between the patients and the health care 
team. This may be a function of prolonged hospitalisation which permits 
relationships to develop between the people concerned. In general, 
however, the results indicate that, although clinical improvement was 
evident, this did not, of necessity, improve the overall quality of life, 
at least in hospitalised patients. Such findings may simply be a 
reflection of hospitalisation, which separates the patient from his normal 
environment, although they do suggest that control of distressing symptoms 
will not necessarily lead to concomitant improvement in either daily 
activities or psychosocial factors.
TABLE 4.10. COMPARISON OF THE RESULTS OBTAINED FROM ADMINISTRATION OF THE
QUALITY OF LIFE INDEX ON 2 OCCASIONS (N = 38).
Patient Group Section Range X (+SD) ,t' Ii
Improving 1 (SDS) +9 - +289 87.4 (+92.5) 3.892 <0.05
(N = 17) 2 (ADL) -652 - +902 4.5 (+329.5) 0.057 NS
Total -643 - + 1165 95.4 (+385.7) 0.992 NS
Deteriorating 1 (SDS) -725 - -17 -227.8 (+254.0) 3.586 <0.001
(N = 16) 2 (ADL) -646 - + 125 -137.0 (+211.7) 2.637 <0.05
Total -1106 - -28 -375.0 (+425.2) 3.385 <0.001
Unchanged 1 (SDS) -1 - -33 8.8 (+13.7) 1 .868 NS
(N = 5) 2 (ADL) +22 - +70 42.0 (+22.3) 4.220 <0.05
Total +5 - +69 33.2 (+28.4) 2.246 NS
Range = range of changes recorded over time
It is clear, however, that an increase in symptom distress is 
associated with a decrease in well-being since, with only 3 exceptions, 
patients showing a clinical deterioration showed a decrease in SDS, ADL 
and total scores. Again, of those achieving higher scores on the ADL 
index, the improvement was predominantly due to an increase in the scores 
obtained for items related to communication with the caring team. One 
patient reported a decrease in the degree of pain he was suffering, 
perhaps indicating the success of his pain control regime, although this 
score was offset by a decrease in the scores for constipation and bowel 
pattern. This shows that the index is able to identify areas of change and 
supports the suggestion that it could enable patient care to be dynamic 
and responsive to patients1 changing needs. In general, the results 
suggest that the index accurately reflects clinical deterioration.
Although the number of patients whose condition remained unchanged was 
very small (N = 5) the results showed only minor changes in all three 
scores thus suggesting that the instrument provides a reliable and stable 
means of assessing general well-being. These findings permit the
conclusion that the QLI could be used in longitudinal studies of 
individual patients since it appears to be sensitive to clinical change.
It was anticipated that those patients with metastatic disease and 
those receiving in-patient treatment would show a greater degree of 
symptom distress and a lower overall quality of life than those patients 
who were newly diagnosed or undergoing out-patient therapy. This was 
supported by the results (Tables 4.11 and 4.12).
TABLE 4.11. COMPARISON OF THE RESULTS OBTAINED FROM PATIENTS WITH
METASTATIC DISEASE (M) AND NEWLY DIAGNOSED (EARLY STAGE) (E) PATIENTS.
M (N = 30) E (N = 30) •t" P
Section 1 (SDS) Range 288 - 1053 673 - 1100 6.425 <0.001
x (+SD) 704 (+227.8) 1000.7 (+109.9)
Section 2 (ADL) Range 723 - 1246 979 - 1500 8.647 <0.001
x (+SD) 961.7 (+124.4) 1287.4 (+172.6)
Total Score Range 1107 - 2283 1877 - 2600 9.532 <0.001
x (+SD) 1665.5 (+291.1) 2298.1 (+217.8)
Range = range of scores obtained
Table 4.11 shows that the index is able to discriminate between those 
patients with metastatic disease and those in the early stages of the 
disease since the differences between the groups were all highly 
significant. In all cases (ie. between individual items, sectional scores 
and total scores) the patients with metastatic disease achieved low scores 
suggesting that their degree of symptom distress was generally higher and 
their quality of life lower than that of the newly diagnosed. Since, in 
general, the physical condition of those with metastatic disease was lower 
than that of the newly diagnosed these results are consistent with the 
expected findings.
Similarly, Table 4.12 shows the differences between patients undergoing 
radiotherapy on an in-patient or out-patient basis. As expected there are
TABLE 4.12. COMPARISON OF THE RESULTS OBTAINED FROM PATIENTS UNDERGOING
RADIOTHERAPY ON AN IN-PATIENT (A) OR OUT-PATIENT (B) BASIS.
A (N = 60) B (N = 60) 't' P
SDS Range 275 - 1100 538 - 1100 3.093 <0.01>0.001
x (+SD) 733.8 (+201.8) 887.1 (+138.2)
ADL Range 365 - 1491 742 - 1500 5.367 <0.001
x (+SD) 1032.6 (+263.1) 1264.1 (+210.6)
Total Score Range 911 - 2585 1384 - 2600 5.461 <0.001
x (+SD) 1766.3 (+430.4) 1912.41 (+535.3)
Range = range of scores obtained. NS = Not significant
significant differences between the groups which appear to suggest that 
in-patients, in general, suffer a greater degree of symptom distress, 
greater restriction on the activities of daily living and a lower overall 
quality of life. This is further illustrated by Figure 4.4 which 
highlights the differences between the two groups with regard to 
particular symptoms and, in Figure 4.5, with regard to the overall scores 
obtained (Uniscale). Table 4.13 compares the incidence of significant 
symptom distress between the two patient populations.
TABLE 4.13. COMPARISON OF IN-PATIENTS AND OUT-PATIENTS:
INCIDENCE OF SIGNIFICANT SYMPTOM DISTRESS. 
(Score <50 on individual items).
In-Patients 
Symptom No. affected(%)
Out-Patients 
Symptom No. affected(%)
Tiredness 27 (45.0) Tiredness 28 (46.7)
Appearance 21 (35.0) Mood 14 (23.3)
Concentration 21 (35.0) Sleep 11 (18.3)
Mood 21 (35.0) Appetite 10 (16.7)
Mobility 21 (35.0) Concentrat i on 10 (16.7)
Sleep 17 (28.3) Constipation 7 (11.7)
Appetite 14 (23.3) Pain 6 (10.0)
Constipation 12 (20.0) Appearance 5 ( 8.3)
Pain 7 (11.7) Nausea 4 ( 6.6)
Nausea 4 ( 6.7) Mobility 4 ( 6.6)
Diarrhoea 4 ( 6.7) Diarrhoea 1 ( 1.6)
Although both groups of patients recorded tiredness as the symptom 
causing the most significant distress marked differences were seen 
between the in-patients and out-patients with regard to the incidence of 
distress from other symptoms. Out-patients primarily believed that the 
tiredness they were experiencing was due, primarily, to the difficulties 
associated with travelling to and from the hospital on a daily basis and 
the, frequently long, wait for treatment or doctor's appointments. This 
is clearly a significant factor contributing to a decrease in patient 
well-being and interacts with the physical side-effects of the treatment. 
In-patients on the other hand, were unable to identify a specific cause of 
this problem; it is possible that the act of hospitalisation and the 
development of 'disuse phenomena' and boredom are contributory factors.
Depressed mood and the inability to sleep were the next most commonly 
reported causes of distress in out-patients compared with changes in 
appearance, concentration, mood and mobility in in-patients, all of which 
significantly affected 35% of the patients studied. Since depressed mood 
and an inability to sleep will, clearly, influence tiredness it is 
possible that, despite out-patient's reports to the contrary, these 
factors are significant, if unrecognised, contributors to the degree of 
tiredness. Similarly, mood changes may contribute to tiredness in the 
in-patients as may changes in the ability to concentrate since this may 
inhibit the ability to make use of distraction techniques. Difficulty in 
mobilisation may also contribute to tiredness. It is not surprising that 
fewer out-patients reported poor mobility as a major problem; this would 
be an expected observation as, by implication, out-patients should be more 
mobile and less ill than in-patients.
FIGURE 4.4. COMPARISON OF SEVERITY OF SELECTED SYMPTOMS BETWEEN IN-PATIENTS
OUT-PATIENTS UNDERGOING RADIOTHERAPY.
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FIGURE 4.5 COMPARISON OF OVERALL SCORES IN IN-PATIENTS AND OUT-PATIENTS.
UNISCALE (Overall Score).
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4.4.3 Discussion.
Further evaluation has shown that the instrument is sensitive to 
changes in general condition both with regard to individual patients and 
in the population as a whole when it appears to discriminate between those 
showing clinical signs of improvement or deterioration. Equally it appears 
to demonstrate the differences between those receiving radiotherapy as an 
in- or out-patient when it would be anticipated that out-patients would be 
generally in better health than in-patients.
The symptom distress scale (Section 1 of the questionnaire) is 
particularly sensitive and could, clearly, enable identification of the 
severity of particular symptoms which would, in turn, enable the design of 
appropriate interventions to reduce their impact. Since the instrument 
appears sensitive to changes with time it could provide a means of 
evaluating the effectiveness of such interventions enabling care to be
dynamic and responsive to patient's changing needs.
It is, however, interesting to note that changes in the degree of
symptom distress are not, of necessity, associated with an improved ADL, 
particularly in the hospitalised patient. Since it has been suggested
(Coe, 1978) that hospitalisation per se causes a marked depersonalisation 
by stripping the patient of personal items, regulating the resources 
available to him and restricting his mobility within the hospital it is
not surprising to find that the overall QL of out-patients exceeds that of 
in-patients. In addition, it is to be expected that those patients 
'suitable1 to receive treatment on an out-patient basis are generally in 
better health than those requiring hospitalisation although out-patients 
frequently report that the treatment itself is tiring; the, sometimes 
prolonged, wait for hospital transport, appears to exacerbate this effect. 
Thus the findings of these studies serve to support the use of this
instrument as an assessment tool both in individual patients - in whom it 
could serve to enhance care - and in population studies which depend on 
identification of the differences between particular groups.
It appears that tiredness is a common accompaniment to malignant
disease affecting a significant number of patients and correlating closely 
with many of the other variables . Of particular concern in the context of
these studies is the relationship between tiredness and appetite since it
has previously been shown (Chapter 1) that cancer carries with it a 
significant number of nutritional changes many of which may contribute to 
the development of malnutrition. Thus, if tiredness acts to depress the 
appetite, over and above that caused by cancer per se, care should be 
directed towards its alleviation. However, from the data available, it is 
not possible to identify which of these symptoms is the cause and which 
the effect. It is equally possible that a loss of appetite, which will, 
ultimately, result in a decline in nutritional status, is a factor
contributing to tiredness.
Similarly, there is good correlation between mood and appetite and it 
is also possible to suggest that nutritional depletion may be a factor 
contributing to the observed mood changes. This highlights the close 
relationship between the symptoms included in the QLI and nutritional 
status and appears to support the hypothesis that quality of life and 
nutritional status are closely inter-related and, at least to some extent, 
inter-dependent.
4.5 CONCLUSIONS.
An instrument has been developed and has been shown to be both valid 
and reliable, to be feasible in clinical practice and to be acceptable to 
the large number of in-patients involved. The studies described have shown 
that it is sensitive to the differences between individual patients and to 
support the predicted differences between groups of patients. The LASA 
scale appears to permit such differentiation in a way which would not be 
possible if using a Likert-type scale when the intervals between scale 
points cannot be truly interpreted since it cannot be assumed that these 
are equal (Abdellah & Levine, 1986).
It is less easy to establish the 'meaningfulness1 (value) of the 
instrument. However, since it has been shown to be valid, reliable and 
sensitive this appears to support its value and patient interviews 
following participation, suggest it is useful since they believe that it 
covers the areas of their life most affected by the presence of the 
disease. Thus the tool appears to have value as an assessment tool.
Tiredness is clearly the most significant factor in determining 
response to the QLI; it is also the symptom most commonly reported as a 
cause of distress. Multiple regression analysis suggests that an inability 
to, or disturbance of, sleep is significant in determining variations in
the total score. PCA suggests that symptom distress has a marked influence 
on QL. Since both tiredness and inability to sleep are contributors to
this component it can be suggested that symptom distress per se
contributes to disturbed sleep and tiredness.
Although statistical analyses suggest simplification of the index is
possible this would result in a significant loss of information in
attempts to assess individual patients.
CHAPTER 5.
FOOD INTAKE, NUTRITIONAL STATUS AND QUALITY OF LIFE.
It has been suggested (Chapter 2) that a decline in nutritional status 
is associated with a corresponding decrease in the quality of life. A 
prolonged reduction in food intake will result in a decrease in 
nutritional status so that it can be suggested that a decrease in food
intake per se will decrease the quality of life. The studies described
were undertaken in an attempt to discover:
a) Whether hospitalised cancer patients eat 'adequate' amounts of food 
and how best this may be assessed.
b) Whether such patients are malnourished or likely to become so.
c) Whether undernutrition is associated with a reduced quality of life.
5.1 ASSESSMENT OF DIETARY INTAKE.
Dietary intake, and the validity of data obtained, were evaluated in 
two separate studies the first of which relied on the dietary recall 
method, which was validated by means of weighed intake studies, and the 
second on three day weighed intakes.
5.1.1 Study 1. Validation of the Dietary Recall.
18 male and 18 female patients were randomly selected for inclusion in
this study providing a group of subjects representative of the in-patient 
population at any given time. Details of those completing the study are 
given in Table 5.1; 4 patients were discharged before completion.
All food and drink presented over a 24 hour period was weighed using a 
dietary balance accurate to 1g; plate waste was also weighed thus enabling 
accurate recording of the food consumed. Participants were interviewed on 
the following afternoon when they were asked to recall what they had eaten 
on the previous day and to estimate the quantity. Since patients were 
unaware of the pending interview this meant that not only was there an 
accurate record of consumption but there was also an opportunity to
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TABLE 5.1. DETAILS OF PATIENTS COMPLETING DIETARY RECALL STUDY.
HALES FEMALES
Age Site of Primary Treatment Age Site of Primary Treatment
Disease Disease
76 Bronchus RT 76 Lymphoma 0
78 Prostate 0 79 Lung CT
57 Bladder RT 56 Bladder CT
77 Lymphoma CT 57 Ovary CT
57 Prostate RT 61 Breast RT
61 Prostate RT 66 Cervix RT
75 Osteosarcoma RT 74 Ovary RT
66 Prostate CT 66 Bladder RT
66 Bladder RT 78 Bronchus RT
73 Bladder CT 79 Cervix RT
73 Lymphoma CT 76 Bronchus CT
65 Bladder RT 75 Breast CT
79 Lung CT 73 Colon CT
75 Bronchus CT 78 Bladder RT
77 Colon CT 65 Breast CT
75 Lymphoma CT
76 Breast CT
Mean age (yrs) Mean age (yrs)
71.2 +7.5 70.3 +7.4
CT == Chemotherapy. R == Radiotherapy. 0 = No Treatment
evaluate the use of the 24hr recall as a measure of food consumption for
use in later studies.
The weighed intake data were compared with those of the dietary recall
and the nutrient composition calculated using the Superdiet computer
programme [based on data presented by Paul and Southgate (1978)]. This
enabled analysis of both actual and recalled food consumption. The results
were compared using Student's 't' test for paired data and, in the case of
2.
energy consumption, also by means of Chi squared (X ) analysis using 
Brandt and Snedecor's formula (Bailey, 1981). Actual food consumption was 
compared with the Recommended Daily Amounts (RDA) (DHSS, 1979) (see 
Appendix 3).
Results.
Detailed results for energy and protein intake are presented in Table
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TABLE 5.2. ENERGY AND PROTEIN INTAKE: ACTUAL V RECALL DATA (N = 32).
ACTUAL RECALL
Age S kcal %RDA Protein %RDA Protein kcal %RDA Protein %RDA Protein
(g) %energy (g) %energy
76 F 840 50.0 27.5 65.5 13.1 1286 76.6 53.4 127.1 16.6
78 F 1796 107.0 49.1 116.9 10.1 1366 81 .4 54.2 129.1 15.9
57 F 1675 87.4 49.9 106.2 11.9 1941 101 .0 63.1 134.3 13.0
56 F 627 32.7 14.5 30.9 9.3 343 17.8 12.8 27.2 14.9
76 M 1998 92.6 67.4 124.8 13.5 1565 72.5 49.8 92.2 12.7
66 F 1367 71 .3 45.6 97.0 13.4 1520 79.3 47.5 101 .1 12.5
66 F 1209 63.0 45.3 96.4 14.9 820 42.8 32.4 68.9 15.8
73 F 2009 104.0 53.1 112.9 10.6 2777 144.0 72.4 154.1 10.4
65 F 120 6.3 3.2 6.8 10.7 612 31 .9 30.9 65.8 20.2
79 F 1705 101.0 72.7 173.0 16.9 1713 102.0 56.6 139.8 13.2
76 F 2222 132.0 62.5 148.8 16.9 1693 101 .0 46.6 110.9 11.0
75 F 1299 77.4 64.7 154.0 19.9 1196 71.3 49.0 116.7 16.4
78 M 1079 50.0 50.0 92.6 18.5 949 44.0 39.0 72.2 16.4
57 M 1533 91 .4 54.5 90.8 14.2 2605 155.0 91 .6 152.7 14.1
78 F 666 39.7 19.8 47.1 11 .9 897 53.5 26.6 63.3 11.9
79 M 829 39.2 29.6 54.8 14.3 1043 43.5 47.6 88.2 18.3
61 M 1687 70.4 69.4 115.7 16.5 1760 81 .6 54.3 90.5 12.3
74 F 1184 61.7 33.9 72.1 11.5 1297 67.6 38.8 82.6 11.9
57 M 1043 43.5 47.7 79.5 18.3 940 39.2 29.4 49.0 12.5
77 M 1760 81.6 54.3 100.6 12.3 1687 70.4 69.2 128.2 16.4
76 F 898 53.5 26.7 63.6 11.9 667 39.4 19.3 45.7 11.6
66 M 633 26.4 25.1 41 .8 15.9 897 53.5 26.3 43.8 11.7
73 M 1072 44.7 43.4 72.3 16.2 1294 67.6 38.6 64.3 11.9
61 F 1296 67.6 38.8 82.6 12.3 1072 44.6 43.3 92.1 16.2
75 F 1290 76.9 39.8 94.8 12.3 2131 88.9 39.1 93.1 16.2
65 M 2132 88.9 106.0 176.7 19.9 1289 76.9 105.0 175 32.6
73 M 1605 66.9 56.2 93.7 14.0 1239 51.7 61.4 ■ 102.3 19.8
79 F 1469 87.5 38.4 91 .4 10.5 2110 88.9 93.3 222.1 17.7
66 M 1239 51 .7 61 .6 102.7 19.9 1604 66.9 56.0 94.1 13.9
75 M 1574 73.0 50.9 94.3 12.9 1574 73.0 50.8 94.1 12.9
77 M 1563 72.4 60.2 111.5 15.4 1523 73.6 38.7 71 .7 10.2
75 M 1522 70.6 38.7 71 .7 10.2 1563 72.4 60.1 111.3 15.4
S = Sex. M = male. F = Female.
RDA = Recommended Daily Amount/intake. Calculated according to age, sex 
and level of physical activity.
Protein as %energy = RDA is calculated to represent 10% of the
recommendation for energy (DHSS, 1979).
5.2; the intakes of other nutrients are summarised in Table 5.3.
Although Student's 't' test (paired data) revealed no significant 
difference between the actual and recall data with regard to the
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TABLE 5.3. ACTUAL NUTRIENT INTAKE COMPARED WITH RECALL DATA.
ACTUAL RECALL
NUTRIENT MEAN RANGE MEAN RANGE t P
INTAKE (+SD) INTAKE (+SD)
Energy (kcal) 1345(472) 120-2777 1405(5.34) 342-2222 0.807 NS
Fat(g) 52.3(19.5) 3.2-106 53.6(24.4) 12.8-105 0.776 NS
Protein(g) 46.9(19.4) 1.6-96 49.9(20.4) 9.1-136 1 .181 NS
CHO* (g) 175.5(61.8) 74.8-306 185(73.0) 54.6-331 1 .036 NS
Iron(mg) 6.6(3.1) 0.8-13.9 6.8(2.8) 1.6-14.5 0.270 NS
Calcium(mg) 824.4(287.8) 392-1313 733.6(293.4) 126-1401 0.838 NS
Thiamin(mg) 0.8(0.4) 0.08-1.7 0.8(0.4) 0.2-1.6 0.754 NS
Riboflavin(mg) 1.6(0.7) 0.07-3.2 1.5(0.6) 0.3-2.9 1 .004 NS
Niacin(mg) 13.3(7.3) 1.2-29.7 12.6(6.5) 3.1-36.6 0.371 NS
Folate(qg) 88.0(45.6) 11.2-235 83.5(39.3) 1.4-186 1.116 NS
Vitamin C(mg) 26.0(15.8) 0.5-64.8 26.9(18.5) 2.3-80.8 1 .107 NS
Vitamin A(qg) 1001.2(1464.5) 8.5-6489 504.8(353.1) 40.1-1914 0.471 NS
Vitamin D (qg) 1.6(1.6) 0.004-6.73 1.5(1.4) 0.03-6.4 0.901 NS
* CHO = Carbohydrate
macronutrients (energy, fat, protein and carbohydrate) the calculated 
correlation coefficients, with the exception of energy, protein and 
riboflavin intake, failed to support this finding. The Chi squared 
coefficient (X2) of 2083.8 revealed no association between the energy 
consumption of the 2 sets of data (ie. actual and recall).
Table 5.3 shows the range of energy intake of both the actual and 
recall data revealing not only differences between the groups but also a 
wide range in actual intake with some patients achieving, or exceeding, 
the RDA whilst others are grossly deficient. Only 12 patients consumed 
>75% of the RDA for energy and, of these, only 4 achieved 100% or more. A 
greater number (12) exceeded the RDA for protein although 10 consumed <75% 
of the recommended intake. In all cases protein represented at least 10% 
of the energy intake although this recommendation assumes an adequate 
energy intake.
When looking at the mean energy intake (Table 5.3) it can be seen that 
this falls below that recommended for any group of adults, male or female
119
of any age. The mean protein intake falls below the RDA for males between 
the ages of 18-75 years and for females between 55-74 years although it 
exceeds requirements in all those over the age of 75 years assuming that 
energy intake is adequate.
The mean intake of riboflavin, niacin, vitamin A and calcium meets or 
exceeds the RDA (Appendix 3) although it must be recognised that the 
intake of some individuals within the group falls well below that 
recommended. The intake of folate and vitamin D falls well below the 
recommendation whilst, although some individuals have achieved the RDA for 
thiamin, vitamin C and iron, most do not achieve this.
Discussion.
The fact that the 't * test showed no significant difference between the 
actual food consumption and the recall data does not, in itself, support a 
relationship between the sets since it relies on the difference between 
the means and takes no account of individual differences. However, both 
the correlation coefficient and the X test take such differences into 
account and show considerable discrepancy between the 2 sets of data 
and that there is considerable intra-subject variation. This suggests that 
the sets represent a heterogeneous population such that there is little 
agreement between them. There is, however, no consistent pattern with 
regard to over- or under-estimation. Indeed, the assessment of individual 
patients generally shows considerable discrepancy between actual and 
recalled consumption. The recall data provided by 4 patients were within 
+2.6% of their actual food consumption.
Since there is little agreement between the two sets of data this 
supports the previous suggestion that dietary recall is an unreliable tool 
when attempting to assess food intake.
This study, together with Study 2, was also designed to evaluate the 
'adequacy' of food consumption in cancer patients. This will be discussed
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with the results that follow.
5.1.2 Study 2. 3 Day Weighed Intakes.
30 patients were selected at random from those admitted to the oncology 
unit (15 male, 15 female) and asked to participate in this study which 
involved accurate weighing/measurement of all food and drink consumed over 
a three day period. Food was weighed as previously described. The volume 
of water, tea or coffee was not measured although that of added milk, 
sugar or squash was ascertained. Nutrient intake was estimated as 
previously described. The mean intake and standard deviation was 
calculated for all nutrients and data across the 3 days were compared 
using analysis of variance.
TABLE 5.4. PATIENTS PARTICIPATING IN THE 3 DAY WEIGHED INTAKE STUDY.
(N = 28).
MALES FEMALES
Age Site of Primary Treatment Age Site of Primary Treatment
Disease Disease
65 Bladder RT 75 Bronchus CT
57 Rectum CT 78 Brain RT
63 Colon CT 76 Breast CT
78 Prostate 0 75 Anal canal RT
65 Prostate RT 61 Bladder RT
65 Bladder RT 59 Lymphoma CT
76 Bronchus CT 56 Bladder RT
65 Melanoma CT 60 Cervix RT
63 Lung RT 57 Breast RT
76 Rectum 0 56 Lung CT
51 Colon RT 70 Lung CT
57 Lymphoma CT 77 Breast CT
65 Prostate CT 47 Ovary 0
75 Uterus RT
57 Cervix CT
Mean age (yrs) Mean age (yrs)
65.1 7.9 65.2 10.2
CT = Chemotherapy. RT = Radiotherapy. 0 = No Treatment.
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TABLE 5.5. 3 DAY WEIGHED INTAKE: MEAN NUTRIENT CONSUMPTION (N = 28).
Mean (+SD)
Energy (kcal) 1177.7 491 .3
Energy (%RDA) 60.4 21.8
Fat (g) 45.7 19.1
CHO* (g) 155.4 70.3
Protein (g) 41.9 17.9
Iron (mg) 5.3 2.5
Calcium (mg) 672.4 322.5
Thiamin (mg) 0.97 0.44
Riboflavin (mg) 1.1 0.48
Niacin (mg) 9.8 6.7
Folate (qg) 62.2 30.7
Vitamin C (mg) 29.4 18.1
Vitamin A (qg) 573.9 1095.5**
Vitamin D (qg) 1 .7 1.1
* CHO = Carbohydrate
** Vitamin A results distorted
(see text).
Results.
Details of the patient sample are given in Table 5.4; although 30 
patients started the study, data are presented from only 28 since 1 male 
withdrew on day 2 and 1 male was discharged unexpectedly.
Mean nutrient consumption is presented in Table 5.5 which shows that 
the energy intake is well below the RDA for all adults and, as can be seen 
from Table 5.6 (overleaf), few patients achieved >75% of the RDA on any of 
the study days. Similarly the protein intake failed to meet the RDA except 
for those females aged >75 years (6 subjects) although it should be noted 
that only one of these achieved the RDA for energy throughout the study 
period. Indeed the mean intake of the majority of nutrients was 
significantly below that recommended.
When studied on an individual basis (Table 5.6) it can also be seen 
that on 37 of the 84 days observed patients were consuming 50% or less 
of the RDA for energy. On 45 occasions protein consumption exceeded 75% 
of the recommended protein intake although, of these, only 21 approached 
an adequate energy intake so that, on most occasions the value of the
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TABLE 5.6. ENERGY AND PROTEIN INTAKE OF THE PATIENT SAMPLE (N = 28).
ENERGY PROTEIN
Age Sex DAY 1 DAY 2 DAY 3 DAY 1 DAY 2 DAY 3
kcal %RDA kcal %RDA kcal %RDA g %RDA g %RDA g %RDA
75 F 841 50.0 821 48.9 613 36.5 27.5 65.5 32.4 77.1 30.9 73.6
78 F 1287 76.6 1367 81.4 1197 71 .3 53.4 127 54.2 102 49.0 117
76 F 667 39.7 633 37.7 627 37.3 19.9 47.4 25.0 59.5 14.6 34.5
75 F 613 36.5 821 48.9 837 49.8 30.9 73.6 32.3 76.9 27.5 65.5
61 F 1369 72.1 1210 63.4 1300 68.4 45.6 97.1 45.3 96.4 64.7 138
65 M 1688 70.3 1812 75.1 1606 66.9 69.4 116 54.3 90.5 56.2 93.7
51 M 1838 76.6 1687 70.3 1597 66.5 54.2 90.3 53.4 89.0 49.0 81 .7
59 F 1943 102 1521 80.1 1715 90.3 63.1 134 47.5 102 56.6 120
60 F 1566 82.4 1511 79.5 1677 88.3 49.8 106 47.5 102 49.9 106
56 F 821 43.2 950 50.0 627 33.0 32.4 68.9 39.0 82.9 14.4 30.4
57 F 613 32.3 343 18.1 633 38.2 30.9 65.7 12.8 27.2 25.1 53.4
65 M 1240 51 .7 1298 54.1 1470 77.4 61 .6 103 38.8 64.7 38.4 64.0
57 F 1943 102 1715 90.3 1691 89.0 63.1 134 56.1 119 46.6 99.1
75 F 899 53.5 821 48.9 941 56.0 26.6 63.3 32.4 77.1 29.4 70.0
77 F 1715 90.3 1695 101 1707 1020 56.6 134 46.6 112 72.7 173
63 M 1838 76.6 1197 49.9 1295 54.0 53.4 89.0 49.0 81 .7 38.6 64.3
76 M 686 31 .9 627 29.2 668 31 .1 30.9 57.2 14.6 26.9 19.3 35.7
65 M 1958 81 .6 1689 70.4 707 71 .1 54.3 90.5 69.2 116 72.7 121
78 M 1999 93.0 2011 93.5 1943 90.4 67.4 125 53.1 98.3 63.1 117
56 F 627 33.0 613 32.3 633 33.3 14.5 30.9 30.9 65.7 25.0 53.2
47 F 854 39.7 640 29.8 627 29.2 14.5 26.9 25.0 46.3 19.9 36.9
65 M 2134 88.9 761 73.4 1606 66.9 106 177 54.3 90.5 56.2 93.7
57 M 1606 66.7 470 61.3 1566 65.3 56.2 93.7 38.4 64.0 60.2 100
75 F 615 36.6 633 37.7 667 39.7 30.9 73.6 25.0 59.5 19.9 46.2
63 M 1027 42.8 627 26.2 343 14.3 32.4 54.0 14.5 24.2 12.8 21 .3
57 M 1712 71 .3 899 37.5 821 34.2 49.0 81.7 26.6 44.3 32.4 54.0
65 M 1711 71 .3 300 54.2 1535 64.0 45.6 44.3 64.7 108 54.5 90.8
76 M 950 44.2 899 41 .8 942 43.8 39.0 72.2 26.7 49.4 29.6 54.8
protein consumed was limited.
These data are further broken down in Table 5.7 which shows the mean 
nutrient intake on each of the study days. Analysis of variance (ANOVA) 
shows that the is no significant difference in nutrient consumption 
between study days with the exception of the vitamin A intake. It should 
be noted however that this finding may have been distorted by the 
exceptionally high vitamin A consumption of 5 subjects on the second study 
day (Table 5.8) when both liver and carrots were on the menu. Calculation 
after exclusion of these subjects shows that there is no significant 
difference in consumption amongst the majority of the subjects.
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TABLE 5.7. MEAN DAILY NUTRIENT INTAKE: ANALYSIS OF VARIANCE.
Day 1(+SD) Day 2(+SD) Day 3(+SD) F P
Energy (kcal) 1312.9(517) 1163.3(462) 1163.3(473) 0.22 NS
Energy (%RDA) 62.8(22.2) 56.6(21.8) 57.2(22.7) 0.27 NS
Fat (g) 47.4(18.3) 44.9(19.5) 44.8(19.3) 0.17 NS
CHO* (g) 158.3(72.1) 157.5(69.8) 150.4(67.5) 0.11 NS
Protein (g) 45.6(19.5) 39.6(14.9) 38.8 (19.2) 0.95 NS
Iron (mg) 5.8(2.9) 4.9(2.3) 5.1 (2.3) 1.26 NS
Calcium (mg) 116.5(305.3) 651.5(339.7) 645.9(316.5) 0.40 NS
Thiamin (mg) 0.9(0.5) 1.0(0.4) 0.9(0.4) 0.71 NS
Riboflavin (mg) 0.9(0.4) 1.0(0.4) 1.2(0.6) 1.28 NS
Niacin (mg) 9.9(4.7) 10.2(8.2) 9.3(5.6) 0.20 NS
Folate (i^ g) 64.9(34.3) 62.4(28.3) 59.3(30.2) 0.38 NS
Vitamin C (mg) 25.2(15.8) 29.9(17.6) 33.1(20.3) 1 .54 NS
Vitamin A (i^ g) + 381.7(250.9) 999.9(1743.2) 340.3(229.8) 3,51 <0.05
Vitamin D (i^ g) 1.8(1.2) 1.7(0.95) 1.7(1.3) 0.02 NS
* CHO = Carbohydrate. + Vitamin A results distorted (see text! •
TABLE 5.8. VITAMIN A (uq) INTAKE OVER THE THREE STUDY DAYS.
Patient Day 1 Day 2 Day 3
15 342 330 414
16 185 220 239
17 261 4679 998
18 671 2295 541
19 414 4710 221
20 770 2235 394
21 185 371 199
22 517 7501 247
23 187 194 221
24 621 601 591
25 185 220 243
26 311 220 233
27 770 779 749
28 852 594 998
Patient Day 1 Day 2 Day 3
1 185 220 276
2 961 320 110
3 40 220 198
4 198 199 247
5 221 194 187
6 601 221 220
7 184 219 187
8 51 36 180
9 306 134 340
10 308 271 416
11 271 287 134
12 185 220 233
13 660 220 234
14 247 287 274
Discussion.
Since, as previously shown (Chapter 2), the intra-subject variation in 
nutrient intake usually exceeds the inter-subject variation (Beaton et al, 
1983; Gibson et al, 1985) it has been stated that the dietary intake of a 
group can be determined with a greater precision than that of an
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individual. This being the case the mean intakes shown in Tables 5.5 and 
5.7 suggest that, as a population, cancer patients fail to consume enough 
food to meet their daily requirement for nutrients thus supporting the 
results of the previous study (Table 5.3). However, it must be recognised 
that comparison with the Recommended Daily Amounts (DHSS, 1979) may not be 
appropriate for this population since such recommendations refer to the 
'normal' healthy population making no allowance for the demands of illness 
or additional needs due to GI disorders or metabolic abnormalities 
(DHSS, 1979). This means that the actual nutrient requirements of these 
patients is likely to exceed that recommended since they are at 
significant risk of malnutrition (see Chapter 2). A total of 116 patient 
days have been observed and, of these, 70% failed to demonstrate an energy 
intake >75% of the RDA. Since nutritional status depends on an
appropriate nutrient intake, and since cancer patients are likely to have 
increased requirements, this is clearly a matter of considerable concern 
and suggests that, as a group, cancer patients require nutritional 
support.
However, Table 5.6 shows that, as expected (Beaton et al, 1983; Gibson 
et al, 1985), intra-subject variation in nutrient intake is marked; this
may distort the results obtained from the group as a whole. This is
demonstrated by Table 5.8 which clearly shows that variation is greatest 
for those nutrients found in high concentrations in a limited number of 
foods (eg. vitamin A) (Liu et al, 1978; Beaton et al, 1979; Gibson et al, 
1985). There is less variation in the intake of the macronutrients (Table 
5.7).
5.2 CONCLUSIONS.
In looking at data from individual patients it can be seen that those 
those consuming <75% of the RDA for energy are also consuming inadequate 
amounts, or an inappropriate balance, of the other nutrients. Whilst
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recognising the limitations of the recommended intakes in assessment of 
the individual they can be applied to the population as a whole; thus the 
results of these studies indicate that the food intake of hospitalised
cancer patients is generally inadequate.
The comparison between a single day weighed intake and recall data
clearly demonstrates the inadequacy of the recall method as an assessment 
tool. The weighed intake studies show that, as predicted, there is 
considerable intra-subject variation in intake thus suggesting that a
single day's intake fails to give an accurate indication of the 'normal' 
food consumption. However, the mean nutrient intake calculated over a 
period of days may be distorted by an abnormal consumption of a single 
nutrient(s) on one of the study days. This is, however, simply identified 
by inspection of the data. Thus, in attempts to gain an overview of the 
food intake a 3 day weighed intake appears to be the most appropriate 
method and was used in the following studies.
5.3 FOOD INTAKE AND THE QUALITY OF LIFE.
A group of patients (9 male, 11 female), identified as likely to remain 
in hospital for a minimum of six weeks, were recruited for inclusion in a 
study designed to investigate the relationship between food intake and 
quality of life. The need for prolonged hospitalisation meant that it was 
not possible to control for age, sex, diagnosis or mode of treatment. 
However, since the aim was to investigate the relationship between food 
intake and QL it was felt that such control was not essential.
Three day dietary intake was assessed, as previously described, during 
the first, third and sixth week of the study (assessment 1, 2 and 3 
respectively). The QLI was completed on the third day of each assessment 
period.
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TABLE 5.9. FOOD INTAKE AND QUALITY OF LIFE: MEAN ENERGY INTAKE COMPARED
WITH MEAN QLI SCORE.
Assessment 1 2 3
Mean Energy Intake(+SD) kcal 1539.8(507.4) 1502.8 (335.9) 1515.6(336.8)
Mean Energy Intake(+SD) %RDA 74.4(22.3) 72.8(15.4) 71.7(15.4)
Mean Total QLI Score(+SD) 1733.9(652.9) 1712.7(508.3) 1701.6(425.5)
Mean % Total QLI Score(+SD) 66.7(25.1) 65.7(19.7) 65.4(16.4)
Results.
Mean energy intake, together with mean QLI score, are presented in 
Table 5.9. Again it can be seen that the energy intake of the population 
as a whole falls below 75% of the RDA changing little between the three 
assessment periods. Similarly QLI scores show only marginal 
changes throughout the study period. However, when examined on an 
individual basis (Table 5.10), changes are more evident. In order to 
investigate this further the changes in QL score and energy intake were 
calculated between the three occasions. The regression line and the 
significance of the relationship, was calculated (Figures 5.1A, 1B and 
1C). It was found that changes in energy intake were associated with a 
concurrent change in QL score so that as energy intake increases so QL 
score increases and, as energy consumption falls so too does the QL score. 
In all cases the relationship is statistically significant (P<0.001). 
Discussion.
The results presented show quite clearly that there is a relationship 
between the patient's self-assessed quality of life and his energy intake 
(ie. food intake) suggesting that the QLI is sensitive to quite small 
changes in food consumption. It is not possible to conclude from these 
findings which of the factors is the cause and which the effect.
TABLE 5.10. ENERGY INTAKE AND QUALITY OF LIFE SCORE OVER THE STUDY PERIOD.
Assessment 1 Assessment 2 Assessment 3
Pt Energy %RDA QLI Energy %RDA QLI Energy %RDA QLI
1 2286 105 2490 2150 100 2301 2280 95 2067
2 1992 83 2111 2136 89 2214 1824 76 2164
3 1488 61 1910 1296 54 1716 1200 50 1697
4 1992 83 1816 1824 76 2779 1800 75 1774
5 1080 45 943 1296 54 1147 1728 72 1691
6 1272 53 1330 1200 50 1306 1056 44 1141
7 1104 46 997 1200 50 1174 1608 67 1267
8 2760 115 2591 1776 74 2116 1776 74 2097
9 1680 70 2411 1464 61 2117 1440 60 2045
10 988 82 909 1102 58 1061 1216 64 1179
11 1235 65 1126 1330 70 1271 1463 77 1377
12 627 33 761 893 47 974 1064 56 996
13 1691 89 1211 1729 91 1346 1919 101 1457
14 1976 104 2497 1843 97 2314 1691 89 2174
15 1558 82 2316 1520 80 2306 1596 84 2397
16 760 40 714 1083 57 817 1216 64 919
17 1349 71 1611 1558 82 1814 1824 96 1911
18 1786 94 2347 1672 88 2260 1406 74 2114
19 1729 91 2276 1563 87 2007 1235 65 1847
20 1425 75 2311 1330 70 2214 969 51 1717
Pt = Patient Number 
Energy recorded in kcal
FIGURE 5.1.
REGRESSION LINES (CHANGE IN QUALITY OF LIFE VERSUS CHANGE IN ENERGY INTAKE).
A. WEEK 1 V WEEK 3.
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FIGURE 5.1 (Continued).
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5.4 NUTRITIONAL STATUS AND THE QUALITY OF LIFE.
It has been suggested (Chapter 2) that there is a close relationship 
between nutritional status and the quality of the patient's life. The 
following study was designed to investigate this further.
Method.
A random sample of 60 patients (30 male, 30 female) was drawn from 
those admitted to the oncology unit. Body weight and height were measured 
which, when taken with assessment of frame size, enabled determination of 
ideal body weight (IBW). Frame size was established by measurement of the 
wrist circumference distal to the styloid process of the wrist crease of 
the right hand; height was measured using a wall mounted stadiometer. 
Body frame size was related to the height wrist circumference ratio (r) as 
follows:
r = ______Height (cm)_____
Wrist circumference (cm) (Grant et al, 1981)
Usual body weight (UBW) was obtained by patient recall enabling 
calculation of the percentage weight change; current weight was expressed 
as % UBW.
Skinfolds were measured, using Harpenden calipers, over 3 sites - 
triceps, subscapular and iliac crest. The triceps skinfold thickness (TSF) 
was also added to the subscapular skinfold to obtain the sum of skinfolds 
which, together with TSF, was compared to percentile charts (Bishop et al, 
1981).
Mid-arm circumference (MAC) and TSF were measured in the non-dominant 
arm enabling calculation of both arm muscle circumference (AMC) and arm 
muscle area (AMA) as described by Heymsfield et al (1982).
Attempts were made to classify patients into 2 groups - the 
malnourished and the 'normal' (ie. not undernourished). 3 approaches were 
adopted.
1. The criteria of Grant et al (1981), based on current %UBW, were used
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to estimate the degree of caloric depletion. Patients were classified as 
follows:
Current weight 85-95% UBW - Mild caloric depletion 
Current weight 75-84% UBW - Moderate caloric depletion 
Current weight <75% UBW - Severe caloric depletion
2. The criteria of Klidjian (1981), developed for use in surgical patients, 
were applied to the patient sample (Table 5.11).
TABLE 5.11. DIAGNOSIS OF MALNUTRITION (Klidjian, 1981).
Diagnosis of malnutrition is made on the basis of two or 
more of the following:
<90% weight for height
>10% weight loss
TSF <10mm (men) <13mm (women)
AMC <22cm (men) <20cm (women)
Grip strength <44kg (men) <84kg (women) 
Albumin <35g/l 
Transferrin <2g/l 
Lymphocyte count <1,500ml
3. A scoring system was devised in which values from 0-3 were assigned 
to TSF, MAMC and AMA, after comparison with the percentile charts (Bishop
et al, 1981), and totalled. Values were assigned as follows:
Percentile >50 25-50 10-25 <10
Score 3* 2 1 0
*Standard values fall between the 50th and 75th percentile.
The 'normal1 patient scores 9; values <9 signify malnutrition.
Quality of life was assessed using the method previously described. The
correlation matrix was constructed and Cronbach's coefficient alpha was 
calculated. The data were analysed using multivariate statistical
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techniques.
The quality of life scores (QLS) of malnourished and 'normal' patients 
were compared using the correlation coefficient and the Student's 't' test 
for unpaired data.
Since anthropometric measurements are known to be subject to error, 
particularly as a function of the inexperience of observers (Hass & 
Flegal, 1981; Lohman, 1981), a pilot study was undertaken to evaluate the 
reproducibility of the findings with regard to measurement of skinfold 
thicknesses over the triceps, subscapular area and iliac crest. A sample 
of 62 patients were selected for the pilot study. Skinfolds were measured 
on 3 consecutive days; on each occasion each skinfold was measured three 
times and the mean value taken for evaluation. Findings were compared by 
means of the correlation coefficient (r) and by Student's 't' test for 
paired data.
Results.
a) Pilot Study: Reproducibility of Anthropometric Techniques.
TABLE 5.12. REPRODUCIBILITY OF ANTHROPOMETRIC DATA.
Measure Days r 't' P
TSF 1 v 2 0.99 225.64 <0.001
1 v 3 0.99 211.64 <0.001
2 v 3 0.99 220.39 <0.001
Subscapular 1 v 2 0.98 198.84 <0.001
1 v 3 0.99 195.22 <0.001
2 v 3 0.98 358.06 <0.001
Iliac Crest 1 v 2 0.99 243.61 <0.001
1 v 3 0.98 337.90 <0.001
2 v 3 0.98 242.93 <0.001
The results of the pilot study are summarised in Table 5.12; it can be 
seen that anthropometric findings were highly reproducible,
b) Main Study: Nutritional Status.
If body weight is regarded as 'normal' when in the range 90-120% of the
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ideal body weight (IBW) (Wright and Heymsfield, 1984) then Table 5.13 
shows that the mean body weight of both male and female patients was in 
the normal range both prior to illness and since its onset. However, the 
large standard deviation shows that some subjects were significantly 
outside this range. This is confirmed in Table 5.14 (overleaf) which shows 
comparison of the body weight of individual subject with the standard 
percentile charts as well as their current weight as a percentage of usual 
body weight. Significant weight loss was noted in 38 (63.3%) of the
population. 9 patients (8 female, 1 male) had gained weight since the 
onset of illness although it should be noted all were suffering oedema, 
lymphoedema or ascites (Table 5.15) which may have distorted the results 
obtained; this may also obscure the differences between the sexes with 
regard to mean body weight.
TABLE 5.13. BODY WEIGHT CHARACTERISTICS OF THE PATIENT SAMPLE.
Female Male Total
Mean age (years) 56.6 + 13.03 62.4 + 14.3 59.5 + 13.9
PRE-ILLNESS 
Mean Body Weight 
Mean Body Weight 
Mean Body Weight
(Kg)
(%UBW)
(%IBW)
63.5 + 9.0 
100
108.7 + 25.4
75.9 + 11.3 
100
103.7 + 14.5
69.9 + 11.9 
100
107.9 + 15.9
SINCE.ILLNESS 
Mean Body Weight 
Mean Body Weight 
Mean Body Weight
(Kg)
(%UBW)
(%IBW)
61.4 + 10.5
95.4 + 8.2 
107.8 + 20.4
68.9 + 10.7
90.9 + 7.8 
94.6 + 13.9
64.2 + 13.6 
93.1 + 8.2 
101.2 + 18.6
% LOSING WEIGHT 
Mean Weight Loss (%) 
Range of Weight Loss (%)
56.6 
9.8 + 6.1 
26.3 - 2.8
70.1 
17.1 + 26.1 
22.9 - 2.0
63.3
11.2 + 6.4
26.3 - 2.0
% GAINING WEIGHT 26.7 3.3 15.0
Mean Weight Gain (%) 
Range of Weight Gain (%)
9.1 + 8.9 
2.8 - 30.3
3.9 + 0 
3.9
8.6 + 8.6 
2.8 - 30.3
% WEIGHT UNCHANGED 16.7 26.6 21.7
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TABLE 5.14.
BODY WEIGHT: COMPARISON WITH STANDARD PERCENTILE CHARTS 
AND USUAL BODY WEIGHT.
MALES FEMALES
Age Wt
(Kg)
Percentile %UBW Depletion
State
Age Wt
(Kg)
Percentile %UBW Depletion
State
23 75.0 >50<75 100 Nil 49 52.3 >10<25 96.6 Nil
44+ 93.6 <5 87.2 Mild 27 53.4 >10<25 81 .5 Moderate
63 57.3 <5 81.9 Moderate 66 67.0 >50<75 103 Nil
62 79.6 >25<50 80.7 Moderate 70 67.0 >50<75 92.4 Mild
55 66.8 >09<25 95.9 Nil 30 63.6 >50<75 90.9 Mild
47 72.3 >25<50 92.1 Mild 58 54.4 >10<25 100 Nil
73 66.8 25 80.8 Moderate 35 63.3 50 88.6 Mild
65 82.7 >75<90 100 Nil 60 58.0 >10<25 94.8 Mild
67 76.4 >50<75 82.8 Moderate 60 72.7 >50<75 114 Nil
32 82.7 >50<75 100 Nil 79 75.5 - 109 Nil
61 70.9 >25<50 95.7 Nil 55 72.3 >50<75 110 Nil
61 44.0 <5 87.3 Mild 47 60.5 >25<50 92.9 Mild
75 75.0 100 Nil 38 62.0 >25<50 90.6 Mild
67 67.3 >25<50 92.3 Mild 51 51 .0 > 5 < 10 96.2 Nil
62 79.5 >50<75 100 Nil 39 63.2 50 97.2 Nil
64 65.5 >10<25 95.3 Nil 66 56.4 >10<25 92.5 Mild
89 81 .8 - 96.2 Nil 61 66.0 >50<75 - -
73 61 .8 >10<25 90.6 Mild 74 35.6 <5 73.7 Severe
57 60.0 >5< 10 88.7 Mild 55 50.5 >10<25 100 Nil
86 57.3 - 93.6 Mild 55 71 .5 >50<75 - -
79 86.0 - 87.8 Mild 40 60.5 >25<50 94.9 Mild
59 73.0 >25<50 85.2 Mild 56 50.9 >10<25 88.8 Mild
51 53.6 <5 78.6 Moderate 55 76.4 >75<90 100 Nil
78 76.4 - 100 Nil 65 69.6 >50<75 91.6 Mild
74 64.1 >10<25 77.0 Moderate 71 48.2 > 5 < 1 0 93.8 Mild
66 66.1 >10<25 100 Nil 76 66.5 - 102 Nil
51 67.3 >10<25 80.9 Moderate 62 82.7 >75<90 98.9 Nil
66 64.2 >10<25 83.4 Moderate 69 52.0 >10<25 89.0 Mild
62 71 .4 >25<50 100 Nil 54 70.0 >50<75 96.3 Nil
63 77.3 50 97.5 Nil 55 47.6 > 5 < 1 0 91 .0 Mild
TABLE 5.15. PATIENTS GAINING WEIGHT.
P Sex Age Primary Disease Weight Gain Current Comment
Kg % %UBW
1 F 49 Breast 1.8 3.0 96.6 Lymphoedema
2 F 66 Leiomyosarcoma 1 .8 2.8 103.0 Sacral oedema
3 F 60 Breast 9.1 14.3 114.3 Lymphoedema & 
lower limb oedema
4 F 79 Breast 6.4 9.2 109.0 Lymphoedema
5 F 55 Leiomyosarcoma 6.4 8.1 110.0 Lower limb oedema
6 F 76 Lymphoma (NH*) 1.0 1 .5 102.0 Ascites
7 F 62 Breast 19.1 30.3 98.9 Lymphoedema
8 F 54 Breast 2.7 3.9 96.3 Lymphoedema & 
lower limb oedema
9 M 86 Bronchus 2.2 3.9 93.6 Ankle oedema
FIGURE 5.2. WEIGHT LOSS IN RELATION TO TIME*.
WEIGHT 
LOSS (%)
20
10 20 30 40 50 60 70 80
TIME (WEEKS)
* Patients gaining weight are excluded from this figure.
Figure 5.2 illustrates the rate of weight loss in relation to time 
showing that, within the total population, weight loss is progressive and 
increases with time. However, in the females studied, the rate of loss 
decreased with time.
The anthropometric findings are summarised in Table 5.16 (overleaf). 
When compared with the percentile charts (Tables 5.17a and b and 5.18a and
b) it can be seen that this group of patients is markedly depleted. The 
mean values for all parameters are significantly below standard values 
with the exception of MAMC in females which exceeds the standard. However, 
when compared to percentile charts it can be seen that the number of 
patients failing to reach the standard is significant although there are
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TABLE 5.16. ANTHROPOMETRIC MEASUREMENTS: COMPARISON BETWEEN SAMPLE
MEAN AND STANDARD.
FEMALES MALES
Triceps Skinfold Thickness (mm) 
Standard mean 23.0 
Sample mean 15.9 + 6.4
Midarm Circumference (cm)
Standard mean 29.4 
Sample mean 27.3 + 3.9
Mid Arm Muscle Circumference (cm) 
Standard mean 22.2 
Sample mean 24.1 + 2.6
Mid Arm Muscle Area (cm )
Standard mean 39.2 
Sample mean 33.7 + 12.2
Hand Grip Strength (kg)
Standard 34.0 
Sample mean 17.9 + 5.1
Triceps Skinfold Thickness (mm) 
Standard mean 12.0 
Sample mean 8.7 + 3.0
Midarm Circumference (cm)
Standard mean 31.8 
Sample mean 27.2 + 3.9
Mid Arm Muscle Circumference (cm) 
Standard mean 28.0 
Sample mean 21.9 + 3.5
Mid Arm Muscle Area (cm )
Standard mean 62.4 
Sample mean 41.72 + 12.7
Hand Grip Strength (kg)
Standard mean 44.0 
Sample mean 31.9 + 10.04
TABLE 5.17.
a. COMPARISON OF TSF IN CANCER PATIENTS WITH THE NORMAL POPULATION.
b. COMPARISON OF MAMC IN CANCER PATIENTS WITH THE NORMAL POPULATION.
Standard values lie in >50<75 percentile group in all cases.
Female (n = 28) Male (n == 25)
Percentile Predicted Actual Predicted Actual
<5 1.4 2 1.25 16
<10 2.8 2 2.5 18
<25 7 2 6.25 21
<50 14 6 12.5 22
<75 21 12 18.75 25
<90 25.2 24 22.5 25
<95 26.6 28 23.75 25
<100 28 28 25 25
Female (n = 28) Male (n == 25)
Percentile Predicted Actual Predicted Actual
<5 1.4 7 1.25 4
<10 2.8 10 2.5 5
<25 7 20 6.25 8
<50 14 26 12.5 20
<75 21 27 18.75 24
<90 25.2 27 22.5 25
<95 26.6 28 23.75 25
<100 28 28 25 25
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TABLE 5.18.
a. COMPARISON OF AMA IN CANCER PATIENTS WITH THE NORMAL POPULATION.
Female (n = 28) Male (n = 25)
Percentile Predicted Actual Predicted Actual
<5 1.4 11 1.25 13
<10 2.8 14 2.5 17
<25 7 17 6.25 21
<50 14 20 12.55 23
<75 21 22 18.75 24
<90 25.2 26 22.55 24
<95 26.6 27 23.75 24
<100 28 28 25 25
b. SUM OF SKINFOLDS: COMPARISON OF CANCER PATIENTS AND THE NORMAL POPULATION.
Female (n = 28) Male (n = 25)
Percentile Predicted Actual Predicted Actual
<5 1.4 7 1.25 4
<10 2.8 10 2.5 4
<25 7 18 6.25 12
<50 14 26 12.5 21
<75 21 27 18.75 25
<90 25.2 28 22.5 25
<95 26.6 28 23.75 25
<100 28 28 25 25
Standard values lie in >50<75 percentile group in all cases.
clear differences between the groups. Mean MAC is similar between the 
sexes although these, clearly, represent different percentages of the 
standard values (93.2% female, 85.5% males) and significant differences 
were noted between the groups with regard to compositional changes.
Mean TSF, taken with the predicted values (Table 5.17a), suggests that 
females lose considerable amounts of limb fat whilst preserving greater 
amounts of arm muscle (Table 5.18a). Males, however, appear to lose 
greater amounts of muscle whilst retaining limb fat. Both AMC and AMA are 
markedly below that expected, particularly in males. TSF is also below 
standard although this is more marked in females.
Similarly, when looking at the sum of skinfolds (triceps + subscapular
skinfold), the majority of the sample (47; 26 female, 21 male) fall below 
the 50th percentile (Table 5.18b). The relationship between the percentage 
weight change and the sum of skinfolds is slight (r = 0.50 total
population; 0.33 males, 0.50 females).
HGS was markedly below 85% of the standard value in both male and 
female patients and was negatively correlated with age (Males: r = -0.5, 
't' = -3.341, P>0.01<0.001; Females: r = -0.5, 'tf = -2.455,
P>0.01<0.001). It should be noted that, to date, no standard values have 
been established which include a correction for age.
Correlation coefficients have been calculated between the 
anthropometric parameters both within the total sample and between the 
sexes. Correlation between the indices was generally poor; those showing 
significant correlation are listed in Table 5.19. Current body weight 
appears to be the index most closely correlated with other parameters such 
as MAC, AMA, %UBW and sum of skinfolds (SS). The relationship between 
weight and SS appears to be sex specific and is insignificant in the 
total population. Similarly the relationship between MAC and SS and AMA 
and SS is more significant in males than in females. MAC and AMA are 
closely correlated as are %UBW and % weight change.
TABLE 5.19. SIGNIFICANT CORRELATIONS BETWEEN NUTRITIONAL PARAMETERS.
Total Sample Male Female
A B r t P r t P r t P
Weight* MAC 0.60 5.65 <0.001 0.63 3.46 <0.001 0.63 4.28 <0.001
Weight AMA 0.56 5.07 <0.001 0.52 3.22 <0.01 0.49 2.95 <0.01
Weight %UBW 0.38 3.21 <0.01 0.42 2.45 <0.02 0.58 3.77 <0.001
Weight SS 0.33 14.9 <0.001 0.64 4.37 <0.001 0.53 3.32 <0.01
Weight %Wt change 0.37 3.07 <0.01 0.36 2.04 <0.05 0.63 4.33 <0.01
TSF SS 0.89 3.23 <0.01 0.78 6.68 <0.001 0.90 11 .0 <0.001
TSF MAC 0.39 3.23 <0.01 0.54 3.43 <0.01 0.48 2.91 <0.01
MAC SS 0.49 4.33 <0.001 0.70 5.24 <0.001 0.50 3.02 <0.01
MAC AMA 0.85 12.3 <0.001 0.95 16.1 <0.001 0.83 7.77 <0.001
AMA HGS 0.45 3.70 <0.001 0.37 2.10 <0.05 0.30 1 .67 NS
AMA SS -0.03 0.22 NS 0.51 3.11 <0.01 -0.03 1 .31 NS
%UBW %Wt change 0.79 9.97 <0.001 0.86 8.75 <0.001 0.72 5.43 <0.001
HGS Age -0.19 1 .49 NS -0.53 3.34 <0.01 -0.42 2.46 <0.02
* Weight = current weight. SS = Sum of skinfolds.
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FIGURE 5.3. CORRELATION MATRIX: NUTRITION AND QUALITY OF LIFE STUDY.
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Correlation coefficients >0.25 significant at P<0.05 or above.
5.4.1 Quality of Life.
Figure 5.3 displays the correlation matrix obtained from this study. It 
can be seen that the majority of the zero order correlations were both 
positive and of statistical significance (P<0.05). Most items contribute 
significantly to the total score (P<0.001). The remainder (diarrhoea, 
concern over earning ability, communication with family and with doctors) 
are also related to the total score although to a lesser degree (P<0.05); 
only communication with the nursing staff appears totally unrelated to the 
score obtained.
Symptoms causing distress to this patient sample (ie. score <50 on 
individual items) are shown in Table 5.20.
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TABLE 5.20. SYMPTOMS CAUSING DISTRESS TO PATIENTS IN THE NUTRITION AND
QUALITY OF LIFE STUDY.
Symptom Number of patients (%)
Tiredness 30 (50.0)
Appearance 26 (43.3)
Physical Activity 26 (43.3)
Concentrat i on 21 (35.0)
Mood changes 21 (35.0)
Constipation 20 (33.3)
Appetite 20 (33.3)
Sleep 19 (31.6)
Pain 11 (18.3)
Nausea 10 (16.7)
Diarrhoea 6 (10.0)
Reliability was calculated giving a Cronbach's coefficient alpha of 
0.92 which confirms the reliability of this index for use in this patient 
population. Multiple regression analysis yielded two significant 
predictors of the quality of life - the ability to sleep and appetite 
(Table 5.21). Principal components analysis yielded 5 major components 
which, together, accounted for 63.1% of the variance in total quality of 
life score (Table 5.22).
TABLE 5.21. RESULTS OF MULTIPLE REGRESSION ANALYSIS 
(QUALITY OF LIFE STUDY).
Symptom Variance (%) Cumulative 
Variance (%)
't' P
Sleep 60.9 60.9 9.65 <0.001
Mood 19.8 80.7 7.76 <0.001
Appetite 6.2 86.9 5.28 <0.001
Flavour 2.1 89.0 3.40 <0.001
Life changes 1.5 90.5 3.13 <0.01
Communication (N)* 1 .5 92.0 3.37 <0.01
Tiredness 2.4 94.4 4.80 <0.001
Bowel pattern 1.0 95.4 3.61 <0.001
Mobility 1.0 96.4 4.00 <0.001
Concentration 0.5 96.9 3.04 <0.01
* Communication (N = communication with nurses.
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TABLE 5.22. COMPONENT CORRELATIONS (LOADINGS) OF THE FIRST FIVE 
PRINCIPAL COMPONENTS (Quality of Life Index).
1 2 3 4 5
1. No pain 0.4
2. Not feeling sick 0.2
3. Appetite normal 0.2
4. Sleep well 0.3
5. Physical activity normal 0.2
6 No diarrhoea 0.3
7. Not constipated 0.2 0.4
8. Not tired 0.2
9. Concentration normal 0.2
10. Feel happy 0.2
11 . Appearance unchanged 0.2
12. Eat normally 0.2 -0.3 -0.3
13. Food tastes normal 0.2
14. Texture of food feels normal 0.2 0.3
15. Sleeping normally 0.3
16. Breathing normal 0.4
17. Urination normal
18. Bowel function unchanged 0.2
19. Recreational activity normal 0.2 0.3 0.3
20. Can do everything I used to do 0.2 0.3
21 . Not worried about the future 0.2
22. Not worried about earning ability 0.2
23. Do not feel isolated 0.3
24. Can discuss feelings with family 0.3 0.4
25. Can discuss feelings with doctors 0.4 0.3 0.3
26. Can discuss feelings with nurses 0.5
VARIANCE ACCOUNTED FOR 34.3% 9.8% 7.0% 6.4% 5.6% TOTAL
I 63.1%
NB Only the main contributors of each component are shown.
5.4.2 RELATIONSHIP BETWEEN NUTRITIONAL STATUS AND QUALITY OF LIFE.
Attempts were made to identify a relationship between these two 
parameters. As previously described patients were divided into 2 groups, 
malnourished and 'normal', by means of three different classification 
systems. The first, based on the system of 'caloric depletion' (Grant et 
al, 1981) revealed only 26 patients to be suffering no depletion whilst 32 
displayed varying degrees of caloric depletion (Table 5.14). The second 
method, based on Klidjian (1981) revealed only 14 patients in the 'normal'
TABLE 5.23. COMPARISON OF NUTRITIONAL STATUS DERIVED
BY DIFFERENT METHODS.
FEMALES
Pt Grant(1981) 
Depletion
Klidjian(1981) HNS
1 _ _ M
2 Moderate Malnourished M
3 - Malnourished M
4 Mild Malnourished M
5 Mild - -
6 - Malnourished M
7 Mild Malnourished -
8 Mild Malnourished M
9 - Malnourished M
10 - - -
11 - - -
12 Mild Malnourished M
13 Mild - M
14 - Malnourished M
15 - Malnourished M
16 Mild - M
17 - Malnourished M
18 Severe Malnourished M
19 - Malnourished M
20 - - M
21 Mild Malnourished -
22 Mild Malnourished M
23 - Malnourished M
24 Mild - -
25 Mild Malnourished M
26 - Malnourished -
27 - Malnourished -
28 Mild Malnourished -
29 - - -
30 Mild “ —
* HNS, M = Malnourished
MALES
Pt Grant(1981) 
Depletion
Klidjian(1981) HNS
1 — — M
2 Mild Malnourished M
3 Moderate Malnourished M
4 Moderate Malnourished M
5 - Malnourished M
6 Mild Malnourished M
7 Moderate Malnourished M
8 - Malnourished M
9 Moderate Malnourished M
10 - Malnourished M
11 - - M
12 Mild Malnourished M
13 - Malnourished M
14 Mild Malnourished -
15 - - M
16 - Malnourished M
17 - Malnourished -
18 Mild Malnourished M
19 Mild Malnourished M
20 Mild Malnourished
21 Mild Malnourished -
22 Mild Malnourished M
23 Moderate Malnourished M
24 - - -
25 Moderate Malnourished M
26 - - -
27 Moderate Malnourished M
28 Moderate Malnourished M
29 - Malnourished M
30 — Malnourished M
category whilst 46 were classified as malnourished. Using the method 
devised for this study (HNS) 42 patients were found to be malnourished 
whilst 11 were normal. Table 5.23 compares these findings.
Regardless of the classification system adopted, analysis, using the 
Student's 't' test for unpaired data, showed that there was no significant 
difference between the apparently malnourished and 'normal' patients with
142
TABLE 5.24. ANALYSIS OF QL SCORE AND UNISCALE RESULTS BETWEEN 
'MALNOURISHED' AND 'NORMAL' PATIENTS.
Classification Method 't' P
Grant (1981) QL score 0.174 Not significant
Grant (1981) Uniscale 0.210 Not significant
Klidjian (1981) QL score 0.707 Not significant
Klidjian (1981) Uniscale 0.251 Not significant
Holmes (1987) QL score 0.279 Not significant
Holmes (1987) Uniscale 0.116 Not significant
regard to either QL score or the Uniscale (Table 5.24).
Similarly the correlation coefficients (Table 5.25) between the 
nutritional scores (HNS) and QL score suggested little relationship 
between these parameters.
TABLE 5.25. ZERO ORDER CORRELATIONS BETWEEN NUTRITIONAL SCORE (HNS)
AND QL SCORE.
r 't' P
Total sample 0.177 1 .255 Not significant
Male patients 0.271 0.705 Not significant
Female patients 0.271 1 .376 Not significant
It appears, however, that the effect of nutritional status on QL may 
differ between males and females; this is demonstrated in Figure 5.4 
(overleaf) which suggests that, although males achieve a higher QL score 
than females when their nutritional status is low. QL increases slowly as 
the nutritional condition improves. The QL score in females, however, 
appears more sensitive to changes in nutritional status.
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FIGURE 5.4.
REGRESSION LINES CALCULATED TO DEMONSTRATE DIFFERENCES IN THE
RELATIONSHIP BETWEEN NUTRITIONAL STATUS AND QUALITY OF LIFE IN 
MALES AND FEMALES.
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Regression Equation: Males: QLS = 1617.32 + 30.76NS
Females: QLS = 1278.77 + 63.87NS
5.5. DISCUSSION.
The results obtained indicate that/ as predicted, the cancer patient 
population is significantly nutritionally depleted. Comparison of
current body weight with usual weight showed that the majority (63.3%) 
had lost weight (mean loss 11.2+6.4%); the results presented in Table 
5.14 suggest that, using data presented by Grant et al (1981) based on
usual body weight, many patients (53.3%) display some degree of caloric 
depletion.
Some workers (eg. Blackburn et al, 1977) suggest that Ideal Body Weight 
(IBW) is a good index of nutritional status whilst others (eg. Durnin & 
Fidanza, 1985) suggest this is inappropriate since individuals of the same 
height and weight can carry very different proportions of fat and fat-free 
mass. Indeed, from the results obtained, it can be seen that the findings 
would differ considerably had IBW been used as an index of body weight 
since mean %IBW was 102.2 +^18.6% suggesting that most of the patients, 
particularly the females (see Table 5.15) were at, or near, IBW despite 
the significant mean weight loss.
Table 5.14 shows that those gaining weight were suffering from some 
form of fluid retention as a result of which all were within +15% of 
their usual body weight. However, others also displayed marked oedema 
despite significant weight loss. This confirms that body weight per se 
is a poor indicator of nutritional status in this group of patients. 
Oedema, ascites and lymphoedema will cause a relative increase in total 
body water masking losses of fat and fat-free mass. However, a loss of 
body weight is always significant. Thus, serial measurements could be of 
greater value than 'one-off' estimates and will provide a baseline against 
which to judge future weight loss.
As shown in Figure 5.2 percentage weight loss in females appears to 
decrease with time. However, since a greater proportion of females 
exhibited overt signs of fluid retention (see Table 5.15), it is possible 
that fluid overload is responsible for the apparent decline in weight loss 
as disease progresses.
The results of the anthropometric studies highlight the difficulties 
associated with treating cancer patients as a homeogeneous group and the 
wide range of results obtained indicate that such patients must be
assessed and treated on an individual basis. It was for this reason that 
attempts were made to develop a scoring system for use in nutritional 
assessment (see later discussion).
When compared to the percentile charts of Bishop et al (1981) it can be 
seen that these patients are significantly depleted particularly with 
regard to TSF and AMA; males also display a markedly reduced MAMC.
Although, in females, AMC was predominantly >50% standard AMA is markedly 
reduced so that these results indicate that, in general, cancer patients 
display a depletion of both body fat and fat-free mass. However, these 
standards were developed for use in an American population and, since 
they are known to be both heavier and taller than the UK population 
(Knight, 1984), it is to be expected that the other anthropometric 
standards also exceed those which would apply to the UK population. As a 
result it is possible that the degree of depletion found in this
population is, in fact, lower than the findings would suggest.
The sum of skinfolds (TSF and subscapular) confirms a reduction in body
fat since 47 patients (78%) fall below the 50th percentile. Although
some workers (eg. Bray et al, 1978) suggest that percentage weight change 
correlates closely with the sum of skinfolds (r = 0.75 male; 0.74 females) 
this relationship is not confirmed by the findings of this study. Although 
there is a relationship between these parameters in the total population 
this is less apparant in males (r =0.33) than females (r = 0.50) perhaps 
suggesting that this relationship does not hold in the presence of 
malignant disease.
Few of the subjects reached the 'normal' value for hand grip strength 
(11 (36.7%) males, 0 females). HGS was negatively correlated with age
(Table 5.19) suggesting that HGS decreases as age increases. Such a 
finding is not unexpected. However, factors other than the nutritional 
condition must be taken into account including subject motivation,
understanding of the procedure and occupational factors (Bohannon, 1987) 
so that it is by no means clear if such standards are appropriate across 
the age range. It is suggested that occupational variation can be overcome 
by testing the patient's non-dominant arm, although there was little 
difference in the results obtained using the dominant or non-dominant arm 
(r = 0.89, 't' = 3.796, P<0.001).
Despite the criticisms which can be levelled at this technique Keys et 
al (1950) have suggested that a reduction in HGS is associated with 
substantial weight loss provided this is uncomplicated by disease. 
Clearly this is not a 'normal' sample so that it is not surprising to find 
little relationship between these parameters (r = 0.25, 't' = 1.930, P not 
significant). Within the total population HGS is more significantly 
related to AMA (r = 0.45, P>0.001) which is perhaps to be expected since 
HGS reflects muscle function).
The quality of life was assessed. The resultant correlation matrix 
(Figure 5.3) bears considerable resemblance to those obtained in both the 
pilot study (Chapter 3) and the main study (Chapter 4). Cronbach's 
coefficient alpha (0.92) again confirms the reliability of the index in 
this population.
The number of patients affected by particular symptoms is also 
comparable with those previously obtained and multiple regression analysis 
yields similar significant predictors of QL, namely inability to sleep, 
appetite and mood changes. The findings will be discussed further in 
Chapter 7.
Since changes in body weight reflect the adequacy of the energy intake, 
and since the QLI appears sensitive to changes in the energy intake, some 
relationship between QL score and nutritional status was anticipated. 3 
approaches were attempted in an attempt to demonstrate this.
The first, based on the method of Grant et al (1981) which links %UBW
with levels of caloric depletion, enabled comparison of those patients who 
were depleted with those in the 'normal1 range. However, as previously 
discussed, body weight is open to considerable distortion due to, for 
example, fluid retention and/or pathological changes such as tumour 
growth. Thus this may be an • inappropriate means of classification. 
Student's 't ' test showed no differences between the groups with regard to 
QL score.
The Klidjian (1981) classification system (Table 5.11) also includes 
weight for height, as well as HGS, and since, as previously shown, weight 
for height is of doubtful value, and the role of HGS in nutritional 
assessment unclear, this casts doubt on two of the parameters included. 
Although weight loss is always significant some patients have gained 
weight, which is largely attributable to fluid retention, which may mask 
nutritional changes. As a result weight loss per se may not be 
appropriate as a single indicator of nutritional status in this 
population. Since biochemical indices, such as serum albumin and 
lymphocyte count, were not available this restricted the parameters 
available for use in making a diagnosis of malnutrition. However, serum 
albumin is an inappropriate indicator of nutritional status (see Chapter 
1) and the lymphocyte count may be significantly reduced by cancer 
therapy, particularly chemotherapy, reflecting drug-induced effects rather 
than nutritional status per se. However, based on the parameters listed 
in Table 5.11, it was possible to classify 14 patients as 'normal' (ie. 
not apparently depleted) and 46 as malnourished but, again there was no 
difference between the groups with regard to QL score.
The HNS appears to have some advantages in that it excludes body weight 
and relies on two simple measurements. However, the percentile charts, 
against which the findings were compared, were developed for use in an 
American population and it is not clear whether or not they are applicable
to the British population. With regard to the QL score no differences 
could be detected between the groups.
Selecting the patients with very high or very low QL scores, and 
examining their nutritional data, indicated that this approach also was 
unlikely to be successful in demonstrating a relationship between 
nutritional status and quality of life.
Since, as previously shown, QLS is strongly correlated with food intake 
(represented by energy intake) it seems clear that there must be a 
relationship between these two parameters despite the fact that it has not 
yet proved possible to demonstrate this statistically. It seems likely 
that this difficulty relates primarily to the problems associated with 
assessment of nutritional status in this patient group since the 
consistency of the results obtained using the quality of life index 
appears to support its value as an assessment tool. It is, however, 
difficult to see how this problem can be overcome.
Clearly, body weight, and other anthropometric indices, are 
inappropriate indices of nutritional status in this group of patients 
since they are subject to distortion for a variety of reasons (see both 
Chapter 2 and previous discussion). Furthermore, as has been shown, 
available standards do not, of necessity, apply to the UK population.
Similarly, hand grip dynamometry is reported to be an unreliable and
insensitive index of muscle function (Bohannon, 1987), even in health, and
is, therefore, unlikely to accurately reflect muscle function in the 
nutritionally depleted individual.
Thus, assessment of nutritional status in patients with cancer is
fraught with difficulties and it is, at present, unclear how best these 
may be overcome.
Whilst recognising the limitations and problems associated with the 
recording of food intake, and also recognising that it is difficult to
calculate the nutritional requirements of the cancer patient, it may be 
that the best methods of assessment currently available are simple 
observation combined with evaluation of the food intake.
It is clear from the results presented that the food intake of the
hospitalised cancer patient population is generally inadequate confirming 
previous findings (Moloney et al, 1983; Walsh et al, 1983). A total of 
296 patient days have been observed showing a mean daily intake of 
1341+480 kcal which is significantly below that required by any member 
of the adult population, even in health (DHSS, 1979). The relatively large 
standard deviation clearly indicates a considerable range of intake 
(860-1821 kcal) such that the energy intake of some patients fails to meet
even 50% of the RDA and, even at the top of the range, falls below that
required. If the energy intake fails to meet the requirements of the 
healthy individual it seems likely that it will fall even further below 
that required by the majority of cancer patients. Similarly the intake of 
most other nutrients was well below that required.
It should, however, be noted that studies have previously shown that 
the food intake of hospital patients is generally low (Table 5.26). Taken 
together, these findings suggest that hospitalisation per se is associated 
with an inadequate food intake. Since the hospital population is, of 
necessity, comprised of sick individuals such findings are, perhaps, not
TABLE 5.26. MEAN INTAKES OF PROTEIN AND ENERGY OF SURGICAL PATIENTS
ON THE SECOND POSTOPERATIVE DAY.
Type of Surgery N Protein (g) % RDA Energy (kcal) % RDA
Gastrointestinal (1) 8 0 0 415 15.9
Thoracic (2) 11 28.5 49.9 828 32.5
Genitourinary (3) 14 67.9 111.7 1865 82.4
(1. Jex, 1985 2. Eccles, 1985 3. Briggs, 1982).
unexpected; anorexia is common in ill health. Similarly, anorexia is
common in cancer patients and studies have previously shown that food 
intake tends to be below that recommended for healthy individuals of the 
same sex and age (eg. Moloney et al, 1983; Walsh et al, 1983). However, 
many of those included in this study consumed all the food offered to 
them, and supplemented this with snacks and confectionary brought in from 
home, yet failed to meet the required energy (nutrient) intake. As cancer 
patients are, already, at nutritional risk this indicates a need for 
nutritional support in this group of patients.
It is recognised, however, that estimations of food intake are, in 
themselves, of limited value in critical evaluation of nutritional status 
reflecting, as they do, the basic unreliability of the technique(s) 
employed (see Chapter 2). Clearly they represent only current dietary 
habits and it is, in any case, difficult to judge the importance of 
short-term intake in individual patients. Inter-individual variability
(Beaton et al, 1983; Gibson et al, 1985) make it difficult to conclude 
whether a low intake represents a change from the norm in that individual.
With regard to the assessment of the quality of life the results 
obtained show considerable similarity with those previously obtained. 
Tiredness was, again, the symptom causing major distress and sleep the 
factor responsible for most of the variance in responses to the QLI. In
this study, however, the correlation between appetite and tiredness is
less strong, although it is still of statistical significance; the 
relationship between mood and tiredness remains strong as does that 
between mood changes and appetite. Furthermore, the findings further 
support the reliability of the index; the correlation between appetite and 
the ability to eat (r = 0.71) and those between the ability to eat and the 
flavour and texture of food were both high and statistically significant.
Since this population is, generally, in poor nutritional status the
interactions between tiredness, mood and appetite may be of clinical 
importance. Similarly, although only one third of the patients reported 
significant distress from appetite changes these may be influential in the 
decline of nutritional status. It is, in any case, possible that appetite 
loss is a cause for concern in a greater number of patients also this may 
not be identified by the patients themselves (Wesdorp et al, 1983).
Changes in the perceived flavour and texture of food may also be 
significant in determining appetite and, therefore, nutritional status. 
Taste changes are a recognised problem in the cancer patient population 
(DeWys, 1978); changes in texture perception are not documented although 
anecdotal evidence suggests they may be significant determinants of food 
intake in this patient population.
CHAPTER 6.
ACCEPTABILITY OF NUTRITIONAL SUPPLEMENTS.
Since, as previously shown, cancer patients carry a greatly increased 
risk of malnutrition and, as food intake has been shown to be generally 
inadequate, there is, clearly, a need for positive action to increase the 
nutrient intake. One way in which this could be achieved is through the 
provision of nutritional supplements designed to augment the normal diet.
However, despite the increasing awareness of the importance of 
nutrition in the care of sick individuals, and an increasing availability 
of specialised nutritional products, few studies have investigated their 
use, particularly in cancer patients. Studies have shown improvements in 
anthropometric and biochemical indices of nutritional status, and an 
increased rate of rehabilitation and shortened hospital stay, in elderly 
patients with fractured neck of femur when supplementation was given by 
overnight, nasogastric feeding (Bastow et al, 1983). Others (Bannerjee et 
al, 1978), however, have shown little benefit in elderly patients taking 
sip-feed supplements since these reduce the intake of 'normal' food so 
that, overall, nutrient intake was decreased.
Most studies carried out in cancer patients consider either the role of 
enteral or parenteral feeding, or the palatability/acceptability of sip 
feeds. Clearly, palatability is an important factor in determining the 
acceptability of such feeds particularly in those whose taste sensation 
may be disrupted or in whom food aversion is likely. Palatability studies 
have generally concluded that patient compliance with a supplementary 
regime is determined by the volume of supplement required and by the 
development of flavour fatigue (Hall, 1983) such that compliance is most 
likely when a range of supplements, in a wide variety of flavours, is 
offered (Auty et al, 1983; Fuller, 1985) thus increasing the patient's 
choice and permitting them an element of control. It should, however, be
noted that the research quoted was carried out in surgical patients with 
non-malignant disease.
Since, whenever possible, the oral route is preferred for nutritional 
supplementation this chapter describes an investigation of the 
palatability and acceptability of two nutritional supplements which were 
made available for trial. The aim was to identify an acceptable means of 
supplementing affected patients.
6.1 FACTORS CONTRIBUTING TO THE ACCEPTABILITY OF FOODS.
The term 'taste' describes the specific chemosensitivity of the oral 
cavity which is located primarily on the lingual surface but also on the 
palate, epiglottis, larynx, pharynx and oesophagus. It is normally 
stimulated by direct contact with chemical molecules or ions in solution 
as they are taken into the mouth (Pfaffman, 1978).
The most familiar tastes are those of sweetness, sourness, bitterness 
and saltiness although taste is also associated with other hedonic 
experiences such as 'pleasantness' and 'unpleasantness'. Acceptability 
depends not only on the hedonic qualities of a food but also on its 
organoleptic properties (ie. taste, smell, appearance and 'mouth feel'). 
For example, sugar, and other sweet foods, are attractive to both man and 
animals and are consumed in significant quantities whether or not the 
animal is hungry (Pfaffman, 1978). Evidence suggests that this starts even 
before birth as the human neonate prefers sweet solutions whereas bitter 
or sour solutions produce aversion. Such effects are seen even in infants 
born without a cerebral cortex suggesting that the sweet preference may be 
innate involving only the lower nervous centres (Steiner, 1977). Indeed, 
it is suggested that 'Neonatal processing may provide our aesthetic 
pleasure whereas the emphasis on survival may originate from subcortical 
processing' (Keverne, 1978).
Whatever the cause it is clear that the sweet preference persists into
adult life when there is good agreement between the availability and 
consumption of sugar since people in countries with a high per capita 
income consume large quantities of sugar (Cantor, 1975). This is, for 
example, seen in Japan where cakes and pastries are now sold as commonly 
as they are in Europe and other parts of the Western world (Beidler, 
1982). This shows that, although man and animals may display an almost 
reflex behaviour to some tastes (such as sweet and bitter), modification 
of this apparantly innate biological basis of taste preference is 
possible.
Much of this response appears to result from learned behaviour. The 
sensory qualities associated with taste, odour and the organoleptic 
properties, which are, together, referred to as flavour contribute to the 
hedonic value of a food and become associated with pleasurable sensations. 
Hedonic value thus plays a major role in food selection and preferences 
and, therefore, in food intake and, indirectly, on nutritional status. It 
can, however, be altered by visceral feedback so that, for example, 
changes in taste sensation such as those observed in cancer patients, can 
cause aversions to previously preferred food so that, once a food becomes 
associated with unpleasant symptoms, that food is subsequently avoided 
(Garcia et al, 1974). It is well known that man associates digestive 
disturbances with any unusual or novel foods which have been recently 
consumed (Revusky & Bedarf, 1967; Garb & Stunkard, 1974) so that taste 
and visceral reflexes can be seen to be closely related and may, at times, 
form a biological basis for aversions to specific foods. Furthermore, such 
aversion can persist long after all symptoms have subsided. This effect 
can be so pronounced that taste aversions can result from single trial 
conditioning (Garcia & Kimeldorf, 1957); unusually food aversion learning 
can result after a delay of many hours between the conditioned stimulus 
and an aversion to the taste (Garcia et al, 1966).
However, it appears that acceptability can also be modified by 
nutritional status. For example, Nisbett (1972) found food-deprived
organisms were highly discriminating and that food deprivation enhanced 
acceptance of good tasting food. In hungry human subjects Cabanac (1971) 
found that ingestion of 200 ml glucose, sucrose or orange solution became 
relatively more unpleasant but, when body weight was reduced by 10% (and 
held stable for several weeks), this ingestion-induced unpleasantness
disappeared. The work of Sharma et al (1977) appears to support this
finding since chronically food-deprived frogs demonstrate an increased 
response to glucose when compared with well-fed animals. Amino acid
responses are also greater but responses to quinine (bitter) and acetic 
acid show no consistent pattern. Despite these studies much of the early 
work (eg. Richter, 1942) on the ability of animals (particularly rats) to 
self-select their diet in response to imposed specific nutrient 
deficiencies is now explained on the basis of learning and, in fact, 
Beidler (1982) believes that learned behaviour determines most of man's 
food preferences. Cultural, traditional, religious, social and economic 
factors all contribute to food selection (Gifft et al, 1972). Yet some 
examples of self-selection still remain unexplained. For instance, it has 
been noted that individuals with adrenocortical insufficiency increase 
their consumption of salt whilst others consume large amounts of liquorice 
(Barron, 1973) which contains glycerrhizin, which has corticoid action and 
so could help to maintain both water and mineral balance in affected 
individuals. It is not, however, clear how an individual learns of the 
association between liquorice ingestion and the relief of symptoms.
6.2 Food Selection.
Clearly food selection and eating behaviour are complex and subject not 
only to physiological controls but also to social, cultural and 
psychological influences which determine the acceptability of a food item.
Dietary choice depends on many specific cues which help man to decide 
when, what and how much to eat. This then represents an integration of 
physiological, psychological and social determinants which facilitate or 
inhibit ingestion and which depend not only on the environment but also on 
previously established food preferences and aversions. Acceptability is 
largely derived through a conditioning process in which the hedonic and 
organoleptic properties of a food are assessed and become associated with 
pleasant, or unpleasant, sensations on the basis of which a food is 
accepted or rejected. Palatability is, therefore, a major contributory 
factor. Such 'hedonic conditioning' appears to form the foundation of the 
process through which the nutritional functions of food are related to its 
sensory characteristics since it appears that acceptability can be 
modified by changes in nutritional status as food-deprived organisms are 
highly discriminating and food deprivation enhances the acceptability of 
good tasting foods.
For a substance to be recognised as a food it must create a sensory 
impression which evokes a positive response tempting the subject to 
ingest. Logically, therefore, the senses of smell and taste appear 
important in food intake regulation; aroma leading us to a food enhancing 
or detracting from its enjoyment. Taste determines whether that food is 
swallowed and additional mouthfuls taken. In this context then aroma acts 
as the investigating sensory event but hedonic value finally determines 
the rate and volume of ingestion. Evidence has suggested that the initial 
impression created by a food may be modified by the internal state 
(fasted, normal or satiated) (Mower et al, 1977) so that ingestion may be 
affected. However, changes in perceived hedonic value were always in a 
direction which would restore homeostasis.
This may be significant in the acceptance of food by a sick individual 
in that a food which is normally acceptable may be rejected on the basis
of the 'internal condition' and may be particularly important in cancer 
patients in whom early satiety is common. Alternatively an item which is 
normally rejected may be acceptable as is common, for example, during 
pregnancy. It is, therefore, difficult to predict which food items will be 
accepted or rejected by a given individual at a given time. This is 
particularly true of the individual with cancer in whom anorexia and 
alterations in taste sensation are also common complaints.
As previously shown taste changes have been reported by many workers 
(eg. DeWys & Walters, 1975; Carson & Gormican, 1977; Gorshein, 1977), an 
enhanced recognition threshold for sweet tastes being the most common 
abnormality. It is suggested that such abnormalities may be a determinant 
of the reduced food intake in at least some patients (DeWys, 1977) and may 
have implications for dietary therapy/nutritional support (Carson & 
Gormican, 1977) and influence individual acceptance of oral nutritional 
supplements.
Such problems may be exacerbated by learned food aversions which are 
demonstrated by rejection of even previously accepted or preferred foods 
after they have been paired with aversive treatments or symptoms. As it 
is clear that tumour growth itself is associated with marked anorexia it 
has been suggested that a generalised food aversion may develop in 
response to aversive physiological effects of tumour growth (Bernstein, 
1982). This is particularly relevant to the introduction of nutritional 
supplementation since it is known that aversions are most likely to 
develop to the most novel food(s) consumed around the time that discomfort 
is experienced (Revusky & Bedarf, 1967). It is, therefore, important that 
the supplement selected is acceptable to the patient. Two supplements 
were made available for trial. It was decided that, before these were 
administered to patients, acceptability should be determined in a normal, 
healthy population.
6.3 ASSESSMENT OF THE PALATABILITY/ACCEPTABILITY OF A FOOD.
Sensory analysis divides into two general areas depending on whether 
objective or hedonic acceptance information is required. Both, however, 
comprise a rating of those properties which can be directly perceived with 
the mouth, nose and eyes (Topel, 1976). Objective testing normally relies 
on use of trained, selected assessors and standard methods which ensure 
reproducibility. Organoleptic and hedonic tests, on the other hand, are 
carried out in untrained consumers, either unselected or selected to 
conform to some preselected criteria, and display a marked subjective 
character. Since organoleptic tests have been defined as 'simply tasting, 
smelling, looking and feeling' (Jellinek, 1985) they represent an 
assessment of the appearance, odour, taste and mouth-feel of the food all 
of which contribute to its hedonic value and are appropriate to the study 
to be undertaken.
The overall view of a food includes:
Optical impressions (Seeing)
Olfactory impressions (Smelling)
Gustatory impressions (Tasting)
Haptic impressions (Feeling, touching) (Topel, 1976) 
Zausch (1968) identified 6 steps involved in both the sensory and 
organoleptic perceptions of a food or food item:
Taking in (Ingesting/receiving)
Becoming conscious (Recognising)
Classification (Anchoring)
Retaining (Memorising)
Rendering (Describing)
Evaluating (Rating)
all of which arise after the optical, olfactory, gustatory and haptic 
impressions identified by Topel (1976) and are modified by the impressions
FIGURE 6.1. ASSESSMENT OF A FOOD ITEM.
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of texture and odour (whilst tasting) (Rothe, 1978) (Figure 6.1).
Nonetheless it is necessary to differentiate between the emotional and 
the subjective aspects of organoleptic testing and the objective, 
scientifically conducted sensory analysis. In scientific terms 
organoleptic testing can be regarded as unsatisfactory as it is subject to 
a number of deficiencies:
a. It does not comply with the main principles of science ie. 
objectivity and reproducibility.
b. The sensory abilities of individuals are subject to varying
degrees of sensitivity.
c. Individual sensitivity can be influenced by external circumstances
(eg. the environment, other people).
d. The sensory ability of organoleptic tasters has not been previously 
assessed.
e. Scoring systems contain hedonic terms which, due to their
subjectivity and ambiguity, cannot be applied to exact or direct
quality judgements.
In view of the nature of the products to be tested and the population 
for which they are intended, it was decided that organoleptic testing and 
hedonic evaluation were sufficient to establish its acceptability 
particularly as training a panel of assessors is a time consuming 
procedure which was not justified for a single test of acceptability.
The following factors were taken into account in the design of the 
study.
6.3.1 Factors affecting Taste Sensitivity.
Many factors may affect the responses of assessors and, therefore, the 
overall results. Wherever possible such effects must be reduced, or 
eliminated, to allow optimal accuracy and objectivity. These may be 
described in terms of three major categories:
Physiological factors. Sensitivity to taste stimuli may depend on the
physical state. For example:
a. Health. Individuals in poor health may make poor assessors
b. Smoking. Both smokers and non-smokers are eligible as assessors as
there are sensitive and less sensitive individuals in each group
(Jellinek, 1985). Assessors who smoke should be asked to wait at 
least 30 minutes after smoking before tasting the samples and not to 
smoke during the test as it may affect non-smokers who may be 
disturbed by the odour of smoke.
c. Both sexes, and all age groups, make equally good assessors although
women are believed to be more conscientious and accurate than men
(Jellinek, 1985). Female sensitivity may be affected by the
menstrual cycle.
d. There is some evidence that taste sensitivity fluctuates throughout
the day. It is, therefore, wise if time is left after meals before
taste sessions are held.
Psychological Factors. All sensory testing relies on psychological 
techniques; the attitudes of tasters may significantly affect their 
responses to sensory stimuli.
a. Motivation. Unwilling or unenthusiastic tasters may fail to 
concentrate giving hasty and careless test results. Testers should be 
encouraged to recognise that their efforts are both useful and relevant; 
this can be a key motivating factor. Understanding the motives of the test 
will increase interest but care must be taken to ensure that providing 
information does not provide clues which may bias descriptive work.
b. Bias refers to factors, other than flavour, which may influence 
the decisions and prejudice the results. All possible clues will be used 
in making a decision whether these be conscious or unconscious. A certain 
amount of information must be given concerning the objectives of the tests 
but too much can introduce bias particularly as assessors commonly wish to 
'please' the experimenter by giving the 'correct' answers. Care must be 
taken that no hint is given as to the possible or expected results.
c. The objectives of the test must be carefully considered when the 
questionnaire is designed and care taken not to introduce bias. It must be 
easily understood and be designed to encourage clear cut decisions and 
should be based on close-ended questions; open-ended questions provide 
responses which are difficult to assess.
6.3.2 Factors related to Presentation and Preparation of Samples.
Since it is important that samples acquire no foreign tastes or odours 
care must be taken in their preparation and, as the method of presentation 
can introduce bias, care must be taken when presenting samples. Test 
samples should, wherever possible, be tasted under conditions similar to 
those of ordinary consumption. As far as possible all samples should be 
of the same size although sufficient must be provided for discriminatory 
sensations to be perceived.
The order in which the samples are tasted is important as tasters may 
react to a given sample because of the qualities of the preceding sample. 
Two possible effects of this reaction are the Contrast effect and the 
Convergence (Halo) effect. The contrast effect represents a judgemental 
(psychological) phenomenon appearing when samples of different qualities 
or preference levels are evaluated. The order of presentation of samples 
may affect evaluation of following samples so that they rate higher or 
lower than they would when rated independently. The convergence effect 
also represents a psychological phenomenon in which test samples are 
perceived as similar to preceding samples regardless of their quality. 
Both can be overcome by randomising the presentation of samples so that 
all possible permutations are used.
6.4 SENSORY EVALUATION OF TWO NUTRITIONAL SUPPLEMENTS:
NORMAL SUBJECTS AND CANCER PATIENTS.
6.4.1 Method.
A questionnaire (Appendix 4) was developed using criteria designed to 
assess the organoleptic/hedonic properties of the product and, hence, its 
acceptability. The terms included were derived from Amerine et al (1965) 
and Vaisey Genser et al (1977). Overall 'pleasantness' was assessed using 
a 5-point category (Likert type) scale.
Volunteers were asked to refrain from smoking for at least 45 minutes 
prior to participation in the study and to avoid spicy or strong tasting 
foods. The test was carried out in the afternoon; although most 
participants had taken lunch this was felt appropriate since the 
product(s) are designed for use as a supplement to normal food intake. 
Every attempt was made to motivate the participants' interest whilst 
reducing the introduction of bias into the study. The atmosphere in which 
the test was carried out was as odour free as possible to minimise the 
introduction of extraneous odours. Communication between participants was
discouraged so as to prevent the transfer of opinions from one assessor 
to another.
Each volunteer was given 3 x 30ml samples - one hot (60*0, one at room 
temperature (20°C) and one cold (6°C) - the questionnaire being
completed with regard to each of the samples. The samples were presented 
in a random order; additional samples were given on request to enable a 
thorough evaluation to be carried out.
The information given to the participants regarding the products 
(Osmolite and Ensure) is shown in Table 6.1. It was hoped that this 
approach was adequate to motivate their interest whilst reducing the 
introduction of bias into the study.
The same method was used in testing both of the supplements.
TABLE 6.1. INFORMATION GIVEN TO THE PARTICIPANTS REGARDING 
THE PRODUCT TO BE TESTED.
This product is designed to be used as a supplement for patients who 
are nutritionally depleted and unable to consume sufficient nutrients 
through diet alone. It is intended for use as a drink or 'sip feed1 
three cans to be consumed each day over a period of 3-4 months.
In order to assess its acceptability as a drink you are asked to 
evaluate the product in terms of its taste, odour, colour and texture 
as well as 'mouth-feel' and after-taste.
You will be given 3 samples to drink - one cold, one at room 
temperature and one warmed. Please drink each slowly and complete the 
attached questionnaire with regard to each of the samples.
Your help is greatly appreciated. Thank you!
Results.
OSMOLITE.
51 females and 25 males, ranging in age from 19-79 years, participated 
in the study. Most found the supplement unpleasant more than 60% rating 
it at 2 or less on the category rating scale. At all temperatures it was
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was described as 'unattractive' in appearance by 50% and 'offputting' by a 
further 47% when the hot sample was presented.
The description of odour changed as the temperature decreased 59% 
rating this 'unpleasant' when hot, 50.5% at room temperature and 46% when 
cold. As the temperature increased so too did the 'musty' odour rising to 
67% with the hot sample; the sensation of a 'processed' odour rose 
similarly to 77%. 33% reported an 'oily' or 'fatty' odour although this
decreased through the temperatures to 15% when the samples were hot. It 
appears that the undesirable odour characteristics were most notable when 
the product was presented at 6°C.
Similarly marked changes were noted in the taste depending upon the 
temperature of presentation although the terms 'processed', 'musty' and 
'unpleasant' were consistent across the range. 'Pleasantness' increased 
marginally when the product was hot. As the temperature increased the 
sensations of 'fattiness' and 'saltiness' increased; a 'soapy' taste was 
noted by 35% when the samples were cold (Table 6.2).
TABLE 6.2. ASSESSMENT OF TASTE (% Response).
Description Cold Room Temperature Hot
Alkaline 0 2.6 2.6
Bland 10.5 14.5 13.2
Bitter 5.3 1.3 2.6
Briny (Salty) 9.2 15.8 17.1
Processed 59.0 76.3 63.2
Soapy 35.0 7.9 6.6
Sour 1.3 1 .3 1 .3
Sweet 9.2 5.3 9.2
Pleasant 11.8 6.6 14.5
Musty 50.0 52.6 63.2
Insipid (flat) 1.3 3.9 3.9
Tasteless 1.3 1 .3 5.3
Unpleasant 73.7 76.3 76.3
Watery 2.6 1.3 1 .3
Fatty 9.2 15.8 22.4
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The texture was consistently described as creamy (60%) and the flow as 
thick and viscous. More than 50% described the flow as 'clinging' which 
was consistent with the description of mouth-feel. 89% complained of an 
after-taste consistently described as 'persistent', clinging' and 
'unpleasant'.
Discussion.
The study population appeared to represent a cross-section of the 
normal population; adequate numbers were included to permit an effective
hedonic assessment (Jellinek, 1985).
The majority found this product unacceptable. Taken with the assessment 
of appearance the description of an unpleasant odour is of considerable 
importance since these organoleptic aspects are the first to be assessed 
and provide motivation for subsequent ingestion. Future consumption may, 
therefore, be discouraged. The recognition of a 'processed' odour was 
significant but whether this would markedly affect consumption is unclear.
Changes in the taste sensations generated appear largely dependent on 
the temperature of presentation although the descriptions 'unpleasant', 
'processed' and 'musty' are cause for concern as they may significantly 
reduce the willingness to continue to ingest the supplement. The
'clinging' after-taste may also detract from consumption.
Conclusions.
The preceding discussion suggests that, as the product is unacceptable 
to many 'normal' people, it is probable that this supplement would not be 
consumed by patients. However, it is possible that, in cancer, changes in 
taste sensation and, therefore, food acceptability may mean that the 
supplement is more acceptable although the possibility of learned food
aversion must not be overlooked.
6.4.1a Trials in Cancer Patients.
15 cancer patients (7 male, 8 female) all of whom reported subjective
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taste changes, were asked to assess Osmolite under similar conditions. 
Results.
2 patients rejected the product on the basis of its general appearance 
and odour thus refusing to taste it. 10 patients described it as
'unpleasant1, 'musty' and 'processed' in both odour and taste and finding 
the mouth-feel 'unpleasant' and the after-taste 'clinging' and
'persistent'. 2 described the product as 'tasteless' and the texture as 
'pleasant' and were prepared to consume additional samples. However, all 
patients subsequently complained of abdominal discomfort and flatulence; 4 
complained of nausea.
Discussion.
As these patients were tested on different occasions there was little 
liklihood of the results being influenced by a single individual reaction 
and it was felt that these were unbiased and objective findings. In view
of the unanimity of these results it was not considered necessary to
assess the product further.
Clearly the appearance, taste and odour are the dominant features in 
the rejection of the supplement although the persistent and clinging 
after-taste may also be a contributory factor. Those individuals finding 
the product acceptable may, later, suffer discomfort and, as a result, be 
unwilling to continue to consume the supplement.
6.4.1b ENSURE.
An assessment of the palatability and acceptability of a second 
supplement was carried out using the method previously described.
Results.
34 males and 38 females participated in this study ranging in age
from 19-79 years of age. Most found the product attractive in appearance,
only 13.9% reporting this as 'off-putting'. The description of odour was 
equally divided between pleasant and unpleasant at all temperatures.
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The overall recognition of the flavour (vanilla) was low (maximum 
16.7%) nonetheless, the majority found the product both 'sweet' and 
'pleasant' except when it was presented at room temperature. However, 
even many of those finding the product acceptable amplified this 
describing it as a 'bit too sweet' and 'rather sickly'.
40.3% described the product as 'processed' and reports of a 'soapy' 
taste increased with the temperature (23.6% with the hot sample). A 
'briny' taste was reported by 16.7% when the sample was presented at room 
temperature. The texture was consistently described as 'creamy' although 
this decreased when the temperature increased; conversely, the description 
of an 'oily' or 'fatty' texture increased with temperature. The 
after-taste and mouth-feel were both described as 'clinging' this 
description increasing with temperature [54.2% (cold); 58.3% (room 
temperature); 68.1% (hot)].
Within an hour of consumption 67% of the participants were complaining 
of a continued regurgitation which persisted for 1-2 hours and which was 
described as both 'unpleasant' and 'disturbing'.
TABLE 6.3. RANKING SCALE - ENSURE: NORMAL SUBJECTS (% Response).
Score Cold Room Temperature Hot
1 (Unpleasant) 11.1 18.1 13.8
2 15.3 18.1 15.3
3 13.8 23.5 13.8
4 29.2 23.6 16.7
5 (Pleasant) 30.6 16.7 40.4
Table 6.3 shows the overall acceptance of the product at all 
temperatures using the ranking scale.
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Discussion.
Although more than 50% of the participants found the odour 'acceptable' 
the number describing it as 'unpleasant' [33% (cold); 45.8% (room 
temperature); 40.3% (hot)] could be significant in reducing consumption by 
an individual as could recognition of a rubbery odour (16.7%) particularly 
when the product is presented at room temperature. Again the recognition 
of a 'processed' odour/taste was significant but whether this would 
markedly affect consumption is not clear.
Nonetheless, this product was found to be considerably more acceptable 
than the previous supplement although one third did find it unpleasant a 
fact which may have a significant impact on any clinical trial. The area 
of major concern may relate to 'sweetness' since >50% reported the product 
as overly sweet. The availability of various flavours may help to 
overcome this difficulty although it should be noted that all of these are 
sweet. This could be a particular difficulty in cancer patients since 
changes in the recognition of sweet tastes (DeWys, 1977) are common.
Of additional concern are the reports of a persistent after-taste (72%) 
although only 25% described this as 'unpleasant'. The incidence of post 
ingestional symptoms was found to be low although the continued 
regurgitation may be significant and reduce compliance. Clearly the 
product should be introduced slowly to allow tolerance to develop before 
attempting to increase the intake to the desired level.
6.4.1c Trial in Cancer Patients.
Ensure was then tested in a population of cancer patients 36 of whom 
(15 male, 21 female) participated in the study which was conducted over 
several days in the oncology unit.
Results.
41.7% of the patients reported no changes in their taste sensation the 
remaining 57.3% reporting subjective changes which were most marked with
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TABLE 6.4. REPORTED TASTE CHANGES.
Taste Number Male Female
Increased Sweet 7 3 3
Bitter 2 1 1
Salt 3 2 1
No change 15 5 10
Decreased Sweet 6 3 4
Bitter 3 1 2
Salt 0 0 0
regard to sweet taste (Table 6.4).
At all temperatures the odour and texture were acceptable to most 
patients although the appearance was described as unattractive by 25%. 
Most described the flavour as 'sweet' and 'pleasant' although those 
reporting an increased recognition of sweet taste found it less acceptable 
and all felt they would have difficulty in consuming larger amounts. 88% 
recognised a 'processed' taste but felt they could 'get used to it'. 
However the reports of a 'soapy' taste (55.6%) (hot sample) may be 
significant since the patients felt this would detract from repeated 
consumption at this temperature; when served cold this taste was no longer 
evident.
A persistent, sweet after-taste was reported by the majority of 
patients when the supplement was served at all temperatures although most 
did not find this unacceptable. The patients complained of few symptoms 
following ingestion although, after 30-45 minutes, 69.4% were complaining 
of continued regurgitation, a similar finding to that obtained in normal 
subjects. Undoubtedly the product must be introduced slowly to allow 
tolerance to develop and to enhance compliance although it is worth noting
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TABLE 6.5. RANKING SCALE - ENSURE 2: NORMAL SUBJECTS (% Response).
Score Cold Room Temperature Hot
1 (Unpleasant) 27.8 41 .7 22.2
2 11.1 27.8 25.0
3 25.8 11.1 19.4
4 22.2 11.1 13.8
5 (Pleasant) 13.8 8.3 19.4
that the maximum consumption during this trial was only 90ml. Table 6.5 
shows the overall acceptance of the supplement in the patient sample. 
Discussion.
Tables 6.3 and 6.5 show that it is difficult to predict the 
acceptability of this supplement in a given population whether or not 
taste changes are present. Its sweetness may prove to be a limiting factor 
in determining acceptability in some cancer patients although the 
availability of several flavours may help to increase variety, and 
restrict flavour fatigue.
Conclusions.
These results mean that it is difficult to predict the acceptability of 
this supplement in a cancer patient population or whether they would 
continue to consume the product over prolonged periods. As a result a 
study was carried out both to investigate its acceptability and compliance 
in this group of patients.
6.5 COMPLIANCE STUDY.
There has been considerable research into compliance with both medical 
and dietary regimes although little of this has considered adherence to 
sip feed supplementation regimes. Larsen et al (1983) have looked at 
compliance with a single supplement in cancer patients considering the 
effects of factors such as level of education, percentage weight loss,
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previous health beliefs and taste preferences. They concluded that none of 
these factors influenced compliance and that an educational programme, 
designed to increase understanding about the supplement, had no effect. 
Supplement intake appeared to be related solely to individual responses. 
The importance of palatability and taste preferences has, however, been 
emphasised by other workers (eg. Auty et al, 1983; Fuller, 1985).
The studies described above indicate that it is difficult to predict 
the acceptability of the supplements under investigation, particularly 
Ensure, in this patient population. As a result it was decided to 
investigate compliance in a small patient sample.
Method.
Patients prepared to participate in this study were identified by the 
ward staff and two staff nurses (one on the male ward and one on the 
female) were prepared to take responsibilty for the day-to-day running of 
the trial. They were, therefore, responsible for ensuring the patients 
were offered the correct amount of the supplement and for maintaining the 
study records although the wards were visited regularly to ensure no 
problems had arisen and to follow the patient's progress.
20 patients (10 male, 10 female) were asked to participate by drinking 
3 cans (750mls) of the supplement each day over a three week period. 
However, in view of the previously identified problems with 
gastrointestinal tolerance, manifested by persistent regurgitation, 
the product was introduced slowly according to the schedule shown in Table 
6.6. 3 flavours were offered (coffee, vanilla and egg-nog) which could be 
consumed at any time of the day, hot or cold and with/without the addition 
of any desired flavouring agents.
All patients were free to withdraw from the study at any time and, 
following withdrawal, were asked to complete a questionnaire (Appendix 4) 
designed to evaluate subjective responses to the product.
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TABLE 6.6. SCHEDULE FOR THE INTRODUCTION OF ENSURE TO
THE STUDY POPULATION.
Day Required
Amount
3 1 cans 
250 ml
4 2 cans 
500 ml
Day Required
Amount
1 Half can 
125 ml
2 Half can 
125 ml
5 days onwards - 3 cans (750 ml) per day
Results.
10 patients of each sex were recruited into the study over a period of 
4 weeks; no attempt was made to restrict the sample to particular disease 
states or treatment regimes. Since a nutritional booklet was available on 
the wards most patients were aware of the need to 'eat well1 and most 
recognised that this was not easily achieved not least because they were 
in hospital and so did not have access to their preferred food(s). As a 
result they felt that a drink may be helpful.
The results are summarised in Table 6.7. From this it can be seen that, 
by sixth day, most patients had withdrawn from the trial, primarily due to 
gastrointestinal problems which included nausea and continued epigastric 
TABLE 6.7. SUMMARY OF RESULTS OF COMPLIANCE STUDY IN CANCER PATIENTS.
Day Required Number of Patients Number of Patients Reasons for
Consumption Continuing Withdrawing Withdrawal
1 Half a can 
(125 ml)
20 -
2 Half a can 
(125 ml)
19 1 Nausea
3 1 can 
(250 ml)
15 4 GI problems
4 2 cans 
(500 ml)
5 10 GI problems
5 3 cans 
(750 ml)
5 —
6 3 cans 
(750 ml)
3 2 GI problems
7 3 cans 
(750 ml)
3 2 —
>7 3 cans 1 - -
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burning/discomfort. Since, on the earlier trials, 90ml of the product 
produced regurgitation it is possible that the supplement was introduced 
too rapidly thus failing to allow GI tolerance to develop although, it 
should be noted that the manufacturers do not recognise this as a problem 
suggesting that the desired amount may be introduced immediately.
The completed questionnaires revealed that, although GI problems 
precipitated withdrawal, most subjects described the product as unpleasant 
(Table 6.8). Particular comments related to the fact that the product was 
'processed' and 'very sweet' and also that it was 'sickly' and 'clings to 
the roof of my mouth'. The after-taste and regurgitation meant that the 
taste persisted for prolonged periods after consumption. These factors 
primarily accounted for the description 'unpleasant' although the comments 
'fatty', 'oily' and 'slimy' were also common. No differences were noted 
between the different flavours involved.
3 patients, however, found the product acceptable. One in particular 
was drinking 6 or 7 tins/day and continued to ask for more! It should be 
noted that none of these patients complained of any GI problems.
TABLE 6.8. RANKING SCALE. PARTICIPANTS - COMPLIANCE STUDY.
Score Patient Numbers
1 (Unpleasant) 12
2 2
3 2
4 1
5 (Pleasant) 3
Discussion.
The results presented show that compliance with this supplementation 
regime was poor primarily due to the onset of GI discomfort supporting the 
suggestion that aversion may develop after a limited number of pairings of 
a food with disturbing GI symptoms (Garcia et al, 1974; Leathwood et al,
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1986). Aversion is, in any case, likely against any novel or unfamiliar 
foods consumed around the time discomfort is experienced (Revusky & 
Bedarf, 1967). The continued regurgitation, nausea and epigastric 
discomfort meant that not only was supplement consumption discontinued but 
the intake of 'normal' food was also inhibited so that the net effect was 
a decrease in nutrient intake.
It is also clear that the product itself was regarded unpleasant by 
this patient population and described as generally too sweet and sickly. 
Furthermore, the clinging mouth-feel and prolonged after-taste undoubtedly 
contributed to the poor compliance rate.
The complaints of an overly sweet taste suggest a problem of taste 
preference but contradicts the findings of Larsen et al (1983) who stated 
that taste preference were not related to compliance in a group of cancer 
patients. Others have suggested that both palatability and taste 
preferences do, indeed, play a role in compliance (Auty, 1983; Fuller, 
1985). The latter would appear correct since logic dictates that if a 
food (or supplement) does not taste 'good' continued consumption is highly 
unlikely.
One patient consumed quantities of the supplement that were far in 
excess of those required. He had an extremely positive attitude towards 
the regime largely because his disease and treatment made it difficult for 
him to eat normally. He was, furthermore, aware of the need to eat well to 
'maintain his strength' and promote recovery. This supports the work of 
Glanz (1980) who suggested that compliance is influenced by the patient's 
attitude to their disease and found a correlation between compliance and 
the patient's faith in the efficacy of the treatment. Similarly, Marston 
(1970) has demonstrated that patients are less likely to adhere to 
therapeutic regimes if they do not fully understand the reason for their 
treatment.
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It is possible that the patients studied did not fully understand the 
value of supplementation either because they were aware that this was a 
research project, and, by implication, not expected to benefit them as 
individuals, or because they had no faith in the value of nutritional 
supplementation. Several commented that they would be able to eat 
adequately when they went home.
Conclusions.
Both the organoleptic properties and the GI tolerance pose difficulties 
with regard to the acceptability of the two supplements made available 
for this project such that they were rejected by both normal subjects and 
cancer patients.
6.6 RECIPE DEVELOPMENT.
Whatever the reason it is clear that difficulties would be experienced 
if prolonged supplementation regimes were attempted using these products. 
For this reason a range of recipes, incorporating the supplements, have 
been developed (Appendix 6); casual tasting tests have shown these are 
acceptable to healthy volunteers. It has not, however, proved possible to 
try these in a patient sample since a) cooking facilities are limited on 
the wards and b) it has not been possible to obtain further supplies of 
the supplements involved.
In developing recipes incorporating these supplements (Appendix 6) 
several important factors had to be taken into account. For example, 
boiling could result in denaturation of some of the more labile, 
heat-sensitive nutrients. Moreover, when over-heated, both products 
undergo marked colour changes rendering them unattractive and 
unacceptable. This meant that gentle heat and slow cooking methods
were required. Clearly this limits its use and restricts the range of 
dishes available.
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In view of the processed, musty and unpleasant flavours reported in the 
taste trials it was important that the flavouring agents selected were 
sufficiently dominant to overcome the taste sensations generated by the 
supplements themselves and to disguise the undesirable odour 
characteristics. It was also necessary to develop a range which 
including both sweet and savoury dishes to add variety and interest and to 
take account of individual preferences. Furthermore, in view of the taste 
changes experienced by many cancer patients, a range of recipes may 
increase the liklihood of acceptability in this population.
Sweet Dishes.
The liquid texture of the products suggested that they could be used to 
replace milk in many recipes; this represented the first approach when 
they were used to make a range of 'milk' puddings. The requirement for 
prolonged cooking meant the techniques used had to be modified and some 
degree of colour change had to be accepted. However, such 'bland' 
dishes do not always sucessfully r^ask the original flavour of the 
supplements and so may be of limited value. The addition of dried fruit 
(eg. raisins, sultanas, apricots) can be used to enhance the flavour if 
desired. Similarly, use of the flavoured varieties of Ensure (eg. egg nog 
or coffee) can significantly alter the flavour of the dishes.
The textural similarity to 'evaporated milk' indicated that these 
products might hold a foam, particularly when chilled. This proved to be 
the case although the foam produced was unstable; the addition of a 
gelling agent(gelatine) to stabilise it. This finding enabled the 
development of a range of 'mousse-like' desserts using a range of 
flavoured, commercially available, jellies and tinned fruits which also 
increased the energy value of the finished product. The addition of 
yoghurt was found to improve the texture by thickening the mixture and, 
through its flavour, to improve the taste. The use of 'sharp' or acidic
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flavours (eg. lemon, orange or pineapple) caused the mixture to curdle. 
However, although this could be unacceptable to some individuals, it does 
create an additional texture and does not appear to impair the flavour.
It must be recognised that, although such dishes proved acceptable to 
normal subjects, the volumes of supplement involved are small (30-60ml per 
dessert) and it would be necessary to consume a large number if this were 
to make a significant difference to the nutrient intake. A glucose polymer 
syrup can be added to any of these recipes without detrimental effect so 
that this may prove helpful in attempts to increase the energy intake. It 
is possible that a protein concentrate (powder) could also be added 
although, to date, it has not proved possible to try this.
Savoury Recipes.
The flavour of the Osmolite is such that it was believed that savoury 
flavours (eg. cheese, onion, tomato) may prove useful in masking its 
taste. Due to its liquid nature it was necessary to identify means of 
thickening any mixture in which it was incorporated. As boiling was 
undesirable many of the 'standard' techniques (eg. flour, cornflour or 
arrowroot) could not be used. This was, ultimately, achieved using either 
egg (to 'set' the mixture) or bread to thicken. However, both of these 
methods, whilst increasing the nutrient density, also increase the bulk to 
be consumed which may prove detrimental to the total food consumption. 
Nonetheless, a range of interesting dishes can be made based on cheese, 
tomatoes, onions, bacon and fish although there is a similarity between 
them with regard to both texture and cooking methods which may, in itself, 
prove to be a disadvantage.
Although attempts were made to incorporate Ensure into savoury dishes 
its sweet nature meant that this was less successful. The sweetness 
tends to detract from the savoury nature of the dishes creating an unusual 
flavour which may, nevertheless, be acceptable to some individuals.
178
However, Ensure powder can be added, successfully, to 'normal' dishes, 
such as scrambled egg, soups, mashed potatoes or milk puddings and will 
improve their nutrient density without significantly affecting their 
flavour or adding significantly to the bulk to be consumed.
Conclusions.
Although these products can be incorporated into a range of dishes 
(Appendix 6), which can sucessfully mask thete taste and odour, 
disadvantages remain not least because the aim is to supplement the 
normal diet and not replace it. By incorporating it into prepared dishes 
in this way, it becomes an integral part of food consumption and will, at 
least to some extent, remove the freedom of choice usually associated with 
meal selection/ingestion. Furthermore, although the recipes are quick and 
easy to make they may seem complex to the sick individual so that 
additional motivation is required in meal preparation; this may 
contribute to a reluctance to consume the supplements.
The savoury dishes can result in a significant nutrient consumption 
but, due to the bulk which must be consumed, may restrict the total food 
intake. Furthermore, although the taste and odour of the product may be 
successfully masked it is by no means clear whether such composite dishes 
would overcome the difficulties associated with gastrointestinal tolerance 
to the products which, as previously shown, may be significant in 
determining continuing consumption.
Casual tasting tests have shown that the sweet dishes are both 
attractive and palatable although consumption achieves only a small 
supplement intake which is of only limited value. However, use of the 
savoury recipes requires ingestion of larger amounts of bulky dishes of a 
high nutrient density. This could prove difficult for anorexic or 
nauseated patients or those suffering from early satiety.
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For these reasons 'instant1, and straightforward, means of consumption 
may be required. The addition of coffee or chocolate are simple ways of 
altering the flavour and may prove acceptable as a warm or cold drink. 
'Instant' powder soups can be added to the heated product and it can be 
used to dilute 'condensed' soups, particularly those with a strong 
flavour. Whether these will prove acceptable depends largely on individual 
preference. Casual trials of 'coffee' showed this to be unacceptable to 
many 'normal' participants (15 when N = 20). The addition of an egg and 
30ml brandy/sherry/whisky can make a tolerable 'egg flip'. However, 
recent circulars from the Department of Health (Wright Warren, 1988; 
Thomson, 1988) instruct that raw eggs should, no longer, be used in this 
way due to the risk of salmonellosis. This unfortunate development has 
significantly limited a useful means of supplementation available in most 
clinical settings.
As previously mentioned the limited availability of the products 
restricted any further attempts at improving consumption. Similarly, the 
removal of Crown immunity from hospital premises has led to difficulties 
in trying these recipes in the clinical setting, which have been 
exacerbated by the limited cooking facilities available on the wards. The 
composite dishes, particularly those of a savoury nature, must be cooked 
just prior to consumption so that there would be difficulties in using 
them in the hospital setting due to the, sometimes prolonged, interval 
between preparation and service of meals. Recipes, such as those 
developed, may be useful in the community when either the patient himself 
or his relatives can prepare them prior to consumption. It appears that, 
in the clinical setting an alternative means of supplementation, which is 
not associated with such difficulties, would be desirable.
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CHAPTER 7.
GENERAL DISCUSSION.
7.1 THE QUALITY OF LIFE INDEX.
A measurement instrument has been designed in an attempt to obtain 
information about the quality of life (QL) of patients undergoing 
treatment for malignant disease. This has been evaluated by means of three 
main studies involving a total of 241 patients representing a cross- 
section of all those admitted to an oncology unit over a three year 
period. The Symptom Distress Scale (Section 1 of the questionnaire) has 
been tested in an additional 120 patients.
7.1.1 Reliability.
Reliability was assessed on each of the three occasions by means of 
Cronbach's coefficient alpha yielding a consistently high figure (0.92 - 
0.97). Carmines and Zeller (1979) suggest that, as a general rule, 
reliability should not be less than 0.8 for a widely used instrument 
stating that, at this level, random measurement error will have only a 
small effect on estimates of reliability. Although Barker Baussell (1986) 
suggests coefficient alpha tends to give a slight over-estimation of a 
measure's true reliability he does not justify this statement and the 
generally accepted view is that alpha gives a conservative estimate of 
reliability (Carmines & Zeller, 1979) and Novick and Lewis (1967) have 
shown that alpha is, generally, the lower boundary of the reliability of 
an unweighted scale. This being the case the reliability of a scale cannot 
be less than alpha. The consistently high coefficient alpha suggests that 
the reliability of this scale is high.
Test-retest methods are commonly used to evaluate reliability and were 
used in the pilot study yielding high reliability coefficients. There are, 
however, serious limitations to their use as a result of which they were 
felt generally inappropriate for use in these studies. QL is, by
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definition, a dynamic construct which changes with time as different 
factors impinge on the individual (eg. disease processes, methods of 
treatment, social factors) so that it is difficult to identify the 
appropriate time interval which should be left between the two 
administrations. If this is too short, memory (practice) effects may 
affect responses; Nunnally (1978) suggests such effects may be significant 
even after an interval of two weeks or more. However, measurement of a 
dynamic construct after an interval in excess of two weeks may mean that 
significant changes have occurred so that differences in response may 
reflect such changes rather than instability/unreliability of the 
instrument. Such an approach would, therefore, be of limited value in 
studies such as those described. Since memory effects may well have 
affected responses the test-retest method, used in the pilot study after 
an interval of 1-2 hours, may well have yielded artificially high 
reliability estimates. It was for this reason that Cronbach's coefficient 
alpha was also calculated.
It is recognised that both the alternative-form method and the split- 
half technique could also be employed in evaluating reliability. The 
alternative-form method relies on administration of another measure of the 
same construct thus requiring two test administrations at an interval of 
at least two weeks to allow for day-to-day fluctuations in the individual 
concerned (Nunnally, 1964). This is clearly advantageous since it reduces 
the extent to which individual memory can inflate the reliability 
estimate. However, alternative-form reliability is appropriate only if the 
phenomenon to be measured is relatively enduring as opposed to being 
subject to rapid or radical alteration (Carmines & Zeller, 1979). 
Furthermore, the value of this technique is limited by the practical 
difficulties associated with construction of alternative forms of 
assessment which will display the properties of parallel measurements; no
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pre-existing method of measuring QL has, to date, proved completely 
acceptable.
In contrast, the split-halves method can be conducted on a single test 
administration which is clearly advantageous when measuring a dynamic 
construct. Using this technique the total set of items is divided into 
halves and the scores on the two halves correlated to provide an estimate 
of reliability; the two halves are regarded as approximations of alternate 
forms. There is, however, a certain indeterminancy in using this method 
due to the different ways in which the items can be grouped into halves. 
The usual means of division is to place even-numbered items in one group 
and odd-numbered items in the second although other methods may also be 
used so that, for a 10-item scale, there are 125 different possible splits 
(Carmines & Zeller, 1979). It is probable that each of these will lead to 
a different correlation between the halves and, therefore, a different 
reliability estimate.
It was for these reasons that internal consistency was estimated since 
this requires only a single test administration and provides a unique 
estimate of reliability for a given test administration as coefficient 
alpha for a test having 2N items is equal to the average value of the 
alpha coefficients obtained for all possible combinations of items into 
two half-tests (Novick & Lewis, 1967). Moreover, Nunnally (1978) has
demonstrated that coefficient alpha can also be derived as the expected 
correlation between an actual test and a hypothetical alternative form of 
the same length. Thus it appears that coefficient alpha was the 
appropriate technique for use in these studies; the repeatedly high
reliability coefficients suggest that the results may be interpreted with 
some degree of confidence. It must, however, be recognised that the
reliability coefficient is not a stable property of the instrument but 
rather of the test administration and, as such, must be calculated each
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time the test is administered.
7.1.2 Validity.
Validity, the extent to which any measurement instrument measures what 
it is intended to measure, is more difficult to establish since, in 
reality, 'one validates not a test but the interpretation of data 
arising from a specified procedure (Cronbach, 1971). This means that one 
validates not the measurement instrument per se but the instrument 
with regard to the purpose for which it is being used. Thus, although 
the definition of validity appears straightforward several different types 
of validity must be considered in evaluating any tool each of which adopts 
a different approach in assessing the extent to which it measures what it 
purports to measure (Table 2.3).
Since the index developed includes the items identified by patients as 
areas of concern, and also includes terms considered relevant by other
researchers, it could be said that it has face validity. This could,
however, be regarded too simplistic and it could, in any case, be 
suggested that this is not face validity but content validity ['the 
extent to which an empirical measure reflects a specific domain of 
content' (Carmines & Zeller, 1979)]. Indeed, face validity is a weak and 
subjective evaluation since no-one knows what a specific measure should 
look like (Barker Baussell, 1986), particularly when this is designed to 
measure an abstract construct such as QL. The value of face validity is, 
therefore, limited.
Content validity, however, considers the appropriateness of the items 
included in an instrument as a sample of all the possible items which
could be included when attempting to assess a single attribute. In the
case of a complex attribute, such as QL, evaluation of content validity is 
clearly difficult particularly since Barker Baussell (1986) suggests the 
utility of the concept (content validity) is directly proportional to the
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amount known about that which is being measured. Since QL has been
recognised as an abstract term it can be seen that assigning content 
validity is difficult particularly as there are no well-defined, objective 
criteria against which the instrument can be judged, nor is there an 
universally accepted definition of the construct. Thus the definition
adopted is clearly open to the subjective views of the researcher.
Having said this, however, reference to the relevant research and 
theory surrounding QL, combined with patient interviews, has helped to 
identify those items considered important in any assessment of QL in 
cancer patients (eg. Priestman & Baum, 1976; Young & Longman, 1983; Selby
et al, 1984; Padilla & Grant, 1985). As a result it is believed that the
instrument developed has some degree of content validity. Comparison with 
the Karnofsky Performance Status Index (KPS) (Karnofsky et al, 1948), 
previously used to evaluate QL, supports validity although the limitations 
of the KPS must be recognised since this relies on assessment by an 
observer and evaluates QL only on the basis of physical performance.
Similarly, patient interviews, and comparison of the total score with 
that obtained on the Uniscale, yielded high correlations and appeared to 
support validity. However, since the interviews were carried out 
immediately after completion of the index it is difficult to ensure their 
independence and the Uniscale, forming part of the questionnaire was, 
perhaps, completed too soon since patients may wish to appear consistent 
in their responses. It is however, unclear what time interval should be 
left between completion of the instrument and the Uniscale since, as 
previously stated, QL is dynamic and, therefore, subject to change, 
particularly in cancer patients. Opinions sought from members of the 
nursing staff as to the content of the instrument failed to identify any 
areas of omission.
Construct validity describes the extent to which an instrument relates
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to other measures consistent with the theoretically derived hypotheses 
concerning the construct to be measured (Carmines & Zeller, 1979). Clearly 
such assessment is reliant on definition of the construct under 
consideration. These studies propose that both cancer per se, and/or its 
treatment, may affect the patient's assessment of his QL and, although it 
was recognised that pre-existing factors may influence QL, it was believed 
that self-assessment procedures would compensate for such effects, at 
least to some extent. The close relationship between the Uniscale and the 
total scores, does, to some degree, support construct validity although, 
as previously discussed, the independence of these measures is not 
assured. It is not possible, on the basis of a single study, to determine 
whether or not a measure truly possesses construct validity rather this 
depends on a pattern of consistent findings over a variety of different 
studies (Barker Baussell, 1986), preferably involving different 
researchers. However, the findings of the studies described display 
remarkable consistency (see page 189) suggesting that construct validity 
can be ascribed to this tool although further work is clearly required.
Overall, it is believed that the QL index represents a valid assessment 
of QL since its content is congruent with that identified in the 
literature and by patients themselves. Similarly, the nursing staff have 
identified no omissions from the instrument. Furthermore, the reliability 
of the instrument supports its validity since no instrument can be valid 
if it is not reliable and if its content does not reflect its purpose 
(Barker Baussell, 1986). It must, however, be recognised that this index 
was designed specifically to evaluate the effects of cancer and its 
treatment on QL and, as a result, may not be applicable in assessment of 
QL in the general population.
7.1.3 Sensitivity.
For an instrument to be useful it must be capable of detecting small
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differences between groups of patients or within individual patients over 
time (Selby, 1985). It was for this reason that a LASA scale was selected 
since this does not restrict the subject to direct quantitative terms and 
permits him to make as fine a discrimination as he wishes (Freyd, 1923). 
This decision was supported by the findings of the pilot study.
The results presented in Chapter 4 indicate that the tool is sensitive 
to changes in individual patients such that the scores display alterations 
which reflect changes in the clinical condition. The results do, however, 
suggest that, although clinical improvement/deterioration was evident, 
this did not, of necessity, affect overall QL despite changes in the 
symptom distress score (SDS) since these were offset by changes in the 
activity of daily living (ADL) score. Since QL comprises many diverse 
areas, of which physical distress is only one, such findings are not 
surprising and, as a result, some patients with advanced or widespread 
disease judged their QL to be very good, scoring higher than those with 
less severe disease. In general, however, an increase in symptom distress 
was associated with a decrease in overall well-being although this was 
often offset by improvements in other areas (eg. communication). The fact 
that such details could be identified supports the sensitivity of the 
instrument. However, the fact that symptom distress per se does, so 
often, appear to represent a decline in well-being, and overall QL, this 
could suggest that the symptom distress scale itself may be more useful 
than the instrument as a whole in assessment of the individual 
particularly since symptom control is an area at which nursing 
interventions can be directed. The sensitivity of the tool suggests that 
it could provide a useful, reliable and valid tool for evaluating the 
effects of such interventions. However, such an approach may mean that 
other areas of concern are not identified so that action is not taken to 
reduce their impact and improve overall QL. Certainly the
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interviews/assessments conducted provided a useful means through which 
counselling could be initiated and the responses to the questionnaire 
clearly identified areas of greater and lesser concern to individual 
patients.
Regular use of the questionnaire, recording the results in the 
patients' notes, would enable detection of changes, permitting 
interventions to be commenced which could maintain/improve the quality of 
care and, in turn, the quality of life. Further evaluation would be 
required if the tool was to be used in this way.
7.1.4 Acceptability and Feasibility.
Of all the patients studied over the period of the research described 
only 5 refused to participate (for reasons unrelated to the study eg. 1 
patient could not read and a second could not speak English); none 
withdrew once in possession of the questionnaire. It was easily completed 
and, following the pilot study, no difficulties were observed or reported. 
The questionnaire is short and takes an average of 10-12 minutes to 
complete; it is easily administered taking only about 3 minutes to 
explain. As a result it is a tool which could readily be used in clinical 
practice since it requires neither complex or specialised instruction nor 
excessive amounts of time to complete.
Scoring is straightforward and takes little time. It provides scores on 
either individual items or QL as a whole and is, therefore, feasible for 
use in routine clinical practice. It must, however, be recognised that 
scores obtained from LASA scales have no true quantitative terms although 
they do represent positional values which indicate the patient's response 
to individual items providing a rank order of their severity. It is this 
factor which would render the tool useful in assessing individual 
patients.
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7.1.5 'Meaningfulness1.
'Meaningfulness1 is the term used to describe the practical value of 
any measurement instrument and represents a pragmatic test of any tool. 
The value of an instrument is related to its reliability, validity and 
sensitivity since a tool which is unreliable cannot give meaningful 
results; similarly, if it is insensitive it loses its meaningfulness 
(Abdellah & Levine, 1986).
The previous discussion has described the consistent reliability of the 
tool across a number of studies in different patient populations. 
Similarly, it has been established, as far as this is possible, that the 
tool is valid for the purpose for which it is intended. It can, 
therefore, be regarded as providing meaningful results both in individual 
patients and in the population as a whole. The data presented in Chapter 4 
indicates that the tool is sensitive to changes in individual patients and 
that contained in Chapter 5 suggests that there is a close relationship 
between QL and food intake although, as previously stated it is not clear 
whether this is a causal relationship and, if it is, which is the cause 
and which the effect. Nonetheless, the reliability and apparent validity 
and sensitivity of the tool suggest that it is capable of giving 
meaningful results.
The consistency of the results obtained supports this conclusion. For 
example, the symptoms identified as causes of significant distress (ie. a 
score <50 on individual items) show marked similarity across the studies 
affecting a similar percentage of patients although there are some 
differences in the rank order (Table 7.1 overleaf).
Multiple regression analysis of the QL studies (excluding the pilot 
study) identified sleep as the factor accounting for >60% of the variance 
in the responses. Although there are some differences between the analyses 
(Table 7.2) these are to be anticipated since they represent different
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TABLE 7.1.
COMPARISON OF THE SYMPTOMS CAUSING SIGNIFICANT DISTRESS IN DIFFERENT
PATIENT POPULATIONS.
Number of Patients affected (%)
Study Number 1 2 3 4
Symptom
Appearance 27 (45.0) 37 (30.8) 38 (31.4) 12 (20.0)
Tiredness 21 (35.0) 52 (43.3) 53 (43.8) 30 (50.0)
Concentration 21 (35.0) 32 (26.7) 32 (26.5) 11 (18.3)
Mood 21 (35.0) 40 (33.3) 42 (34.7) 14 (23.8)
Mobility 21 (35.0) 42 (35.0) 42 (34.7) 16 (26.7)
Sleep 17 (28.3) 28 (23.3) 29 (23.9) 12 (20.0)
Appetite 14 (23.3) 26 (21.7) 27 (22.3) 11 (18.3)
Constipation 12 (20.0) 24 (20.0) 24 (19.8) 7 (11.7)
Pain 7 (11.7) 24 (20.0) 23 (19.8) 6 (10.0)
Nausea 4 ( 6.7) 16 (13.3) 15 (12.4) 4 ( 6.7)
Diarrhoea 4 ( 6.7) 12 (10.0) 27 (22.3) 3 ( 5.0)
1 = Pilot Study (N = 60)
2 = Symptom Distress Study (N = 120)
3 = Main Quality of Life Study (N = 121)
4 = Nutrition/Quality of Life Study (N = 60)
TABLE 7.2. COMPARATIVE MULTIPLE REGRESSION ANALYSIS.
(Only major factors are shown)
Main Quality of Life Study Nutrition/Quality of Life Study
Variable % variance 
accounted for
Variable % variance 
accounted for
Sleep 62.1 Sleep 60.9
Appetite 16.2 Mood 16.8
Nausea 6.3 Appetite 6.2
Recreation 3.6 Flavour of food 2.1
patient populations. There is also marked similarity between the findings 
on principal components analysis (PCA) (see Table 4.7 and 5.22); again 
some differences are to be anticipated due to differences between the 
populations studied.
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7.2 THE QUALITY OF LIFE.
The tool which has been developed appears to be both reliable and 
sensitive, and to possess some degree of validity, suggesting that it is 
capable of being useful in clinical practice. It can be seen that QL may 
be affected by both malignant disease and its treatments; the results 
suggest QL may change as the disease progresses. Since it is not possible 
to obtain pre-illness data it is not possible to quantify the extent of 
change nor is it possible, from a single questionnaire, to identify the
direction in which the changes have occurred. The sequential studies, 
although involving only a small number of patients, indicate that the 
index is capable of identifying even small changes in QL which occur with 
time. Use of the Uniscale can indicate a decrease in QL but fails to 
provide a mechanism through which an improvement can be identified. This 
may be significant since it cannot be assumed that either the illness or 
its treatment, of necessity, result in a decreased QL. Indeed, a small 
number of patients have indicated improvement in overall QL despite the 
presence of distressing symptoms.
Symptoms causing significant distress show marked similarity throughout 
the studies described with only minor differences in the rank order (Table
7.1). Table 7.3 shows the aggregated results of all the observations. From 
this it can be seen that a significant number (155) of patients found 
tiredness the most distressing symptom whilst changes in sleeping pattern 
accounted for the majority of the variance in the total scores. It could 
be concluded that an inability to sleep was the primary cause of
tiredness. PCA, however, suggests this is not, of necessity, a causal 
relationship and that physical discomfort arising from accompanying
symptoms is a contributory factor. This area requires further
investigation.
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TABLE 7.3. SYMPTOMS CAUSING SIGNIFICANT DISTRESS: 
AGGREGATED RESULTS OF ALL THE OBSERVATIONS* (N = 361) 
(Score <50 on individual items)
Symptom Total Number of Patients Affected (%)
Tiredness 155 (42.9)
Mobility 131 (36.3)
Appearance 127 (35.2)
Mood 122 (33.8)
Concentrat ion 106 (29.4)
Sleep 92 (25.5)
Appetite 86 (23.9)
Constipation 76 (21.1)
Pain 66 (18.3)
Nausea 46 (12.7)
Diarrhoea 34 ( 9.4)
(^Includes data from pilot study, symptom distress study, main quality of 
life study and nutrition/quality of life study).
Changes in the level of physical activity (mobility), in appearance and 
in mood were the next most frequently reported causes of significant 
distress. Mobility was, generally, correlated with changes in recreational 
activity and with life changes.
It is of considerable interest that pain does not appear to cause 
significant distress to the patient population although it is a commonly 
feared symptom and is, clearly, of marked significance to affected 
patients. This finding is consistent with that of Twycross (1972) who 
suggested that in only a few patients is pain severe or intractable. It 
could, however, be suggested that patients fail to report the true extent 
of their pain for fear of becoming addicted to pain relieving drugs (see 
Chapter 3).
It is possible that the discussion of symptoms causing distress is 
weakened by the arbitrary nature of the cut-off point selected [ie. a 
score <50 on individual items (50% of the total possible score)]. This 
point has not been validated for use in a patient sample. Indeed, McCorkle 
and Young (1978) used a cut-off point equivalent to 75 on a LASA scale. It
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FIGURE 7.1. NUMBER OF SYMPTOMS CAUSING DISTRESS TO INDIVIDUAL PATIENTS.
(Significant distress = score <50 on individual items)
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is not clear which of these is the most appropriate and it is possible 
that neither truly reflects the patient's view of the level of distress he 
is suffering. It is difficult to see how this can be overcome.
Within these limitations it is worrying to note that 96% of the total 
sample (N = 361) reported significant distress from at least one symptom, 
67% from 2 or more and 4% from all symptoms included in the scale (Figure
7.1). Thus only 4% (14 patients) reported no symptom as a cause of marked 
distress. This is, clearly, a matter of considerable concern not least 
because symptom control/relief is an area at which nursing interventions 
can be directed. The Symptom Distress Scale could provide an effective 
assessment tool enabling evaluation of the care provided rendering this
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dynamic and responsive to changes in the patient's condition.
The activities of daily living most affected were recreational 
activity, sleeping patterns and the ability to eat; psychosocial factors 
causing concern were those related to communication and social isolation. 
It has been suggested that the alienating environment of a hospital ward 
has a detrimental effect not only on the rate of recovery but also on 
emotional well-being. Cartwright (1983) has noted varying degrees of 
dissatisfaction with the formal and bureaucratic character of the care 
provided in hospitals. For example, although hospitalisation results in 
standardisation of patient care, which, whilst advantageous in terms of 
bureaucratic efficiency, also formalises care allowing little 
individualism within that standard. It also results in marked 
depersonalisation by stripping the patient of personal items, regulating 
the resources available to him and restricting his mobility (Coe, 1978). 
Such effects gradually convert a sick individual into a patient who then 
becomes an almost passive recipient of his care which embraces the complex 
systems of specialised hospital treatments (Mechanic, 1968). This takes 
care of the patient's 'illness' needs but often excludes his individual 
or personal needs. Yet illness must be approached from the perspective of 
the individual's interpretation. One way of achieving this is through the 
sharing of information and improved communication.
For example, empirical evidence suggests that sharing of information 
both improves the rate of recovery and enhances the outcome of medical 
intervention following surgery (Skipper & Leonard, 1968). Successful 
communication is, therefore, an important part of any therapeutic regime 
since successful interactions may restore confidence and improve the sense 
of well-being (quality of life?) (Turner, 1987). At the same time 
successful communication may enhance compliance with the therapeutic 
regime. Thus the apparent failure of communication, combined with feelings
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of social isolation, is of considerable concern. Clearly this situation 
could be improved if nurses were aware of the true situation. An 
assessment tool, such as that described, could be of value in improving 
this aspect of care.
In general, concern about the future or about earning ability appeared 
to be a function of age the younger patients being more concerned than 
older patients many of whom were retired and in receipt of private or 
Government pensions.
Study of the completed questionnaires enabled identification of the 
areas of concern to individual patients and it was found that use of the 
instrument provided a useful means by which patient counselling could be 
initiated once particular problems had been identified. However, although 
scores on individual items have been added to give a total score, it 
should be noted that scores given on a LASA scale do not provide a true 
score but rather provide a rank order of their importance to the patient 
(Abdellah & Levine, 1986). The score has, however, been used as the 
dependent variable in the statistical analyses.
The need for a score depends on the intended use of the tool. If, for 
example, it is to be used to assess changes with time, or in response to 
specific interventions, then a numerical score, recorded in the patient's 
notes, could be used to provide an indication of change. A record of 
individual items causing significant distress could also be valuable since 
the total score may enable global changes to be ascertained but gives no 
insight as to the cause of that change. It has been suggested (Selby et 
al, 1984) that, if scores are to be summated, attention to the relative 
weight of each item is required since their effects may not be equal. 
Clark and Fallowfield (1986), however, suggest that this may represent an 
insoluble methodological problem since a weighting system would require an 
observer to judge the relative importance of the factors included
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(Priestman & Baum, 1976). It is, in any case, likely that the relative 
importance of items will change with the individual concerned (Abdellah & 
Levine, 1986) and it could be argued the LASA scale overcomes this 
problem, at least to some degree, by giving positional values which 
indicate their rank order from the patient's perspective.
7.3 FOOD INTAKE AND NUTRITIONAL STATUS.
The studies described show that, as predicted, assessment of food 
intake is fraught with difficulties. It is clear that a 24-hour recall is 
an inaccurate and inappropriate guide to actual food consumption since it 
has been shown that there is little agreement between the data obtained 
from weighed intake studies and a dietary recall. In contrast to previous 
findings (Young, 1953; Stunkard & Waxman, 1981) it did not appear that 
under- or over-estimates were associated with higher or lower intakes or 
with portion size. The recall method may, however, be useful in providing 
an overview of food consumption.
Since the intra-subject variation in nutrient intake is considerable 
(Beaton et al, 1983; Gibson et al, 1985) it is generally believed that the 
intake of a group or population can be estimated more accurately than that 
of an individual. This being the case it can be concluded from the results 
presented that the nutrient consumption of cancer patients in general is 
inadequate failing to meet the requirements of healthy individuals of the 
same age, sex and level of activity. It must, however, be recognised that 
comparison with the Recommended Daily Amounts (DHSS, 1979) may be 
inappropriate since these refer to the majority of the 'normal' population 
and take no account of any additional needs arising from illness. Since, 
as shown in Chapter 1, cancer patients are subject to many anatomical, 
physiological, biochemical and physiological changes which may interact to 
both nutrient requirements and food intake it is likely that their actual 
nutrient needs are increased over and above those of the 'normal'
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individual and for prolonged periods of time. The results presented 
indicate that nutrient intake is generally inadequate and are consistent 
with previous findings (eg. Moloney et al, 1983; Walsh et al, 1983). It 
should, however, be noted that these findings differ little from those 
obtained in other patient populations (Table 5.26). This suggests that the 
food intake of hospital patients in general fails to meet their nutrient 
needs. However, in view of the vulnerability of the cancer patient to 
nutritional depletion, the chronic nature of the illness and the effects 
of such depletion on the response to treatment this poses a particular 
threat to his well-being and indicates the need for nutritional support. 
This will be beneficial not only in terms of general health but also in 
terms of quality of life since it can be suggested that food intake and QL 
are closely related. Although it is by no means clear which of these 
factors is the cause and which the effect it can be postulated that an 
improvement in food intake will result in a concurrent improvement in QL. 
Since food intake and nutritional status are closely inter-related, and 
since there is little doubt that a reduced nutritional status is 
deleterious to general health, it seems likely that nutritional support 
per se will also contribute to overall well-being and quality of life.
In view of the strong relationship demonstrated between tiredness, mood 
and appetite it could be suggested that factors associated with the 
symptoms of disease may, themselves, influence the food intake. Similarly, 
reports of apparent changes in taste sensation and the perception of food 
texture could influence consumption. As many of the patients ate all the 
food offered to them, and consumed additional snacks and confectionary, 
these factors did not, in general, appear to significantly affect food 
intake although it is not possible to gauge the extent of any change which 
has occurred since the onset of disease or that due to admission to 
hospital. However, it should also be noted that patients were able to
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request a small or large portion so that they had some degree of control 
over their food consumption. It may be that decreases in appetite were 
more common than the findings suggest but that, as suggested by Wesdorp et 
al (1983), patients failed to recognise this and, therefore, did not rate 
it as a cause of significant distress/concern. As no pre-illness data 
were available it is not possible to investigate this hypothesis further.
Since there is considerable consistency in the findings of the
individual studies it is possible to identify other factors which may
influence food consumption. For example, both pain and nausea would be 
expected to reduce food consumption and, in general, nausea correlates 
well with appetite, It can, therefore, be suggested that food intake is 
inhibited by nausea although it should be noted that only a small 
percentage (12.7%) of patients regard this as a major cause of distress. 
Pain, however, does not generally correlate well with either appetite or 
the ability to eat although its correlation with tiredness is moderately
good. Thus, pain, through its relationship with tiredness, may,
indirectly, contribute to a decline in food consumption. Surprisingly pain 
does not correlate well with mood. Nonetheless, these findings suggest 
that symptoms may interact to affect both food consumption and, therefore, 
nutritional status and QL.
Attempts were made to investigate the relationship between nutritional 
status and quality of life in greater depth although, despite the previous 
findings, it has not proved possible to demonstrate a clear relationship. 
The consistency of the QL index, combined with the known limitations of 
the techniques of nutritional assessment, suggests that the difficulties 
encountered may relate primarily to these techniques rather than to the 
index itself. Although some general conclusions have been drawn about the 
nutritional status of the patients concerned, and are consistent with 
those anticipated due to the low food intake, it is probable that the
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standard techniques of nutritional assessment are not generally applicable 
to cancer patients. For example, although body weight can, under normal 
circumstances, provide an approximate estimate of body energy stores 
(Garrow, 1974) it is open to distortion and pathological factors, such as 
oedema, ascites or tumour growth, can influence weight for height 
estimations limiting the value of the weight:height index. Some workers, 
however, (eg. Durnin & Fidanza, 1985) suggest this index is inappropriate, 
even in health, since individuals of the same height and weight may 
display significant differences with regard to body composition.
Measurement of triceps, and other, skinfolds may be affected by 
differences in compressibility (Brozek & Kinzey, 1960), sex (Lee & Ng, 
1965), anatomical site (Himes et al, 1979) and with hydration status (Hass 
& Flegal, 1981). Compositional changes, due to under- or over-nutrition, 
may also affect the findings. Many of the patients studied were overtly 
under-nourished, others displayed marked fluid retention, so that 
imprecision in the results obtained is likely. Furthermore, since the 
anthropometric standards applied (Bishop et al, 1981) were developed for 
use in the USA, and since the Americans are known to be both taller and 
heavier than the British (Knight, 1984), it is probable that these 
standards exceed those appropriate to the UK population.
Hand grip strength, although it has been used as a nutritional index 
(Klidjian et al, 1982), may be affected by factors other than the 
nutritional condition (Bohannon, 1987) and takes no account of age or 
occupational variations between subjects so that, again, it is not clear 
whether the standard values apply across the age range. It was anticipated 
that variance due to occupational factors could be overcome by testing the 
non-dominant arm although, in practice, there was little difference 
between the dominant and non-dominant arm. This may suggest that the 
effect of occupation on grip strength is limited.
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Biochemical indices, although not considered in this study, may, in 
theory, provide an alternative assessment method. Evaluation of, for 
example, the serum concentrations of various transport proteins, urinary 
creatinine or 3-methylhistidine (3-MH) excretion or immunocompetence may 
overcome the difficulties inherent in anthropometric assessment. All such 
methods, however, have serious limitations many of which are exacerbated 
by the presence of malignancy. For example, there is concern regarding the 
use of serum albumin as a nutritional indicator since a low plasma 
concentration reflects the presence of illness or psychological stress 
rather than nutritional status per se. Furthermore, hypoalbuminaemia may 
be due to non-nutritional causes such as malignancy itself (Picou & 
Waterlow, 1962), hepatic disease, nephrotic syndrome or protein-losing 
enteropathy which, as previously shown, is not uncommon in malignant 
disease (Creamer, 1964; Wangel & Deller, 1966). Indeed, protein-losing 
enteropathy will affect the concentration of all serum proteins (Long, 
1984) so that, although they are of value in assessment of uncomplicated 
starvation they are less effective when this is complicated by disease.
Similarly, immunocompetence may be decreased not only by starvation or 
malnutrition but also by the chemotherapeutic approach to treatment and 
by radiotherapy when a significant amount of the bone marrow is included 
in the treatment field. Finally, assessment of both creatinine and 3-MH 
are difficult to achieve not least because of the difficulties associated 
with obtaining reliable 24-hour urine collections but also because such 
indices are unreliable in hypercatabolic patients (Long, 1984), such as at 
least some of those with malignant disease.
Assessment of nutritional status is, clearly complex and the value of 
current techniques appears limited, particularly in the cancer patient. 
However, whilst recognising the limitations of the techniques employed, 
some general conclusions have been drawn about the nutritional status of
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the subjects and about cancer patients in general.
Despite the known distortions of records of body weight in these 
patients a weight loss is always significant and it is clear that most 
patients lose weight as their disease progresses. Since some patients had 
overt fluid retention and still displayed weight loss it is probable that 
loss of body tissue was masked by fluid overload so that the actual loss 
exceeded that recorded. It is possible that fluid retention (see Table 
5.15) also masks a loss of tissue in those patients gaining weight. There 
is no obvious explanation for the fact that that the extent of weight loss 
in females appears to decrease with time whilst, in males, weight loss 
continues and increases with time (see Figure 5.2). Investigation of this 
area would require considerable clinical research. However, since the 
sample did not include only those patients with sex-specific tumours this 
does not appear to be a significant factor although it cannot be 
discounted. Since a greater proportion of females exhibited- overt fluid 
retention (see Table 5.15) it is, again, likely that fluid overload is 
responsible for the apparent decline in weight loss. The cause of such 
retention requires further study.
In attempting to evaluate the relationship between nutritional status 
and quality of life three approaches were adopted in order to classify the 
patients by nutritional status. Two of these were based on pre-existing 
methods of identifying malnourished patients (Grant et al, 1981; Klidjian, 
1981), the third was developed once the limitations of the other methods 
had been recognised. In no case was it possible to demonstrate a 
relationship between apparent nutritional status and QL. However, since 
the techniques of nutritional assessment are imprecise, the scoring 
systems are also unreliable so that such findings are not surprising. It 
is clear that nutritional assessment of individual patients is an area in 
need of further investigation.
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Despite the failure to demonstrate a clear relationship between 
nutritional status and QL a relationship was found between food intake 
and QL. As a result it seems safe to assume that there is a similar close 
interaction between a patient's nutritional condition and his quality of 
life. This being the case, and in view of the inadequate food consumption, 
even when all the food offered was consumed, there is clearly a need to 
provide additional nutrients either through the normal hospital food 
supply or by means of nutritional supplements.
Since, whenever possible, the oral route is preferred for nutritional 
supplementation, the acceptability of two nutritional supplements, 
believed typical of those commercially available, was assessed. As casual 
tasting tests indicated that the organoleptic properties of both products 
were likely to prove unacceptable it was decided to test them first in a 
normal, healthy population so as to gain an estimate of their hedonic 
properties and general acceptability. It was believed that, if the 
products were unacceptable to normal subjects, it was likely that they 
would be rejected by patients. Compliance with any dietary regime depends 
not only on the acceptability of the recommendations made (Auty, 1983; 
Fuller, 1985) but also on the patient's understanding of the reasons 
underlying such recommendations (Marston, 1970).
Sensory analysis, designed to evaluate the organoleptic and hedonic 
properties of the supplements, was carried out. The first product was 
found to be generally unacceptable by the majority of both normal subjects 
and patients regardless of the temperature of presentation. As a result 
compliance with any regime incorporating this product was unlikely.
The organoleptic properties of the second product indicated that it was 
clearly acceptable to a greater number of the subjects but it was 
difficult to predict whether it would prove acceptable to a sufficient 
number of patients. In practice, acceptability in patients proved to be a
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significant problem primarily due to epigastric discomfort, regurgitation 
and other GI symptoms confirming that GI discomfort can promote aversion 
to any food which becomes linked with its causation (Garcia et al, 1974; 
Leathwood et al, 1986). Aversion is most likely to develop against any 
novel food(s) consumed around the time discomfort is first experienced 
(Revusky & Bedarf, 1967). Only one patient continued to consume the 
product beyond the time required in the study primarily due to his strong 
motivation to 'maintain his strength'. This confirms the need for the 
patient to have faith in the regime he is offered (Glanz, 1980).
If these products were truly typical of those available these findings 
clearly indicate that, if they are to be used effectively, the 
organoleptic properties require considerable improvement.
7.4 IN SUMMARY.
A method of assessing quality of life has been developed for use in 
cancer patients evaluation of which suggests that it provides a reliable, 
valid and sensitive means of assessment capable of yielding useful 
results.
Studies of the food intake of hospitalised patients suggests that, in 
general, this is inadequate in that it fails to meet the nutrient needs 
defined for 'normal' healthy individuals. It is, however, clear that the 
nutrient needs of cancer patients are uncertain although it can be 
suggested that it is likely that these exceed those of the healthy 
population.
It has been demonstrated that there is a relationship between food 
consumption and quality of life although it has not been established which 
of these is the cause and which the effect of the changes noted. Since 
this relationship exists it seems likely that there is also a relationship 
between nutritional status and quality of life although it has not, yet,
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proved possible to demonstrate this.
It is suggested that the failure to identify the relationship between 
these two parameters primarily reflects the difficulties associated with 
assessing nutritional status in the cancer-bearing patient in part due to 
distortions of many common indices resulting from physiological or
pathological changes and in part to the absence of appropriate standards 
for use in a British population.
Despite the limitations of the techniques employed the results,
together with the inadequate food consumption of the majority of the 
patients, suggests that most patients are under-nourished and require some 
form of nutritional support.
Sensory analysis of two supplements, believed typical of those 
available, indicates that achieving compliance with supplementation 
regimes is difficult so that new methods of supplementation are required.
7.5 SUGGESTIONS FOR FUTURE RESEARCH.
1. There is a need for longitudinal studies to evaluate the changes in
quality of life which occur throughout the disease process or, for 
example, during a course of treatment.
2. Statistical analysis suggests that a shortened version of the
questionnaire, consisting of only 5 variables (physical comfort,
pyschosocial, communication factors, future concerns, isolation and 
changes in bowel habits) may be useful for population studies. 
Comparative studies would enable evaluation of the shortened
questionnaire.
3. Tiredness appears to be a significant factor in determining QL in
cancer patients. PCA suggests that the physical discomfort arising from 
the accompanying symptoms is a contributory factor. This area needs 
further investigation.
Since the food intake of hospitalised cancer patients is, generally, 
inadequate there is a need to identify ways in which this can be 
improved. One way in which this could be achieved is by means of 
nutritional supplements. Sensory analysis and compliance studies 
suggest their acceptability is low so that there is a requirement to 
develop an appropriate range of supplements acceptable to a wider range 
of patients.
It has been shown that the techniques available for assessment of 
nutritional status are open to distortion for a variety of reasons and 
are, therefore, unreliable, particularly in cancer patients. There is a 
need for new techniques, and appropriate standards, to be developed. 
There appear to be differences in the extent of weight loss between 
male and female patients. Considerable clinical research would be 
required to elucidate the reasons for such differences.
Since it has been suggested that there is a relationship between both 
food intake and nutritional status and quality of life there is a need 
for longitudinal studies to investigate this area further. Such 
study is, at present, hampered by the lack of an appropriate measure of 
nutritional status.
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APPENDIX 1.
(This questionnaire is not to scale).
SELF ASSESSMENT INSTRUMENT FOR MEASURING THE QUALITY OF LIFE
The following pages contain many different statements. Please take your 
time and think about what each statement says and then place a mark 
across the line at the point which most closely resembles how you feel 
today.
Patient Index Number:
Notes:
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SECTION 1.
With regard to your general physical condition please describe
*How much pain you are feeling.
Worst pain I ._________
have ever had.
*How much nausea you are experiencing.
I feel as sick _______________________________________  I do not feel
as I possibly sick at all.
could be.
*How is your appetite?
I cannot face ________________ ______________________  My appetite is
food at all. normal for me.
*How do you sleep?
Could not be _______ ________________________________ Sleep as well
worse. as ever.
*How mobile are you?
Completely _______________________________________  Normal level
unable to move of physical
my body. * activity for
me.
*How are your bowels?
a. Diarrhoea
Could not 
be worse.
No diarrhoea.
b. Constipation.
Could not 
be worse.
I am not 
constipated.
*How tired do you feel?
Could not 
feel more tired.
I do not feel 
at all tired.
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*Are you able to concentrate?
I cannot 
concentrate 
at all.
My ability to 
concentrate is 
normal for me.
rKow is your moody
Could not feel 
more miserable.
Could not feel 
happier.
*What do you feel about your appearance?
The worst it 
has ever been.
My appearance 
has not changed.
*ls there any one symptom which causes you severe distress? 
If so which one?
*Do you think the symptoms you are experiencing are caused by the 
disease or the treatment.
SECTION 2. ACTIVITIES OF DAILY LIVING.
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Please describe how you feel with regard to your normal activity
*1 cannot eat 
at all
I am able to 
eat normally
*The flavour 
of food has 
changed
My food tastes 
normal
*The texture 
of food has 
changed
The texture of 
food feels 
normal
*1 cannot 
sleep at all
I am able to 
sleep normally
*1 find
breathing very 
difficult
My breathing is
perfectly
normal
*Urination has 
become very
I am able to 
pass urine 
normally
*My bowel 
pattern has 
completely 
changed
My bowels are
functioning
normally
*1 do not take 
part in my 
usual
recreational
activities
I continue with 
my usual 
recreational 
activities
*1 cannot do 
anything I 
used to do
I can do every 
thing I used to 
do
*1 am worried 
about the 
future
I am not 
particularly 
worried about 
the future
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*1 am worried _________________________ __________________ I am not worried
my future about my future
ability to ability to earn
earn
*1 f e e l ______________________________________ ____ _ I do not feel
totally isolated
isolated
*1 cannot ____________________________________________ I can discuss my
discuss my feelings with my
feelings with family
my family
*1 do not feel ____________________________________________ I can discuss
I can discuss anything with my
anything with doctors
my doctors
*1 do not feel _________________________________ __________ I can discuss
I can discuss anything with
anything with the nurses
the nurses
APPENDIX 2.
A SUMMARY OF THE STATISTICAL TECHNIQUES EMPLOYED.
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THE CORRELATION COEFFICIENT.
When two or more of a series of observations are obtained it is often 
found that the observations in one series vary correspondingly with those 
in the other. They may increase/decrease in parallel or as one increases 
the other may decrease proportionately. This relationship is described as
the correlation; the correlation coefficient is denoted by the symbol 'r'
and is calculated by the following equation:
r = g(x - 3?) (y - y ) 
yt l(x - x)* (y - y)1
in which x = dependent variable y = independent variable
x = mean of x observations y = mean of y observations
£ x  = sum of x observations ^y = sum of x observations
The null hypothesis is that there is no relationship between the
variables studied (r = 0). Interpretation of the correlation coefficient
is difficult not least because correlation does not, of necessity,
indicate a causative connection. Moreover, if there is a connection
between the variables it may be indirect. Nonetheless, by reference to
standard tables (eg. Fisher & Yates, 1963) a measure of the significance
of any relationship can be gained. However, to gain a true measure of the
significance of a correlation coefficient it is necessary to apply a
significance test. This can be achieved by calculation of the standard
error of the correlation (SEr) from which a ' t 1 value can be calculated
which takes into account not only the size of the correlation coefficient
but also the size of the sample. This is calculated as shown below:
t = r /n - 2 
71 - r*
The 't' table is then entered at n - 2 degrees of freedom.
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STUDENT’S ,t 1 TEST (Student, 1908).
This technique is used to test the null hypothesis that there is no
difference between the means of a sample and that of the population or
that there is no difference between the means of two samples. It'is most 
suitable for use with small samples (<60)(Swinscow, 1981). In brief the 
't' test is used to evaluate the probability that there is no significant 
difference between 2 groups. It is carried out by establishing multiples 
of the standard errors to which probabilities can be attached since, with 
small samples, such multiples of the standard error are larger.
For analysis of the data in the studies described two forms of the ’ t' 
test were required a) for paired data and b) for unpaired data.
a) Paired data. This approach is used to test the difference between the 
sample and the population mean and is applied when the data in the two 
groups can be linked in pairs. It relies on the difference between members 
of each pair and is calculated by means of the following equation:
t = d + y~sp2
v n __
in which d = difference between pairs, d = mean of the differences
SD = standard deviation 
n = total number of items.
b) Unpaired data. This technique is applied when the data is in two
groups but cannot be linked in pairs. It is calculated using the formula
given below.
t = *Xt - Xj
/SDS SD1
_  /  n, n2
where x = mean - Sample 1 x = mean - Sample 2
n(= number of items - Sample 1 n^= number of items - Sample 2
SD = Standard Deviation 
The significance of the ' t* value is determined by reference to the ' t' 
tables (eg. Fisher & Yates, 1963).
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CRONBACH'S COEFFICIENT ALPHA.
Coefficient alpha provides a practical means of evaluating the 
reliability of a measurement instrument (questionnaire) and overcomes many 
of the difficulties associated with this procedure. For example, alternate 
forms reliability is an unwieldy technique when attempting to do anything 
other than develop an instrument. The split-half technique, reliant on a 
single test administration to a single group of subjects, involves 
splitting the total set of items into halves and correlating the scores to 
provide an estimate of reliability. In this context the halves can be 
considered approximations of alternative forms although the resultant 
reliability coefficient describes the reliability of the halves rather 
than the test as a whole. Although a statistical correction can be made 
[using the Spearman-Brown prophecy formula (Brown, 1910; Spearman, 1910)3 
this technique is also complex and unwieldy and, furthermore, relies on 
the arbitrary splitting of a test into only two parts when there are many
possible ways of achieving this each of which may result in different 
reliability coefficients.
These difficulties can, however, be overcome by assessment of internal
consistency. The most commonly used measure of internal consistency is
Cronbach's coefficient alpha (Cronbach, 1951) which provides a unique 
estimate of reliability for a given test administration (Carmines & 
Zeller, 1979) and is useful for multiple-item measures that can only be 
administered on one occasion.
Coefficient alpha can be expressed as follows:
ot= Np/[1 + p(N -1)] 
where N is equal to the number of items and p equals the mean inter-item 
correlation.
This equation shows that the value of alpha depends on the average
inter-item correlation and on the number of items in the scale. Thus, as
the average inter-item correlation. increases, and as the number of items 
increases, the value of alpha will increase. It should, however, be noted 
that, in some instances, adding items to a scale can reduce reliability if 
the additional items substantially reduce the average inter-item 
correlation.
The interpretation of Cronbach's alpha is closely related to 
reliability estimates based in the split-halves technique. Specifically 
the alpha for a test with 2N items is equal to the average value of the 
alpha coefficients obtained for all possible combinations of the items 
into two half tests (Novick & Lewis, 1967). An alternative view states 
that alpha represents a unique estimate of the expected correlation of a 
test with an alternative form containing the same number of items 
(Carmines & Zeller, 1979) and Nunnally (1978) has demonstrated that alpha 
can also be derived as the expected correlation between an actual test and 
a hypothetical alternative form. Clearly, if all the variation in observed 
scores arises from errors of measurement the reliability coefficient will 
be zero. Alternatively, if no measurement error is present, the 
reliability coefficient will be 1. Thus, the closer the alpha coefficient 
to 1 the less the error of measurement and the more reliable the 
technique.
Alpha is mathematically simple to calculate, once the correlation 
matrix has been constructed, and is, in general, a lower bound to the 
reliability of an unweighted scale of N items; furthermore, it is equal to 
the reliability if the items are parallel (Novick & Lewis, 1967). Thus, 
the reliability of a scale can never be lower than alpha even if the items 
are not parallel measures and, in most situations, provides a conservative 
estimate of a measure's reliability (Carmines & Zeller, 1979).
CHI-SQUARE TESTS.
It is often necessary to compare the distribution of a discrete 
variable in a sample with the distribution of a variable in the second 
sample. Chi-square analysis was used in these studies to compare the 
observed energy intake (Sample 1) with that calculated from data obtained 
by dietary recall (Sample 2) and based on the null hypothesis that there 
would be no difference in the intake recorded by the two methods of 
assessment. The formula below is that used to compute the chi-square 
statistic:
Here, 0 stands for the observed value and E for the expected value of 
each cell in a table. The difference between these is squared and divided 
by the expected value; this quantity is computed and summed over all cells 
in the table to determine the chi-square value.
To calculate the expected number for each cell it is necessary to 
consider the null hypothesis which states that the numbers in each cell 
are proportionately the same in Sample 1 and in Sample 2. A parallel table 
is constructed in which the proportions are the same for both samples. 
The proportions are calculated by adding the values for individual cells 
in each of the samples and dividing this by the overall total for both 
samples. Thus, by simple proportions from the totals, an expected number 
is found to match each observed number.
ANALYSIS OF VARIANCE (ANOVA).
ANOVA literally means analysis of the variance among all the 
observations in a study and enables simultaneous comparison of several 
means and is particularly important when there is likely to be substantial 
day-to-day variation as well as variation between subjects. It is based 
on the null hypothesis that all sample means are equal. In the studies
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described this can be taken to mean that there is no difference in the 
intake of individual nutrients on each of three days of a weighed dietary 
intake study.
It is calculated from the mean squares of the variation between 
patients and days. Unless the mean squares between patients is 
sufficiently greater than that between days the null hypothesis must be 
rejected and least some differences between patients admitted. Calculation 
is complex and analysis was carried out using a programme written for use 
on the BBC microcomputer. It was based in completion of a table such as 
that shown below:
Source of variation Sum of squares Degrees of freedom Mean Squares
Between patients ZT.l/ni- C k - 1 M
Residual By subtraction N - k sz
Total c N - 1
where TL = total number of n^ observations for an individual patient 
k = number of patients
^Xiji= sum of squares of individual observations 
x = individual observations
C = correction factor given by C = G 1
N
when G = sum of all observations 
N = total number of observations
MULTIPLE REGRESSION ANALYSIS.
It is often useful to be able to express the mean value of one variable 
in terms of other variables. For example, it may be desirable to study the 
effects of changes in variable x on a single variable y. To achieve this
the effect on y of simultaneous changes in x,, x z , x^ , ..... must be
studied. Alternatively an insight into the causative mechanism behind
changes in a dependent variable y may be required and can be achieved by
identifying which of the set of variables x, , x r , x^, appears to
have most influence on the dependent variable. Finally, prediction of the 
value of the dependent variable in future individuals may be required; for
example, if future progress can be shown to be dependent on particular
independent variables it may prove possible to predict prognosis or 
alternative methods of treatment (Armitage et al, 1969).
The technique most appropriate to such analysis is multiple regression 
analysis. Such techniques represent a direct extension of the 
correlational procedure and enable identification of the individual 
contribution of each independent variable to the overall multiple 
regression coefficient (R). The approach is to express the mean value of 
the dependent variable in terms of the value of a set of independent 
variables. Since the independent variables may be either closely related 
or highly correlated it is preferable for these to be described as 
predictor or explanatory variables.
Several models are available for identification of predictor variables. 
These include the general model, in which the total and individual 
contribution of independent variables to the dependent variable can be 
established, or the stepwise model, in which independent variables are 
entered into the equation in order of importance (defined as the amount of 
variance they individually share with the dependent variable). The latter 
technique has the advantage of allowing analysis to be terminated once the 
remainder of the independent variables no longer constitute a significant 
contribution to the total correlational scheme. However, several options 
exist within the stepwise model such as the forward stepwise technique, 
the backward stepwise method and the forward and backward model although 
each of these is likely to produce the same final result (Barker Baussell, 
1986). The forward stepwise technique is that most commonly employed 
(Barker Baussell, 1986). For the purposes of the studies described 
multiple regression analysis was carried out using the Genstat Statistical 
Programme (Lawes Agricultural Trust, 1983) on a Prime computer.
In brief the process relies on a computation of a correlation matrix 
involving all the possible relationships between all the variables
involved. The next step is to search through the zero-order correlations 
between the independent variables and the single dependent variable so as 
to identify the strongest correlate of the latter. From hereon the method 
becomes more complicated since the second, and subsequent, highest 
independent-dependent variable correlation cannot easily be identified 
since this relies on the highest partial correlation between remaining 
variables when the frequency of the previous finding is held constant, 
Such analysis continues until most of the variance in the dependent 
variable has been explained.
The statistical significance of the multiple regression coefficient at 
each step of the analysis can be established by reference to statistical 
tables. In the case of the Genstat programme the 't' statistic is computed 
and significance determined by reference to the 't' tables (eg. Fisher & 
Yates, 1963) thus establishing whether or not the regression coefficient 
represents a statistically significant increase in the amount of dependent 
variable variance explained.
PRINCIPAL COMPONENTS ANALYSIS.
It often happens that observations are made on a large variety of 
separate variables on each individual even though the overall number of 
characteristics they are intended to measure is much lower. The purpose of 
the individual variables is, therefore, to obtain information about the 
value of the dependent variable with, perhaps, little interest on 
what has contributed to that value. This is often because no single 
question would be adequate to obtain the desired information. Such is the 
case with an abstract variable such as quality of life. In some cases, 
however, sufficient information is available to enable a combined score 
(from a group or groups of variables) to be calculated; in others, 
analysis is required to determine which variables might sensibly be
combined so as to provide almost all the information about the way in 
which one individual differs from another (Armitage & Berry, 1987). One
way in which this can be achieved is by means of principal components
analysis (PCA), a complex procedure which permits new variables to be 
defined. The method of analysis involves calculation of latent roots of 
the covariance or correlational matrix; in the studies described this was 
carried out on the correlation matrix using the Genstat computer 
programme (Lawes Agricultural Trust, 1983).
Interpretation of any of the components identified involves
consideration of the relative values of the coefficients for that
component. If all the coefficients are approximately equal than the 
component can be interpreted as an average of all variables. If some of 
the coefficients are small then the corresponding variables can be ignored 
and the component interpreted in terms of a subset of the original 
variables. By this means this method can produce a reduction in the 
dimensionality of the date although this is only of value if the 
interpretation appears to represent some meaningful characteristics. It 
can, therefore, be seen that interpretation is, at least to some extent, 
subjective and depends on knowledge of the field of application. This 
means that decisions must also be made with regard to the number of 
components to be included since it is seldom worth including extra 
components unless they can be given a meaningful interpretation. Once this 
has been decided the data have effectively been reduced to that number of 
dimensions (Armitage & Berry, 1987).
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APPENDIX 3.
RECOMMENDED AMOUNTS OF FOOD ENERGY AND NUTRIENTS 
FOR GROUPS OF PEOPLE IN THE UNITED KINGDOM.
(Department of Health and Social Security (DHSS), 1979, Report on Health 
and Social Subjects No.15, Her Majesty's Stationery Office, London).
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APPENDIX 4.
QUESTIONNAIRE: ACCEPTABILITY/PALATABILITY OF A NUTRITIONAL SUPPLEMENT.
This product is designed to be used as a supplement for patients who are
nutritionally depleted and unable to consume sufficient nutrients through
diet alone. It is intended for use as a drink or a 'sip feed' three cans 
to be consumed each day over a period of 3 - 4 months.
In order to assess its acceptability as a drink you are asked to evaluate
the product in terms of its taste, odour, colour and texture as well as 
the 'mouth feel' and after taste.
You will be given 3 samples to drink - one cold, one at room temperature 
and one warmed. Please drink each slowly and complete the attached 
questionnaire with regard to each of the samples.
Your help is greatly appreciated. Thank you!
Male |_| Female |_|
Age Group 16 - 19 |” | 2 0 - 2 9  □  30 - 39 |“ | 40 - 49 □
50 - 59 I” ! 60 - 69 |“ | 70 - 79 FI
APPEARANCE Attractive 
Unattractive 
Tempting 
Offputting
ODOUR Aromatic (pleasant)
(unpleasant)
Has no smell
Burnt
Creamy
Dusty
Earthy
Fragrant (pleasant)
Heavy
Insipid - flat
Medicinal
Musty
Oily/fatty
Processed
Rancid
Rubbery
Soapy
Stale
Vanilla like
Watery
Cold Room
Temperature
Hot
TASTE Alkaline 
Bland 
Bitter
Briny (salty)
Processed
Soapy
Sour
Sweet
Pleasant
Musty
Insipid (flat) 
Tasteless 
Unpleasant 
Watery
Cold Room
Temperature
Hot
TEXTURE Coarse 
Creamy 
Foamy 
Oily/fatty 
Rough 
Slimy 
Smooth 
Watery
FLOW Thick, viscous 
Thin, watery 
Clinging
MOUTH FEEL Dry feeling in mouth 
Cooling 
Clinging 
Irritating
AFTER TASTE: Have you experienced any sensation which persists once the
supplement is no longer present in your mouth?
yes |“ | No |“ |
If so can you describe it in relation to the three temperatures?
a.) Cold
b.) Room temperature
c .) Hot
Could you rate this drink on a scale of 1 - 5 in which 5 represents
pleasant and 1 unpleasant?
Cold 1 2  3 4 5
Room temperature 1 2  3 4 5
Hot 1 2 3 4 5
Do you find this filling? Yes - very |_|
Yes - a little |_|
No n
Do you feel any untoward symptoms now that you have drunk this supplement? 
Eg. Nausea | _ |
Abdominal pain |_|
Abdominal discomfort |_|
Indigestion |_|
Flatulence |_|
Bloating |_|
Other (please specify) |_|
None I I
Do you think you would be willing/able to consume 3 tins (750ml) of this 
supplement per day for 3 months?
Yes - easily |_|
Yes - with difficulty |_|
I doubt it ||
No
Have you any suggestions about how palatability could be improved?
Have you any general observations you would like to make?
Thank you for your help.
APPENDIX 5.
QUESTIONNAIRE: ASSESSMENT OF NUTRITIONAL SUPPLEMENTS - IN-PATIENTS.
This product is designed to be used as a supplement for patients who are 
nutritionally depleted and unable to consume sufficient nutrients through 
their normal food intake. It is intended for use as a drink or a 'sip 
feed1 three cans to be consumed each day over a period of 2 - 3 weeks. If 
you find the supplement is helpful we will continue to supply it for you 
whilst you are in hospital. On the other hand, if you dislike it or find 
it of no help, please feel free to say so and stop taking it.
You will be offered 3 different flavours - vanilla, coffee and eggnog - 
and will be asked to drink 3 cans a day. You may drink them whenever you 
like during the day, hot or cold and may add any other flavouring agents 
you like. We suggest that you start by drinking half a can a day gradually 
increasing this so that you are taking the full amount after 4 - 5  days.
We would be interested to know how you feel about this drink and to help 
you to give us your opinion we have attached a questionnaire. We would be 
grateful if you would fill this in for us when you have stopped taking the 
supplement. In order to assess its acceptability you are asked to evaluate 
the product in terms of its taste, odour, colour and texture as well as 
the 'mouth feel' and after taste.
If you have any questions please speak to ...................  or to me
when I come to visit you each day during the study.
Your help is greatly appreciated. Thank you!
Male | _ I
Age Group 16- 19 | | 2 0 - 2 9
50 - 59 I” ! 60 - 69
Female |_|
30 - 39 |“ | 40 - 49
70 - 79 I"I
APPEARANCE Attractive 
Unattractive 
Tempting 
Offputting
ODOUR Aromatic (pleasant)
(unpleasant)
Has no smell
Burnt
Creamy
Dusty
Earthy
Fragrant (pleasant)
Heavy
Insipid - flat
Medicinal
Musty
Oily/fatty
Processed
Rancid
Rubbery
Soapy
Stale
Vanilla like
Watery
Coffee Egg Nog Vanilla
TASTE Alkaline 
Bland 
Bitter
Briny (salty)
Processed
Soapy
Sour
Sweet
Pleasant
Musty
Insipid (flat) 
Tasteless 
Unpleasant 
Watery
Coffee Egg Nog Vanilla
TEXTURE Coarse 
Creamy 
Foamy
Oily/fatty
Rough
Slimy
Smooth
Watery
FLOW Thick, viscous 
Thin, watery 
Clinging
MOUTH FEEL Dry feeling in mouth 
Cooling 
Clinging 
Irritating
Sort of taste
AFTER TASTE: Have you experienced any sensation which persists once the 
supplement is no longer present in your mouth?
Yes |“ | No |“ |
Does this apply to all the flavours?
Yes No
a.) Coffee |_| |_J
b.) Eggnog |“ | |“ |
c.) Vanilla |_| |_|
Could you rate this drink on a scale of 1 - 5 in which 5 represents 
pleasant and 1 unpleasant? Please put a ring around the number which most 
closely represents your opinion.
Coffee 1 2 3 4 5
Egg Nog 1 2 3 4 5
Vanilla 1 2 3 4 5
Do you find it filling? Yes - very III
Yes - a little III
No n
Which flavour do you prefer?
How did you prefer to drink it? 
Hot I”! Cold n Room temperature
Did you add any other flavours to the supplement? If so what did you add 
and what effect did it have?
Supplement Flavour added Effect
(If more room is required please continue on the back of this sheet)
Why did you stop drinking the supplement?
Did the supplement cause any untoward symptoms? 
If so, what were they?
Eg. None |_|
Nausea |_|
Abdominal pain |_|
Abdominal discomfort |_|
Indigestion |_|
Flatulence |_|
Bloating |_|
Other (please specify) |_|
Have you any suggestions to make about the use of this product?
Have you any general observations you would like to make?
Thank you for your help.
APPENDIX 6.
RECIPES DEVELOPED USING THE NUTRITIONAL SUPPLEMENTS.
SAVOURY DISHES.
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OSMO FISH PIE.
1/2 lb of firm white fish
1 bay leaf
1/2 small onion
6 ozs mashed potato
140 ml Osmolite
1/2 egg
Worcester sauce to taste (optional)
Salt and pepper
1. Place fish and onion in a frying pan with the bay leaf and salt and 
pepper to taste. Cover with water and simmer until fish is cooked. 
Drain and cool reserving fish and onion
2. Skin fish, remove bones and flake fish
3. Warm Osmolite gently and mix into mashed potato and mix well until 
smooth
4. Add the egg, onion, Worcester sauce and salt and pepper to taste
5. Gently mix in the fish
6. Pour into an oven proof dish. Garnish with tomato
7. Transfer mixture to an oven proof dish; bake at 220 C for 
approximately 20 minutes until warmed through and bubbling. Mixture 
should be golden.
Serves one
PER SERVING (Approx.)
Calories 550
Protein 50.6g
Carbohydrate 5 0.6g
SWEETCORN SOUP.
1 x 12oz can of sweetcorn (drained)
200ml Osmolite 
1 slice of onion 
Salt and pepper
1. Put about half the corn, onion, Osmolite and onion in blender and 
liquidise until smooth
2. Pour this mixture into a saucepan, add remaining sweetcorn and heat 
the mixture gently. DO NOT BOIL
3. Serve at once with crusty bread
Serves 1
PER SERVING (Approx.)
Calories 315 Fat 7.0g
Protein 16.6g Sodium 104mg
Carbohydrate 72.4g Potassium 870mg
Fat 18g
Sodium 376mg
Potassium 150mg
CHEESE PUDDING.
1 slice white bread made into breadcrumbs
2 oz mature cheddar cheese + a little grated cheese 
1/4 tspn mustard powder
140 ml Osmolite
1 egg - beaten
1/2 oz butter or margarine
Salt and pepper to taste
1. Gently warm Osmolite in saucepan DO NOT BOIL
2. Remove from heat and add butter/margarine
3. Add breadcrumbs and mustard powder
4. Mix well and leave to stand for 5 minutes
5. Meanwhile grate 2 oz cheese and add to the mixture
6. Mix well, Make well in centre and add egg
7. Tip into a greased oven proof dish and sprinkle with grated cheese
9. Bake in hot oven 220°C x 20 minutes.
(For variation add a little chopped ham or gently fried onion to the 
mixture.)
Serves 1
PER SERVING (Approx.)
Calories 542 Fat 31g
Protein 30.8g Sodium 747mg
Carbohydrate 36.2g Potassium 393mg
CHEESE BREAD AND BUTTER PUDDING.
2 slices white bread (crusts removed and buttered)
1 1/2 oz Mature Cheddar 
140 ml Osmolite 
1 egg - beaten 
Worcester sauce (optional)
Salt and pepper to taste
1. Cut bread into fingers
2. Layer bread and cheese in oven proof dish ending with bread layer
3. Season to taste
4. Mix beaten egg into Osmolite and pour this over the bread/cheese
layers
5. Sprinkle liberally with grated cheese
6. Bake in a hot oven (200°C) until crisp and golden (about 45 minutes).
Serves 1
PER SERVING (Approx.)
Calories 580 Fat 26.6g
Protein 30g Sodium 933mg
Carbohydrate 56.6g Potassium 416mg
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OSMOLITE PROVENCALS.
140ml Osmolite 
1 egg
1/2 slice white bread 
1/2 small courgette 
1/2 small onion 
1 small tomato 
1 tspn tomato puree 
1/2 tspn sugar 
1 tspn cooking oil 
1 clove garlic (optional)
Salt and pepper to taste
1. Thinly slice courgette and finely chop onion and garlic (if using)
2. Cut tomato in half, reserve half for garnish and finely chop the
remainder
3. Heat cooking oil in a small frying pan and fry the onion and garlic 
until beginning to soften but NOT coloured.
4. Add courgette and tomato and continue to fry gently for 3 - 4  minutes.
5. Use blender to make breadcrumbs from the bread (or tear into small
pieces)
6. Meanwhile heat Osmolite gently in a saucepan but do NOT boil
7. Add bread to Osmolite mixing well; leave to stand for a few minutes.
8. Add tomato puree, sugar and salt and pepper to taste to mixture in
frying pan. Mix well and remove from heat.
9. Beat egg into Osmolite mixture add vegetables mixing well
10. Pour into oven proof dish
11. Slice remaining tomato and arrange overlapping slices on top
12. Bake in oven (200°C) for 1 5 - 2 0  minutes until risen and golden
13. Serve immediately.
Serves 1
PER SERVING (Approx.)
Calories 305
Protein 15.4g
Carbohydrate 36.7g 
(Figures exclude courgette)
TOMATO AND BACON SAVOURY.
2 rashers back bacon 
1/2 small onion 
2 tspns tomato puree 
1 tspn sugar 
1 slice white bread (as soft breadcrumbs)
140ml Osmolite 
1 egg
Salt and pepper 
1 tspn cooking oil 
Tomato for garnish
1. Cut bacon into small pieces and fry gently with onion (finely chopped)
in cooking oil until onion is soft but not browned
2. Remove from heat and mix in the tomato puree and sugar. Leave to cool
3. Meanwhile heat Osmolite gently but DO NOT BOIL; add breadcrumbs and
leave to stand for about 5 minutes
Fat 11.5g
Sodium 315mg
Potassium 519mg
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4. Add beaten egg and tomato/bacon/onion to Osmolite mixture; mix well
5. Pour into oven proof dish, garnish with fresh tomato.
6. Bake in oven (200°C) for 15-20 minutes until golden and well risen.
Serves one
PER SERVING (Approx.)
Calories 772
Protein 29g
Carbohydrate 49.7g
VEGETABLE SOUP.
6ozs precooked mixed vegetables (eg. carrot, onion, tomato, celery)
1 small boiled potato - diced
1/2oz cooked peas/sweetcorn (or mixture)
200ml Osmolite 
Salt and pepper
1. Put selected vegetables and Osmolite into a blender and liquidise 
until smooth or pass through a sieve
2. Pour mixture into a saucepan, add peas/corn and diced potatoes
3. Heat gently and season to taste
4. Serve hot with bread or toast
Serves 1
NUTRITIONAL VALUE variable as dependent on vegetables selected.
SWEET DISHES.
LIME FLUFF.
1/2 lime jelly 
2 tspns Polycose liquid 
90 ml boiling water 
120 ml Osmolite
1. Dissolve jelly in water
2. Leave to cool
3. When just beginning to thicken stir in Polycose
4. Whisk Osmolite until light and fluffy
4. Add jelly and fold in gently
5. Pour into serving dishes
6. Cool/refrigerate until ready to eat
Makes 2.
PER SERVING (Approx.)
Calories 308 Fat 4.2g
Protein 9.00g Sodium 122mg
Carbohydrate 56.7g Potassium 194mg
Fat 53g
Sodium 1452mg
Potassium 689mg
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BLACKCURRANT DELIGHT.
1/2 Blackcurrant jelly
90 ml boiling water
2 tspns Polycose syrup
2 tbspns natural yoghurt
60 ml Osmolite
1. Dissolve jelly in water
2. Stir in Polycose
3. Leave to cool until nearly set
4. Whisk Osmolite until light and fluffy
5. Stir in yoghurt and mix well
6. Add jelly and mix until jelly well distributed
7. Pour into serving dishes
8. Cool/refrigerate until ready to serve
Makes 2.
PER SERVING (Approx.)
Calories 272
Protein 8.7g
Carbohydrate 51.4g
EGG CUSTARD.
190 ml Osmolite
1 egg
1/2 oz sugar
2 drops vanilla essence
3 tspns Polycose syrup
Pinch ground nutmeg/mixed spice (optional)
1. Beat egg and stir in sugar
2. Gently warm Osmolite and add to egg mixture stirring all the time
3. Stir in vanilla essence
4. Pour into oven proof dish
5. Sprinkle with nutmeg/ground spice
6. Stand in baking tray, pour cold water around dish until it comes 
halfway up side of dish
7. Bake in oven 140-150°C for approximately 20 minutes; serve immediately.
PER SERVING (Approx.)
Calories 354 Fat 13g
Protein 15.1g Sodium 248mg
Carbohydrate 225g Potassium 366mg
RICE PUDDING.
1 tbspn skimmed milk powder 
125ml Osmolite
1 oz pudding rice
2 dspn sugar 
1 egg
Pinch ground nutmeg/mixed spice
Fat 2.5g
Sodium 103mg
Potassium 213mg
1. Precook rice in boiling water for about 5 minute; drain and cool
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2. Mix skimmed milk powder with Osmolite whisking well until smooth
3. Add sugar
4. Beat egg and add to Osmolite mixture
5. Add rice, mix well
6. Pour into oven proof dish
7. Sprinkle with nutmeg/mixed spice (optional).
8. Bake in oven, 140 - 150°C for approximately 25 minutes until rice is
cooked through and pudding has a creamy texture.
(Can make without egg)
PER SERVING (Approx.) (With Egg)
Calories 407
Protein 16.4g
Carbohydrate 390g
Fat 13.7g
Sodium 253mg
Potassium 388mg
PER SERVING (Approx.) (Without egg)
Calories 321 Fat 6.9g
Protein 9.3g Sodium 172mg
Carbohydrate 390g Potassium 307mg
STRAWBERRY JELLY.
90 ml water
120 ml Osmolite
1/2 strawberry jelly
1. Dissolve jelly in water
2. Leave to cool
3. When cool add Osmolite and mix well
4. Pour into serving dish and leave until set
Makes 2.
Other jellies can be substituted although citrus flavours tend to 'curdle1.
PER SERVING (Approx.)
Calories 408 Fat
Protein 13.6g Sodium
Carbohydrate 72.5g Potassium
7. 5g 
227mg 
371 mg
GROUND RICE.
2 heaped tbspns ground rice 
140ml Osmolite
1 tbspn sugar (or to taste)
2 tspns Polycose liquid 
Jam to serve
1. Place ground rice, sugar, Polycose and Osmolite in a saucepan and mix 
gently breaking up any lumps in the mixture
2. Heat gently stirring constantly until mixture thickens (about 5 
minutes)
3. Remove from heat pour into serving dish
4. Serve immediately with jam to taste.
Serves 1
PER SERVING (Approx.)
Calories 293
Protein 6.9g
Carbohydrate 5 2.8g
Fat 5.Og
Sodium 124mg
Potassium 224mg
APPLE AMBER.
60 ml Osmolite 
2 tbspns stewed apple puree 
Mixed spice to taste (optional)
1. Refrigerate Osmolite until well chilled
2. Pour into dish and whisk well until double in volume
3. Gently mix in the stewed apple
4. Sprinkle with spice and serve immediately
Serves 1
PER SERVING (Approx.)
Calories 86
Protein 2.8g
Carbohydrate 14.6g
Fat 2.1g
Sodium 54mg
Potassium 169mg
STRAWBERRY YOGHURT FLUFF.
1/2 strawberry jelly 
90 ml water 
90 ml Osmolite 
2 tbspns natural yoghurt 
2 tspns Polycose
1. Dissolve jelly in water
2. Leave to cool until beginning to thicken
3. Whisk Osmolite until light and fluffy
4. Fold in yoghurt
5. Add jelly and ensure mixed well
6. Pour into serving dishes and leave until set 
(Add tinned/fresh strawberries for a fruity taste)
Makes 2.
PER SERVING (Approx.)
Calories 272
Protein 8.7g
Carbohydrate 51.4g
Fat 2.6g
Sodium 103mg
Potassium 213mg
MANDARIN JELLY DELIGHT.
1/2 orange jelly 
3 tbspns natural yoghurt 
90 ml water 
2 dspns caster sugar 
2 tspns Polycose syrup 
Mandarin segments to taste 
A little whipped cream
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1. Dissolve jelly in water
2. Set aside until cool and beginning to thicken
3. Add 1 tbspn yoghurt to jelly and blend well
4. Put a few mandarin segments in base of dish and just cover with
yoghurt jelly mixture. Refrigerate so that jelly sets and holds
mandarins in place.
5. Whisk Osmolite until light and fluffy
6. Fold in remaining yoghurt
7. Stir Osmolite mixture into jelly/yoghurt mixture and mix well
8. Pour over mandarins
9. Leave until set then decorate with mandarin segments and whipped cream. 
Makes 2.
PER SERVING (Approx.)
Calories 409
Protein 11.3g
Carbohydrate 174g
APPLE YOGHURT DELIGHT.
60 ml Osmolite 
2 tbspns thick, natural yoghurt 
2 tbspns stewed apple puree 
Mixed spice to taste (optional)
1. Refrigerate Osmolite until well chilled
2. Pour into dish and whisk well until double in volume
3. Gently stir in the yoghurt
3. Mix in the stewed apple
4. Sprinkle with spice and serve immediately
Serves 1
PER SERVING (Approx.)
Calories 109
Protein 27.7g
Carbohydrate 17. 4g
HONEY YOGHURT DRINK.
100ml Osmolite 
2 tspns runny honey 
5ozs natural yoghurt
1. Chill both yoghurt and Osmolite
2. Mix Osmolite and yoghurt together stirring well until the mixture is 
smooth
3. Stir in the honey and whisk well
PER SERVING (Approx.)
Calories 207 Fat 5.0g
Protein 11.7g Sodium 203mg
Carbohydrate 30.3g Potassium 513mg
Fat 2.5g
Sodium 89mg
Potassium 277mg
Fat 3.8g
Sodium 150mg
Potassium 340mg
Z b  1
BREAD AND BUTTER PUDDING.
2 slices white bread - crusts removed and cut into fingers 
140ml Osmolite 
1 egg
10g butter 
15g sugar 
15g sultanas
1. Butter the bread fingers
2. Layer bread, with sugar and sultanas into an oven proof dish
3. Beat egg and add to Osmolite mixing well
4. Pour egg and Osmolite mixture over the bread slices
5. Bake in a moderate oven (160-180°C) until crisp and golden
6. Serve hot with cream or custard if wished.
Serves 1.
PER SERVING (Approx.)
Calories 506 Fat 209.7g
Protein 19.3g Sodium 688mg
Carbohydrate 255.8g Potassium 415mg
ENSURE can be substituted for Osmolite in all these recipes. This is 
particularly successful with the sweet recipes.
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Abstract—An attempt was made to define the concept o f ‘quality o f life’ and 
outline the development o f  a self-assessment instrument for detecting the changes 
' in life as a whole which result from the presence and treatment o f malignant 
disease. A comparison was made between three different scoring systems, 
familiar in psychometric assessment, although less familiar in nursing.
The items selected for inclusion in the measurement instrument were based 
on an existing symptom distress scale and on the previously identified concerns 
o f cancer patients. The relationship between such symptoms and the activities 
o f daily living was explored. Each item, and the instrument as a whole, appeared 
to be reliable and to represent a valid means o f assessing the impact o f the disease 
on patient well-being. It was simple to use and straightforward to score and 
appeared accurately to reflect the patients’ general condition.
When caring for patients with cancer we tend to emphasize the survival rates associated 
with particular types o f  the disease and/or treatment but only rarely do we comment on 
the quality o f  that survival. The length o f  survival is discussed in terms o f  disease-free 
intervals and changes related to the volume o f the tumour, the toxicity o f  treatment and, 
on occasions, to patient performance status, although these provide little information about 
. the physical, emotional or social well-being o f the patient. The patients’ notes rarely reveal 
the difficulties o f  living with either the diagnosis or its treatment (Schneider, 1978), although 
both are subject to considerable individual variation. The sufferer o f a potentially incurable
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disease is exposed to many difficulties; not only is his future unpredictable but the methods 
o f  treatment are themselves toxic, inducing many unpleasant side-effects. It is, therefore, 
important that we are aware o f  the impact these can have on the quality o f  the patient’s 
life, particularly in those for whom cure, or improved survival, is unlikely (Priestman, 1984).
The need for a method by which to measure the quality o f survival (quality o f  life) is 
now increasingly recognized; this reflects a change on the part o f  members o f  the health 
care team as the value o f  cancer therapy is now judged not only on the duration o f  survival 
but also on its quality (Burge et al., 1975; Hutchinson et al., 1979; Dietz, 1980). However, 
such measurements are not easily achieved, particularly as there are few adequately 
evaluated instruments devised for this purpose. As individuals can be the only proper judge 
o f  their well-being (Neugarten et al., 1961) a means o f  measuring subjective parameters 
must be identified which will also take account o f  the impact o f  the disease, and its 
treatment, upon this.
Defining the quality o f life
Clearly, before the quality o f life can be evaluated, it is necessary to define those qualities 
making both life and survival valuable (Bayles, 1980). Shin and Johnson (1978) suggested 
that this consists o f  “ the possession o f  resources necessary to the satisfaction o f  individual 
needs, wants and desires, participation in activities enabling personal development and self 
actualisation and satisfactory comparison between oneself and others” , all o f  which are 
dependent on previous experiences and knowledge. Patterson (1975) approached this 
differently by identifying certain characteristics deemed essential to any evaluation o f  quality 
o f life. These included general health, performance status, general comfort, emotional status 
and economic status, all o f which are contributory to the proposition made above. It is 
clear, therefore, that quality o f life is an abstract and complex term representing individual 
responses to the physical, mental and social factors which contribute to ‘normal’ daily 
living. It comprises many diverse areas, all o f  which contribute to the whole (Fig. 1); thus, 
\  when attempting to assess this, it is necessary first to define the scope and detail required.
Personal sa tisfa ctio n
Emotional sta tu s S e lf  esteem
Q uality
Performance a b ilityGeneral health
tife
Comparison with othersEconomic sta tu s
Previous knowledge /experience
Fig. I. Factors contributing to the overall quality of life.
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M ethodology
(i) The scope o f  the instrument
The scope o f  the study is particularly important as measurement o f  the severity o f  specific 
symptoms may fail to assess their overall impact on the patient's whole life. However, 
a comprehensive instrument may fail to identify areas o f  particular concern and require 
considerable concentration so that interviewees may find difficulties in its completion.
As the spectrum o f  disease which may result from the presence o f  malignancy comprises 
many different, although interacting, factors, it was considered necessary to assess the 
severity o f  symptoms and the impact o f  these on the activities o f  daily living as outlined 
by Henderson (1969). However, it was also recognized that the therapeutic modalities 
employed in treatment may also cause problems which are almost unrelated to the disease 
itself. Thus two groups o f  items were selected; these defined the scope o f  the study (Table 
1). The first (Section 1) were drawn from an existing Symptom Distress Scale (McCorkle 
and Young, 1978) and included aspects related to both the symptoms o f  disease and the 
side-effects of'treatment. The second group were selected to assess the impact o f  such 
symptoms on the activities o f  daily living and included also several items related to 
psychosocial problems such as social isolation and the ability to communicate with family, 
friends and members o f  the caring team, as affected individuals commonly complain that 
they feel separated from their ‘significant others’ as a result o f  having the disease. Ethical 
Committee approval was sought, and granted, for the instrument finally adopted.
Table 1. Items selected for inclusion in the measurement instrument
Section 1 (symptoms) Section 2 (ADL)*
1 Pain 12 Ability to eat
2 Nausea 13 Flavour o f food
3 Appetite 14 Texture o f food
4 Sleep 15 Sleep
5s Mobility 16 Respiration
6 Bowel habits—diarrhoea 17 Urination
7 Bowel habits—constipation 18 Change in bowel pattern
8 Tiredness 19 Recreational activity
9 Concentration 20 Changes in life as a whole
10 Mood 21 Worry about future
11 Appearance 22 Concern over earning ability
23 Isolation
24 Communication with family
25 Communication with medical staff
26 Communication with nursing staff
*ADL = activities o f daily living.
(ii) Selection o f  the scoring system  
A number o f  scoring systems have previously been used in attempts to assess the quality 
o f  life in both patient and non-patient samples. These have included the use o f  questionnaires 
(Lefebrve, 1979), linear analogue (LASA) scales (Priestman and Baum, 1976; Selby e t al., 
1984) and Likert (category rating) type scales (Burge et al., 1975). Patient performance 
status has also been evaluated as an index o f the quality o f  survival; the Karnofsky scale 
(Karnofsky et al., 1948) evaluates performance on a scale o f  0-100% , rising in increments 
o f  10%, or, as modified by Priestman (1984) on a scale o f  1-10 rising in increments o f  
1, and the Zubrod index on a scale o f  1-4 rising in increments o f  1 (Zubrod et al., 1960).
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However, the narrow scope o f these instruments may fail to provide satisfactory quantitative 
information about the overall well-being o f  the patient.
LASA scales have several advantages, as they are easy for the subject to grasp and, as 
they are not restricted to quantitative terms, allow the subject to make as fine a 
discrimination as he wishes (Freyd, 1923). However, some workers believe that this lack 
o f  quantification makes it difficult to estimate the degree o f change (McCorkle and Young, 
1978); a five- or six-point Likert type scale has been used in an attempt to overcome such 
difficulties (e.g. McCorkle and Young, 1978; Young and Longman, 1983). Yet a five-point 
scale has a mid-point which may provide an ‘easy way out’ for individuals not wishing 
to make a clear decision.
Since no comparative evaluation o f  LASA and Likert type scales appears to have been 
carried out, it was decided to carry out such a study. A  questionnaire was designed which 
could be based on a linear analogue, a five-point and a six-point scale at each end o f  which 
were written statements representing the possible extremes o f  the subjective response to 
particular questions (Table 2).
Table 2. Examples o f possible scoring systems
1. Linear analogue
Worst pain I have ever had   No pain
2. Five-point scale
1 cannot face food at all 1 2 3 4 5 My appetite is norm al for me
3. Six-point scale
I cannot sleep at all 1 2 3 4 5 6 1 sleep as well as ever
(iii) The study population
An unselected convenience sample o f 72 patients was drawn from all those admitted 
to the Oncology Unit at St Luke’s Hospital, Guildford, between November 1984 and January 
1985. Participants were interviewed by the same investigator and asked to complete the 
questionnaire on two occasions separated by an interval o f  1-1.5 hr during which time 
they were closely observed to ensure that no intervening factors affected their responses. 
The different types o f  questionnaire were allocated on a random basis, the aim being to  
obtain 20 completed pairs in each group.
(iv) Analysis o f  results
Reliability was established using the test-retest method and by computation o f  Cronbach’s 
coefficient alpha (a).
Validity o f a measurement instrument is dependent on the extent to which it measures 
what it is intended to measure. However, when attempting to assess subjective feelings, 
it is difficult to validate their depth and there are few accepted criteria against which to 
judge empirical data. In addition, there is no universally accepted method o f  assessing the 
quality o f life. Validity was, therefore, evaluated indirectly.
The instrument has face validity in that it includes the items considered by the 
investigators, and by previous studies (e.g. Priestman and Baum, 1976; Patterson, 1975; 
Selby et al., 1984), to be contributory to the overall quality o f  life. Two notable areas were
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excluded, the ability to work and the ‘normality’ o f the sex life, which could not be included 
due to Ethical Committee restrictions on the use o f  the instrument.
Content validity was established as far as possible by inclusion o f  those items identified 
by the investigators and supported, in a series o f  unstructured patient interviews, by a large 
number o f  patients (80) as having an impact on their life overall.
Construct validity can only be confirmed by a pattern o f  consistent findings involving 
different researchers over a number o f  different studies.
Results
The majority o f  patients (939b) responded positively when asked to participate, expressing 
great interest in the study. It was interesting to note how many patients subsequently 
discussed their concerns and anxieties with the interviewer. There were few difficulties 
associated with completion o f  the instrument, although, when using the five-point scale, 
many o f  the subjects responded to the absence o f  a symptom or change by circling the 
question rathefr than the last point o f  the scale (5); further questioning established that 
this meant ‘normal’—the problem was noted for future reference. Such problems did not 
arise in completion o f  the six-point scale. A  total o f  seven completed questionnaires were 
found to be invalid for further study. The average completion time did not vary significantly 
between the three forms o f  the instrument, being between 10 and 12 minutes in all cases.
Test-retest reliability was established for all forms o f  the instrument on both individual 
items and total scores. The highest reliability coefficient was obtained using the linear 
analogue scale (0.97, P  <  0.001) whilst the six-point scale produced the lowest coefficient 
(0.72,0.01 P > 0.001). The coefficient o f stability showed all questions to be stable. Analysis 
o f  variance showed there to be no signifcant difference between the responses obtained 
using any o f  the scales. As a result there was no statistical basis for selecting one scale 
in preference to another. Use o f  the LASA instrument was associated with fewer problems 
of\ completion; once explained to the patients this was found to be simple and 
straightforward to use, allowing greater flexibility and discrimination between the responses 
to individual items. It was possible to measure the response with considerable accuracy 
and to distinguish between areas o f  greater and lesser concern. In addition, the problem  
o f  response sets was overcome and the occurrence o f  apparent memory/practice effects 
was minimized. On this basis it was decided that the responses given by the LASA instrument 
were more likely to reflect accurately the patient’s true feelings.
Computation o f  Cronbach’s coefficient alpha yielded an a  o f  0.8 (total instrument),
0.9 (Section 1 . . . Symptom Distress) and 0.7 (Section 2 . . . Activities o f  Daily Living). 
As this provides a conservative estimate o f  reliability this justifies the selection o f  the LASA  
instrument.
The correlation matrix (Fig. 2) yielded several interrelated areas o f  concern, chief amongst 
them being those between pain, nausea, tiredness and an inability to eat and those between 
appearance, nausea, tiredness, concentration and mood. It is interesting to note that many 
o f  the patients linked their feelings o f  isolation with an inability to discuss their feelings 
with members o f  the nursing staff. Similar results were shown by all the patient samples. 
Table 3 shows the number o f patients distressed by particular symptoms in the total sample. 
These were consistent with those previously identified, thus appearing to support the validity 
o f  the measurement instrument.
The division o f  the items into two sections was intended to allow calculation o f  the
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Table 3. Symptoms causing major distress*
Symptom T otalt °Io
Appearance 27 45
Tiredness 21 35
Inability to concentrate 21 35
Feeling miserable 21 35
Loss o f  mobility 21 35
Inability to sleep 17 28.3
Loss o f appetite 14 23.3
Constipation 12 20
Pain 7 11.7
Nausea 4 6.7
Diarrhoea 4 6.7
♦Receiving ratings <  5 on linear analogue scale.
3 or less on six-point scale.
2 or 1 on five-point scale.
17V=60.
contribution o f  symptom distress to the overall score. Those patients achieving a low 
symptom distress score also achieved low scores on the second section (r 0.88, P  <  0.001), 
thus confirming the original hypothesis that the severity o f  symptoms has a significant 
impact on the activities o f  daily living.
Discussion
The purpose o f this study was to define the concept o f quality o f  life and to design and 
evaluate a means o f  assessing this in patients suffering from cancer.
Quality o f life was recognized to be a dynamic concept representing individual responses 
to the physical, mental and social effects o f  illness which influence the extent to which 
personal satisfaction with life circumstances can be achieved, and which allows favourable 
comparison with others according to the selected criteria. In other words, it represents a 
highly individual evaluation o f the present situation and an investigator must be careful 
that he/she does not impose his/her values on any such evaluation.
Clearly, although the quality o f life may be significantly affected by illness, it may also 
be influenced by other, pre-existing factors. However, as this study was designed to estimate 
the changes resulting from the presence o f  disease, or from its treatment, it was felt that 
these could be disregarded since use o f self-assessment techniques should compensate for 
such pre-existing problems.
The items selected for inclusion in the measurement instrument were intended to cover 
those areas important to general health as well as those identified as being o f  particular 
concern to the cancer patient. No distinction was made between those symptoms arising 
from the disease and those from its treatment as this was not felt to be important when 
assessing their impact on life as a whole.
The subsequent evaluation o f the chosen design was encouraging. Patients found all three 
scoring systems acceptable and quick and easy to complete and reported that they felt it 
represented a valid assessment o f the important areas o f their lives which had been affected 
since the onset o f their disease. Several patients wondered why no questions relating to 
‘sex’ had been included as this was an area o f life which had undergone significant change; 
others questioned the omission o f ‘work’ particularly when a question relating to concerns 
over earning ability had been included. It is hoped that it will be possible to rectify these 
omissions in future studies.
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From the completed questionnaires it proved possible to identify those areas o f  particular 
concern to individual patients and it was found that use o f the instrument provided a useful 
mechanism by which patient counselling could be initiated once particular problems had 
been identified. The total score appeared to represent an accurate reflection o f  the patient’s 
general condition when compared to the nurses’ verbal opinion and to the investigator’s 
objective assessment.
All forms o f  the instrument were shown to be reliable using the test-retest method and, 
in the case o f  the LASA instrument, by computation o f  Cronbach’s coefficient alpha. The 
results for individual items also appear to be reliable. The LASA instrument has been shown 
to be the method o f  choice due to the flexibility and discriminant ability between variations 
in responses to individual items. Patients found this simple to use and appreciated the ability 
to discriminate between the differing degrees to which activities had been affected by their 
symptoms. This is consistent with previous findings (Aitken, 1969; Revill et al., 1976).
The demonstrated relationships between particular symptoms can be satisfactorily 
explained. For example, the positive correlation between pain and constipation can be 
explained as a consequence o f  the regular administration o f narcotic analgesics such as 
diamorphine. The incidence o f  tiredness may also result from the use o f  such agents or 
from the regular use o f anti-emetics, thus explaining the relationships between pain, nausea, 
tiredness and constipation. An inability to eat is an understandable effect o f  such symptoms. 
The problem causing most concern in the patient sample related to changes in appearance 
which correlated strongly with nausea, tiredness, concentration and m ood, all o f  which 
would appear to be closely interrelated.
Pain can serve as an isolating factor, sufferers feeling ‘separated’ by their feelings and 
discomfort. The negative correlation between pain and the failure to communicate with 
the nursing staff is significant, perhaps indicating a failure o f nurses to identify the need 
for measures to relieve pain and enhance patient comfort and, therefore, quality o f  life. 
It is interesting to note that this problem did not appear to arise where communication 
with the medical staff was concerned.
Overall, it appears that the measurement instrument developed in this study provides 
a reliable, reproducible and valid means o f  assessing patient well-being and quality o f  life. 
It is simple to use, easy to complete and quick to score. Evaluation suggests that this may 
be a valuable tool for use by all staff involved in the care o f the cancer patient.
Implications and recommendations
Although this instrument was not designed specifically to identify areas in which nursing 
intervention could be appropriate, there appear to be several implications for nursing 
associated with its use. It was felt to be a matter o f concern that the patients involved 
should associate their feelings o f isolation with an inability to discuss their anxieties with 
members o f the nursing staff. The prime reasons given were “ the nurses are too busy to 
waste time talking to me” and “ they seem so young . . . they wouldn’t understand” . The 
fact that they subsequently discussed their worries and concerns with the interviewer, who 
appeared to have time to listen, highlights the need o f  such patients for counselling and 
support services; this alone could help to alleviate many o f  the anxieties associated with 
living with both the diagnosis and treatment o f malignant disease. Whilst little can be done 
about the youth o f  nursing staff it seems vital that they should devote time to talking to 
the patients and making it clear that they do, in fact, recognize and understand individual 
difficulties. This surely forms an important part o f  total patient care?
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Many o f  the symptoms associated with malignant disease, or with its treatment (e.g. 
nausea or anorexia), are not immediately apparent and it is quite possible that the nurse, 
or even a close family member, would not be aware that the patient was suffering such 
a symptom unless he pointed this out. In addition, the degree o f  distress experienced by 
a particular patient, whatever its cause, cannot be readily assessed and can only be ‘guessed 
at’ by an observer, however well trained. This effect is particularly pronounced in areas 
where self care is encouraged. The use o f  this questionnaire could allow the presence, or 
severity, o f  such distress to be identified and an analysis o f  individual symptoms, or the 
relationship between symptoms, could provide valuable information which would enable 
care to be planned more effectively and improve the evaluation o f  the prescribed care. 
For example, constipation, a common sequel o f the regular administration o f  the narcotic 
analgesics often prescribed for cancer patients, is, itself, a source o f considerable abdominal 
pain and discomfort and may result in nausea and an associated loss o f  appetite. Effective 
relief o f  constipation could, therefore, result in a significant improvement in the patient’s 
general condition. Thus use o f  such a self-assessment instrument could be a valuable aid 
to improving total patient care.
Further research is needed to establish the reliability and validity o f  this instrument in 
different patient populations and consideration should be given to studies designed to assess 
changes in patient well-being as related to the effects o f  specific nursing interventions.
References
Aitken, R. C. B. (1969). Measurement o f  feelings using visual analogue scales. Proc. R. Soc. Med. 62, 989-993. 
Bayles, M. D. (1980). The value o f life. Am . J. Nurs. 80, 2226-2230.
Burge, P . S., Prankerd, T . A. J . t Richards, J. D. M., Sare, M., Thompson, D. S. and Dietz, J. H. (1975). Adaptive
rehabilitation in cancer: a programme to improve quality o f survival. Postgrad. Med. 68, 145-153.
Freyd, M. (1923). The graphic rating scale. J. educ. Psychol. 14, 88-102.
Henderson, V. (1969). The Basic Principles o f  Nursing Care. I.C .N ., Geneva.
Hutchinson, A ., Farndon, J . R. and Wilson, R. G. (1979). Quality of survival o f patients following mastectomy. 
Clin. Oncol. 5, 391-92.
Karnofsky, D. A ., Abelman, W. H ., Craver, L. F. and Burchenal, J. H. (1948). The use o f nitrogen mustards 
in the paliative treatment o f carcinoma. Cancer (November), 634-656.
Lefebrve, K. A. (1979). Behavioural consequences of cancer diagnosis and treatment; rehabilitation implications 
and suggestions. Arch. Phys. Med. Rehab. 60, 527-528.
McCorkle, R. and Young, K. (1978). Development o f a Symptom Distress Scale. Cancer Nurs. 1, 373-378. 
Neugarten, F., Havighurst, R. and Tobin, S. (1961). The measurement of life satisfaction. J. Gerontol. 16, 134-143. 
Patterson, W. (1975). The quality of survival in response to treatment. J. Am. Med. Ass. 233, 280-281. 
Priestman, T. J . (1984). Quality o f life after cyclotoxic chemotherapy: discussion paper. J. R. Soc. Med. 77, 
492-495.
Priestman, T. J . and Baum, M. (1976). Evaluation o f quality o f life in patients receiving treatm ent for advanced 
breast cancer. Lancet i, 899-901.
Revill, S. I., Robinson, J. O ., Rosen, M. and Hogg, M. I. J.(1979).The reliability of a linear analogue for evaluating 
pain. Anaesthesia 31, 1191-1198.
Schneider, L. (1978). Identification of human concerns by cancer patients. In Current Perspectives in Oncologic 
Nursing. Kellog and Sullivan (Eds), pp. 89-98. C. V. Mosby, St Louis.
Selby, P . J ., Chapman, J . A. W ., Etazadi-Amoli, J ., Dailey, D. and Boyd, N. F. (1984). The development of 
a method for assessing the quality o f life o f cancer patients. Br. J. Cancer 50, 13-22.
Shin, D. C. and Johnson, D. M. (1978). Avowed happiness as an overall assessment o f the quality o f life. Social 
Indicators Res. 5, 475-492.
Young, K. J. and Longman, A. J . (1983). Quality o f life and persons with melanoma: a pilot study. Cancer 
Nurs. 7, 219-225.
Zubrod, C. G ., Schneiderman, M., Frei, E ., Brindley, C ., Gold, G. L., Schnider, B., Oveido, R., Gorm an, 
J ., Jones, R., Jonsson, U ., Colsky, J ., Chalmers, T ., Ferguson, B., Dederick, M ., Holland, J . ,  Selawry, O ., 
Regelson, W., Lasagna, L. and Owens, A. H. (1960). Appraisal o f methods for the study o f chemotherapy 
o f cancer in man: comparative therapeutic trial of nitrogen mustard and triethvlene thiophosphamide. J. Chron. 
Dis. 11, 7-33.
(Received 6 January 1986; accepted fo r  publication 2S April 1986)
Cancer and Metastasis Reviews 6: 357-381 (1987)
©  Martinus Nijhoff Publishers, Boston -  Printed in the Netherlands.
Malignant disease: nutritional implications of disease and treatment
Susan Holmes1 and John W.T. Dickerson2
1 Division o f  Nursing Studies,2 Division o f  Nutrition and Food Science, Department o f  Biochemistry Univer­
sity o f  Surrey, Guildford, U.K.
Key words: protein-energy malnutrition (PEM), anorexia, cachexia, surgery, radiotherapy, chemotherapy, 
quality of life
Abstract
Protein-energy malnutrition (PEM) is common in cancer patients and may develop into the syndrome known 
as ‘cancer cachexia’. This is characterised by complex disturbances in carbohydrate, lipid, protein, and 
electrolyte metabolism. The aetiology is equally complex, with host and therapeutic factors contributing to 
the reduced food intake and effects on host tissues. Anorexia is of prime importance, differing in its cause 
from one patient to another and often presenting a barrier to successful nutritional support. Further research 
is necessary to elucidate the interaction of central and peripheral factors that may be involved in the aetiology 
of anorexia. Because of the interplay of biochemical, physiological, and psychological consequences of 
cancer, the nutritional support of the patient presents a considerable challenge to the caring professions.
Introduction
Protein energy malnutrition (PEM) frequently ac­
companies malignant disease [1-3] affecting about 
40% of all patients hospitalised for the treatment of 
cancer [4]. PEM is associated with a poor prog­
nosis, reduced response to anti-neoplastic therapy, 
prolonged, or enhanced, morbidity of therapeutic 
side effects, and a reduced quality of life [5, 6].
Such malnutrition varies in onset, occurring at dif­
ferent stages in the progress of the disease. It is not 
directly correlated with food intake, with the stage, 
histological type, or site of the tumour, duration of 
disease, or the site or number of metastases.
Weight loss is not always associated with a large 
tumour burden, and may occur with a small pri­
mary tumour even preceding diagnosis [6], Shils [7] 
reported that 45% of newly hospitalised adult can­
cer patients had lost at least 10% of their body 
weight and 25% had lost 20% or more. Such weight 
loss is accompanied by a marked reduction in body 
fat and a loss of muscle mass.
This ‘starvation’ is now well recognised and has 
come to be known as ‘cancer cachexia’, a syndrome 
characterised clinically by emaciation, debilitation, 
and inanition associated with anorexia, early sati­
ety, anaemia, and marked asthenia. Profound ab­
normalities of host metabolism accompany cach­
exia including disturbances of carbohydrate [8. 9], 
protein [10,11], and fat [12-14] metabolism. These 
changes are believed to be responsible for the nu­
tritional problems in the cancer bearing host, since 
weight loss can be observed even when the food 
intake is apparently adequate. Yet it has been ar­
gued [15] that much of this weight loss can be 
attributed to an inadequate food intake resulting 
from anorexia; alternatively, it has been suggested 
[16] that ‘normal’ individuals will compensate for 
any increase in body energy requirements by in­
creasing their food intake. Clearly cancer patients 
fail to compensate in this way and nutrient intake 
fails to keep pace with nutrient requirements. Yet 
some patients fail to gain weight or maintain their 
current weight on energy intakes of 3-4,000 kcal/
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day [15]. In the absence of obvious causative fac­
tors, such as coexistent endocrine disorders (or 
other anatomical lesions) or sepsis, it appears that 
malignant disease per se induces profound nutri­
tional problems. It is difficult to imagine, however, 
that even a small tumour can create such marked 
nutrient deficits; this places great importance on 
the metabolic disturbances induced by malignancy.
It has been suggested [18] that some tumours 
produce peptides, or other metabolites, which in­
teract with host/tumour tissues, inducing metabolic 
derangements and releasing peptides and/or amino 
acids that can be used by tumour tissue [19, 20]. 
Recent evidence, however, suggests that metabolic 
changes are mediated largely by the immune sys­
tem [21]. Cachectin, a polypeptide hormone, is of 
particular interest, since it has been implicated in 
the causation of both shock [22] and the cachexia of 
chronic disease [23]. When administered to ani­
mals, cachectin induces a state of anorexia and
Table 1. Pathogenesis of cancer cachexia
Possible contributory factors
Anorexia
Nausea and vomiting 
Taste aberration 
Early satiety 
Mechanical obstruction .
Vomiting 
Diarrhoea
Protein losing enteropathy 
Ulceration 
Haemorrhage
Radiation therapy 
Systemic drug therapy 
Surgery
? systemic effects of tumour
Protein 
Carbohydrate 
Fat
Hormones 
Water 
Electrolytes
‘Toxohormones’, peptides, 
and other small molecules
‘Nitrogen trapping’ by the tumour
weight loss, and an apathetic, unkempt appearance 
[21]. It seems, therefore, that the impact of cachec­
tin induced catabolic effects may be sufficient to 
account for the wasting accompanying neoplastic 
disease [24, 25]. Cachectin may thus ‘orchestrate’ 
the complex metabolic derangements that result in 
cachexia [21].
In general cachexia appears to be of a multifac­
torial aetiology, with the factors acting synergistic- 
ally to produce the clinical picture [26] (Table 1). 
The relative importance of these factors is subject 
to considerable individual variation.
Inadequate food intake
This may be related to mechanical obstruction, 
anorexia and early satiety, taste aberration, food 
aversion, or methods of treatment.
The anatomic location o f  the tumour may con­
tribute to an inability to ingest, digest, or absorb 
nutrients via the gastrointestinal (GI) tract. In ad­
dition, it has been suggested that malignancy any­
where in the body may be associated with second­
ary changes in the small intestine, leading to 
hypoplasia or flattening of the mucosa and a sub­
sequent malabsorption [27, 28]. A  significant pro­
tein losing enteropathy follows secondary disor­
ders of the GI lymphatic channels or ulceration of a 
region of the mucosa [29, 30]. However, such 
changes may be the effect, rather than the cause, of 
cachexia [31]. Since the GI tract is one of the most 
metabolically active organs of the body it is not 
surprising to find marked intestinal changes ac­
companying malnutrition and, therefore, cachexia. 
Certainly, in the malnourished individual, gas­
trointestinal efficiency is severely reduced due to 
changes in the mucosal cells coupled with a reduc­
tion in the brush border and a decline in intestinal 
enzyme activity. GI motility also declines and an 
overgrowth of facultative and anaerobic bacteria 
occurs [32], resulting in greatly impaired absorp­
tion. It is not clear to what extent the intestinal 
changes are due to nutritional deficiency and to 
what extent they are due to the malignancy itself.
The aetiology of anorexia, like that of cachexia, 
has yet to be elucidated, although it too is believed
Deficient food intake
Excessive loss of body 
protein
Malabsorption
Metabolic disturbances 
affecting:
Tumour metabolites
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to be of multifactorial origin. Anorexia may vary 
from mild to severe and its severity may go un­
noticed by the patient [33]. The many factors that 
may cause anorexia are not mutually exclusive and 
may act synergistically to exacerbate the problem, 
including:
1. Production of toxic factor(s) or hormone(s) that 
interact in some way with one or more of the 
mechanisms involved in controlling feeding be­
haviour [34].
2. Abnormalities of hypothalamic control of feed­
ing behaviour [e.g., 35].
3. Psychological and emotional responses to the 
disease and its treatment, including the depres­
sion, fear, and hopelessness felt by many cancer 
patients [e.g., 36].
4. Metabolic abnormalities of uncertain origin, in­
cluding increased tissue protein breakdown [37,
38].
5. Effects related to methods of treatment [e.g.,
39].
It has been suggested that ‘toxohormones’ pro­
duced by tumours exert peripheral effects on both 
neuroreceptor or neuroendocrine cells, or direct 
effects on the hypothalamus and other sensors 
within the central nervous system [34]. Although 
this hypothesis has received some support [40,41], 
and despite the isolation of cachectin [23], other 
workers [17] suggest that no such anorexigenic pep­
tides have been isolated to date. An alternative 
view states that tumour metabolites are involved in 
the regulation of compounds (such as the cate­
cholamines and serotonin) believed responsible for 
the.regulation of nutritional homeostasis [18,42]. It 
is clear that the mechanismscontrolling food intake 
are complex and subject to a variety of internal and 
external influences. Despite this, body weight re­
mains remarkably constant in the healthy individ­
ual, which suggests the presence of some form of 
physiological control and raises the question of 
whether this physiological mechanism fails in the 
presence of malignant disease.
One such mechanism has come to be convention­
ally regarded as the central site of the organisation 
and integration of feeding behaviour. It has been 
suggested that the hypothalamus and related cen­
tres play a major role in originating the sensations
of both hunger and satiety, operating a reciprocal 
excitation/inhibition system [34]. The proposition 
[15, 44] that a tumour generates spurious signals 
that are interpreted centrally as indicators of sati­
ety before true satiety signals have been generated 
has, therefore, received some support as the cause 
of the early satiety characteristic of malignant dis­
ease. However, neither damage to the ven­
tromedial nuclei, which characteristically causes 
hyperphagia [44, 45] nor damage to the lateral 
nuclei, which causes anorexia [46], with sub­
sequent recovery can block the development of 
anorexia or prevent cachexia. This suggests that 
depression of food intake is mediated extra-hy- 
pothalamically [16], and is consistent with previous 
findings [47,48] of decreased serotonin associated 
with increased food intake and a decrease in turn­
over, resulting in hyperphagia [49, 50].
Studies of plasma and brain amino acid patterns 
and central serotonin (5-HT) metabolism [51, 52] 
have shown that, in the presence of malignancy, 
brain tryptophan levels decline as serotonin rises, 
correlating closely with the onset of anorexia. It 
seems that tumour induced metabolic abnor­
malities result in a decrease in plasma albumin 
concentration in association with an elevation of 
plasma free fatty acids (FFA), with the result that, 
plasma free tryptophan rises, as tryptophan is the 
only amino acid binding to serum albumin and as 
plasma FFA compete for the same binding sites. 
This in turn leads to an increase in brain tryptophan 
concentration, inducing an increased synthesis and 
turnover of serotonin. When this is taken in con­
junction with reports of serotonergic mechanisms 
of satiety [e.g., 47, 48] it becomes possible to sug­
gest that anorexia is mediated by serotonin. How­
ever, further studies [53] have shown that inhibi­
tion of serotonin synthesis can postpone but NOT  
eliminate the onset of anorexia, and others have 
failed to reproduce previous findings [e.g., 54,55]. 
It therefore becomes clear that although seroto­
nergic mechanisms may play a contributory role in 
the anorexia of malignant disease, other mecha­
nisms must also be involved.
Anorexia is not exclusive to malignant disease, 
although its high incidence and prolonged deleteri­
ous effects, together with its major role in the
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.development of cachexia, make it a matter of con­
siderable concern. Continued research into its 
pathogenesis is essential if effective methods of 
treatment are to be found.
Behavioural and symptomatic contributors to 
anorexia
Although it appears that metabolic mechanisms 
play an important role in the genesis of anorexia, 
the important contribution of behavioural and 
symptomatic factors cannot be overlooked. There 
is little doubt that fear of cancer, and emotional 
responses to the diagnosis, can adversely affect 
appetite [36], although this does not explain the 
anorexia occurring in the undiagnosed patient.
There are periods during the course of the dis­
ease when the patient is particularly vulnerable to 
emotional distress [36], due to uncertainties associ­
ated with the disease, its diagnosis, and its treat­
ment. Before the diagnosis is confirmed patients 
are subject to considerable stress; confirmation of 
the diagnosis promotes further emotional trauma. 
A weight loss of 5-10 lbs, related primarily to psy­
chological/emotional factors rather than to the dis­
ease process itself [36], is not unusual during this 
period. Previous beliefs and attitudes towards can­
cer and its treatment [56], combined with con­
tinued fear of recurrence, appearance of a new 
symptom (whether or not this is disease related), 
and anxiety regarding methods of treatment are all 
important contributors to anorexia. Thus, as an 
emotional response, anorexia may be experienced 
throughout the course of the disease.
Continued progression of the disease can lead to 
marked depression, which could be seen as a psy­
chological basis for the anorexia/cachexia syn­
drome. In this case appropriate anti-depressive 
therapy would be expected to reduce the incidence 
of weight loss/anorexia/cachexia. However, this 
has not responded to tricyclic drug therapy [33], 
and Plumb et al. [57], using the Beck Depression 
Inventory, have shown that affected patients ob­
tain low scores on the non-physical symptoms of 
depression (such as worthlessness, loss of self 
esteem, pessimism, guilt, and suicidal tendencies).
High scores were demonstrated with regard to 
physical symptoms (such as anorexia, weight loss, 
insomnia, fatigue, and loss of interest in usual ac­
tivities), which appears to suggest that depression 
is not a significant factor in the pathogenesis of 
anorexia. It is felt that the term ‘depression’ is often 
inappropriately applied to the cancer patient, in 
whom symptoms suggestive of depression are often 
somatic in origin and reflect the physical rather 
than the psychological condition [36]. Depression, 
like anorexia, has been associated with seroto­
nergic mechanisms, and it is possible that they are 
closely related; this area warrants further investiga­
tion.
Disruption of lifestyle resulting from the pre­
sence of malignant disease, combined with effects 
induced by treatment regimes, clearly highlight the 
close relationships between an individual’s social, 
psychological, and cultural environment and his 
nutritional status. These, in turn, influence his 
quality of life.
Physical symptoms such as pain, nausea, and 
vomiting may also influence food intake; control of 
such symptoms is essential if nutritional status is to 
be maintained.
Taste aberration
Appetite changes and anorexia are often attribut­
able to taste aberrations which, together with 
anosmia, may blunt the normal excitatory stimuli 
associated with food intake [58]. Such changes 
largely concern alterations in bitter and sweet 
thresholds [26, 59], although there is no consistent 
pattern. Limited evidence suggests such changes 
improve in patients showing an objective response 
to therapy [60]. The cause of taste changes is not 
yet clear, although evidence suggests a correlation 
with trace mineral deficiencies [61]; this has yet to 
be confirmed in cancer patients although it is sug­
gested that such deficiencies are common.
Damage to the small intestine, such as that pre­
viously discussed, can result in significant losses of 
zinc that are reflected by low serum zinc levels [62]; 
rapid tissue breakdown, such as that induced by 
chemotherapy or radiotherapy, will increase excre­
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tion. Zinc deficiency has, in turn, been associated 
with hypoguesia and dysguesia. This mechanism 
may, therefore, be responsible for the taste aberra­
tions associated with cancer. The literature with 
regard to trace elements in malignant disease has 
been extensively reviewed [e.g., 63].
Learned food aversions may arise as a result of 
taste changes, as well as from an association be­
tween symptoms and the disease or its treatment 
[55,64]. This has come to be regarded as a variant 
of classical conditioning, in which a conditioned 
stimulus (taste) becomes associated with an uncon­
ditioned response (e.g., discomfort) [65]. Animal 
studies [55,66] have shown that just one pairing of 
a food with GI discomfort induced by radiotherapy 
is sufficient to promote continued avoidance of that 
food and repeated pairings of food with discomfort 
may cause aversion to even the most familiar foods 
[67]; conditioned aversions such as these may per­
sist long after symptoms have subsided [43,64] and 
may be significant in the development of anorexia 
and the promotion of weight loss in patients ac­
tively treated for cancer [64].
Metabolic abnormalities
Changes in energy expenditure
Many metabolic changes occur in the presence of 
malignant disease [68] and manifest themselves in 
alterations of energy expenditure.
Although there is considerable variation, many 
workers have demonstrated an increased energy 
expenditure in the tumour bearing host [e.g., 69]. 
Following tumour transplantation it has been 
shown that spontaneous motor activity declines 
[35], yet oxygen consumption is increased [70], 
suggesting the initiation of an unexplained process 
that increases energy requirements [71]. Two hy­
potheses have been considered [72]: First, the met­
abolic activity of malignant tissue is continuous, in 
contrast to the diurnal periodicity of normal 
tissues, thus imposing a greater energy demand. 
However, the metabolic activity of tumour cells is 
low when compared to that of the host [73]. Sec­
ond, alterations in pathways of intermediary me­
tabolism could result in a selective removal of nu­
trients by the tumour, forcing the host to use more 
energy-expensive pathways. For example, on the 
basis of animal studies [72] it was concluded that a 
tumour could act as a ‘nitrogen trap’, sequestering 
host proteins in a competition for nutrients. How­
ever, hyperalimentation does not decrease energy 
expenditure although both the nutrient supply and 
the metabolic pool are augmented.
The demonstrated increase in whole body 
glucose production [17, 20] could explain an in­
crease in Cori cycle activity (Fig. 1), particularly in 
metastatic carcinoma [20]. This is an energy-wast- 
ing process that circumvents aerobic glycolysis, 
consuming energy and resulting in a net energy loss 
(8 molecules of ATP per mole of glucose). This 
glucose is lost to the host, who might have used it to 
generate ATP through the Tricarboxylic Acid Cy­
cle [74, 75]. It has, however, been estimated that 
this increased activity is unlikely to have significant 
effects on daily energy expenditure [76].
Cancer patients commonly demonstrate disturb­
ances of glucose metabolism. These have been re­
ported variously as impaired glucose tolerance [77- 
79], decreased insulin sensitivity [8,80], decreased 
insulin release in response to a glucose load [77, 
79], and decreased activity of energy producing 
enzymes in skeletal muscle [79]. Fasting plasma 
alanine levels are significantly decreased, while 
branched chain amino acids are unchanged. It has 
been suggested that an increased alanine flux for 
gluconeogenesis reflects a basic metabolic abnor­
mality that could be explained on the basis of in­
sulin resistance demonstrated in these patients [17].
Alternatively, the studies of Lundholm et al. [9] 
suggest differences in the intermediary metabolism 
of glucose in non-tumour involved host tissues, 
such as skeletal muscle. It is suggested that the 
increased glucose turnover primarily comprises in­
creased Cori Cycle activity (80%), but also in­
creased glucose oxidation (15%) [9], and has been 
calculated to explain 30%-40% of the increased 
oxygen consumption in the cachectic patient [81, 
82].
Whatever the cause, these effects are associated 
with an inappropriately high oxygen consumption 
and lead to a negative energy balance. This may
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Fig. 1. Glucose-lactate (Cori) cycle in the cancer patient
explain, at least in part, the progressive weight loss 
associated with some forms of malignant disease. 
However, the results of studies to date are equivo­
cal, and not all tumours are associated with an 
elevated metabolic rate. It is clear, therefore, that 
this is not the only factor contributing to the ob­
served nutritional depletion. However, when a pa­
tient has an elevated metabolic rate and is also 
anorectic he is at a considerable risk of malnutri­
tion [83], although such individuals are not easily 
identified, and it will continue to prove difficult to 
promote anabolism in affected patients until the 
mechanism underlying these effects is elucidated.
Changes in protein metabolism
Tumour cells have been shown to have a high 
capacity for concentrating amino acids both in vivo 
and in vitro. The difficulties associated with the 
precise control of nutrient intake and the use of 
radioisotopes in patients with malignant disease 
have, however, meant that many aspects of protein 
metabolism have been studied in animals, making 
direct extrapolation of data difficult.
Although the studies of Feninger and Mider [72] 
were carried out in only a few neoplasms, this work 
led to the concept of ‘nitrogen trapping’ by the 
tumour, with subsequent evidence suggesting this 
may apply to some forms of cancer, particularly in 
experimental animals. It is questionable, however, 
whether the ‘nitrogen trap’ hypothesis applies in
human cancer when the ratio of tumour size to 
body size is much lower than in experimental ani­
mals [17]. It has been suggested [84] that progres­
sive weight loss, abnormal gluconeogenesis, and 
the demonstrated lactate recycling may result from 
imbalance of the essential amino acids due to selec­
tive uptake of amino acids by tumour cells. The 
administration of radiolabelled amino acids ini­
tially results in marked labelling of normal tissues 
but, with time, tumour tissues display significantly 
higer specific activity as normal tissue protein turn­
over occurs. It has been demonstrated [85] that 
radiolabelled proteins are taken up by tumour 
tissues to a greater extent than non-neoplastic 
tissues, suggesting that tumours have a selective 
advantage in extracting whole proteins, such as 
albumin, from the circulation, particularly since 
hypoalbuminaemia is commonly associated with 
neoplastic disease. Such changes in amino acid me­
tabolism may prevent the host from effectively de­
creasing gluconeogenesis. It is also possible that 
the presence of malignancy may alter the regula­
tory mechanisms of normal tissue. For example, it 
has been shown [86] that the livers of hepatoma 
bearing rats fail to respond to nutritional stressors, 
such as a protein free diet, in the same way as those 
of non-tumour bearing animals.
Although reports are equivocal it appears that 
the tumour bearing host responds to an increased 
tumour burden by increasing tissue protein break­
down, thus demonstrating a decreased ability to 
use those mechanisms designed to conserve lean 
body tissue and preserve total body protein. Mal­
nourished cancer patients have been reported to 
differ from malnourished non-cancer bearing indi­
viduals by displaying both increased protein syn­
thesis and protein turnover [87]. Thus, even in the 
presence of cachexia and the associated starvation 
there is a failure of adaptation, with the tumour 
failing to recognise normal control mechanisms 
and maintaining its activity despite host starvation
[88]. The reasons for this failure have not yet been 
elucidated.
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Albumin metabolism
The metabolism of albumin is often regarded as an 
indicator of total protein metabolism, as it is the 
protein present in the plasma in the largest 
amounts. It is believed particularly relevant to the 
study of cachexia because it clearly demonstrates 
the differences between the hypoalbuminaemia as­
sociated with starvation and malnutrition and that 
associated with cachexia [89]. In simple starvation, 
once carbohydrate stores have been depleted as a 
source of energy, the body utilises fat; in cachexia, 
however, fat stores are not mobilised and, instead, 
muscle protein is broken down to provide energy 
through gluconeogenesis [88, 90].
Both albumin synthesis and catabolism are af­
fected by many factors including nutritional status, 
physiological stress, osmotic pressure, hormones, 
and disease status [91]. The exogenous supply of 
amino acids is of particular importance, since even 
short-term protein deprivation will result in a 
marked decrease in albumin synthesis.
As previously shown, hypoalbuminaemia is 
common in malignant disease. When this is associ­
ated with cachexia and PEM both synthesis and 
catabolism of albumin are reduced [92], although 
the causes of the hypoalbuminaemia of malignancy 
per se have not been established and the results of 
studies to date have been equivocal. It has been 
suggested that this results from a reduction in syn­
thesis possibly associated with a low catabolic rate 
[93-96]; others, [e.g., 97] have reported an in­
creased catabolism. The albumin metabolism of 
patients with lesions of the GI tract, and an associ­
ated reduction in food intake, was compared with 
that of malnourished patients with anorexia sec­
ondary to widely disseminated malignant disease
[89]. The former patients correlated closely with 
patients suffering PEM, displaying a low to normal 
fractional catabolic rate (FCR) and a normal to 
high fractional synthetic rate (FSR), while the lat­
ter displayed a normal to high FSR and a markedly 
increased FCR. As a result it is suggested that an 
elevated FCR may correlate with a poor prognosis 
unless the tumour is responsive to anti-neoplastic 
therapy. However, it is to be expected that the 
response to such therapy will be reduced in the
presence of hypoalbuminaemia, since albumin 
functions in the binding of many substances within 
the circulation, including many of the cancer 
chemotherapeutic agents. The future of successful 
treatment depends on an understanding of both the 
changes in whole body protein metabolism and the 
causes of hypoalbuminaemia. Without this, drug 
therapy may be of limited value, and the efficiency 
of nutritional support may also be limited [98]. 
Clearly, the apparent inevitability of hypo­
albuminaemia means that this cannot be used as an 
index of nutritional status in these patients [99].
Changes in fat metabolism
Most workers agree that a loss of fat accounts for 
the majority of the weight loss observed in cancer 
patients [69, 100, 101]. Studies have shown that, 
during the course of tumour growth, carcass fat 
(exclusive of that present in the tumour) declines to 
less than 10% of its normal value in a number of 
tumour systems [102-104]. Despite the presence of 
anorexia this fat loss cannot be exclusively at­
tributed to an inadequate food intake, since pair- 
fed controls carry considerably more fat than tu­
mour bearing animals and force feeding does not 
prevent the loss [105, 106].
Marked hyperlipidaemia, which is not accom­
panied by ketosis or ketonuria, has been noted in 
tumour bearing animals [107], suggesting that fat 
lost to the body during tumour growth is com­
pletely oxidised. As energy expenditure is greater 
in tumour bearing animals and as this could be 
quantitatively accounted for in some studies by the 
energy value of the ‘lost’ lipid, it seems possible 
that fat is mobilised to meet the increased demand 
for energy [13,14,107]. Such animals also display a 
decreased ability to clear neutral fats from the 
serum [13, 14], although the rate of removal of 
infused lipids appears increased in the cancer pa­
tient [108]. It is worth noting that, although some 
tumours studied in vitro have demonstrated a pref­
erence for fatty acids as an energy substrate [109], 
in vivo studies have demonstrated a slower tumour 
growth when the majority of calories in a total 
parenteral feeding regime are given as fat [110]. As
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cachexia seems to result from an almost obligatory 
‘parasitism’ by the tumour [4] it would appear un­
likely that a tumour would elaborate lipid mobilis­
ing substances [44], since this might restrict its 
growth. Yet fat mobilising peptides have been iso­
lated from the urine of both fasted animals and 
humans [111, 112] and in those with widespread 
malignant disease even when food intake is ‘nor­
mal’. Peptides with lipid mobilising activity have 
been isolated from both pituitary [113, 114] and 
hypothalamic [115] extracts and lipolytic activity 
has been reported in extracts from other parts of 
the brain. Such peptides could thus account for the 
hyperlipidaemia of malignant disease. However, 
studies suggesting a relationship between a rise in 
plasma FFA and clinical activity of the tumour [116] 
have not been confirmed [20,117]. Although FFA 
oxidation can be reduced by glucose administration 
in controls, it is less reduced in cancer patients [19], 
indicating a failure of normal homeostatic mecha­
nisms that could be the result of insulin resistant 
[8].
These effects, whatever their cause, again con­
firm that the presence of malignancy results in 
alterations of the normal mechanisms of control. 
Evidence for the role of lipid mobilising substances 
in the causation of hyperlipidaemia is equivocal, 
since this may restrict the growth of some tumours. 
The degree and extent of hyperlipidaemia may be 
dependent on the type of tumour. Nonetheless, the 
loss of body fat combined with inappropriate oxy­
gen consumption and loss of lean body mass can 
only contribute to a state of negative energy bal­
ance and a continuing weight loss.
Micro (trace) nutrients and malignancy
Current knowledge regarding micronutrient re­
quirements is inadequate and based only on the 
Recommended Daily Allowances (RDA) for the 
so-called ‘normal’ individual. The RDA itself rep­
resents the minimum daily intake believed neces­
sary to prevent a recognisable deficiency disorder 
together with a ‘safety margin’ which varies with 
the nutrient. It does not represent an optimal in­
take. Since not all essential trace nutrients have yet
been identified, it is unlikely that a deficiency dis­
order would be recognised. Nonetheless, it is be­
lieved that deficiency is uncommon as long as a 
‘normal’ food intake is maintained. This conclusion 
may well be invalid in the cancer patient. Indeed 
there are good grounds for considering that dietary 
requirements may be higher in cancer patients, for 
they may not be able to absorb nutrients efficiently 
via the GI tract. There are, in addition, many rea­
sons to suppose that malignancy may alter micro- 
nutrient requirements, since uncontrolled tumour 
growth may result in varying degrees of physiologic 
stress which, in turn, may alter both the acquisition 
and utilisation of micronutrients [118]. There is. 
therefore, a great need for longitudinal metabolic 
studies to indicate how micronutrients are handled 
by patients with cancer.
Vitamins
Table 2 shows that patients with malignant disease 
are likely to suffer some degree of vitamin defi­
ciency; this may significantly affect their continuing 
resistance to the disease and determine their re­
sponse to treatment. Undoubtedly, much of the 
depletion is secondary to an inadequate intake, but 
this is exacerbated in some cases by abnormal 
losses through the alimentary and renal tracts [7]. 
Although the mechanisms through which these de­
ficiencies arise generally remain unresolved [2], 
they may result from the administration of anti­
neoplastic drugs [120].
Most of the available information about vitamins 
in the cancer patient concerns vitamins C, A , and
Table 2. Vitamin abnormalities in cancer patients3
% Affected
71
49
37
23
15
15
0
“Based on Caiman (1975) [1191.
Abnormal leucocyte Ascorbic Acid
Anaemia
Thiamine
Abnormal folic acid 
Vitamin A 
Carotene
Abnormal vitamin B
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B2 (riboflavin). Thiamine (B,) deficiency is com­
mon and may be of clinical significance due to the 
close relationships between this vitamin and drug 
metabolism [121]. Folic acid and vitamin E have 
also been studied.
Ascorbic acid (vitamin C)
It has been suggested that ascorbic acid has many 
roles in both the development and treatment of 
malignant disease [122,123]. In addition, ascorbic 
acid plays a major role in drug detoxification 
through effects on hepatic microsomal enzymes 
and may, therefore, modify the activity of chem­
otherapeutic agents.
Both human and animal studies have shown that 
tumour tissues have a higher concentration of 
ascorbic acid than adjacent normal tissue [124]; at 
the same time plasma and leucocyte levels in pa­
tients with lung cancer, for instance, fall below the 
threshold levels for incipient scurvy [125]. Simi­
larly, in children, relapsed acute lymphoblastic leu­
kaemia results in reduced plasma and leucocyte 
ascorbic concentrations that are unrelated to die­
tary intake, impaired absorption, or administration 
of chemotherapy [126].
Since ascorbic acid is closely involved in the 
modulation of the immune system and in drug me­
tabolism, and since increased utilisation has been 
demonstrated during tissue repair and following 
burns and surgery (i.e., following periods of phys­
iological stress), it seems possible to suggest that 
ascorbate utilisation may be increased in the cancer 
patient in whom many types of physiological stress 
are manifest. Evidence for such an increase in re­
quirements has been obtained in breast cancer pa­
tients [127]. High dose ascorbic therapy, which has 
been used in the treatment of patients with ad­
vanced malignancy [121], may therefore be a useful 
adjunct to treatment. However, presently avail­
able evidence [128,129] does not support this view. 
In studies of this kind greater attention should be 
given to tumour specificity; this is a criticism that 
can be made of many investigations into human 
cancer.
Retinol (vitamin A)
Over 90% of human cancers are believed to be of 
epithelial origin [130]. As vitamin A  is essential for 
maintaining the normal differentiation of epithelial 
tissues [131], and as cancer is regarded by some as a 
disease of differentiation, it therefore seems possi­
ble that vitamin A  (retinol), its precursor p car­
otene, or its analogues, known collectively as reti­
noids [132], could be anti-carcinogenic by rein­
forcing expression of the normal phenotype and 
preventing expression of the malignant phenotype. 
If this is so then retinoids may function like steroid 
hormones to control phenotypic expressions. It is 
therefore possible that adequate vitamin A  or (3 
carotene might prevent cancer, or that retinoids 
might be used to control the disease.
Considerable epidemiological evidence suggests 
an association between reduced cancer risk and 
above average blood retinol levels [133] or above 
average intakes of carotene [134-137]. Peto et al. 
[137] proposed a number of mechanisms that sug­
gest that dietary |3 carotene, rather than retinol, 
may have this effect. They suggested that car- 
otenoids may have a direct effect on cellular dif­
ferentiation in target tissue, and may then be con­
verted to retinoids in the target tissue and protect 
the tissue by either enhancing immunological func­
tion or quenching singlet oxygen.
However, the case for a protective effect of (3 
carotene depends entirely on epidemiological evi­
dence, and interpretation of epidemiological die­
tary surveys is often uncertain. For instance, the 
protective effect observed may result not from the 
nutrient under study but from some other constitu­
ent of food; for example, it has been suggested that 
some other constituent of vegetables [138], such as 
ascorbic acid or phenolic compounds [139, 140], 
might have a protective effect.
Evidence appears to support a relationship be­
tween low blood retinol levels and cancer. Thus, 
compared with non-cancer controls, low plasma 
retinol values have been found in patients with 
squamous and oat cell bronchial carcinoma [141], 
and low retinol values, associated with low retinol 
binding protein (RBP) concentrations, have been 
reported in patients with lung cancer [142]. In a
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study of patients with cancer of the oropharynx and 
oral cavity, mean plasma retinol and (5 carotene 
levels fell with advancement of disease [143]. Fur­
ther support for the view that retinol levels are 
related to the stage of the disease has been found in 
patients with bladder [144] and cervical [145] can­
cer; low plasma retinol concentrations associated 
with low RBP values were found only in patients 
with undifferentiated, extensive bladder cancer or 
with Stage III cervical cancer. It seems likely that 
the low retinol values in these patients were due to 
reduced synthesis of RBP, possibly due to mal­
nutrition. This might account for the low retinol 
values observed in patients with lung cancer, which 
has been described as a ‘starving disease’. If this is 
so, then the results of these studies lend little sup­
port to an anti-cancer role for retinol. However, 
this does not explain the results of prospective 
studies [133,146] in which lower retinol concentra­
tions were found in subjects subsequently develop­
ing lung cancer when compared with those who did 
not develop the disease (although it must be noted 
that measurements on subjects participating in the 
Basle Cardiovascular study during 1970-1973 failed 
to show such an association [147]).
Evidence for the protective effect of vitamin A  
and its analogues against the actions of chemical 
carcinogens in experimental animals has been re­
viewed by Hicks [148]. The importance of animal 
studies lies in their use in elucidating the scientific 
basis of anti-tumour action, but care should be 
exercised in extrapolating the results to human 
cancer. For instance, the extrapolation of studies 
involving the importance of carotene to humans is 
complicated by the fact that rodents do not ac­
cumulate carotenoids and are very efficient at con­
verting carotene to retinol, while humans show a 
considerable accumulation of carotenoids and inef­
ficient conversion of carotene [149].
Experimental evidence linking retinoids and 
cancer has led to studies of the value of retinoids in 
treating a variety of human pre-malignant and ma­
lignant conditions. These have included the treat­
ment of cutaneous metastatic melanoma with all 
trans retinoic acid [150] and the use of “Ro 
10-9359” in pre-malignant and malignant skin con­
ditions [151] and in advanced neoplasia [152],
Riboflavin (vitamin B2)
Rivlin [153] has reviewed the relationship between 
the induction of cancer, its subsequent growth, and 
the dietary intake of riboflavin. Dietary riboflavin 
deficiency has been shown to both reduce the inci­
dence of tumours after the application of car­
cinogens and inhibit the growth of tumours.
Thiamine (Vitamin B,)
Thiamine deficiency is common in both early ma­
lignancy and advanced disease [154], particularly 
when treatment with 5-fluorouracil (5-FU) is in­
stigated either alone or in combination with other 
drugs [155]; this deficiency can be corrected by 
giving large doses of the vitamin. Although 5-FU is 
a cocarboxylase antagonist affecting the con­
version of thiamine to thiamine pyrophosphate [2, 
154], it is by no means certain that giving thiamine 
will not stimulate tumour growth or decrease the 
anti-neoplastic effect of the drug [98]. Further 
work is clearly necessary before patients being 
treated with 5-FU can be given large doses of vi­
tamin B,.
Folic acid (folate)
Folate is essential for cell division; as a result folate 
status is of considerable importance in malignant 
disease. Folate deficiency has been associated with 
malignancy [156,157], and abnormalities in its me­
tabolism have been linked to acute and chronic 
leukaemias, disseminated lymphomas [158], and 
various metastatic carcinomas [159]. Catabolism of 
folate is reduced in the presence of malignancy 
[160], at least in the rat, which suggests that the low 
folate levels are the result of sequestration by tu­
mour tissues [160], reflecting an increased require­
ment for folate in malignant disease due to the 
presence of additional cell mass. Thus, the specific 
interaction between the drug methotrexate (a 
folate antagonist) and folate can be used to inhibit 
tumour growth, although a folate ‘rescue’ is essen­
tial following a period of drug action. However, 
administration of folate, except under carefully
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controlled conditions, may increase or stimulate 
tumour growth, so caution should be applied when 
considering folate as a supplemental therapy.
Tocopherol (vitamin E)
It is assumed that vitamin E acts as a ‘scavenger’ of 
free radicals through its actions as an electron do­
nor, and in this way plays a role in the prevention of 
carcinogenesis. Its role in malignant disease is un­
clear, although it has been shown that tocopherol 
utilisation differs between normal and malignant 
cells [118].
Studies of tocopherol accumulation by tumour 
tissues have produced equivocal results, with some 
suggesting this is decreased [161, 162] and others 
that it is increased [163]. This situation remains 
unresolved, so it is not possible to postulate what, if 
any, changes occur in vitamin E status within the 
cancer bearing host. As a result it is not possible to 
assess the role of supplemental vitamin E in the 
treatment of malignant disease, although it is com­
monly recommended by many of the ‘alternative’ 
approaches to cancer treatment because of its anti­
oxidant activity [164]. This approach may, in fact, 
be detrimental to the host.
Trace elements
The growing awareness of the importance of trace 
elements in health has led to an increased interest 
in the trace element status of the cancer patient. It 
is now clear that trace metals are fundamental to 
many biological processes that may be disrupted by 
an impaired intake, increased utilisation, and/or 
increased excretion. The cancer patient may suffer 
any or all of these effects, and trace element defi­
ciency may contribute to many of the metabolic 
alterations manifested in the presence of malig­
nancy; this area may be worthy of investigation. In 
general the role of trace metals in carcinogenesis 
has received more attention than their metabolism 
in the cancer bearing host. Data currently available 
relates principally to surveys of the serum, urine, 
and tissue concentrations of various elements. Few
replacement studies have been reported, an excep­
tion being zinc replacement therapy [165], which 
has been shown to improve oral ulceration follow­
ing chemotherapy and, at the same time, to stimu­
late appetite and improve taste sensation. It is, 
however, possible that the latter effects result sim­
ply from an improved oral status rather than from a 
systemic effect of zinc. However, some changes 
have been observed in the metabolism of certain 
trace elements, notably iron, selenium, copper, 
and zinc.
Iron
The role of iron in the initiation of carcinogenesis 
warrants further study, since the incidence of neo­
plasia appears to increase in conditions of iron 
excess. For example, primary hepatic carcinoma 
develops in African populations in whom siderosis 
is common. It has been suggested that iron func­
tions as a cocarcinogen through its activation of 
free radical mechanisms [166], since iron has been 
shown to be a potent initiator of lipid peroxidation.
In the presence of malignancy, radio-labelled 
iron is cleared from the plasma at an accelerated 
rate that increases in parallel with the rate of tu­
mour dissemination [118]; these effects are similar 
to those seen during the inflammatory response. A 
direct correlation has been shown between the ex­
tent of disease and decreases in the saturation of 
transferrin in patients with Hodgkin’s disease [167]. 
Although the uptake of nutrients may vary be­
tween normal and malignant cells an increased 
storage of iron has not generally been demon­
strated; in fact, the iron content of certain tumours 
(e.g. kidney, lung, and stomach) has been shown to 
be lower than that of adjacent normal tissues [118]. 
However, mammary tumours and the Reed- 
Sternberg cells of Hodgkin’s disease contain a sig­
nificantly increased iron concentration, suggesting 
that significant variations exist between tumours of 
different types.
The role of iron, and/or changes in its metabo­
lism or utilisation, in the presence of malignancy 
remain to be resolved; this may be of significance 
when planning appropriate nutritional support reg­
imes.
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Copper, zinc and selenium
Copper, zinc, and selenium are all essential nu­
trients; selenium is essential for normal growth (at 
least in some species) and copper and zinc are 
co-factors in a number of important enzyme sys­
tems [168,169].
Many forms of malignancy (e.g ., acute/chronic 
leukaemia, Hodgkin’s and non-Hodgkin’s lym­
phoma, gastric and lung cancers) are associated 
with abnormalities of copper status, and hyper- 
cupremia is common. Serum copper levels can, 
therefore, be used to indicate tumour activity [2] 
and to evaluate subsequent response to treatment 
[118].
Zinc is essential to malignant growth [170]. It is 
possible that uptake of zinc by tumour cells results 
in deficiency in the host and, as zinc deficiency is 
known to inhibit protein synthesis, it has been sug­
gested that zinc deficiency may reduce the avail­
ability of those micronutrients reliant upon serum 
transport proteins [171]. When combined with 
anorexia and other disturbances to food (nutrient) 
intake this could, in itself, explain many of the 
micronutrient abnormalities associated with neo­
plastic disease and could, in addition, form the 
basis of the mechanism underlying the commonly 
reported taste changes, since both hypoguesia and 
dysguesia are frequently associated with zinc defi­
ciency.
It has been suggested that selenium deficiency is 
a predisposing factor for malignant and cardiac 
disease, both of which have been associated with 
oxidative damage. Since selenium is known to 
function as an antioxidant [172], being an impor­
tant constituent of the enzyme glutathione perox­
idase, this hypothesis appears to have some merit. 
In addition, selenium is believed to play a role in 
immunostimulation, enhancing the ability of the 
immune system to prevent neoplastic growth [173]. 
It is therefore possible that an adequate selenium 
intake could help to prevent the occurrence of 
malignant disease, although it must be noted that 
selenium is associated with a marked toxicity, so 
supplementation is not generally recommended. 
Despite this, selenium is now recommended by 
some of the ‘alternative’ approaches to treatment
[e.g., 164], although its effects on established tu­
mours are not yet known. However, it has been 
suggested [174] that selenium has an inhibitory 
effect on the growth of malignant cells through 
selective effects on c-AMP metabolism. Further 
study is urgently needed in this area.
Fluid and electrolyte disturbances
Patients with cancer often present with systemic 
symptoms of their underlying disease, the severity 
of which may bear no relationship to the site or 
extent of the tumour. Fluid and electrolyte disturb­
ances are common and, in patients with advanced 
malignancy, both intra- and extra-cellular water is 
increased [175]. Such fluid retention can mask a 
loss of body tissue, so as disease progresses the 
measurement of body weight declines in value as a 
means of assessing nutritional status.
Hyponatraemia is the most frequent electrolyte 
abnormality and is usually of a multifactorial 
aetiology. However, fluid retention and increased 
urinary sodium losses have been attributed to an 
inappropriate secretion of antidiuretic hormone 
(ADH ), usually, but not exclusively, in conjunc­
tion with bronchogenic or oat cell carcinomas [176].
Hypercalcaemia, associated with fatigue and 
anorexia and accompanied by both weight loss and 
constipation, is also common. In fact, malignant 
disease is the most common cause of hyper­
calcaemia in hospitalised patients [177]. The cause 
is uncertain. It has been suggested that, in patients 
with bone metastases, hypercalcaemia is due to the 
release of calcium following bone destruction [177]. 
It is clear, however, that hypercalcaemia can arise 
even when there is no direct bone involvement 
when removal of the tumour may result in the 
return of serum calcium to within the normal 
range. Such effects are most common in squamous 
cell carcinomas of the bronchus or head and neck, 
or in renal cancers [178]. This suggests a role for a 
circulating mediator such as parathyroid hormone 
(PTH), although intestinal absorption of calcium is 
not, in general, increased, and circulating PTH 
levels are elevated only in about 10% of hyper- 
calcaemic cancer patients [177].
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Certain tumours (such as medullary tumours of 
the thyroid) secrete excessive amounts of cal­
citonin [179], prostaglandins [180], and histamine 
[181], which may serve to explain hypercalcaemia in 
the absence of bone disease. Calcitonin induces 
secretion of water and electrolytes by the jejunal 
mucosa [182] and could, therefore, be a factor con­
tributing to both diarrhoea and electrolyte disturb­
ances in patients with extra-intestinal malignancy. 
Malabsorption and diarrhoea have also been asso­
ciated with an increased secretion of histamine 
[183].
Prostaglandins are known to cause bone destruc­
tion, and prostaglandin production has been shown 
to occur in invaded bone [185]; this could account 
for both the pain and the destruction associated 
with bone metastases, although it seems unlikely 
that it could contribute to the hypercalcaemia oc­
curring in the absence of bone disease.
It is clear that hypercalcaemia is a common cause 
of morbidity in cancer patients and one that is 
exacerbated by immobilisation and dehydration. 
Although successful methods of treatment are 
available (e.g ., Mithramycin, steroid therapy), at­
tention should be directed towards its prevention; 
continued research into its causes is thus essential.
Other electrolyte abnormalities, together with 
disturbances of acid-base balance, may result from 
complications of the disease itself or from its treat­
ment [185,186]. Weight loss and accelerated cata­
bolism can result in urinary losses of both sodium 
and potassium, although serum levels remain 
within the normal range. Hypocalcaemia may arise 
in the presence of hypoalbuminaemia.
The preceding discussion has shown that almost 
all tumours result in significant nutritional and met­
abolic alterations in the host. These may appear 
early in the disease, or later as the cancer pro­
gresses and metastasises. These alterations result 
in changes that act synergistically to create ‘chaos’ 
in host metabolism [187]. Although the mecha­
nisms by which many of these effects arise are not 
yet understood, it is clear that cancer cachexia has 
marked effects on the patient’s ability to withstand 
the impact of both the disease and its treatment, 
causing a decline in nutritional status and quality of 
life. Due to this incomplete understanding it is not
possible, at present, to take effective measures to 
prevent its development except through control o f  
the primary disease by effective anti-neoplastic 
therapy. There are, however, secondary factors 
that may contribute to a further decline in the 
nutritional condition; these include side effects and 
complications of treatment.
Nutrition and cancer therapy
The treatment of neoplastic disease can impose 
many significant nutritional disabilities on the pa­
tient as a result of factors that either limit food 
intake or cause malabsorption of nutrients. Such 
effects may be transient or severe and permanent: 
they assume particular importance when viewed in 
the context of the many other factors that may 
interact to put the patient at nutritional risk.
Surgery
The many biochemical and physiological disturb­
ances following surgery are well-documented [e .g .. 
188]; in general these are short-lived and do not 
result in long-term nutritional disability unless sur­
gery is extensive, complicated, or superimposed 
upon the nutritional consequences of cancer per se.
However, as surgery is the treatment of choice 
for most tumours within the gastrointestinal (GI) 
tract, it is to be expected that such tumours, and 
their treatment, may have a major impact on nutri­
tional status. The extent of the resultant nutritional 
disability depends upon many factors, including 
the site of the tumour and the extent of resection 
(Table 3).
Mastication and deglutition may be severely dis­
rupted by resection of tumours of the oropharnyx. 
mandible, or tongue, and difficulties such as xe­
rostomia and fibrosis add to the difficulties in swal­
lowing. Many of the problems can be alleviated bv 
tube feeding although this may be required for 
prolonged periods; for example, Pittam et al. [189] 
found 45% of patients required enteral feeding for 
more than 15 days post-operatively. For the patient 
at serious risk of aspiration, permanent tube feed­
ing may be necessary.
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Oesophagectomy may induce gastric stasis, hy- 
pochlorhydria, diarrhoea, and significant malab­
sorption o f fat leading to steatorrhoea [190]. Simi­
lar effects are noted following truncal vagotomy; it 
has been suggested that such symptoms are related 
to the bilateral vagotomy that is inherent in the 
procedure, rather than to the oesophagectomy per 
se. However, the precise mechanisms are unknown 
[190, 191]. Physiological and nutritional conse­
quences o f partial and total gastrectomy have been 
extensively reviewed [191]. These effects increase 
proportionately with the extent of resection. Mal­
absorption of both protein and fat are common 
[192], although this does not always correlate with 
the observed degree of weight loss. Nonetheless, 
malnutrition, defined by a weight below 85% of 
ideal body weight, has been found in 30% of pa­
tients [193]. A  major contributor to weight loss 
appears to be self-imposed dietary restriction that 
may arise for several reasons including 
oesophagitis, loss of the food ‘reservoir’, and 
dumping syndrome. Myriad GI symptoms may fol­
low gastric surgery; these include nausea, vomit­
ing, abdominal cramps, and diarrhoea, as well as 
an increase in sympathetic autonomic discharge; 
these symptoms can be so unpleasant that an aver­
sion to eating develops. Dumping syndrome occurs 
in between 10%-25% of all patients undergoing 
subtotal gastrectomy; in total gastrectomy the per­
centage is still higher [191]. The incidence can be 
reduced, and nutritional deficits corrected, by well- 
planned dietary measures involving frequent small 
meals with high protein and fat and low carbohydr­
ate content. Persistent anorexia may have to be 
treated by slow drip, tube feeding. Functional pan­
creatic insufficiency may arise due to rapid entry of 
food/fluid into the small intestine, which results in 
dilution of the digestive enzymes; in such cases the 
use of pancreatic enzymes may be helpful [83].
Resection of the small intestine can result in 
significant nutritional or metabolic disturbances, 
the extent of which is dependent on the area re­
sected. Although the absorptive area may be re­
duced following resection, malabsorption does not 
usually reach significant proportions until at least 
75% of the bowel is removed since the remaining
Table 3. Possible nutritional effects of gastrointestinal surgery
Resection of the oropharyngeal region Chewing/swallowing difficulties 
Prolonged dependence on tube feeding
Oesophagectomy 
Oesophageal reconstruction
Gastric stasis 
Hypochlorhydria J 
Fat malabsorption -  steatorrhoea 
Diarrhoea
Secondary to 
vagotomy
Gastric resection 
(Partial/total)
Dumping syndrome 
Malabsorption
Achlorhydria -  Pernicious anaemia 
(lack of intrisic factor) 
Hypoglycaemia
Small intestine Duodenum 
Jejunum 
Ileum
Massive resection
Pancreatobiliary deficiency
Decreased efficiency of absorption
Bile salt malabsorption
Pernicious anaemia (B,, malabsorption)
Hyperoxaluria
Severe malabsorption
Malnutrition
Metabolic acidosis
Colon Fluid and electrolyte imbalance
Pancreatectomy Pancreatic exocrine insufficiency 
Diabetes mellitus
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bowel has been shown to increase its absorptive 
capacity [194-196]; subsequent radiation therapy 
may exacerbate malabsorption in affected patients.
Ileal resection is associated with poor absorption 
of vitamins of the B group and conjugated bile 
salts, so that administration of the B vitamins is 
necessary to prevent deficiency. Inhibited reab­
sorption of bile salts results in prolonged and dis­
tressing diarrhoea; cholestyramine can be used to 
bind bile salts and minimise symptoms [197]. These 
are excreted when bile salt reabsorption ceases and 
the limited ability of the liver to replace them re­
sults in a decreased luminal concentration of bile 
salts so that fat absorption is impaired and steator­
rhea results [197]. This leads to calcium ion defi­
ciency due to the formation of insoluble calcium 
soaps that are subsequently excreted. Such defi­
ciency, in turn, increases the likelihood of hyperox­
aluria with the associated risk of renal calculi, as 
urinary oxalate is increased due to a failure to 
precipitate oxalate as calcium oxalate in the intes­
tine [198].
Dietary measures can be taken to overcome 
these problems. The diet should include an in­
creased intake of medium chain triglycerides 
(MCT), since they do not require emulsification 
prior to absorption, together with a reduction in 
long chain fats and oxalate containing foods and an 
increased intake of calcium salts. Hypomag- 
nesaemia may also occur, so a magnesium-rich diet 
may also be important.
The effects of large bowel resection on nutri­
tional status are limited. Total resection or ileoanal 
anastamosis may cause profuse diarrhoea leading 
to significant losses of both fluid and electrolytes. 
Such losses diminish as the remaining bowel 
adapts.
Pancreas
Although only about 10% of patients are suitable 
for resection, it has been suggested that total pan­
createctomy is the only treatment for tumours of 
the pancreas [199,200]. Resection has a significant 
effect on nutritional status, leading to a loss of 
digestive enzymes as well as to diabetes mellitus.
All patients will develop diabetes which, in 20% of 
the patients, will be partcularly labile [201]; pan­
creatic exocrine insufficiency leads to malabsorp­
tion of fat and fat soluble vitamins as well as of 
amino acids and some minerals, notably calcium 
and magnesium [202]. Similar effects are seen in 
22%-28% of all patients undergoing pancreatic 
duodenectomy for disease of the head of pancreas 
or periampulary regions [203-205]. Administration 
of pancreatic enzyme preparations can significantly 
ameliorate these symptoms, and the use of MCT 
and oligosaccharides may be beneficial since pan­
creatic enzymes seem less necessary for their ab­
sorption [83]. The management of diabetes is less 
straightforward, since the ‘traditional’ diabetic diet 
with its increased percentage of fat and protein may 
exacerbate preexisting steatorrhea [202].
Cancer chemotherapy
Most of the drugs used to treat malignant disease 
exert profound cytotoxic effects and, since they are 
unable to discriminate between normal and cancer 
cells, may have marked effects on healthy ‘normal’ 
tissues. This lack of selectivity is the cause of many 
of the toxicities observed with this form of treat­
ment. However, the continued development of 
new drugs, together with variations in their dos­
ages, have resulted in marked changes in the treat­
ment of malignant disease. Nonetheless, cancer 
chemotherapeutic agents continue to contribute to 
host malnutrition through a variety of direct and 
indirect mechanisms that cause many symptoms 
such as nausea and vomiting, mucositis/stomatitis, 
organ injury, and learned food aversions. Many 
drugs adversely affect intestinal function to a de­
gree dependent on the dose and duration of treat­
ment, the rate of drug metabolism, and individual 
susceptibility. The current tendency to administer 
cyclic chemotherapy in multiple combinations can 
increase both the range and severity of side effects. 
Because most chemotherapeutic agents adversely 
affect dietary intake [206] (Table 4), there may be 
prolonged periods of impaired food intake leading 
to weight loss and a progressive debility.
Virtually all drugs will cause nausea and vomit­
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ing, although certain agents, notably chloroethyl- 
nitrosurea, streptozotocin, cis-platin, and im­
idazole carboxamide (DITC) [207], are most 
commonly involved. These effects, normally medi­
ated by the area postrema (a chemoreceptor zone 
of the fourth ventricle) [208], can have a significant 
nutritional impact on the host, causing anorexia 
and a decline in voluntary oral intake as well as 
fluid and electrolyte imbalance, general weakness, 
fatigue, and weight loss.
General mucosal toxicity may result in diarrhoea 
accompanied by severe abdominal pain and, in 
severe cases, proctitis, mucosal ulceration, 
haemorrhage, and/or intestinal perforation. How­
ever, since the renewal rate of the GI mucosa is 
rapid, such effects are usually short-lived. If pro­
longed, the result may be dehydration, electrolyte 
imbalance, inanition, and accelerated malnutri­
tion. Alternatively, constipation may occur, par­
ticularly when vinca alkaloids are employed, caus­
ing pain and adynamic ileus through effects on the 
autonomic nervous systm [209-211]. Diarrhoea can 
contribute to the malabsorption of nutrients that is 
a common effect of antineoplastic therapy. This 
results from toxic effects on the intestinal mucosa 
and/or the major organ systems.
Patients undergoing chemotherapy are ‘at risk’ 
of nutritional difficulties; active and aggressive nu­
tritional support should be considered as a means 
of helping the patient to cope with the problems 
associated with this type of treatment and enhanc­
ing both response to treatment and quality of life.
However, the indirect effects of chemotherapy 
may also play an important role in the decline of 
nutritional status. For example, moniliasis or can­
didiasis are common, particularly in patients with 
leukaemia and lymphoma affecting the oral cavity, 
pharynx, or oesophagus and causing a sore, painful 
mouth, odynophagia, dysphagia, and a dramatic 
decline in oral intake.
Learned food aversions may also arise as the 
result of an apparent association between specific 
foods and GI discomfort. In fact, it has been esti­
mated that some 43% of patients receiving GI toxic 
chemotherapy develop such aversions [64], usually 
to novel foods [212], although repeated associ­
ations between GI discomfort and specific foods 
can cause aversion to even familiar foods. Such 
effects may persist well after symptoms have sub­
sided and may have significant implications for the 
nutritional support of such patients, indicating the
Table 4. Effects of some cancer chemotherapeutic agents on the gastrointestinal tract
Drug Anorexia Mucositis Nausea Vomiting Diarrhoea Intestinal Other
and oral ulceration
ulceration
Adriamycin * * * * Hepatic
dysfunction
Bleomycin * * * *
Cytarabine * * * * * *  Altered taste
Abdominal pain
Cis-platin * * *
Dactinomycin * * * * *
5-Fluorouracil * * * *
Melphalan * *
6-Mercaptopurine * * * * *  Hepatic
dysfunction 
Abdominal pain
Methotrexate * * * *
Procarbazine * * *
Vinblastine * * * *
Vincristine * * Abdominal pain
Constipation 
Jaw pain
need for flexible feeding regimens and the avail­
ability of a variety of flavours and textures.
Radiation therapy (Table 5)
Since the intestinal mucosa is second only to the 
bone marrow in its sensitivity to radiation, curative 
doses of irradiation, particularly when directed at 
any portion of the GI tract, can result in severe 
nutritional deficiencies in a small, but significant, 
number of patients receiving either internal or ex­
ternal radiation and in whom intestinal toxicity 
may prove a limiting factor to intensive treatment. 
This arises from effects of treatment on normal 
tissues and appears dependent on the dose, time, 
and fractionation of the administered dose as well 
as the area of the treatment field. Acute or chronic 
effects may arise during, immediately following, or 
many years after radiotherapy; these include 
changes in the vasculoconnective tissue and result 
in changes in the small blood vessels, destruction of 
the endothelium, and degeneration of the muscle. 
Because affected tissues are fibrotic and poorly 
vascularised, they are less resistant to mechanical 
injury and infection; after irradiation minor 
trauma, or infection, may induce serious complica­
tions in an already compromised tissue. As a result, 
flattening and/or ulceration of the mucosa epithe­
lium, telangiectasis, arteritis, fibrosis, stenosis, or 
fistula formation may occur, and patients undergo­
ing abdo-pelvic irradiation may experience nausea, 
vomiting, severe diarrhoea, and abdominal cramps 
[213] or, alternatively, may present with complete 
or partial intestinal obstruction which, on occa­
sions, fail to respond to conventional treatment 
(although they may clear spontaneously after 4-5  
days) [214]. Such symptoms are disabling and de­
bilitating and can result in malnutrition and malab­
sorption, since the patient ingests less food and is 
less able to digest and absorb those nutrients avail­
able. Yet they must be accepted to some extent if 
an adequate dose of radiation is to be administered 
to a tumour lying in or near the GI tract. This 
makes aggressive nutritional support an obligatory 
adjunct to radiation therapy, both to prevent dete­
rioration of nutritional status and to allow compen­
satory hyperplasia of the undamaged bowel, for 
which an adequate nutrient intake is essential [84].
It is clear that as malignancy progresses an af­
fected individual is subject to many anatomic, 
physiologic, biochemical, and pharmacological 
effects that may result from one or more of the 
following: the systemic effects of malignancy, the 
local effects of the tumour, or one of many effects 
induced by treatment.
Table 5. Sequelae of radiation therapy: nutritional implications
Treatment area During treatment Post treatment
Oropharyngeal region Loss of taste Altered taste
Xerostomia
Odynophagia
Xerostomia
Damage to teeth Poor dentition
Stomatitis/mucositis Mandibular necrosis
Lower neck/mediastinum Oesophagitis Ulceration
Dysphagia
Fibrosis
Oesophageal stricture
Stenosis/stricture
Abdomen/pelvis Acute bowel damage 
(enteritis)
Chronic bowel damage
Diarrhoea Diarrhoea
Malabsorption Malabsorption
Obstruction Fistulae formation
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Nutritional support in the cancer patient
The preceding discussion clearly demonstrates the 
close relationship between nutritional status and 
malignant disease, in which the altered metabolism 
and the side effects of treatment frequently com­
bine leading to protein energy malnutrition. Such 
malnutrition, in turn, interferes with the response 
to treatment and enhances morbidity, so that 
weight loss must be regarded as an important prog­
nostic factor [6] and regular nutritional assessment 
is mandatory, while nutritional support forms an 
important part of care and treatment. The objec­
tives of nutritional support have been defined as a) 
supportive -  to maintain nutritional status or to 
rehabilitate an already debilitated individual, b) 
part of a therapeutic regime (adjunctive), and c) a 
means of maintaining life [7].
Although its aetiology is not understood, the 
long-term goals of nutritional support should be to 
prevent (or reverse) development of the cachectic 
syndrome and, at the same time, to enhance the 
response to treatment. But, as cancer is only rarely 
an acutely fatal disease [7], the short-term benefits 
of nutritional care must also be considered when 
support may result in a marked improvement in 
well-being and quality of life. It is now clear that 
malnutrition is NOT an obligatory accompaniment 
of cancer [7], and institution of nutritional support 
early in the course of the disease will help to pre­
vent its occurrence; it is considerably more difficult 
to rehabilitate an already malnourished individual. 
Each patient should be individually assessed so that 
factors inducing depletion can be identified.
The anorectic patient perhaps poses the greatest 
challenge, since such a patient is unlikely to meet 
his requirements through the oral route alone. Pro­
vided GI function is reasonably normal, tube feed­
ing, using a flexible, fine bore, non-irritating tube is 
the preferred means of supplementation through 
which complete feeds can be introduced into the 
stomach or upper small intestine. Enteral feeding 
has many metabolic advantages, particularly when 
compared to parenteral feeding, and is associated 
with fewer complications. ‘Ready made’ commer­
cial formulae or locally produced feeding solutions 
can be used to feed the patient by this method. For
the patient with moderate malabsorption, slow, 
continuous gravity drip feeding is indicated [84]. 
However, nasogastric feeding may be associated 
with both emotional and physiological stressors 
[215] including nasal soreness, oesophagitis, and 
deprivation of the pleasures gained from tasting, 
drinking, and chewing food [216], so that active 
steps should be taken to overcome such difficulties. 
The nasoenteral route may also increase upper 
airway resistance and interfere with respiratory ex­
change [216], so an alternative solution should be 
sought in the patient with respiratory disease; feed­
ing can be carried out through an oesophagostomy, 
gastrostomy, or jejunostomy. These techniques 
are not restricted to use in the hospital setting, and 
patients and their relatives can be successfully 
taught to carry them out at home [202]. Thus, for 
the patient at continual risk of aspiration, enteral 
feeding techniques can be used to avoid the need 
for continued hospitalisation.
However, enteral feeding is not always possible, 
particularly for the patient with severe malabsorp­
tion, persistent nausea and vomiting, or functional/ 
mechanical intestinal obstruction. As a result, con­
siderable attention has been focussed on the use of 
total parenteral nutrition (TPN) and many workers 
have shown this to be beneficial in preparing pa­
tients for specific anti-tumour therapy and enabling 
its completion [e.g., 217]. TPN has also been shown 
to improve wound healing and recovery [218] and 
the healing of post-operative fistulae, as well as 
improving general condition and mood. In some 
cases, for example in the patient with severe radia­
tion enteritis, long-term survival may be dependent 
on TPN and home TPN is indicated; training of the 
patient, and/or a family member, can make this a 
feasible proposition [219, 220].
The increasing availability of many different 
methods of nutritional support means that it is rare 
to find a patient who cannot be supported in this 
way. Nutritional support is always indicated in the 
malnourished individual for whom aggressive anti­
neoplastic therapy is planned and in the individual 
who may be expected to become malnourished as a 
result of such therapy. Although there is little 
doubt that nutritional status, tumour growth, and 
anti-tumour therapy are intimately related, it must
375
be recognised that nutritional support per se will 
not cure cancer unless the anti-neoplastic therapy is 
inherently effective [221]. It does, nonetheless, 
prevent malnutrition inevitably presages a poor 
outcome and, at the same time, enhances the pa­
tient’s quality of life [222].
However, in the patient who fails to respond to 
anti-neoplastic therapy and for whom only pallia­
tive care is possible the value of nutritional support 
may be questioned. It can be distressing for all 
those involved to watch the patient ‘wasting away’ 
as the disease, and the associated malnutrition, 
progress, and it can be very disturbing if nutritional 
suport is withdrawn. Good nutritional care can 
help to maintain the patient’s morale, which is of 
particular importance when this is restricted by 
advancing disease; thus, if the patient wishes, sup­
port should continue using oral supplements or 
even tube feeding. However, there comes a point 
at which it is no longer appropriate to prolong life 
by forcing the patient to eat unwanted food, and 
aggressive nutritional support should not be con­
tinued. At this stage the patient should be given 
whatever food is desired in whatever form is re­
quested. Nutrition no longer matters; what matters 
is to maintain the patient’s morale and encourage 
whatever enjoyment remains in the sight, smell, 
and taste of food.
Conclusions
-  Continued research into both the pathogenesis 
and treatment of anorexia is essential before 
effective treatment can be identified.
-  Anorexia is a significant factor in the decline of 
food intake.
-  Whatever its cause, it is clear that the effects of 
malignancy result in a negative energy balance 
and contribute to the observed weight loss. The 
mechanisms must be elucidated before catabol­
ism can be promoted in patients with cancer.
-  Control of pain/discomfort/other symptoms is 
essential if food intake is to be maintained.
-  Hypoalbuminaemia may disrupt drug therapy, 
reducing its effectiveness.
-  Hypoalbuminaemia is common, and therefore
cannot be used as an effective indicator of nutri­
tional status.
-  The future of successful treatment depends on 
an improved understanding of the changes in 
both protein metabolism per se and albumin 
metabolism, without which drug therapy may 
be of limited value and/or the efficiency and 
effectiveness of nutritional support may be lim­
ited.
-  The role, function, and existence of lipid mobi­
lising substances is equivocal.
Key unanswered questions
-  Do changes in energy metabolism apply equally 
to all tumours?
-  To what degree are the reported intestinal 
changes dependent on nutritional deficiency 
and to what extent do they depend on malig­
nancy itself?
-  Is anorexia, like depression, associated with 
serotonergic mechanisms -  are they inter­
related? Is another neurotransmitter involved?
-  Do tumours elaborate lipid mobilising sub­
stances, or cause these to be produced else­
where? If so, is this significant in the weight loss 
observed?
-  Do lipid mobilising peptides account for hvper- 
lipidaemia?
-  Is the degree/extent of hyperlipidaemia depen­
dent on the type of tumour?
-  What, is the role of vitamins and trace el­
ements?
-  Are there any tumour specific (or site specific) 
metabolic changes?
-  What will further longitudinal studies show?
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Summary: In treating malignant disease it often seems that the medical profession is 
primarily concerned with affecting cure or prolonging life, athough it is clear that both 
the disease, and its treatment, may profoundly affect the patient’s normal lifestyle and 
have a significant effect on the quality o f life (Q L). Y et the current emphasis on total 
patient care means that it is no longer enough to be concerned only with the physical 
aspects o f care; the psychosocial effects o f disease are becoming increasingly 
important. Consideration o f the patient’s QL is a legitimate part o f care and 
interventions can be designed to help the patient to incorporate changes in his physical 
state into his normal lifestyle. This paper discusses the concept of quality of life and 
explores the benefits o f ‘meaningful communication’ (education and supportive 
counselling) in terms o f the relief o f stress and anxiety. It considers the effects of such 
communication on the quality o f life o f affected patients. It is suggested that the latter 
can be significantly improved through communication.
Keywords: Cancer Quality o f life Communication
Recent years have seen an increased interest in the psychological and social 
impact of cancer and, therefore, on the quality of life of affected patients. It is 
suggested that, due to the threatening connotations of the disease, cancer 
patients have specific psycho-social problems which are shared by no other 
patient group1 and which may, in themselves, influence life expectancy,2*3 as 
well as the quality of that life. The discussion below examines some of these 
effects on the quality of life and explores the benefits of communication in 
terms o f patient well-being. However, before this can be attempted it is 
necessary to identify what is meant by the term ‘quality o f life’.
The quality of life
Quality of life (QL) is a term everyone understands but few can define and 
is, as Campbell4 states, ‘a vague and ethereal entity, something that many 
people talk about, but which nobody very clearly knows what to do about’. 
As a result, the concept o f QL is one which is particularly difficult to frame 
and to analyse, yet recent years have seen a marked increase in empirical 
research into its assessment.5*6*7*8 Although such studies have undoubtedly
0884-3988/88/040195—09$05.(K)
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provided valuable information, particularly with regard to the care o f the 
cancer patient, they have, to date, developed no systematic line of research, 
primarily owing to the absence of a satisfactory theoretical framework and the 
lack o f a universally accepted definition despite many attempts at the task. 
For example, Shin and Johnson9 suggested that QL consists o f ‘the possession 
o f the resources necessary to the satisfaction of individual needs, wants and 
desires, participation in activities enabling personal development and self- 
actualization and satisfactory comparison between oneself and others’, all o f  
which are dependent on previous experience and knowledge. La Mendola 
and Pellegrini,10 however, suggested that QL is dependent upon ‘individual 
achievement o f a satisfactory social situation within the limits o f perceived 
physical capacity’ although this makes no allowance for comparison with past 
or future satisfaction and, like other workers,11 links Q L to physical 
performance; surely life’s quality does not depend solely upon physical 
ability?
Others have approached this problem differently, describing QL as ‘the 
degree to which an individual succeeds in accomplishing his desires’, 12 ‘the 
degree o f need satisfaction’, 13 or ‘the extent to which a person’s hopes and 
ambitions are matched and fulfilled by experience’14 which, therefore, 
represents a narrowing o f the gap between hopes and reality and implies that 
QL involves many dimensions. These include general health, work and 
leisure, interpersonal relationships, and the social, psychological and emotional 
aspects o f life, thus supporting the suggestion that the quality o f life lies in the 
experience o f life itself4 and lending credence to the more global approach to 
definition.
For example, Patterson15 identified those areas which he believed to be the 
major contributors to QL and included general health, performance status, 
physical comfort and emotional and economic status. Campbell4 proposed 
that QL be identified with measures of happiness, a term he used as a 
synonym for satisfaction or freedom from stress. Y et, although it is clear that 
happiness is a desirable state, it is also clear that, like QL, it is difficult to  
define and no one knows exactly what it is or how it can be achieved.9 It may 
be viewed ‘simply’ as a hedonistic concept,16 as a measure o f satisfaction17 or 
as an appraisal o f the overall quality of experience.18 The latter takes into 
account all aspects of the general condition and allows for inividual 
circumstances. A usten19 claimed that happiness represents the highest 
assessment o f the total condition and Brenner^0 that this be viewed as a global 
assessment of the quality o f life rather than equated solely with affective 
feelings. It seems, therefore, that happiness and QL are inter-dependent and 
can, in fact, be used interchangeably to describe the overall quality of  
individual experience.
This discussion suggests that the quality of life is dynamic and represents 
individual responses to the physical, mental, social and psychological factors 
which contribute to ‘normal’ daily living8 and shows that it is an abstract and 
complex term comprising many diverse areas, all o f which contribute to the 
whole. There is, however, little doubt that the importance o f quality o f life
‘MEANINGFUL COMMUNICATION’ 197
components fluctuates with changes in health status,21 although it may also be 
affected by other pre-existing factors which, together, influence the degree to 
which personal satisfaction with life circumstances can be achieved and which 
allow favourable comparison with others according to the individual’s chosen 
criteria.
Despite the difficulties associated with defining the quality of life, it is a 
phrase much used in cancer care today, perhaps reflecting a change on the 
part of members o f the health care team as the value of cancer treatment is 
now judged not only on the duration o f survival but also on its quality.22,23,24 
After all, medicine has much more to do with the quality o f life than with its 
quantity25 and ‘quality before quantity’ is a popular concept.26 Yet, it is 
suggested that patients want both quality and quantity,27 so that many will 
accept a decrease in quality in order to prolong life. As a result they will 
undergo toxic treatments (such as cytotoxic chemotherapy). Nonetheless, the 
health care professionals commonly state that their aim in patient care is ‘to 
improve (or maintain) the quality of life’.28
Effects of cancer, and its treatment, on the quality of life
The diagnosis of cancer holds considerable fear for patients and the newly 
diagnosed are faced with many threatening possibilities including disabling 
illness, mutilative surgery, loss of a body part, deteriorating physical function 
and death.29 As a result, affected individuals must often meet a new set of 
demands which have previously been outside their sphere of knowledge, skills 
and experience.30 It is not, therefore, surprising to find them described as 
‘individuals experiencing a special and severe form of stress’,31 since they are 
facing many uncertainties not only in terms of the physical and social 
consequences but also in explaining its origins and development.
At the same time changes in general health are, inevitably, accompanied by 
some degree of physiological change. The mere act o f hospitalization will 
cause alterations in normal practices and activities, often promoting a state of 
enforced dependency when the patient becomes dependent on others for his 
survival in his current environment. This enforced dependency has been 
described as the motivation for behaviour in situations regarded as threatening-  
the emotional drive theory7,7'7,4, -  when such behaviour may disrupt 
adjustment and influence adaptation and, should this continue, disrupt the 
quality o f life as a whole.
It is not, however, surprising that patients react in some way to the 
diagnosis o f cancer or that their reactions may be manifested in a variety of 
ways. Although some appear to come to terms with their diagnosis with little 
apparent distress, others display marked psychological/psychiatric disturbances 
(e.g. reference 3). Between these two extremes are those patients described 
as ‘vulnerable’35 who may display signs such as anxiety, anguish, anger, 
hopelessness and abandonment although it is equally possible that their 
distress will not be readily visible to an onlooker.
198 S. HOLMES
Fear may remain an important feature throughout the course of the disease 
-  fear o f recurrence or fear o f death -  inducing a state o f chronic anxiety, 
which has been described as ‘neurotic fear’36,37 and which may be exacerbated 
by stress, ‘the state manifested by a specific syndrome which consists o f all the 
non-specific changes within a biologic system’ (such as man),38 which may be 
provoked by changes internal or external to the body.
An individual admitted to hospital may be suffering physiological stress 
(due to disease or trauma), as well as psychological/emotional stress, 
although these are not, o f necessity, related.37 Reactions to such stressors 
depend largely on factors within the individual39 although both are associated 
with an increased release o f the stress hormones which, in turn, exacerbate 
anxiety.
Anxiety results when an individual cannot fully comprehend the events 
surrounding him (subjective uncertainty) and promotes continued hormonal 
release. In fact, Warburton40 states that emotional stress is a more potent 
stimulator o f pituitary-adrenal activity than physical stress. Individual 
reactions depend on the interpretation and/or appraisal o f any potentially 
threatening situation41 so that an inability to interpret that situation leads to 
feelings o f uncertainty and helplessness which are, in turn, associated with a 
loss of control. Four main categories o f disturbance have been reported in 
newly diagnosed patients. These include disturbances o f affect, motor 
behaviour, cognitive functioning and physiological changes42 all of which 
may, undoubtedly, influence the quality of the patient’s life.
However, responses to the diagnosis are often compounded by reactions to 
the treatment employed. For example, patients who have undergone surgery 
for ano-rectal tumours, with formation of a colostomy, often display marked 
psychiatric morbidity which profoundly influences sexual and social behaviour.4-’ 
Similarly amputation of a limb,44 surgery to the head and neck45 and 
gynaecological surgery46 have been shown to have deleterious psychological 
and social effects which, in turn, since they are important components of life, 
may significantly affect its quality.
Cytotoxic chemotherapy has also been associated with adverse effects, in 
part, due to the toxic effects o f such drugs and, in part, owing to the cognitive 
impairments which have been associated with a wide variety o f chemothera­
peutic agents.47 Radiotherapy too, has been associated with high levels o f  
depression and anxiety48,49,50,51 such that Lyon52 has reported that 51% o f all 
patients suffer depression and 13% display suicidal tendencies. Such effects 
result, in part because the therapy acts as a forceful reminder o f the disease^-’ 
and, in part, due to its association with nuclear technology.
Combination therapy has been found to be a particularly potent cause o f  
both psychiatric and social disturbances54 which may be exacerbated by the 
presence of persistent physical symptoms, whether or not these are treatment 
related.55,56 There is little doubt that these effects may significantly affect the 
quality o f the patient’s life so that affected patients require not only physical 
care but also considerable psychological and emotional support.
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Total care
Clearly cancer is a complex disease and each patient is unique, having varying 
and highly individual needs. Since some 41% of those diagnosed now live for 
many years before recurrence, cancer can now be considered a chronic 
disease. Others may live for many years with continual relapse and remission 
so that care of such patients must be based on an understanding o f the intense 
fears, anxieties and frustrations they are facing.
Yet, Kaplan57 suggests that, although patients’ medical needs are taken 
care of, attention is so firmly directed towards the ‘technical’ aspects of care 
that there is a failure to take account of their total needs. Patients themselves 
have stated that, apart from technical skills, the single most important 
attribute for those caring for affected patients is ‘one hell o f a lot o f sympathy 
and moral support’,58 something which is, all too often, lacking in health care 
today.
It is suggested that many complaints arise because patients are treated as 
‘non-persons’ as a result o f an almost unconscious ‘dehumanizing’ process 
which often arises when ‘caring’ for the sick59*60 with the effect that patients 
often become passive recipients o f their care, a discrepancy attributed to a 
lack of information from the health care professionals.61 It is known that a 
significant number of hospital patients are dissatisfied with both the amount 
and the quality of information they are given.62,63 For example, Garrison, 
Abner, Oakley et a l.4 found that only 37% of patients were given information 
at the time of diagnosis, although 72% actively expressed a desire for 
information. Since Cassileth, Zupkis and Sutton-Smith (65) suggest that 
understanding can help the patient to maintain an element of control, many 
will seek information although, as can be seen, this is not always forthcoming; 
this is, clearly, an area at which intervention should be directed.
However, since the level o f stress and anxiety may be high, and since, for 
most people, hospitals are frightening places,66 cognitive function may be 
impaired. As a result patients may have considerable difficulty in interpreting, or 
retaining, information. The work of Volicer and Bohannon67 clearly 
demonstrates the need for repetition, or reinforcement, by showing that the 
aspects of hospitalization most frequently perceived as distressing are those 
related to the lack o f meaningful communication, particularly, but not 
exclusively, that from the nursing staff. This, in addition, enhances their 
feelings of social isolation.8
At the same time it must be recognized that the patient is part o f a family 
unit and that the family acts as the patient’s ‘first line o f defence’68, this being 
the social context in which illness occurs. The impact o f cancer on the family 
may be significant in changing roles and altering the usual pattern of activity 
to enable the patient to meet the demands o f treatment regimes. Reactions to 
treatment, the side-effects o f that treatment or the symptoms of the disease 
itself may involve the family in stressful situations, particularly as the patient 
may be reliant on members of his family for much of his care and support.
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Although, from the personal perspective, cancer may be considered catas­
trophic69 it is not experienced in isolation and the caring team must be able to 
offer support not only to the patient but also to his ‘significant others’ who 
form a vital part of his support system, without which the quality o f his life is 
markedly reduced.
Freidenbergs, Gordon and Hibbard70 have identified the basic psycho­
logical interventions necessary to the support system for patients with cancer; 
it will be noted that these include the family at all levels:
1. Education to help both the patient and his family to live with the diagnosis, 
the disease itself and the mode o f treatment.
2. Counselling to enable the patient and his family to express their feelings 
and anxieties and to ventilate their emotions.
3. Manipulation of the environment, including interactions between members of 
the caring team, so as to identify and, where necessary, initiate care of 
specific concerns.
Such action, which is largely dependent on the ‘transfer’ o f information, is 
an essential part of the total care of affected patients and one which is often 
neglected. At the same time this would meet the major needs of cancer 
patients both to maintain control over their destiny, to understand the 
technical language and procedures involved in treatment, and also to develop 
the ability to share their thoughts and feelings.71
The provision of information, through repeated ‘meaningful communication’, 
can go a long way towards meeting these needs and give the patients 
‘permission’ to discuss their fears and anxieties. Interactive communication 
can do a great deal to decrease fear, allay anxiety and provide encouragement 
for both the patient and his family, increasing their overall satisfaction with 
the care they receive and, since satisfaction has been equated with happiness,4 
this will clearly help in improving the quality of the patient’s life.
Yet, despite the importance of spending time in ‘meaningful communication* 
with affected patients, staff are frequently perceived as ‘too busy’ to ‘waste’ 
time in talking to individual patients.8 It is clear from the preceding discussion 
that time must be allocated to talking, and counselling, patients; this is a vital 
part of care. Such patients must be allowed time to express their fears and 
anxieties, to ventilate their emotions and to receive active support. It is a 
matter of considerable concern that cancer patients often feel isolated from 
their friends and family as a result o f having the disease and that these feelings 
are exacerbated by hospitalization and an inability to communicate with the 
staff, particularly nurses.8
Conclusion
It is clear that interventions which centre around the provision of accurate 
information (education) and supportive counselling, together with successful 
interactions between members of the caring team, allow the development o f a
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valuable support system. A  support system which allows ‘meaningful 
communication’ between patients and all members of the caring team has a 
valuable role to play in helping the patient to meet his needs and maintain an 
acceptable quality o f life.
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